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Abstract  
 
Introduction 
The number of cancer patients with CIEDs presenting for radiotherapy treatment is 
increasing. Technological advances in CIEDs have now made them more sensitive 
to ionising radiation and electromagnetic interference (EMI) than older bipolar semi-
conductor devices.  External beam radiotherapy has the potential to cause CIED 
malfunction, this might be temporary but nevertheless, could result in catastrophic 
failure of the cardiac conduction system of the heart.  It is not possible to predict the 
exact behaviour of a CIED when it is within, or close to, the radiotherapy treatment 
field. Published literature is inconsistent in its findings regarding the safe levels of 
ionising radiation dose delivered to CIEDs.  The aims of this research are to 
determine the effects of ionising radiation and electromagnetic interferences upon 
CIEDs and leads.   
 
Method 
This research will adopt an experimental approach to data collection, under 
laboratory conditions, when CIEDs and CIEDs leads are exposed to ionising 
radiation and EMI. 
 
Results 
The scientific arm of this research focused on the effect of ionising radiation and EMI 
on CIEDs and CIED leads. The results showed that CIEDs exhibited a range of 
temporary and permanent malfunctions when exposed to cumulative ionising 
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radiation doses ranging from 0.5Gy to 3Gy.  Results also, recommend that CIED 
leads should not be in the treatment field however, if this is unavoidable the radiation 
dose should be kept as low as possible.   All CIEDs exhibited an effect when 
exposed to EMI and it is recommended that all patients with CIEDs receiving 
radiotherapy treatment should be monitored when in the radiotherapy treatment 
room. 
 
Conclusion 
This research identifies how CIEDs are adversely affected by ionising radiation and / 
or EMI, how these effects can be minimised, provide safe radiotherapy tolerance 
doses to CIEDs and issue recommendations for the publication of national guidelines 
for the safe management of patients with CIEDs undergoing radiotherapy treatment.   
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Thesis - An investigation into the effects of 
radiotherapy on implanted cardiac devices 
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Chapter One 
Background and setting the scene 
 
1.1    Introduction 
This research identifies how cardiac implantable electronic devices (CIEDs) are 
adversely affected by ionising radiation and / or electromagnetic interference (EMI), 
how these effects can be minimised, provide safe radiotherapy tolerance doses to 
CIEDs and issue national guidelines for the safe management of patients with CIEDs 
undergoing radiotherapy treatment. 
 
This first chapter provides the background for the research and outlines the context 
of the problem and why this research needs to be carried out.  The limitations of the 
current research and literature are discussed and the contributions are detailed in 
order to explore the principles and theories, which will underpin the research.  This 
chapter includes the study aims and objectives and the approach to achieving them.  
It concludes with an overview of the contents of each chapter. 
 
1.2    Background 
Cardiovascular disease is a group of disorders of the heart and blood vessels and is 
the number one cause of death globally.  An estimated 17.5 million people died from 
cardiovascular diseases in 2012, representing 31% of all global deaths (World Health 
Organisation, 2018).  It is also the main cause of death and disability in the UK, but 
the disease can often largely be prevented with a healthy lifestyle.  CIED 
implantation is indicated for the treatment of a number of cardiovascular diseases.  
The aim is to maintain the patient’s heart rate based on circulatory needs and 
‘pacing’ in a manner that mimics the natural physiology of the cardiac conduction 
system.   
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Cancer is the name given to a collection of related diseases that involve abnormal 
cell growth and results from a series of molecular events that alter the normal 
properties and functions of cells (Stuart, 2014).  There are more than two hundred 
different types of cancer and this disease can be treated by surgery, chemotherapy, 
radiotherapy, hormonal therapy and targeted therapy.  Cancer is the second leading 
cause of death globally, with approximately fourteen million new cases in 2012 and 
the number of new cases is expected to rise by about 70% over the next two 
decades (Torre et al, 2015).  It was responsible for 8.8 million deaths in 2015 or 
nearly one in six of all global deaths (World Health Organisation, 2018).   
 
Globally, life expectancy has increased by more than 37% in the past century (United 
Nations, 2017) whilst in the English and Welsh population it has increased by more 
than 65% in the same period (Office of National Statistics, 2018).  One consequence 
of this is a higher prevalence of cardiovascular morbidity, leading to an increase in 
the number of patients with CIEDs (Fernandez-Ballesteros et al, 2013 and Last, 
1998).  In addition, the age-standardised incidence of cancer has increased by more 
than 25% over the past thirty years (Office of National Statistics, 2016).  It has been 
estimated that 50-60% of all patients with cancer will undergo radiotherapy during the 
course of their illness (National Radiotherapy Advisory Group, 2007).  Therefore, with 
an ageing population, and an increase in the incidence of both cardiovascular 
morbidity and cancer, the number of patients with CIEDs presenting for radiotherapy 
treatment will likely increase (Fernandez-Ballesteros et al, 2013).  These patients are 
therefore experiencing issues in dealing with not one, but two life threatening 
diseases, whilst also possibly being affected by a third factor, of an iatrogenic basis, 
whereby the treatment (radiotherapy) for one of those diseases (cancer) may in itself 
threaten the patient’s life by impacting upon the CIED that is treating/controlling their 
other health (cardiac) condition. 
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1.3    Context of the research problem 
Although most medical treatments pose little danger to the functioning of CIEDs, 
radiotherapy has the potential to alter CIED function.  CIEDs may be affected in two 
ways: direct damage via ionising radiation and / or by electromagnetic interference 
(EMI), both of which may cause temporary or permanent CIED malfunction (Last, 
1998).  Over the past three decades, the demand for smaller, reliable and more 
energy efficient devices has led to the replacement of bipolar transistors with 
complementary metal oxide semiconductor (CMOS) components (Hurkmans et al, 
2012).
  
As the CIEDs evolved they became more complex in design, have thinner 
housing, less shielding and limited battery capacity plus a greater sensitivity to 
ionising radiation than the bipolar semiconductor devices previously used.  Thus 
there is a potential for increased damage and device failure (Little, 1994 and Mouton 
et al, 2002). 
 
CIED leads are insulated flexible wires that conduct electrical signals from the CIED 
generator to the heart muscle and relay information concerning the heart’s intrinsic 
electrical activity back to the CIED pulse generator.  Although ionising radiation may 
affect the function of the CIED, CIED leads are considered to be resistant to these 
effects (Lau, 2008).  None of the CIED manufacturers have issued any ionising 
radiation tolerance doses for CIED leads.  CIEDs are afforded some protection 
against exposure to ionising radiation and EMI, however, the CIED leads still remain 
vulnerable to noise pickup and the effects of EMI (Tiikkaja et al., 2012). 
In discussing CIEDs, leads and their functions, this research looks to provide an 
understanding of how radiotherapy has the potential to alter CIED function by 
ionising radiation and / or EMI.  It will describe the nature of cancer, the management 
of cancer patients with CIEDs receiving radiotherapy treatment and any adverse 
clinical effects that these patients exhibit as a result of exposure of the CIED to 
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ionising radiation and EMI.  The research will also look at the issue of national 
evidence-based guidelines for the safe management of cancer patients with a CIED 
receiving radiotherapy treatment in the UK.   
 
1.4    Limitations in research 
Research has shown that the CMOS circuits in CIEDs can be more sensitive to 
ionising radiation than the bipolar semiconductor devices used previously (Little, 
1996).  However, this increased sensitivity can lead to damage to both the hardware 
and software components of the CIED (Last, 1998).  Mouton et al (2002) state that 
such damage could be transient, for example, dropped beats, transient inhibition, 
altered sensitivity, increased or decreased pulse width and frequency or triggering of 
CIEDs.  However, the consequences could be serious and permanent.  For instance, 
severe circulatory damage could potentially lead to a major catastrophic failure of the 
cardiac conduction system and ultimately death of the patient (Little, 1994). 
 
It is not possible to predict the exact behaviour of any given CIED when it is in, or in 
close proximity to the radiotherapy treatment field (Solan et al, 2004).  In addition, 
there is limited published research on the effect of ionising radiation and EMI on 
CIEDs and the published literature is often inconsistent in its findings and 
recommendations.  This research will investigate if there is any evidence to show 
that radiotherapy and / or EMI can cause device malfunctions or failure with 
potentially life-threatening consequences.  
 
The American Association of Physicists in Medicine (AAPM) report by Marbach et al 
(1994) recommends that the maximum dose to a pacemaker should be limited to 
less than 2Gy.  The largest and most comprehensive study to date by Mouton et al, 
in 2002 supported the AAPM recommendations.  In their in vitro study, ninety-six 
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patients having thoracic radiotherapy treatment whose pacemakers were adjacent to 
the radiotherapy treatment field exhibited a range of short and long-term CIED 
malfunction side effects. Results showed that one pacemaker exhibited clinically 
significant disturbances at a cumulative dose of only 0.15Gy, two pacemakers 
exhibited defects at a dose of 1Gy and nine pacemakers failed at a cumulative dose 
of 2Gy.   
 
Hurkmans et al (2005) directly irradiated nineteen new pacemakers; the commonest 
damage reported was loss of output.  In contrast to the Moulton study, only one 
pacemaker malfunctioned below 50Gy, suggesting modern pacemakers may be 
relatively radioresisitant.  Hurkmans et al (2005) concluded that the 1994 AAPM 
recommendations were still valid.  However, a limitation of this study, was that the 
pacemakers were not returned to the CIED manufacturers for a more detailed 
analysis after exposure to ionising radiation.  Therefore, their conclusions were 
based on CIED in-house testing data only. 
 
To date, Frizzell (2009) has published the most up to date review of CIEDs and 
radiotherapy.  He made a distinction between pacemakers and ICDs.  He further 
recommended that that the maximum cumulative ionising radiation dose to the ICD 
should be limited to less than 0.5Gy as a consequence of their increased sensitivity.   
The evidence and distinction provided by Frizzell, was a major development in the 
management of patients with CIEDs receiving radiotherapy treatment.  He concluded 
that the 1994 AAPM recommendations are no longer a complete guide and policies 
need to be updated to reflect advances in CIED technology.  Research has shown 
that there are no national guidelines and that most radiotherapy departments in the 
UK have neither a formal risk management strategy in place nor a CIED policy 
(Solan et al, 2004).  The AAPM report and Frizzell’s recommendations are the basis 
of most of the current CIED departmental radiotherapy policies in the UK.  However, 
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the AAPM report (Marbach et al, 1994) is more than two decades old and Frizzell’s 
(2009) paper was published in 2009 and these do not reflect recent advances in 
CIED or radiotherapy technology. When this study started there were no UK or 
national guidelines on the use of radiotherapy in patients with CIEDs and most 
radiotherapy departments had no formal risk management strategy or appropriate 
policy in place.  Therefore, there was a need for the research in order to provide 
accurate, up to date and evidence-based guidelines on CIEDs and safe radiotherapy 
tolerance doses. This research must be carried out in collaboration with CIED 
manufacturers and a cardiology department.  CIED manufacturers will provide 
CIEDs, leads, testing equipment, detailed analysis of any abnormalities detected and 
their expertise in evaluating any changes or damage to the CIEDs and leads.  The 
expertise of a cardiology department will provide a clear understanding of the cardiac 
implications to the CIED, leads and the patient.  This holistic approach will provide a 
comprehensive understanding of the management required for patients with CIEDs 
receiving radiotherapy treatment. 
 
1.5    Original contributions to the area of research  
The starting point of this research was to ascertain an understanding of the CIED 
policies in use in UK radiotherapy departments, what these policies were based on 
and how they were implemented or even if such policies existed.  In order to achieve 
this, the researcher carried out the first national audit of radiotherapy department 
CIED policies.   
 
• Previous studies investigated the effect of ionising radiation and EMI on 
CIEDs.  As part of this research project, this is the first study to investigate 
the effects of only EMI on CIEDs  
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• Current literature and advice from CIED manufacturers, consider CIED leads 
to be resistant to the effect of ionising radiation, therefore this is the first 
research project to investigate the destructive effect ionising radiation has on 
CIED leads. 
 
• As a result of the development and improvement in CIED technology, rate 
response activated CIEDs are increasingly being implanted in patients for the 
management of their cardiac conditions.  However, there is no research into 
the effect of ionising radiation and / or EMI on these devices.   This is the first 
research conducted to investigate such effects. 
 
• Results from the research project provided evidence to support 
recommendations for the safe management of patients with CIEDs receiving 
radiotherapy treatment.   Based on the researcher’s knowledge and expertise 
in this field, they were invited to chaired a multi-disciplinary working party 
comprising clinical oncology, cardiology, therapeutic radiography and medical 
physics to develop guidelines for the management of these patients.  These 
guidelines are the first comprehensive recommendations provided to UK 
radiotherapy departments and resulted in a major change in current clinical 
practice.  These guidelines have been supported by all disciplines involved 
and their professional bodies (The Royal College of Radiologists, the Society 
and College of Radiographers and the Institute of Physics and Engineering in 
Medicine). 
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1.6    Study aims and objectives 
Aims: 
• To determine the effect of ionising radiation and EMI on CIEDs and leads 
• To provide data to support the implementation of UK guidelines for the safe 
management of cancer patients with CIEDs receiving radiotherapy treatment 
 
Objectives: 
• To establish current UK practice regarding the management of patients with 
CIEDs receiving radiotherapy treatment 
• To determine the effects of ionising radiation and EMI on patients with CIEDs 
receiving radiotherapy treatment at a radiotherapy centre in Wales (RCW) 
• To evaluate the relationship between cumulative ionising radiation dose and 
EMI and damage sustained to CIEDs 
• To evaluate the relationship between cumulative ionising radiation dose and 
EMI on the physical condition of the leads 
• To determine whether there is a safe minimum radiation tolerance dose to 
CIEDs and leads 
• To determine the effect of ionising radiation and EMI of rate response 
activated CIEDs 
 
This research adopted an experimental approach to data collection.  Due to the 
nature and involvement of ionising radiation in the research, at this stage it would be 
inappropriate to expose patients to the ionising radiation doses and EMI levels 
required to investigate the destructive effects upon the CIEDs and leads by ionising 
radiation and EMI.  The research was therefore conducted under laboratory 
conditions. 
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1.7    Outline of the chapters 
Chapter Two – Cardiovascular diseases, the cardiovascular system and CIEDs. 
This chapter aims to put into context why an increasing number of patients with 
CIEDs are presenting to UK radiotherapy departments for radiotherapy treatment.  It 
describes the nature of cardiovascular disease, the range of cardiovascular diseases 
and the symptoms related to these conditions. It then outlines the components and 
functions of the cardiovascular system and discusses the role of the heart, blood 
vessels and blood within this system.  This chapter details the sequence of 
mechanical and electrical events that make up the cardiac cycle and how this is 
represented in a normal electrocardiogram (ECG) trace. It also explores the clinical 
indications for CIED implantations and how these conditions are represented on 
abnormal ECG traces.  In describing the CIED hardware, there is a basis to compare 
any damage to such hardware as a result of ionising radiation and / or EMI; this 
being one of the main aims of the research.   This chapter concludes that with an 
increasing number of patients with CIEDs presenting for radiotherapy treatment, 
further research is needed to identify and quantify the effects of ionising radiation and 
EMI on CIEDs and the specific hardware components. 
 
Chapter Three – Cancer and the effect of ionising radiation and EMI on CIEDs 
This chapter aims to put into context the effect of ionising radiation and EMI on 
CIEDs and the associated leads.   It discusses the role and function that radiotherapy 
plays in the management of patients with cancer and detailing the radiotherapy 
planning and treatment delivery process. It provides an analysis of how ionising 
radiation and EMI causes CIED malfunctions and discusses the affect and impact on 
both the CIED and the patient.  It will also explore the safety recommendations and 
guidelines that have been previously issued for treating patients with cancer and 
concludes that the policies that are in place are based on evidence, which is twenty-
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three years old and does not reflect advances in CIEDs or radiotherapy technology 
and treatments.  
 
Chapter Four – Research methods 
This chapter formulates the research questions and objectives that led to the 
development of the research design and the research studies.  The purpose of this 
chapter is to outline and explain the reasoning and approach by which the research 
was undertaken.  The chapter will describe the choice of research approach and 
research method to establish current UK practice regarding the management of 
patients with CIEDs undergoing radiotherapy treatment.  It will then detail the choice 
of research approach and present the research design for the three scientific studies 
investigating the effect of ionising radiation and EMI on CIEDs and CIED leads.  The 
chapter will discuss the choice of research approach when conducting a systematic 
review to determine current ‘gold standard’ practice for the safe management of 
patients with a CIED receiving radiotherapy treatment.  
 
Chapter Five - Test compliance, knowledge, understanding and perception 
This chapter will consider current UK practice regarding the management of patients 
with CIEDs undergoing radiotherapy and compare this practice to current ‘gold 
standard’ evidence-based guidelines.  The chapter details the findings of the national 
audit and reinforces the principle that patients with CIEDs are being put at significant 
risk of harm when exposed to ionising radiation and EMI when receiving radiotherapy 
treatment.  In this chapter, the results from two clinical audits carried out RCW are 
documented.  It details the observed clinical reactions in patients and discusses the 
need for research into the effect of ionising radiation and EMI on these contemporary 
CIEDs as part of the PhD.  
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Chapter Six – Scientific Research 
Chapter six presents the findings of the studies, analyses the study’s results and 
discusses the mechanisms that cause CIED malfunctions and or failure.  In reporting 
CIED malfunctions and failure the effect of radiotherapy treatment and the clinical 
impact to the patient will be discussed. Recommendations regarding radiotherapy 
tolerance doses to all CIEDs will be made. 
 
Chapter Seven – Research outcomes  
Chapters five and six discussed the results and conclusions from the PhD research 
project.  This chapter details how the results from these studies informed 
recommendations and guidelines for the management of patients with CIEDs 
receiving radiotherapy treatment.  A multidisciplinary working party was then 
established to publish evidence-based guidelines for the management of such 
patients. This chapter documents the theoretical background upon which the national 
guidelines are based and presents the guidelines developed and published based on 
this research. 
 
Chapter Eight – Final remarks 
Chapter eight summarises the key findings of the research, relates these findings to 
the implications for theory and practice, outlines the limitations of the research and 
offers recommendations for future work. 
! !
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Chapter Two 
Cardiovascular disease, the cardiovascular system and CIEDs.  
 
2.1    Introduction 
CIED implantation is indicated for the treatment of a number of cardiovascular 
diseases.  This chapter describes the nature of cardiovascular disease, the range of 
cardiovascular diseases and the symptoms related to these conditions.  This 
research investigated whether ionising radiation and / or EMI can have an adverse 
effect on the CIED implanted in patients being treated for cancer and cause 
subsequent damage to their cardiac conduction system.  This chapter outlines the 
components and functions of the cardiovascular system and discusses the role of the 
heart, blood vessels and blood within this system.  It details the sequence of the 
mechanical and electrical events that make up the cardiac cycle and how this is 
represented in a normal electrocardiogram (ECG) trace.  
 
CIEDs aim to maintain the patient’s heart rate based on circulatory needs and pacing 
in a manner that mimics the natural physiology of the cardiac conduction system.  
This chapter explores the clinical indications for CIED implantations and how these 
conditions are represented on abnormal ECG traces.  CIEDs provide electrical 
stimuli to cause cardiac contraction during periods when intrinsic cardiac electrical 
activity is inappropriately slow or absent.  The type of CIED implanted depends on 
the patient’s symptoms and their specific heart condition.   Research has shown, that 
in clinical practice, there are two main types of programming for CIEDs; demand 
pacing and rate-responsive pacing (Dell’Oca et al, 2004). 
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The remainder of this chapter describes the CIED hardware and provides a basis to 
compare any damage to this hardware as a result of ionising radiation and / or EMI; 
this being one of the main aims of the research.   
 
2.2    Cardiovascular disease 
Cardiovascular disease is a collective term for conditions affecting the heart or blood 
vessels and comprises many conditions including coronary heart disease, heart 
failure, heart rhythm problems (arrhythmias), cardiomyopathy, congenital heart 
disease, peripheral vascular disease and stroke (Mendis et al, 2017). 
 
Coronary heart disease (CHD) 
CHD also known as ischaemic heart disease is a major cause of death both in the 
UK and worldwide (Shepard et al, 2015).  CHD is the term that describes what 
happens when the heart's blood supply is blocked or interrupted by a build-up of fatty 
deposits (atheroma) in the coronary arteries.  Over time, the walls of the arteries can 
become ‘furred up’ with these fatty deposits (Mendis et al, 2017).  The two major 
forms of CHD are angina and heart attack (acute myocardial infarction).  Angina is a 
chronic condition where short episodes of chest pain occur periodically, caused by a 
temporary shortage of blood supply to the heart.  While it is not usually life 
threatening it can be associated with increased risk of heart attack.  A heart attack is 
caused if a piece of atheroma breaks off, this leads to a blood clot (blockage) 
forming.  Should this clot block the coronary artery and cut off the supply of oxygen-
rich blood to the heart muscle, the heart may become permanently damaged and 
suffer a loss of function (Romero et al, 2015).  A CIED is inserted if the patient is at 
risk of a cardiac arrest, as the heart’s electrical signals cause the heart to stop 
beating altogether.  
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Heart failure and cardiomyopathy 
Heart failure is a life-threatening condition that occurs when the heart is unable to 
maintain a sufficient enough blood flow to meet the body’s needs (McMurray, 2012).  
Heart failure can result in shortness of breath, chronic tiredness and a reduced ability 
to carry out physical activity (Fox et al, 2001).  A study in 2008 by Epstein et al, 
showed that there is considerable evidence that the use of biventricular pacing, by 
providing cardiac resynchronisation therapy (CRT), reduces heart failure symptoms 
and lowers heart failure mortality with or without an ICD.   The New York Heart 
Association classification system (The Criteria Committee of the New York Heart 
Association, 1994) also recommends that patients who have symptoms and are 
classified as class III or class IV undergo CRT implantation.  At classification III 
patients have a marked limitation of physical activity, comfortable at rest. Less than 
ordinary activity causes fatigue, palpitation, or dyspnoea.  At classification IV patients 
are unable to carry out any physical activity without discomfort. Symptoms of heart 
failure at rest and if any physical activity is undertaken, discomfort increases. 
 
Cardiomyopathy is a general term for diseases of the heart muscle and occurs when 
the heart muscle (walls of the heart chambers) becomes stretched, thickened, 
enlarged or stiff (NHLBI.nih.gov, 2018).  Consequently, there is a reduction in the 
effectiveness of the heart as it impairs the heart’s ability to pump blood around the 
body.  Cardiomyopathy and heart failure commonly occur together.  Guidelines 
published by Gersh et al in 2011, document the indications for CIED implantation for 
patients with cardiomyopathy depending on the classification of the disease.  For 
patients with Class I, and Class II, CIED implantation is indicated.  
 
Congenital heart disease 
Congenital heart disease is a general term for a range of birth defects that affect the 
heart or blood vessels that is present from birth (NHLBI.nih.gov, 2018a).  It is one of 
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the most common types of birth defect, affecting up to nine in every one thousand 
babies born in the UK (Nhs.uk, 2018b).  It may include abnormalities of the heart or 
heart valves, such as a hole between chambers of the heart, or narrowing of major 
blood vessels, or a combination of disorders.  
 
Peripheral vascular disease 
Peripheral vascular disease is a blood circulation disorder that causes the blood 
vessels outside of the heart to narrow, block or spasm.  This can be caused by 
blockage of arteries due to cholesterol or fatty substances or caused by widening of 
the arteries such as the aorta, which in severe cases can lead to rupture of the 
arterial wall (NHLBI.nih.gov, 2011).  Peripheral vascular disease typically causes 
pain and fatigue, often in the legs, especially during exercise.  Treatment for 
peripheral vascular disease includes balloon angioplasty, stent implantation or 
atherectomy (a catheter is used to remove plaque inside a blood vessel). 
 
Stroke and transient ischemic attack (TIA) 
A stroke occurs when the artery supplying blood to the brain either suddenly 
becomes blocked or begins to bleed. This may result in part of the brain dying, 
leading to sudden impairment of one or more capacities (for example speaking, 
thinking and/or movement) (NHLBI.nih.gov, 2018c).  A transient ischemic attack 
(TIA) or ‘mini stroke’ is caused by a temporary disruption in the blood supply to part 
of the brain, this disruption results in a lack of oxygen to the brain.  This can cause 
sudden symptoms similar to a stroke, such as speech and visual disturbance, and 
numbness or weakness in the face, arms and legs.  However, a TIA doesn't last as 
long as a stroke, with the effects often only lasting for a few minutes or hours and 
can be fully resolved within 24 hours (Meschia et al, 2014). 
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2.3    Cardiovascular system 
The cardiovascular system is the transport system of the body and is a complex 
network consisting of the heart, blood vessels and blood.  It is responsible for 
transporting oxygen, nutrients, hormones, and cellular waste products throughout the 
body.  The body takes oxygen and other nutrients from the blood, while at the same 
time eliminating waste products like carbon dioxide, transferring them back into the 
blood, so they can be removed. The heart powers the cardiovascular system, which 
pumps and dispenses blood to the arteries with the average heart pumping over 5 
litres of blood throughout the body every minute (Menche, 2012).  Within the 
cardiovascular system, there are several different transport circuits.  The pulmonary 
circuit transports deoxygenated blood from the right side of the heart to the lungs, 
where the blood picks up oxygen and returns to the left side of the heart. The 
pumping chambers of the heart that support the pulmonary circulation loop are the 
right atrium and right ventricle.  The systemic circuit carries highly oxygenated blood 
from the left side of the heart to all of the tissues of the body.  Systemic circulation 
removes waste products from body tissues and returns deoxygenated blood to the 
right side of the heart. The left atrium and left ventricle of the heart are the pumping 
chambers for the systemic circulation loop (Guyton and Hall, 2000). 
 
Functions of the cardiovascular system 
The cardiovascular system has three primary functions: transportation of materials, 
protection from pathogens, and regulation of the body’s homeostasis. 
 
• Transportation: The cardiovascular system transports blood, which contains 
nutrients and oxygen and removes carbon dioxide and waste products. 
Hormones are also transported throughout the body via the blood’s liquid plasma. 
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• Protection: The cardiovascular system uses white blood cells to protect the 
body.  These cells clean up cellular debris and fight pathogens that have entered 
the body. Platelets and red blood cells form barriers to seal wounds and prevent 
pathogens from entering the body and liquids from leaking out. Blood also carries 
antibodies that provide specific immunity to pathogens that the body has 
previously been exposed to or has been vaccinated against. 
 
• Regulation: The cardiovascular system contributes to the body’s ability to 
maintain homeostatic control. Blood vessels help maintain a stable body 
temperature by controlling the blood flow to the surface of the skin. Blood also 
helps balance the body’s pH due to the presence of ions, which act as a buffer 
solution. In addition, the albumins in blood plasma help to balance the osmotic 
concentration of the body’s cells by maintaining an isotonic environment. 
 
The heart 
The heart is a muscular pumping organ located medial to the lungs along the body’s 
midline in the thoracic region. The bottom tip of the heart (apex), is turned to the left, 
so that about 2/3 of the heart is located on the body’s left side with the other 1/3 on 
the right side (Betts et al, 2013).  The top of the heart (heart base) connects to the 
great blood vessels of the body: the aorta, vena cava, pulmonary trunk, and 
pulmonary veins.   The pericardium is the fibrous covering, which encapsulates the 
heart, securing it in place but allowing it to move as it beats (Dorland, 2012).  The 
wall of the heart itself is made up of a specialised muscle called cardiac muscle.   
 
The heart has two sides, the right and left which each have two chambers, a top 
chamber and a bottom chamber. The two top chambers are known as the left and 
right atria, which receive blood from different sources. The left atrium receives blood 
from the lungs and the right atrium receives blood from the rest of the body. The 
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bottom two chambers are known as the left and right ventricles.  The ventricles pump 
blood out to different parts of the body. The right ventricle pumps blood to the lungs 
while the left ventricle pumps blood to the rest of the body. The ventricles have 
thicker walls than the atria, which allow them to perform more work by pumping out 
blood to the whole body.  Valves control the flow of blood, insuring that it flows in one 
direction.  Each heartbeat results in the simultaneous pumping of both sides of the 
heart, making the heart a very efficient pump. 
 
Blood vessels 
Blood vessels are a series of elastic tubing that allow blood to flow quickly and 
efficiently from the heart to every region of the body and back again. The size of 
blood vessels corresponds with the amount of blood that passes through the vessel 
(Nichols et al, 2011).  All blood vessels contain a hollow area called the lumen 
through which blood flows. Around the lumen is the wall of the vessel, which may be 
thin in the case of capillaries or very thick in the case of arteries.  All blood 
vessels are lined with a thin layer of simple squamous epithelium known as the 
endothelium that keeps blood cells inside of the blood vessels and prevents clots 
from forming. The endothelium lines the entire circulatory system, all the way to the 
interior of the heart, where it is called the endocardium. 
 
Blood 
The average human body contains about 4 to 5 litres of blood. As a liquid connective 
tissue, it transports many substances through the body and helps to maintain 
homeostasis of nutrients, wastes, and gases. Blood is made up of red blood cells, 
white blood cells, platelets, and liquid plasma (Boron et al, 2016). 
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2.4    Cardiac cycle 
The cardiac cycle refers to the sequence of mechanical and electrical events that 
repeats with every heartbeat and is measured on the basis of systole and diastole.  
Systole is the period in which the heart is pumping blood and diastole is the period in 
which the heart is resting as well as filling up with blood (Boron et al, 2016). 
 
At the beginning of the cardiac cycle, both atria and ventricles are in diastole. During 
this time, all the chambers of the heart are relaxed and receive blood and the 
atrioventricular valves are open. Atrial systole follows this phase; the left and right 
atria contract at the same time and push blood into the left and right ventricles. The 
next phase is ventricular systole; the left and right ventricles contract at the same 
time and pump blood into the aorta and pulmonary trunk. In ventricular systole, the 
atria are relaxed and receive blood and the atrioventricular valves close immediately 
after ventricular systole begins to stop blood flowing back into the atria. However, the 
semilunar valves are open during this phase to allow the blood to flow into the aorta 
and the pulmonary trunk. Following this phase, the ventricles relax and ventricular 
diastole occurs. The semilunar valves close to stop the blood from flowing back into 
the ventricles from the aorta and pulmonary trunk. The atria and ventricles are in 
diastole together and the cycle begins again (Bloch et al, 1998).  The cardiac cycle is 
coordinated by a series of electrical impulses that are produced by specalised  
pacemaker cells found within the sinoatrial node and the atrioventricular node. 
The cardiac muscle is composed of myocytes, which initiate their own contraction 
without the help of external nerves. The duration of the cardiac cycle is the reciprocal 
of heart rate. Assuming a heart rate of seventy-five beats per minute, each cardiac 
cycle takes 0.8 seconds (Boron et al, 2016). 
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Figure 2.1: Diagrammatic representation of the stages of the cardiac cycle 
 
(Macmillanhighered.com, 2018) 
 
Components of the heartbeat 
The adult heart beats around seventy to eighty times a minute at rest. On listening to 
the heart, with a stethoscope, the heartbeat is audible.  The sound is usually 
described as ‘lubb-dupp’. The ‘lubb’ also known as the first heart sound, is caused by 
the closure of the atrioventricular valves. The ‘dupp’ sound is due to the closure of 
the semilunar valves when the ventricles relax (at the beginning of ventricular 
diastole). Abnormal heart sounds are known as murmurs. Murmurs may indicate a 
problem with the heart valves. 
 
2.5    The Electrocardiogram (ECG) 
The heart has an inbuilt rhythm of contraction and relaxation and a small group of 
specialised heart muscle cells called pacemaker cells help achieve this. The 
pacemaker cells generate an electrical impulse, which spreads over the atria, making 
them contract. The impulse then spreads to the ventricles, causing them to 
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subsequently contract.  Electrocardiography is the process of recording this electrical 
activity in the heart over a period of time using electrodes placed on the skin. The 
electrodes detect tiny electrical changes on the skin that arise from the heart 
muscle’s electrophysiological pattern of depolarising and repolarising during 
each heartbeat (Ye et al, 2012).  
 
During each heartbeat, a healthy heart has an orderly progression of depolarisation 
that starts with pacemaker cells in the sinoatrial node, spreads out through 
the atrium, passes through the atrioventricular node and spreads down and 
throughout the ventricles. This orderly pattern of depolarisation gives rise to the 
characteristic ECG tracing. In a 12-lead ECG, ten electrodes are placed on the 
patient's limbs and on the surface of the chest. The overall magnitude of the 
heart's electrical potential is then measured from twelve different angles (‘leads’) and 
is recorded over a period of time (usually ten seconds).  The results show the overall 
magnitude and direction of the heart's electrical depolarisation captured at each 
moment throughout the cardiac cycle (Ye et al, 2012). The graph of voltage versus 
time produced by this non-invasive medical procedure is referred to as an 
electrocardiogram (ECG). 
 
An ECG conveys a large amount of information about the structure of the heart and 
the function of its electrical conduction system (Walraven, 2010).  It can be used to 
measure the rate and rhythm of heartbeats, the size and position of the heart 
chambers, the presence of any damage to the heart's muscle cells or conduction 
system, the effects of cardiac drugs and the function of implanted pacemakers 
(Mabel and Braunwald, 2012). 
 
Sinus rhythm is the name given to the normal rhythm of the heart where electrical 
stimuli are initiated in the sino-atrial (SA) node, and are then conducted through the 
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atrio-ventricular (AV) node and bundle of His, bundle branches and Purkinje fibres 
(Walraven, 2010).  Depolarisation and repolarisation of the atria and ventricles show 
up as three distinct waves on ECG. A unique labelling system is used to identify 
each.  Each ECG cycles consists of five waves: P, Q, R, S, T corresponding to 
different phases of the heart activities.  
 
Figure 2.2: Diagrammatic representation of the heart (including the heart 
chambers) and the appearance of a standard ECG trace 
 
 
(ECG Research, 2010). 
 
The electrocardiogram translates the heart's electrical activity into line tracings on paper. 
The spikes and dips in the line tracings are called waves. 
 
• The P wave is a record of the electrical activity through the upper heart 
chambers (atria) 
• The QRS complex is a record of the movement of electrical impulses through 
the lower heart chambers (ventricles) – one single heartbeat 
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• The ST segment shows when the ventricle is contracting but no electricity is 
flowing through it. The ST segment usually appears as a straight, level line 
between the QRS complex and the T wave.  
• The T wave shows when the lower heart chambers are resetting electrically and 
preparing for their next muscle contraction 
 
Figure 2.3: Diagrammatic representation of an ECG trace section, showing the 
P wave, QRS complex, ST segment and T wave and the ECG appearance of a 
patient in sinus rhythm 
 
(EKG.Academy, 2018).  
 
The P wave is the first ‘bump’ and is normally an upward ‘bump’ and measures atrial 
depolarisation. The QRS complex follows the P wave and typically starts with a 
negative deflection, Q; then a large positive movement, R; and next a negative 
movement, the S wave. The QRS complex indicates ventricular depolarisation and 
contraction. Following the QRS complex, the T wave is normally an upward 
waveform, indicating repolarisation of the ventricles. The PR interval, PR segment, 
QT interval and ST segment are also evaluated using the ECG analysis in order to 
determine if the ECG tracing represents a sinus rhythm. 
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2.6    Clinical indications for CIED implantation 
Approximately twenty-five thousand people in the UK have a CIED fitted each year 
(Townsend, 2014). However, Dr Francis Murgatroyd, Chair of the British Heart 
Rhythm Society Audit Committee and Clinical Lead of the Cardiac Rhythm 
Management audit (National Audit of Cardiac Rhythm Management Device, 2016) in 
2016 said:  “Pacemakers are implanted in patients to prevent the heart beating too 
slowly or stopping, which can cause blackouts. Although the number of pacemakers 
implanted has increased by 25% over the last twelve years, in line with an ageing 
population, the UK remains somewhat below the European average for implants, 
suggesting that many patients that need pacemakers are not receiving them.”  
(British Heart Rhythm Society, 2016).  CIED implantation is indicated for the 
treatment of a number of cardiovascular diseases for example sick sinus syndrome, 
heart (AV) block, cardiomyopathy and cardiac arrhythmias.   
 
Sinus bradycardia 
Sinus bradycardia defined as a sinus rhythm with a resting heart rate of 60 beats per 
minute or less. However, few patients actually become symptomatic until their heart 
rate drops to less than 50 beats per minute.  The decreased heart rate can cause a 
decreased cardiac output resulting in symptoms such as light-headedness, 
dizziness, hypotension, vertigo and syncope (Wung, 2016).  The action potential 
responsible for this rhythm arises from the sinus node and causes a P wave on the 
surface ECG that is normal in terms of both amplitude and vector. The presence of 
sinus bradycardia in itself does not cause a change in the QRS complex and T wave.  
For this condition a pacemaker will stimulate the heart to speed up when it beats too 
slowly or it will substitute for the natural pacemaker cells of the heart (SA node) or the 
heart tissue that regulates the beating of the ventricles (AV node). 
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Figure 2.4: ECG trace of a patient with sinus bradycardia 
 
(Practical Clinical Skills, 2017) 
 
Heart block 
Heart block,is the second most common reason for pacemaker implantation 
(NHS.uk, 2017).  Heart block, also called atrioventricular block (AV block) is a 
common problem affecting the heart's electrical system and is one of the two major 
causes of bradycardia (slow heart rate).  In heart block, the heart's electrical 
impulses (responsible for telling the heart when it is supposed to beat) are partially or 
completely blocked as they attempt to travel from the atria to the ventricular 
chambers of the heart.  If heart block is severe, it may slow the heart rate to 
dangerously low levels (Fuster et al, 2006). 
 
The three types of heart block are first degree, second degree and third degree, with 
first degree the least severe and third degree the most severe.  
 
• First-degree heart block - The heart's electrical signals are slowed as they 
move from the atria to the ventricles resulting in a longer, flatter line between 
the P and the R waves on the ECG.  First-degree heart block may not cause 
any symptoms or require treatment. 
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• Second-degree heart block – The heart’s electrical signals between the 
atria and ventricles are slowed to a large degree with some signals not 
reaching the ventricles. On an ECG, the pattern of QRS waves doesn't follow 
each P wave.  If an electrical signal is blocked before it reaches the 
ventricles, they won't contract and pump blood to the lungs and the rest of the 
body. 
 
• Third-degree heart block – None of the heart's electrical signals reach the 
ventricles and this can be deemed as complete heart block or complete AV 
block.  In this instance, certain areas in the ventricles may create electrical 
signals to cause the ventricles to contract.  However, this natural backup 
system is slower than the normal heart rate and isn't coordinated with the 
contraction of the atria. On an ECG, the normal pattern is disrupted.  
 
Figure 2.5: Diagrammatic representation showing the difference in appearance 
on ECG trace of patients with first degree, second degree and third degree 
heart block 
 
(Unm.edu, 2016) 
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The severity of heart block can result in a range of symptoms, for example no 
symptoms experienced to dizziness, syncope (loss of consciousness) or even death. 
Heart block that is severe enough to produce symptoms, or that threatens to become 
that severe, can be successfully treated with a CIED.  Brief episodes of heart block 
are not always dangerous, or even abnormal, however, heart block can occur with 
various cardiac diseases, especially coronary artery disease, heart failure 
or myocarditis. Evidence shows, when heart block is produced by heart disease, it 
means there is a permanent disorder of the cardiac electrical system.  This kind of 
heart block often gets worse over time, requiring CIED implantation (Fuster et al, 
2006). 
 
Hypertrophic cardiomyopathy (HCM) 
HCM is an inherited disease of the heart muscle (myocardium), where the muscle 
wall of the heart becomes thickened, most commonly at the septum between the 
ventricles, below the aortic valve. This leads to stiffening of the walls of the heart and 
abnormal aortic and mitral heart valve function, both of which may impede normal blood 
flow out of the heart. The thickness of the muscle and the extent, to which it is 
affected, varies from one person to another (Bhf.org.uk, 2017).  In the majority of 
people, the left ventricle is almost always affected, and in some people the muscle of 
the right ventricle also thickens.  The area of heart muscle that is affected by HCM 
and the degree of stiffening that occurs will determine the symptoms for example, 
shortness of breath, chest pain, palpitations, light headedness and fainting.  In other 
cases, a number of other conditions can develop; these may include abnormal heart 
rhythms, or arrhythmias, including heart block and endocarditis. 
 
Treatment of HCM depends on whether there is narrowing in the path that blood takes to 
leave the heart (called the outflow tract); how the heart is functioning; and if arrhythmias 
are present (Elliott et al, 2016).  The purpose of treatment is to prevent symptoms and 
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complications and these include risk identification and regular follow-up, lifestyle 
changes, medications, and medical procedures.  Patients at risk of life-threatening 
arrhythmias or sudden cardiac death with HCM, require an ICD to be implanted.  The 
ICD constantly monitors the heart rhythm and when it detects a very fast, abnormal heart 
rhythm, it delivers an electrical shock to the heart muscle to cause the heart to beat in a 
normal rhythm again.   
 
On the ECG trace below, the red arrows show a ventricular tachycardia (VT) attack in 
a patient with HCM.  If the patient has an ICD, the device will detect this episode and 
deliver the appropriate shock therapy. 
 
Figure 2.6: ECG trace showing a patient with hypertrophic cardiomyopathy 
(HCM)  
 
(Metealpaslan.com, 2015) 
 
Neurocardiogenic syncope (NCS) 
A drop in blood pressure quickly followed by faster then slower heart rate causes 
NCS.  This results in poor blood and oxygen flow to the brain, which causes a 
temporary loss of consciousness.  NCS is also referred to as vasovagal syncope or 
fainting.  Pacemakers are indicated for patients with frequent NCS who experience 
bradycardia (Chen-Scarabelli and Scarabelli, 2004). 
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Atrial tachyarrhythmia 
Arrhythmia is the most common reason for pacemaker implantation (nhs.uk, 2018b).  
One of the most common types of arrhythmia is atrial fibrillation (AF), which occurs in 
the atria of the heart.  The electrical impulses normally originate at the SA node, 
however in AF, many electrical impulses are conducted randomly and rapidly 
throughout the atria to the ventricles.  The resulting heartbeat is fast and irregular.  
When the atria are beating rapidly and irregularly (fibrillating) they are unable to 
completely empty all of the blood they receive into the ventricles, causing blood clots 
to form in some patients (Katz et al, 2015).  If the patient’s AF conditions has proved 
difficult to treat, the implantation of a pacemaker in conjunction with in atrioventricular 
(AV) node ablation is recommended, this will regulate the heart rate and provide 
symptomatic relief.  
 
Figure 2.7: ECG trace showing patients with atrial tachyarrhythmias (atrial 
fibrillation, atrial flutter and multifocal atrial tachycardia)  
 
 
   (healio.com, 2012). 
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2.7    Cardiac implantable electronic devices (CIEDs) 
The primary functional challenge for CIEDs is to maintain heart rate based on 
circulatory needs and pacing in a manner that mimics the natural physiology of the 
cardiac conduction system.  CIEDs also maintain a minimum heart rate to avoid 
symptomatic or potentially life-threatening bradyarrhythmias or cardiac 
resychronisation between the left and right ventricles in patients with heart failure.  In 
a healthy heart, the sinus node is controlled by the automatic nervous system and 
the heart rate is determined by a number of factors, such as physical activity, 
emotion and blood pressure.  The heart rate is controlled by the CIED discharge rate 
and the excitation and conduction sequence are dependent on the placement of the 
pacing electrodes within the heart. The need for CIEDs increased as the clinical 
indications for implantation extended from atrioventricular (AV) disturbances to the 
management of people with sinus node dysfunction.   
 
NBG Code 
CIEDs are classified by the nature of their pacing mode.  Classification follows the 
NASPE/BPEG Generic (NBG) Pacemaker Code developed by the North American 
Society of Pacing and Electrophysiology (NASPE) and the British Pacing and 
Electrophysiology Group (BPEG) but was last revised in 2002 (Bernstein et al, 2002).  
The code is expressed as a series of up to five letters to indicate the device pacing 
and sensing functions, as well as rate response and programming capabilities.   
 
  
 32 
Figure 2.8:  Table to show revised NASP/BPED Generic (NBG) Pacemaker Code 
 
(Bernstein et al, 2002).   
 
The five positions NBG Pacemaker Code: 
• Position I: Chambers paced - Refers to the chambers paced 
• Position II: Chambers sensed - Refers to the location where the CIED senses 
native cardiac electrical activity 
• Position III: Response to sensing - Refers to CIEDs response to sensed 
native cardiac activity 
- T = Sensed activity results in triggering of paced activity 
- I =  Sensed activity results in inhibition of pacing activity 
• Position IV: Rate modulation - Indicates ability for rate modulation designed to 
alter heart function appropriately to meet physiological needs for example, 
during physical activity. Sensors may measure and respond to variables 
including vibration, respiration, or acid-base status. 
• Position V: Multisite pacing - Allows indication of multiple stimulation sites 
within one anatomical area, for example more than one pacing site within the 
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atria or biatrial pacing.  The fifth position is used by ICDs and their ability to 
pace or shock patients out of tachyarrhythmias. 
 
2.8    Role of CIEDs 
CIEDs provide electrical stimuli to cause cardiac contraction during periods when 
intrinsic cardiac electrical activity is inappropriately slow or absent.  Pacing systems 
consist of a pulse generator and pacing leads.  CIED output generally stimulates the 
cavity of the right atrium and / or right ventricle.  A CIED consists of a battery, a 
computerised generator and wires with sensors (electrodes) at the tip. The battery 
powers the generator and a thin metal case surrounds both.  The wires connect the 
generator to the heart.   
 
Figure 2.9: Image of a CIED – Pacemaker and Lead 
   
(Medtronic.com, 2017) 
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Figure 2.10: Image of a CIED – ICD and lead 
 
   
(Medtronic.com, 2018) 
 
 
The electrodes detect the heart's electrical activity and send data through the leads 
to the computer in the generator.  If the heart rhythm is abnormal, the computer will 
direct the generator to send electrical pulses to the heart via the CIED leads.  
Modern CIEDs have the ability to monitor blood temperature, breathing and can 
adjust the heart rate to changes in activity.  The CIEDs’ computer can also record the 
heart's electrical activity and heart rhythm.  
 
2.9    Programmable CIED functions 
The two main types of programming for CIEDs are demand pacing and rate-
responsive pacing.  Demand pacing CIEDs monitor the patient’s heart rhythm and 
only send electrical pulses to the heart if it is beating too slowly or if it misses a beat.   
A rate-responsive pacing CIED will speed up or slow down the patient’s heart rate 
depending on how active they are  (Kalahasty and Ellenbogen, 2011).  The type of 
CIED implanted depends on the patient’s symptoms and on their specific heart 
condition.    
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Pacing  
Pacing refers to the regular output of electrical current, for the purpose of 
depolarising the cardiac tissue in the immediate vicinity of the lead, with resulting 
propagation of a wave of depolarisation throughout that chamber (Kusumoto and 
Goldschlager, 1996). A CIED will pace at a certain frequency, or rate, for example, 
60bpm.  This rate is programmable, that is, it can be changed by using the 
manufacturer’s programmer.  
 
Sensing  
The heart’s intrinsic electrical activity transmits a small electrical current, through the 
CIED leads, to the pulse generator. This current can be registered or sensed by the 
CIED circuitry. CIED sensing describes the response of a CIED to intrinsic 
heartbeats. The P waves, or atrial activity, are transmitted through the atrial lead to 
the atrial channel of the CIED and sensed as atrial activity. Ventricular activity (the 
QRS complex) is transmitted through the ventricular lead to the ventricular channel of 
the CIED and this is sensed as ventricular activity.  For electrical activity to be 
transmitted from the heart to the CIED, a closed electrical circuit must be present. 
The programmed sensitivity setting indicates the minimum intra-cardiac signal that 
will be sensed (seen) by the CIED to initiate the CIED response (inhibited or 
triggered) (Kalahasty and Ellenbogen, 2011).   
 
Inhibition of output 
A CIED can be programmed to inhibit pacing if it senses intrinsic activity, or it can be 
programmed to ignore intrinsic activity and deliver a pacing stimulus anyway. If a 
CIED is set so that it can be inhibited by intrinsic beats, then the CIED will not deliver 
a stimulus if it senses an intrinsic beat at the correct time (Atlee and Bernstein, 
2001).  For example, if a CIED is set to pace in this way at 60bpm, it will deliver a 
pacing stimulus only if an intrinsic beat does not occur within one second of the last 
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sensed or paced beat.  
 
Triggered pacing 
CIEDs can be programmed to deliver a pacing stimulus whenever intrinsic activity is 
sensed.  This type of pacing is most often used in dual chamber pacemakers, that 
can be programmed to sense activity in one chamber (usually the atrium) and deliver 
a pacing stimulus in the other chamber (usually the ventricle) after a certain time 
delay (Atlee and Bernstein, 2001). This is known as triggered pacing. When referring 
to the appearance of this type of pacing on telemetry or ECGs, it is said that the 
ventricle is tracking the atrium, because if the atrial rate becomes faster, the 
ventricular pacing rate will follow faster, in a 1:1 relationship. Thus the exact rate of 
ventricular pacing will not be determined by any setting on the CIED, but by the 
patient’s own atrial rate. 
 
2.10    Types of CIEDs 
Single-chamber pacemakers 
Single-chamber pacemakers are the most basic pacemaker design that paces the 
atrium or ventricle at a fixed rate.  The system includes one lead that connects the 
pulse generator to one chamber of the heart.  A single-chamber pacemaker can be 
used to control heartbeat pacing by connecting the lead to the right ventricle (Zivin 
and Bardy, 2001). 
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Figure 2.11: Diagrammatic representation showing a single-chamber 
pacemaker and where the attached CIED lead is implanted in the heart 
 
(Consultants and Implantation, 2018) 
 
Dual-chamber pacemakers 
Dual-chamber pacemakers are significantly more complex than single-chamber 
pacemakers; they have pacing electrodes in both the right atrium and the right 
ventricle.  With two leads, the device connects to both chambers on the one side of 
the heart, allowing them to work together, contracting and relaxing in the correct 
cardiac rhythm.   The contractions allow blood to flow appropriately between the 
atrium and ventricle.  The device can be programmed to regulate the pace of 
contractions of both chambers.  Dual-chamber pacemakers are the most common 
devices implanted in patients (Zivin and Bardy, 2001). 
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Figure 2.12: Diagrammatic representation showing a dual-chamber pacemaker 
and where the two attached CIED leads are implanted in the heart 
 
(Uchospitals.edu, 2018) 
 
 
Biventricular pacemakers 
Biventricular pacemakers are also known as a cardiac resynchronisation therapy 
(CRT) devices.  These devices have three leads connected to the right atrium and 
both ventricles.  Biventricular pacemakers are used to treat patients with arrhythmias 
caused by advanced heart failure, as both the left and right ventricles do not pump at 
the same time. The pacemaker is programmed to coordinate the contractions of the 
ventricles, so that they both pump together and this will allow the heart to pump 
blood more efficiently and can relieve heart failure symptoms. The treatment is 
known as cardiac resynchronisation therapy because it resynchronizes the ventricles’ 
pumping action (Asirvatham et al, 2007). 
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Figure 2.13: Diagrammatic representation showing a biventricular pacemaker 
and where the three attached CIED leads are implanted in the heart 
 
(Baylor College of Medicine, 2014) 
 
 
Implantable cardioverter defibrillators (ICDs) 
ICDs have the ability to defibrillate and pace the heart and have the capability of 
correcting most life-threatening cardiac arrhythmias. ICD implantation is the first-line 
treatment and prophylactic therapy for patients at risk for sudden cardiac death due 
to ventricular fibrillation and ventricular tachycardia.  Modern ICDs can be 
programmed to detect abnormal heart rhythms and deliver therapy via programmable 
antitachycardia pacing in addition to low-energy and high-energy shocks (Epstein et 
al, 2008). 
 
The ICD constantly monitors the patient’s heart rhythm through the electrodes and if 
it detects a dangerous or abnormal heart rhythm it can deliver the following 
therapies: 
• Pacing - a series of low-voltage electrical impulses (paced beats) at a fast 
rate to try and correct the heart rhythm 
• Cardioversion - one or more small electric shocks to try and restore the 
heart to a normal rhythm 
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• Defibrillation - one or more larger electric shocks to try and restore the heart 
to a normal rhythm 
 
Rate-response activated CIEDs 
One form of cardiovascular disease is chronotropic incompetence, which is the 
inability of the heart to increase heart rate in line with increased activity or demand.  
Rate adaptive pacing is a treatment-pacing mode, that has been shown to improve 
exercise capacity in patients with chronotropic incompetence (Diaz et al, 2005).  
 
A person’s normal heartbeat fluctuates depending on activity. When at rest, the heart 
rate normally slows and then speeds up during times of activity or stress, to meet the 
increasing demands on the body. Individuals with this abnormality of the cardiac 
conduction system may be unable to properly speed up the heart rate during activity. 
This can result in fatigue, shortness of breath, and / or activity intolerance.   Rate-
adaptive pacing has been designed to increase heart rate according to metabolic 
needs during physical, mental or emotional activity. Rate responsive CIEDs control 
heart rate by sensing physiological or non-physiological signals other than atrial rate 
(Duru et al, 2000). 
 
A rate response activated CIED comprises: 
• A sensor for sensing cardiac activity and generating a corresponding cardiac 
sense signal 
• A pace generator for generating pacing signals in response to a command 
signal 
• A metabolic demand sensor for sensing a metabolic demand and generating 
a corresponding metabolic signal 
• A noise sensor for generating a noise signal when sensing noise 
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• A controller receiving the sensor, metabolic and noise signals and generating 
a command response 
 
Rate response activated CIEDs have specialised sensors built into the pulse 
generator that can sense increasing activity by means of increased body movement 
(vibrations) and / or increased rate of breathing. The sensors will automatically 
increase or decrease the heart rate according to the body's needs. Rate responsive 
pacing closely mimics the normal heartbeat and the sensors should reproduce the 
sinus node as close as possible. 
 
All rate adaptive CIEDs should: 
1. Program the rate adaptive response output to respond as promptly as the 
normal sinus node  
2. Have sensors which detect of the need of increasing heart rate 
3. Increase the heart rate in proportion to the metabolic demand 
4. Control the rate decay during recovery after exercise to match metabolic 
needs 
5. Operate in a closed loop system - making rate adaptive pacing also 
insensitive to inputs not heart related 
6. Have dedicated sensors avoiding unwanted over pacing and requiring 
complex programming 
 
2.11    CIED hardware 
A CIED comprises a pulse generator and lead(s) which all have the same basic 
components (Kalahasty and Ellenbogen, 2011):  
• A power source in the form of a battery 
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• Circuitry (output, sensing, telemetry, microprocessor or micro sequencer, 
memory) 
• A metal casing (can) welded shut to keep out fluids 
• A feed through (a piece of wire surrounded by glass or sapphire) that 
maintains a hermetic seal to provide an electrical connection through the can 
• A means of connecting a pacing lead to the header of the CIED 
• Sensors (for example, sense acceleration, vibration and impedance) 
 
Figure 2.14: Diagrammatic representation of the CIED hardware enclosed in the 
outer casing  
 
(Clinical Gate, 2015a) 
 
The CIED unit delivers an electrical pulse with the correct intensity to the appropriate 
location to stimulate the heart at a desired rate.  Electrical impulses are transmitted 
to the heart through the lead, which is attached to the pulse generator via the 
connector block. A lead is either unipolar or bipolar; a unipolar lead contains one 
insulated coil, whereas a bipolar lead contains two coils, separated by an inner 
insulation. An outer insulation shields a lead from the environment. The tip of a lead, 
which contains an electrode, is implanted into the inner, endocardial surface of the 
heart.  The CIED is usually implanted in the pectoral region, with the lead running 
through the right subclavian vein to the internal surface of the heart.  The casing of 
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the pulse generator functions as housing for the battery and all other electronic and 
electrical circuits. A connector block, made of polyurethane is located at the top of 
the CIED and attaches the CIED to the CIED lead(s). 
 
Figure 2.15: Image of the CIED hardware 
 
(Clinical Gate, 2015) 
 
Pulse generator 
The pulse generator is made of a header block, which contains the setscrews for 
lead connection and a radiofrequency antenna and the device enclosure, which 
houses the electrical components responsible for generating the pulse (via output 
circuits) at the required time (via timing and control circuits) based on events sensed 
(via sensing circuits).  It also contains a power supply (battery) and may include 
components such as telemetry for testability and programmability and memory 
(random access memory - RAM) to store data for diagnostic purposes (Kalahasty 
and Ellenbogen, 2011).   
 
Microprocessors 
Microprocessors are the standard control circuits of CIEDs, as they have a greater 
circuit density and greatly reduced current drain than the previously used bipolar 
devices.  Microprocessors allow sophisticated algorithms, requiring multiple 
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calculations, to be incorporated into implantable devices, and have vastly increased 
data storage.  The microprocessor is constantly accessing its memory for instructions 
on what to do next. The microprocessor can respond to changes in programming 
instructions that allow functions to be added or changed after implantation (Kalahasty 
and Ellenbogen, 2011).   
 
The integrated circuit of pulse generators may contain both read-only memory (ROM) 
and random access memory (RAM).  Almost all manufacturers offer fully RAM-based 
pulse generators.  RAM is used to store diagnostic information regarding pacing rate, 
intrinsic heart rates, sensor output and intracardiac electrograms from episodes of 
high atrial or ventricular rates and mode-switching events.  The rapidly expanding 
diagnostic capabilities of CIEDs has allowed for improved assessment of the 
physiological condition of the patient, including stored information about heart rate 
variability, respiration, intracardaic pressure, patient activity, lung water and 
arrhythmia logs.  
 
Circuitry 
CIEDs incorporate some of the most advanced, high-reliability electronic circuitry 
available. The basic building block is the integrated circuit (IC), which starts as a 
silicon wafer and has a number of miniaturized circuit elements etched into its 
surface during the manufacturing process. Modern pulse generators incorporate 
custom-designed, very large-scale integrated circuits. ICs are built up layer by layer 
and can incorporate millions of electronic elements. The elements are so fine that 
they can barely be seen with an optical microscope (Kalahasty and Ellenbogen, 
2011).   
 
Output circuit 
Output circuitry is usually composed of capacitors and electrical switches controlled 
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by the microprocessor. Output circuitry can deliver voltage in excess of the battery 
voltage, generally through the use of a charge pump. A charge pump provides the 
flexibility to program many discrete voltages and also allows for voltage regulation.  
 
Sensing circuit 
The sensing circuitry of a pulse generator is used for both the amplification and 
filtering of intracardiac signals.  The intracardiac electrogram is conducted from the 
electrodes to the sensing circuit of the pulse generator where is it amplified and 
filtered.  The intracardiac electrogram is filtered to remove unwanted frequencies, a 
process that markedly affects the amplitude of the processed signal.  Following 
filtering of the intracardaic signal, the processed signal is compared with a reference 
voltage to determine if the signal exceeds a threshold detection level (programmed 
sensitivity).  Signals with amplitudes greater than the sensitivity threshold levels are 
sensed as intracardiac events, whereas signals of lower amplitude are discarded as 
noise.  Signals that exceed the threshold levels are sent to the timing circuit and logic 
circuits (Kalahasty and Ellenbogen, 2011).   
 
Most CIEDs also contain noise reversion mode circuits that change the pulse 
generator to an asynchronous pacing mode when the sensing threshold level is 
exceeded at a rate faster than the noise reversion rate.  The noise reversion mode 
prevents inhibition of pacing in the presence of electromagnetic interference.  The 
electronic circuitry of the pulse generator must also be protected from the damage 
caused by overwhelming electrical energy generated in the clinical environment.  
 
Timing circuit 
The pacing cycle length and the timing circuit of the pulse generator regulates pulse 
duration and AV interval.  The timing circuit of a pulse generator is a crystal oscillator 
that generates with a frequency in the kilohertz range.  The output of the crystal 
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oscillator is sent to the digital timing and logic control circuit that operates internally 
generated clocks at divisions of the oscillator frequency.  The output of the logic 
control circuit is a pulse that triggers the output of the pacing pulse, the blanking and 
refractory intervals and the AV delay.  The timing circuit also receives input from the 
sense amplifier to reset the escape intervals of an inhibited pacing system or trigger 
initiation of an AV delay for triggered pacing modes.  The pulse generator also 
contains a rate-limiting circuit that prevents the pacing rate from exceeding the upper 
limit in the case of a random component failure (Kalahasty and Ellenbogen, 2011).  
This runaway protection rate is typically in the range of 180 to 220ppm.   
 
Telemetry circuit 
Telemetry is the word used to describe measurement at a distance.  Programmable 
pulse generators have the capability of responding to radiofrequency signals emitted 
from the programmer as well as sending information in the reverse direction, from the 
pulse generator to the programmer.  The pulse generator is capable of both 
transmitting information from a radiofrequency antenna and receiving information 
with a radiofrequency decoder (Kalahasty and Ellenbogen, 2011).  Telemetry 
information must be sent as radiofrequency signals or as a pulsed magnetic field.  
Information is sent from an external programmer to the pulse generator in coded 
programming sequences with a preset frequency spectrum.  Most pulse generators 
require the radiofrequency signal to be pulsed with a specific frequency in a 
sequence that is typically sixteen pulses in duration.  Thus, the radiofrequency signal 
is quite precise, decreasing the likelihood of inappropriate alteration of the program 
by environment sources of radiofrequency energy or magnetic fields.  The detected 
telemetry bursts from the programmer are sent as digital information from the 
radiofrequency demodulator to the telemetry control logic circuit of the pulse 
generator.  This logic circuit also provides for properly timed pulses to be sent from 
the antenna of the pulse generator to the programmer.  ‘Real-time telemetry’ is the 
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term used to describe the capability of a pulse generator to transmit information to 
the programmer regarding measurements of pulse amplitude and duration, lead 
impedance, battery impedance and delivered current, charge and energy. 
 
CMOS and MOSFET technology   
CMOS and MOSFET technology work on the principle that signals (digital or 
analogue) are controlled by voltage and charge. This is in contrast to BJT devices 
that control signals through current flow. A CMOS device generally has a Gate, 
Source and Drain. The Gate is the terminal that controls the ON or OFF state of the 
Drain-Source switch. In the steady state, no power is dissipated by the gate and 
therefore is favourable for low power consumption applications. The conduction 
channel in a CMOS device is also very thin and can in some cases be approximated 
by a 2 dimensional electron gas (2DEG). Switching currents in a BJT occupy bulk 
regions of a semiconductor. CMOS technology is more sensitive to ionising radiation 
damage. This is because, as already stated, the control of signals as defined by the 
ON or OFF state of the switch is determined by the presence or absence of charge. 
A key feature of the Gate is the very thin but highly insulating gate oxide below the 
gate metal contact. This can be perturbed by ionising radiation in a number of ways: 
 
1. The conductivity of the gate oxide can increase due to defects caused by 
radiation damage. This induces leakage currents that can impair the 
performance of the switch.  
2. The gate oxide can accumulate embedded charge that, over time, can lock 
the switch open or closed, independently of applied gate voltage.  
3. Embedded charge and increased leakage can increase the time taken to 
change the state of the switch. Furthermore, the conduction channel relies on 
a very high degree of purity and crystallinity, of the silicon material. This 
implies a high mobility for the electrons and holes that traverse this channel. If 
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the ionising radiation causes defects to occur in this region, the conductivity 
of the channel may be impaired. 
 
Figure 2.16: Schematic representation - Showing the working principle of a 
MOSFET  
 
(Electronic Projects for Engineering Students, 2017) 
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Figure 2.17: Schematic representation - Showing the working principle of a 
BJT  
 
(Electronic Projects for Engineering Students, 2017) 
   
Power source (battery) 
The power source for most CIEDs today is a solid chemical battery, the most 
commonly used battery chemistry today remains lithium-iodine. However, as CIEDs 
have become more complicated, their power needs have grown.  As a result, the 
demands on the power source have increased exponentially.  Lithium-carbon 
monofluroide, lithium manganese dioxide and hybrid batteries are increasingly being 
used in pacemakers (Greatbatch and Holmes, 1992).  It is also important to consider 
the battery as part of the pacemaker and ICD system.  The longevity of the battery is 
dependent on the usage conditions, but also the number and efficiency of the 
associated components of the integrated circuit boards.  Clinically, once a system is 
implanted, it is important to maximise the longevity of the device by careful 
programming of outputs and selection of options.  The use of capture management 
features, reducing the frequency of capacitor reformations (ICDs), and programming 
outputs to clinically safe margins is essential.  Disabling unused features, such as 
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pre-detection electrogram storage, can help preserve battery longevity.  All modern 
devices have an end-of-service indicator that alert the clinicians to impeding battery 
depletion and allows adequate time for replacement of the device.  These indicators 
include monitored battery voltage, battery impedance and capacitor reformation 
times (ICDs only) (Boston Scientific, 2012). 
 
2.12    CIED leads   
A CIED lead is an insulated conductor cord for transmitting electrical impulses.  In a 
standard pacing or defibrillation lead there are four basic components: conductor 
elements, insulations, electrodes (screws, rings, dots, coils), and connector pieces. 
 
Figure 2.18: Image showing the components of a CIED lead 
 
(Thoracic Key, 2016) 
 
 
The conductor elements are made of multiple metal wires (fila) wound into 
interweaving helices (coils) or braided into wire ropes (cables) (Meagher and Altman, 
1997).  The insulations are made of polymers: silicone (polydimethylsiloxane), 
poly(ether) urethane, fluoropolymers such as ethylene tetrafluoroethylene (ETFE) 
and polytetrafluoroethylene (PTFE), and silicone-polyurethane copolymers. The 
electrodes are made of inert metals (for example iridium, tungsten, platinum) (Lau et 
al, 2008). 
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CIED lead design  
Unipolar pacing leads have the simplest lead design of all CIED leads.  Once 
unipolar leads was the only option for CIED lead implantation, however, these have 
been primarily replaced by bipolar CIED leads.  Unipolar leads have only one 
conductor surrounded by insulation.  The tip of the lead is the cathode and the CIED 
generator completes the circuit as the anode (Kalahasty and Ellenbogen, 2011).   
 
In a bipolar pacing CIED lead, the pulse generator is not part of the pace/sense 
circuit.  Both the ring electrode (anode) and the tip electrode (cathode) are in contact 
with the myocardium.  There are two main bipolar CIED lead designs: co-axial and 
co-radial.   
 
Figure 2.19: Image showing the design of a co-axial CIED lead 
 
(Clinical Gate, 2015b) 
 
In a co-axial lead design, the inner conductor is arranged in a coil and has a central 
lumen to allow passage of a positioning stylet during the implantation procedure.   A 
layer of insulation covers the inner coil, electrically separating it from the other coil in 
the lead. The number of metal wires used in the inner and outer coils can be 
variable, depending on the specifications of the CIED manufacturer.  This lead 
design is an industry standard for most pacing leads (Kalahasty and Ellenbogen, 
2011).    
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Figure 2.20: Image showing the design of a co-radial CIED lead 
 
Clinical Gate, 2015b) 
 
In a co-radial lead design, two conductor strands are coiled in parallel around a 
central lumen.  These strands terminate at the ring and tip electrodes, respectively, 
and are individually coated with a bonded layer of ethylene tetrafluoroethylene 
(ETFE) fluoropolymer insulation.  The coils are then typically covered with a 
polyurethane outer layer of insulation (Lau et al, 2008). 
 
ICD leads are more complex and require multi conductors and use a multilumen 
design with the conductors arranged in parallel rather than co-axial.  The 
components of an ICD lead include the conductors, insulation materials, defibrillation 
coils, lead electrodes and lead connectors (Kalahasty and Ellenbogen, 2011).   
 
CIED lead materials 
Materials used in pacemaker and ICD leads are similar.  Although the materials used 
by each CIED manufacturer are similar, there are significant differences in how these 
materials are applied and in the construction of the CIED leads (Lau et al, 2008). 
 
Conductors 
The primary conductors used in most pacemaker and ICD leads are MP35N and 
silver (Kalahasty and Ellenbogen, 2011).  MP35N is a superalloy that is double 
melted to remove impurities and it is characterised by biocompatibility, high tensile 
strength, and resistance to corrosion. Single wires are combined together into 
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strands and then wound into cables for use as cable conductors.  The number of 
wires used in a cable is directly related to its intended use, with larger cables used 
for high voltage applications, for example ICDs.  Cables can be coated in ETFE 
fluropolymers before being coiled into co-axial radial lead designs, this coating 
protects the silicone or polyurethane insulation.  
 
Electrodes 
The pacing electrode is the interface between the lead and myocardium.  Its design 
and composition greatly influence the overall electrical performance of the pacing 
system.  The complex, textured surface of current pacing leads minimises the 
polarisation effect and improves both sensing and stimulation efficiency.  The ability 
to differentiate a true myocardial electrogram from polarisation induced after 
potentials has dramatically improved with the development of these low-polarisation 
electrodes (Kalahasty and Ellenbogen, 2011).   
 
Insulation 
The materials used in CIED leads for insulation play a vital role in their durability and 
reliability.  The optimal insulation material should be biologically inert and exhibit no 
surface erosions, no molecular chain disruptions, no uptake of low-molecular-weight 
biological materials and no tendency to calcifications, while retaining stable 
mechanical properties.  There is no one specified CIED lead insulation material, and 
some CIED leads use multiple materials.  Pacemaker leads are generally made of 
one insulation type but ICD leads are more complex, utilising a combination of 
insulation material (Lau et al, 2008). 
 
Fluropolymers are fluorocarbon-based polymers that are characterised by high 
resistance to solvents, acids and bases.  Therefore, they have maximum 
biocompatibility and tensile strength, but their stiffness limits their use to thin layers of 
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insulation coating.  This coating on the conductors prevents adverse interaction with 
silicone tubing.  Examples of fluoropolymers are PTFE (polytetrafluroethylene) and 
ETFE (ethylenetertrafluroethylene). 
 
Silicone rubber is a polymer that is made up of silicone-oxygen linkages, that is both 
biostable and biocompatible.  Its main disadvantage is its low tensile strength, 
making it prone to tearing and abrasion wear.  Abrasion wear comes from lead-to-
generator and lead-to-lead interactions within the implantation pocket (Himes and 
Wilson, 2013).  Silicone also has a high co-efficient of friction, making it difficult to 
pass alongside other CIED leads.  
 
CIED developments 
In the last decade, CIED technology evolved rapidly with the development of lithium-
iodide batteries that have greater longevity (Schmidt and Skarstad, 2001).  The need 
to noninvasively change CIED rate and sensing and pacing parameters led to the 
development of CIEDs whose functions could be altered with an external 
programmer using radio-frequency to communicate with the CIED.  Further electronic 
advances led to the development of smaller CIEDs, which utilise integrated circuits 
as opposed to the discrete components used previously.  The advantage of these 
devices to the patient, is that is occupies a smaller area in the chest cavity.  The 
CIED leads are subject to millions of flexures during their lifetime, therefore the lead 
materials use silicone and / or polyurethane, which are more biocompatible and 
reliable than earlier materials.  As a result of technical advances, CIEDs are relatively 
small in size (8-10cc) and can pace reliably for eight to ten years before generator 
replacement is needed (Zivin and Bardy, 2001). 
 
 
 55 
2.13    Chapter conclusion 
This chapter explained the nature and range of cardiovascular diseases and the 
clinical indications of CIED implantation for patients with cardiac conditions.  In 
discussing CIEDs and their functions, this chapter provides an understanding of the 
different types of CIED in clinical use and their specific roles.  This chapter concluded 
by detailing the CIED hardware, to provide an understanding how the hardware can 
be damaged by ionising radiation and EMI in future chapters when the patient 
receives radiotherapy as part of their cancer treatment.   
! !
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Chapter Three  
Cancer and the effect of ionising radiation and EMI on CIEDs 
 
 
3.1    Introduction 
Cancer is a broad term for a class of diseases characterised by abnormal cells that 
grow and invade healthy cells in the body.  Based upon an overview of current 
literature, scientific studies and current clinical guidelines for the management of 
patients with a CIED receiving radiotherapy treatment, this chapter aims to put into 
context the effect of ionising radiation and / or EMI on CIEDs and CIED leads.  It will 
outline the role and function that radiotherapy plays in the management of patients 
with cancer and details the radiotherapy planning and treatment delivery process.  It 
then analyses how ionising radiation and / or EMI cause cardiac device malfunctions 
and discusses the effect and impact on both the CIED and the patient.  
 
In 2013, there were no UK guidelines on the safe use of radiotherapy in patients with 
CIEDs.  Research has shown that patients with a CIED and receiving radiotherapy 
treatment are at risk of CIED malfunction.  This chapter explores the safety 
recommendations and guidelines that have been issued for treating these patients 
and shows that the policies that in place are based on evidence which is more than 
two decades old and does not reflect subsequent advances in CIED or radiotherapy 
technology and treatments.  
 
3.2    Cancer 
Cancer is the name given to a collection of related diseases that involve abnormal 
cell growth and results from a series of molecular events that alter the normal 
properties and functions of cells (World Health Organisation, 2018).  Typically, 
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human cells grow and divide to form new ones as the body needs them, as well as 
replacing older or damaged cells as they die.  The normal control mechanisms that 
prevent cell overgrowth and the invasion of other tissues are disabled in cancer cells, 
leading to cell mutations.  These mutated cells divide and grow as a result of signals 
that normally impede cell growth.  Therefore, they no longer respond to the signals 
that induce cell growth and division. With growth, these cells acquire new 
characteristics, for example changes in cell structure, decreased cell adhesion and 
production of new enzymes. These new characteristics allow the cancer cells to 
spread and invade other normal tissues (Klein, 2008). 
 
3.3    Management of patients with cancer 
As a greater understanding of the underlying biological processes has increased, the 
treatment of cancer has evolved.  As new information about the biology of cancer 
emerges, treatments will be developed and modified to increase effectiveness, 
precision, survivability, and quality of life.  The general principles for the treatment of 
cancer are the same, i.e. interruption in function followed by eradication of tumour 
cells, albeit cancer can develop at many different sites around the body.  There are a 
range of treatments including surgery, chemotherapy, radiotherapy, hormonal 
therapy and targeted therapy (including immunotherapy, for example monoclonal 
antibody therapy) (Enger et al, 2006).  The choice of treatment is dependent upon 
the stage of the disease, the location and grade of the tumour and the general 
medical performance status of the patient, as well as treatment availability and 
patient choice.  
 
The fundamental aim of treatment is the complete removal of the cancer without 
damage to the rest of the body, thereby, achieving a cure with minimal adverse side 
effects to the patient.  This can be accomplished by surgery only, but the propensity 
of cancers to invade adjacent tissue or to spread to distant sites by microscopic 
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metastasis often limits its effectiveness.  Therefore, a variety of treatment modes and 
techniques are used.  The three main techniques used to treat cancer are 
surgery, chemotherapy, and radiotherapy.  They can be used as a single treatment 
modality or used in conjunction with each other.   
 
Treatment option - Surgery 
The aim of surgery can be either the removal of only the tumour, or the entire organ  
(Subotic et al, 2012).   For early stage cancer, surgical removal of a solid tumour is 
the main treatment.   As part of the surgical procedure, some of the normal tissue 
surrounding the tumour is removed, in order to increase the chances that all 
cancerous cells are removed from the body.   In some cases, the lymph nodes near 
the tumour are also removed as the cancer can spread to these nodes first.  Less 
frequently, surgery is used to remove tumours that have spread to more distant sites 
in the body.  Examples of surgical procedures for cancer include mastectomy for 
breast cancer, prostatectomy for prostate cancer, and lung cancer surgery for non-
small cell lung cancer.  In addition to removal of the primary tumour, surgery is often 
necessary for staging of the disease and to inform further management and 
treatment options. 
 
For patients with CIEDs requiring surgery as part of their cancer treatment plan, the 
primary concern is the management of EMI during the surgical process and the 
potential damage to the CIED.  Madigan et al (1999) published a paper on the 
surgical management of the patient with a CIED.  The aim of the study was to identify 
the sources of EMI that may alter the performance of CIEDs and develop strategies 
to minimise their effects on a patient during surgery.  The authors stated that all 
devices should be evaluated pre and post surgery to determine if its function has 
been damaged or failed.  They recommend that if electrocautery is used during 
surgery, CIEDs should be placed in a triggered or asynchronous mode.  Triggered 
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mode is a pacing mode in which a sensed beat triggers a paced beat. This is most 
commonly used in dual chamber pacemakers, so that a sensed atrial beat triggers a 
paced ventricular beat, after an adjustable delay.  Asynchronous mode, is a pacing 
mode that is not inhibited by intrinsic beats.   Activating triggered or asynchronous 
mode, will avoid inhibition due to EMI that could lead to a cardiac arrest rhythm in 
pacemaker-dependent patients (Madigan et al, 1999).  ICDs should have arrhythmia 
detection suspended prior to surgery and if external defibrillation is to be used 
placement of the paddles should be kept as far away from the leads as possible.  
They concluded that patients with CIEDs could safely undergo surgery as long as 
previously stated precautions are taken (Madigan et al, 1999).  
 
Treatment option - Chemotherapy 
Chemotherapy uses one or more anti-cancer drugs as part of a standardised regime 
to kill cancerous cells.   It may be given with  a curative intent (which involves a 
combinations of drugs), or it may aim to prolong life and/or to reduce 
symptoms (palliative chemotherapy).  Conventional chemotherapeutic agents 
are cytotoxic by means of interfering with cell division and cell growth (mitosis) but 
cancer cells vary widely in their susceptibility to these agents.   The side effects vary 
with the type of drug used but can include nausea and vomiting, temporary alopecia, 
constipation, diarrhoea, tiredness, or anaemia (Takimoto and Awada, 2008).  The 
duration of chemotherapy treatment varies depending on the type of cancer and the 
aim of the treatment. 
 
For patients with CIEDs requiring chemotherapy as part of their cancer treatment 
plan, the primary concern is the management of cardiotoxic chemotherapeutic 
agents that may cause an elevation in the cardiac stimulation threshold.  That is an 
elevation in the minimum electrical stimulus needed to consistently elicit a cardiac 
depolarisation.  Each cycle of chemotherapy may cause further increases in the 
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cardiac stimulation threshold and even cause loss of capture and device failure.  
CIED manufacturer (St. Jude Medical, 2013) recommends that patients with CIEDs, 
undergoing chemotherapy with cardiotoxic chemotherapeutic agents should be 
monitored.  If the patient is pacemaker dependent, a full assessment of the cardiac 
stimulation threshold should be performed.  Following completion of chemotherapy a 
CIED check should be carried out to determine any damage to the CIED. 
 
Treatment option - Radiotherapy 
Radiotherapy is the use of ionising radiation to kill cancer cells and shrink tumours.  
Ionising radiation is directed at cancerous cells and tissue to destroy them or slow 
their growth and is used in 50-60% of cases where the cancer is cured (National 
Radiotherapy Advisory Group, 2007). Radiotherapy treatment impairs or destroys 
cells in the area being treated by either damage to DNA directly or creates charged 
particles (free radicals) within the cells that can damage the DNA.  As a result, it is 
impossible for these cancer cells to continue to grow and divide.  Radiotherapy can 
be administered externally via external beam radiotherapy (EBRT) or internally by 
inserting a radioactive source via brachytherapy.  There are a variety of options when 
using radiotherapy.  It may be used to shrink a cancer before surgery, or to reduce 
the risk of a cancer recurring after surgery, and to complement or enhance the 
effects of chemotherapy or as palliation to relieve symptoms.   
 
3.4    Radiotherapy treatment (External beam radiotherapy treatment - 
EBRT) 
Although ionising radiation damages both cancer cells and normal cells, the majority 
of normal cells can recover from the effects of ionising radiation and function 
appropriately.  The aim of radiotherapy treatment is to damage as many cancer cells 
as possible, while limiting harm to nearby healthy tissue.  Ionising radiation can 
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damage cell DNA and result in cell death or inability to reproduce.  Normal cells are 
more able to withstand the damage of ionising radiation, than cancerous cells.  By 
splitting radiotherapy treatments into treatment ‘fractions’, it is possible to take 
advantage of the normal cell repair mechanism and inflict damage on the cancer 
cells while minimising damage to the normal cells.  Fractions of radiotherapy are 
usually delivered in a daily basis with rest days to allow for the healthy tissue to 
repair and for the patient to recover (Kian, 1998).  The precise fractionation of the 
radiotherapy treatment is vital to the overall radiotherapy prescription.  The level of 
radiation dose to each tumour site depends on the radiosensitivity of the cancer type 
and whether there are tissues and organs nearby that may be damaged by ionising 
radiation.  There are side effects to radiotherapy treatment but they are localised and 
confined to the region being treated. 
 
Radiotherapy planning 
In the delivery of radiotherapy treatment, there is a compromise between the 
likelihood of controlling the tumour and cancer cells and the likelihood of causing 
damage to normal tissues.  Individual patient radiotherapy treatment plans are 
produced to enable the delivery of prescribed ionising radiation to the tumour and the 
planned radiotherapy treatment site.  During the radiotherapy treatment planning 
process every patient will undergo a planning CT scan or MRI scan.  Using these 
scans, medical physicists and/or therapeutic radiographers will outline the 
radiotherapy treatment site, anatomical structures, organs of importance and the 
presence of CIEDs.  Certain organs that are in close proximity to the radiotherapy 
treatment site are designated ‘organs at risk’ (OARs); these organs need to receive 
as low an ionising radiation dose as possible to avoid long-term side effects.  If the 
presence of a CIED has been identified from the planning scan, medical physicists 
will need to adhere to departmental protocols to limit the ionising radiation dose to 
the CIED.  On completion of the radiotherapy treatment plan, verification and 
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approval by the clinical oncologist, the patient can receive the prescribed 
radiotherapy treatment.   
 
Linear accelerator  (LINAC) 
For most patients radiotherapy is administered using a linear accelerator, a machine 
which uses high-frequency electromagnetic waves to accelerate charged particles 
such as electrons to high energies through a linear tube.  The high-energy electron 
beam itself can be used for treating superficial tumours, or it can be made to strike a 
target to produce x-rays for treating deep-seated tumours (Williams and Thwaites, 
1995).   
 
Figure 3.1: Image showing a linear accelerator (radiotherapy treatment 
machine) 
 
(Varian.com, 2017) 
 
A linac has a power supply that provides DC power to the modulator, which contains 
a pulse-forming network, which stores electrical energy to provide DC pulses to 
the thyratron.  The thyratron uses these pulses as a switch and delivers the pulses to 
the electron gun and simultaneously to the magnetron or klystron.  The electron gun 
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produces a stream of electrons that enter the proximal part of the wave-guide with 
energy of approximately 50keV.  The magnetron or klystron produces pulsed 
microwaves, which are directed into the wave-guide by a hollow rectangular copper 
piping system, which is filled with SF6 (Mayles et al, 1999). 
 
The wave-guide is a copper tube with the interior divided by copper discs or 
diaphragms, and is evacuated to a very high vacuum by an ion pump.  Ejected 
electrons interact with the microwaves produced by the magnetron or klystron, 
absorb energy and are subsequently accelerated. The wave-guide has side pockets, 
which have the effect of continuously accelerating the electron down the entire 1-
1.5m length of the wave-guide. High velocity energy electrons then exit the thin 
ceramic window at the end of the wave-guide in the form of a 3 mm 'pencil beam'.  If 
the linac is only required to produce a 4MeV or less photon beam, a short wave 
guide is required and is vertically mounted so that the exiting beam is directed down 
onto the patient.  For photon beams above 6MeV or higher photon energy, the wave-
guide is too short, therefore a longer waveguide is needed which is mounted 
horizontally, parallel to the patient, thus requiring the beam to be bent in order for it to 
be focussed onto the patient.  Most linacs have a 'bending magnet' to change the 
electron beam's direction and it does this by applying a magnetic field.  After exiting 
the bending magnet within the linac treatment head, the electrons continue in a 
straight line. At this point, if electrons are required, the electrons will collide with the 
scattering foil, which will spread the electron 3mm pencil beam into an electron 
beam.  If photons are required, the electron beam will collide with the tungsten target 
and because of the velocity of the accelerating electrons, the resulting 
bremsstrahlung x-ray production will be projected forward (Mayles et al, 1999). 
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Figure 3.2: Diagrammatic representation showing x-ray production 
 
(Radccore.org, 2015) 
 
It is necessary to shield the linac treatment head with lead to minimise radiation 
exposure to the patient because of photons that are projected and scattered laterally. 
Following collision with the scattering foil or tungsten target, two ion chambers are 
placed to monitor the beam's dose rate, integrated dose and field symmetry. This is 
to prevent the use of too much radiation and radiation beams that do not meet 
expected profiles. Below these chambers are the primary, secondary and sometimes 
tertiary collimators. The primary and secondary collimators are large lead blocks 
approximately 15cm thick that move on tracks to open a rectangular aperture for the 
radiation to escape. In addition to these beam-defining devices, the treatment head 
also has a field light system, which duplicates the radiation beam size, to enable 
patient set up. There is also an optical distance indicator, which is used to define skin 
source distance.  This is mounted on the gantry, which can rotate around the patient. 
The patient lies on a moveable treatment couch, which can move in many directions 
and setups are used to ensure the patient is in the correct position. The ionising 
radiation beam exits from the gantry of the linear accelerator; this can be rotated 
around the patient, as documented in the radiotherapy treatment plan.  Radiation can 
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be delivered to the tumour from any angle by rotating the gantry and moving the 
treatment couch.  Engineers have deliberately designed these three movements to 
occur around axes that all intersect at a common point, which is situated 100cm from 
the source (the focal point of the radiation beam). This point is called the isocentre 
(Williams and Thwaites, 1995).   
 
Radiotherapy treatments 
The two essential characteristics of a radiotherapy treatment are the localisation of 
the radiation beam to within the radiotherapy target volume and the amount of 
radiation dose delivered to this volume.  The radiation beam is localised within the 
radiotherapy target volume using image-guided radiotherapy (IGRT).  IGRT is 
enables the radiographers to visulaise the tumour before treatment commences and 
uses a cone-beam CT scan with an x-ray tube and detector mounted onto the linear 
accelerator gantry.  This scan will show the size, shape and position of the tumour as 
well as the surrounding tissues and bones in relation to the radiotherapy treatment 
field. A comparison is made before each treatment between the scan taken from the 
radiotherapy planning process and the radiotherapy treatment cone beam CT scan.  
Treatment cone beam scans can be used to check if the target volume has moved 
since the previous treatment.  Should changes have occurred, the patient can be 
repositioned so that the radiation treatment is more accurate (Cancerresearchuk.org, 
2016).   
 
There are no published guidelines that make recommendations on the potential 
contribution of imaging techniques to the cumulative ionising radiation dose to the 
CIED. Murphy et al reported that the dose from a kilovoltage cone beam CT scan is 
likely to be in the region of 10-80mGy (Murphy et al, 2007).  Kan et al reported mean 
skin doses of 6.4cGy per kilovoltage cone beam CT chest scan (Kan et al, 2008). 
 
Even using the lower limit of 10mGy from Murphy et al, it is possible that daily cone 
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beam CT in a 20-fraction radical lung treatment may contribute as much as 0.2Gy. 
Using the Kan et al skin dose estimates, it is possible the CIED may receive more 
than 0.2Gy. 
 
With advances in radiotherapy treatment techniques and equipment, the use of 
intensity-modulated radiation therapy (IMRT) for treating certain patients with cancer 
is increasing.  IMRT allows for improved ‘shaping’ of radiation dose profile conformity 
around the tumour and at-risk nodal structures while sparing adjacent normal tissue 
structures.  IMRT refers to a specific technique of linear accelerator-based 
radiotherapy whereby radiation beams are modulated in a way to produce highly 
conformal dose distributions. The intensity of the radiation beam in IMRT can be 
changed during treatment for the primary objective of reducing radiation dose to 
selected normal tissue structures in an effort to preserve function, while maintaining 
full radiation dose to tumour targets.   Linear accelerator manufacturers utilise 
different techniques and methods to achieve particular intensity-modulated fields 
(Varian.com, 2014). 
 
If the ionising radiation dose to the CIED is within the tolerance dose limits, the main 
concern for patients receiving IMRT with a CIED is the effect of EMI on the device.  A 
CIED response to EMI is observed clinically when patients experience CIED 
mediated tachycardia.  This effect is primarily observed when the ionising radiation 
beam is switched ON and OFF.  IMRT utilises a greater number radiotherapy 
treatment beams than conformal radiotherapy treatment.  Therefore, advances in 
radiotherapy treatment machines and radiotherapy planning and treatment 
techniques have resulted in more patients receiving IMRT as the standard treatment 
delivery.  As a result, the effect of EMI on CIEDs is likely to be clinically observed 
more frequently.  There is a need therefore, to investigate these effects.  
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Quality assurance (QA) 
Within a linear accelerator there are several built-in safety features and measures.  
These ensure that the linear accelerator will not deliver a higher ionising radiation 
dose than prescribed, with the machine routinely checked by medical physicists and 
technicians to ensure it is working correctly.  It is a sophisticated piece of equipment 
that requires several months for installation, acceptance testing and commissioning.  
The manufacturer’s personnel carry out installation, but the acceptance testing and 
commissioning are the responsibility of the radiotherapy department physicists 
(Quality Assurance and Radiotherapy, 1996).  Patients’ treatments do not begin until 
the unit has been commissioned, that is, the machines performance has been tested 
and proven to be acceptable, and baseline readings have been taken that will be 
used as part of the QA programme.  Only then can treatment planning and dose 
calculations for patients’ treatments begin (Quality Assurance and Radiotherapy, 
1996).   
 
All radiotherapy departments are required to deliver a radiotherapy service to a 
consistent standard.  In the UK this standard complies with the Ionising Radiations 
Regulations 1999 and the Ionising Radiation (Medical Exposure) Regulations 2000 
(Department of Health, 2017).  Departments must implement a quality system, which 
conforms to the EN ISO 9001:2000 (ISO, 2012) international standards.  A quality 
standard is the set of accepted criteria against which the quality of the activity in 
question can be assessed.  Various national and international organisations, such as 
the World Health Organisation in 1988, American Association of Physicists in 
Medicine in 1998 (AAPM, 1998), European Society of Therapeutic Radiation 
Oncology (ESTRO, 1995) in 1995 and Clinical Oncology Information Network (COIN, 
1999) in 1999, have issued recommendations for standards in radiotherapy. 
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The procedure of quality assurance (QA) is defined generally as all those planned 
and systematic actions necessary to provide adequate confidence that a product or 
service will satisfy given requirements for quality (Guidance for the commissioning 
and quality assurance of a networked radiotherapy department, 2006).  QA in 
radiotherapy is defined by all those procedures that ensure consistency of the 
radiotherapy prescription and the safe fulfilment of that prescription, with regard to 
the dose to the target volume, together with a minimal dose to normal tissues, 
minimal exposure of personnel and adequate patient monitoring aimed at 
determining the end result of treatment (WHO, 1988).  It must be stressed that 
quality assurance in radiotherapy is concerned with all aspects of the radiotherapy 
process and should involve all groups of staff in a cooperative approach, since 
quality activities are interdependent (Barrett et al, 1999).  Quality control is one part 
of overall quality assurance.  It is concerned with operational techniques and 
activities used.  Its aim is to check that quality requirements are being met and to 
adjust and correct performance if the requirements are not (AAPM, 1998). 
 
Specific Quality Control protocols are written for each linear accelerator.  They have 
a common basis in that they specify the method of testing and test equipment, the 
parameters to be tested and the frequency of testing, the responsibilities of different 
members of staff, the baseline values and tolerances for these values, action levels 
and documentation guidelines (Leer et al, 1995).  A clinical linear accelerator must in 
all circumstances function within the very narrow tolerances obtained at the time of 
acceptance testing. The quality of treatment of a patient can be compromised by 
gross equipment failure as well as by undetected deviation of a single parameter 
(Williams and Thwaites, 1995).  To achieve this, regular quality assurance tests 
consisting of a variety of mechanical and dosimetric checks are performed.  
Radiotherapy departments should carry out this programme at the recommended 
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frequency to maintain conformity with the national standards (Department of Health, 
2017).  The frequency of testing encompasses daily, weekly and monthly checks as 
well as extended tests performed annually.  Some tests or their frequency may have 
to be modified to take into account certain unique characteristics of a given linear 
accelerator.  However, these modifications should be made with the intention of 
improving the QA programme rather than cutting corners (Horiot et al, 1997). All QA 
measurements must be entered in departmental logbooks.  This is important not only 
in following machine performance over the years but also because it is a legal record 
that documents the operational health of the machine for any time in which patients 
were treated.  QA programmes should be adapted when the accuracy requirements 
change, for example in the case of a radiotherapy department deciding to participate 
in a clinical trial (Horiot et al, 1997). 
 
Patient safety 
Patient safety is of paramount importance.  Before treatment is delivered to the 
patient, a treatment plan is developed and approved by the clinical oncologist in 
collaboration with the medical physicists and/or therapeutic radiographers. The plan 
is verified and approved before treatment is given and quality-control procedures 
ensure that the treatment is delivered as planned.  The internal checking system 
within modern linear accelerators does not allow the machine to be turned on unless 
all the prescribed treatment requirements and parameters are met.  During the 
patient’s radiotherapy treatment, the therapeutic radiographer continuously observes 
the patient using a closed-circuit television monitor.  Imaging modalities, for example 
x-rays or cone beam CT, are taken regularly to ensure that the radiation beam 
position doesn't change from the original treatment plan.  Safety of the staff operating 
the linear accelerator is also taken into consideration. The linear accelerator is 
situated in a room with lead and concrete walls so that the high-energy x-rays are 
shielded.   The therapeutic radiographer must turn on the linear accelerator from 
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outside the radiotherapy treatment room, thereby eliminating the risk of accidental 
exposure to ionising radiation.   
 
3.5    CIEDs and radiotherapy treatment 
Although most medical treatments pose little danger to the functioning of CIEDs, 
radiotherapy has the potential to alter CIED function. CIEDs may be affected in two 
ways: direct damage via ionising radiation and by / via EMI, both of which may cause 
temporary or permanent CIED malfunction (Last, 1998).   
 
Before the 1970’s, pacemakers were made up of bipolar semi-conductor devices, 
which when exposed to therapeutic doses of ionising radiation, were resistant to 
radiation damage (Sundar et al, 2005).  The demand for smaller, reliable and more 
energy efficient devices has led to the replacement of the bipolar transistors with 
CMOS components, which have a potential for increased damage and CIED failure 
(Little, 1994 and Mouton et al, 2002). 
 
3.6    Effect of ionising radiation on CIEDs 
Ionising radiation is used in the treatment of cancer.  This radiation deposits energy 
in tumour cells and it directly or indirectly damages the genetic material (DNA) in the 
individual cells, making it impossible for them to continue to grow.  
 
Ionising radiation can be categorised into two types: 
1. Photon radiation – x-rays and gamma rays 
2. Particle radiation – electrons, protons, neutrons, carbon ions, alpha particles 
and beta particles 
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Photon radiation is the most common form of ionising radiation used for cancer 
treatment.  Photons, which are ‘packets’ of energy, destroy cancer cells on the 
surface of an area or penetrate to tissues deeper in the body, depending on the 
amount of energy they possess.  The higher the energy of the photon beam, the 
deeper the distance at which the ionising radiation is delivered to the radiotherapy 
treatment area.  
 
Ionising radiation interferes with the electrical circuits in CIEDs.   Modern CIEDs 
incorporate CMOS circuitry.  These circuits comprise doped semiconductor silicon 
terminals (either negatively or positively doped), with silicon dioxide used as an 
insulating layers between the various circuitry components.  The most sensitive parts 
of the CMOS structure to ionising radiation are the silicon dioxide layers (Rodriguez 
et al, 1991).  High energy particles and electromagnetic radiation possess enough 
energy to break atomic bonds and create excess electron-hole pairs in both the 
silicon semiconductor and silicon dioxide insulator.  Within a silicon semiconductor, 
excess electrons created in the so-called ‘conduction band’ and the corresponding 
holes in the so-called ‘valence band’ rapidly recombine when irradiation stops.  In the 
silicon dioxide insulator, however, the excess electrons in the conduction band soon 
leave by flow towards the adjacent metal case or the silicon semiconductor, but the 
holes in the so-called ‘valence band’ are not very mobile and only respond slowly to 
an electric field.  These holes tend to be attracted to any structural defects within the 
silicon dioxide and remain there, leading to a build-up of trapped positive charge in 
the insulator.  This leads to the formation of aberrant electrical pathways in the 
insulator, which may be temporary or more permanent, resulting in a variety of minor 
or significant malfunctions (Last, 1998).  These malfunctions may include altered 
sensitivity, amplitude changes of electrical signal, telemetry and programming 
defects preventing reprogramming, or adjustment of function or complete loss of 
functioning (Hurkmans et al, 2012).   In some cases, CIEDs may return to normal 
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functioning within seconds to days after irradiation (device recovery), but often these 
changes become permanent if continually exposed to ionising radiation (Last, 1998).  
ICDs have also proven to be more sensitive to radiation than pacemakers due to the 
effect of scatter radiation on the RAM (Frizzell, 2009).  
 
Various theoretical mechanisms of malfunction due to ionising radiation have been 
proposed.  All depend on aberrant accumulation of electrical charge and / or 
abnormal current flow within the semiconductor material inside the device.   
 
Last (1998) stated: 
i. Trapped charge in the insulation layer leads to alterations in the current-
voltage characteristics of individual semiconductor devices, with changes in 
threshold voltages and amount of bias required to produce changes in 
current. 
ii. The build-up of positive charge in the insulator can cause the formation of 
aberrant electrical pathways, which may be transient or permanent.   
iii. The metal case of the pacemaker is used as one electrode and will be at a 
different potential from the other parts of the circuit.  Like an ionised 
chamber, the material within the pacemaker body can be ionised with 
radiation.  These ions can then polarise between the pacemaker body and 
the integrated circuit creating a static field, which disperses slowly by 
leakage currents inside the CMOS itself, leading to failure of the various 
components in the circuitry. 
iv. Photocurrents generated by very high dose rate radiation may have transient 
effects on a CMOS device.  Such effects only become appreciable for high 
instantaneous dose rates and thus are unlikely to be significant at the 
relatively low dose rates occurring during each pulse from a linear 
accelerator. 
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In 2013, Munshi et al discussed the interaction of ionising radiation with CIEDs and 
carried out a review of literature and recommendations regarding CIEDs exposed to 
ionising radiation and subsequently suggested three reasons for the damage to 
them: 
1. Destruction of electrical components, most often with direct ionising radiation 
2. Effects on the random access memory - RAM (which hold patient-related 
data), most often secondary to scatter ionising radiation or EMI.  RAM is an 
array of transistors in the device; low voltage RAM stores programmed data 
and software algorithms.  Low voltage makes the data more volatile 
compared with the older bipolar transistor-based data storage.  For example, 
in cases of single-bit errors in CMOS, the microprocessor should have the 
ability to repair the minor malfunctions by built-in error correction algorithms. 
However, a more pronounced malfunction in the RAM will result in the reset 
of the device. 
3. Loading of the silicon dioxide insulator with excess of electron-hole pairs, 
which may persist to accumulate a net positive charge on the insulator.  The 
resultant formation of aberrant electrical pathways within the insulator leads 
to transient or permanent changes in the CIED function 
 
3.7     Observed types of CIED malfunction    
CIED malfunction is defined as failure to capture or sense electrical impulses or both 
and will require cardiac intervention, for example CIED reprogramming (Last, 1998).  
CIED failure is defined as the inability of a CIED to perform its intended function of 
regulating the beating of the heart and the requirement of repeat surgical CIED-
related procedures after the initial CIED implantation (Maisel et al, 2006). 
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Causes of CIED failure include lead related failure, unit malfunction, problems at the 
insertion site and failures related to exposure to ionising radiation, EMI, high voltage 
electricity or high intensity microwaves.  CIED malfunction has the ability to cause 
serious injury or death, but if detected early enough, patients can continue with their 
needed therapy once complications are resolved. 
 
Last, (1998) used clinical observations and in vitro studies to classify two main types 
of pacemaker malfunction induced by ionising radiation: 
1. Minor malfunctions – Posing little risk to the patient, for example, transient 
or prolonged change to interference or safety mode pacing, increases in 
pulse width, small changes in paced rate and programming and telemetry 
function defects.  Such changes have been detected at doses as low as 2Gy; 
2. Significant malfunctions – Posing a definite risk to the patient such as 
extreme fixed rate output, prolonged pacemaker inhibition or total shutdown.  
Such malfunctions require immediate replacement of the damaged 
pacemaker generator.  These can occur in the range of 15-36Gy. 
 
In 2015, Zeremba et al stated the mechanism of CIED malfunctions could be 
categorised broadly, into three groups: 
1. Transient effects due to interference, manifesting during exposure to ionising 
radiation only 
2. Reverting to backup settings (reset), recoverable after reprogramming the 
CIED 
3. Permanent damage to the CIED 
 
Hashii et al, 2013. further catergorised CIED malfunctions during radiotherapy:   
• Hard errors - relates to damage to the hardware of the CIED 
• Soft errors - relates to software alterations of the CIED 
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1 -  Severe - reset requiring reprogramming of the CIED 
2-  Moderate -  reset not requiring correction by the programmer 
3 - Minor - not detectable at interrogation and only recorded in the data log of 
the CIED 
 
It is not possible to predict the exact behaviour of any given CIED when it is in, or in 
close proximity to the radiotherapy treatment field.   Solan et al (2004) published a 
paper, which detailed the potential life-threatening malfunctions of CIEDs when 
exposed to EMI and ionising radiation.  He concluded that major discrepancies exist 
among CIED manufacturer guidelines and recommendations regarding the 
management of patients with CIEDs receiving radiotherapy treatment.   
 
3.8    Effect of electromagnetic interference (EMI) on CIEDs  
EMI is the term used to describe combined electric and magnetic fields in the 
electromagnetic field.  Electric fields exist whenever electric charges are present and 
a magnetic field is produced when an electric current flows in a conductor with 
magnetic field lines perpendicular to the current flow.  Electromagnetic radiation is 
the term used to describe electromagnetic energy radiating away from its source and 
can be described as ionising or non-ionising radiation.  Ionising radiation is made up 
of very short wavelengths and has sufficient power to move electrons from their 
nuclear orbits.  Non-ionising radiation is made up of longer wavelengths, which are 
less powerful and are not able to move electrons off their orbit around the nucleus.  
Electromagnetic fields are characterised by wavelength, frequency and field strength.  
EMI occurs when electromagnetic waves emitted by one electrical source or device 
impedes the normal function of another electronic device.  In relation to CIEDs, EMI 
is defined as interference of CIED function by any signal generated by an external 
source, that falls within a frequency spectrum being detected by the sensing circuitry 
of the CIED (Munshi,et al, 2013).  CIEDs rely on complex microcircuitry and use 
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electromagnetic waves in order to communicate.  EMI can interfere with the optimal 
function of the CIED.  EMI can occur from multiple sources and can induce voltages 
within the CIED circuit.  This might occur if the patient comes into direct contact with 
a source, or if the CIED enters an electromagnetic field, with the CIED leads acting 
as an antenna (Pinski and Trohman, 2002).   
 
There are three elements that contribute to any EMI compatibility issues. There must 
be an electromagnetic source (linear accelerator environment / radiotherapy room), a 
receptor (CIED) that cannot function appropriately due to EMI and an environment 
between them that allows the source to interfere with the receptor.  The factors 
affecting EMI can be categorised into properties of the emitting device (operating 
frequency), the physical relationship between the devices (distance) and the 
susceptibility of the affected device (electromagnetic shielding).  
 
1. Emitting device (linear accelerator environment / radiotherapy treatment 
room)  
The frequency (which is inversely proportional to wavelength) of the electromagnetic 
radiation emitted from the linear accelerator environment is a significant factor in 
relation to the physical length of various electric components in the susceptible 
device. These act as antennae to receive interfering signals. Long wavelengths (low 
frequencies) transfer minimal energy to small electronic components, and very short 
wavelengths (extremely high frequencies) are easily shielded. Frequencies between 
10 kHz and 1GHz are generally the most problematic.    
 
2. Affected device (CIED) 
Electromagnetic compatibility (EMC) refers to the ability of electronic devices of 
different types to operate in an electromagnetic environment without loss of intended 
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function. The EMC of the affected device affects the degree of malfunction that may 
occur.  
3. Distance and environment 
Electromagnetic field energy decreases as the distance from the source increases 
(inverse squared function of distance from the source).  Therefore, doubling the 
distance from the source results in a four-fold exposure reduction. For example in the 
setting of static magnetic fields created by linear accelerators, the intensity of static 
magnetic fields decreases as a function of distance from the source and creates a 
spatial gradient magnetic field. 
 
3.9    CIEDs response to EMI   
Currently in radiotherapy, much of the research has examined the effects of ionising 
radiation dose on CIEDs, and malfunction only occurs due to cumulative ionising 
radiation dose and dose rates (Mouton et al 2002), suggesting that EMI is not a 
concern.  However, EMI can enter the sensing circuits and mimic the heart’s intrinsic 
rhythm as well as influencing timing cycles. The impact of EMI on CIEDs, depends 
upon the frequency and intensity of the signal, duration of exposure to EMI during 
radiotherapy treatment and the presence of noise reversion filters in the CIEDs.  
Modern CIEDs utilise shielding, filters, and bipolar leads to mitigate EMI (Beinart and 
Nazarian, 2013), yet it can occasionally result in harmful consequences, for example 
pacing inhibition or inappropriate tachyarrhythmia resulting in shock therapy in ICDs 
(Pinski and Trohman, 2002).   
 
 
Historically authors contend that CIEDs are extremely resistant to any sort of EMI 
found in a hospital and that the only sources of concern should be defibrillators and 
possibly arc welding (Grant 1993). Others say that CIEDs are shielded from 
frequencies above 1 kHz and that only ultra high frequencies, 300 MHz–3 GHz, can 
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affect them (Smith and Aasen 1992).  Electromagnetic compatibility (EMC) describes 
efforts to minimise the possibility of EMI.  Internally CIEDs are protected from EMI in 
that the circuitry is shielded, the distance between the electrodes and the antenna is 
minimised and incoming signals are filtered to exclude non-cardiac signals.  CIED 
generators are typically shielded by hermetically sealed titanium or a stainless steel 
case.  Insulation surrounds the CIED leads to improve shielding from radiofrequency 
and magnetic fields and the pulse generator is shielded to reject electric fields above 
2MHz. However, if EMI does enter the CIED, noise protection algorithms integrated 
in the timing circuit aim to reduce its effect on the CIED.  Incorporation of bandpass 
filters allows rejection of frequencies outside the range of interest.  EMI signals 
between 5Hz and 100Hz are not filtered because these overlap the frequency range 
of intracardiac signals (Pinski and Trohman, 2002).  Therefore, EMI in this frequency 
range may be interpreted by the CIED as intracardiac signals, causing CIED 
malfunction and a clinical reaction in the patient.  The noise reversion mode on 
CIEDs is activated when signals are detected in the noise-sampling period.   It is 
stated that cardiac pacemaker programming could be affected by EMI, but only if the 
magnitude of the electric field strength exceeds 200 V m−1 or the magnetic field 
strength exceeds 10 Gauss (Smith and Aasen, 1992).  However, other authors 
contend that the complete inhibition of pacemaker functioning could be achieved with 
electric field strengths as low as a few volts per meter (Venselaar, 1985). 
 
In 2009 Burke et al (2009) published a paper regarding radiofrequency noise from 
clinical linear accelerators.  The purpose of this paper was to report on the 
measurement of the RF emissions from the treatment rooms of three different clinical 
linac configurations.  This data was then used in the program to help develop an 
integrated linear-accelerator-magnetic resonance system.  The results showed that 
RF noise emanating from medical linacs are not specific to one system but their data 
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outlining the field strengths surrounding clinical linacs could be applied to EMI testing 
of modern CIEDs. 
 
The most frequent responses to EMI are inappropriate inhibition or triggering of 
pacemaker stimuli, reversion to asynchronous pacing, and spurious ICD 
tachyarrhythmia detection. Reprogramming of operating parameters and permanent 
damage to the device circuitry or the electrode to tissue interface are much less 
frequent (Pinski and Trohman, 2002).   
 
Possible CIED responses to EMI are: 
1. Stopping the CIED from delivering the stimulating pulses that regulate heart 
rhythm 
2. Triggering the CIED to deliver stimulating pulses irregularly 
3. Triggering the CIED to ignore the heart's own rhythm and deliver pulses at a 
fixed rate 
4. Asynchronous pacing 
5. Mode resetting 
6. Damage to the pulse generator circuitry 
7. Triggering of unnecessary ICD shocks (Pinski and Trohman, 2002).   
 
The linear accelerators used in radiotherapy treatment, can emit various sources of 
EMI, for example couch drive motors, shutters, x-ray tube rotors, x-ray transformers, 
power supplies, magnetrons, klystrons, waveguide assemblies and beam pulse 
forming circuits, all potentially leading to pacing inhibition, fixed-rate pacing, or 
reprogramming of CIEDs (Hurkmans et al, 2012). However, these effects are usually 
transient and are observed when the ionising radiation beam is turned on or off 
(Munshi et al, 2013).  However, the consequences could be serious and permanent.  
For example, severe circuitry damage can potentially lead to CIED reprogramming 
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and / or device failure (Solan et al, 2004; Hurkmans et al, 2005; Hoecht et al, 2002 
and Niehaus and Tebbenjohanns, 2001).  Modern linear accelerators are sufficiently 
shielded, but there is limited literature to identify and quantify the risk of EMI to 
CIEDs during radiotherapy treatment (Pinski and Trohman, 2002).   
  
3.10   Observed clinical cardiac responses to EMI   
Pacing Inhibition 
CIEDs can be programmed to withhold electrical stimulus and inhibit pacing if it 
senses intrinsic activity (heart contractions).  This CIED response is limited to a heart 
rate range up to approximately 300 pulses per minute or 5 Hertz (Pinski and 
Trohman, 2002).  However, EMI that is detected by the CIED in this rate range can 
cause the CIED to incorrectly withhold the electrical stimulus and therefore inhibit 
pacing.  In pacemaker dependant patients, sustained pacing inhibition could have 
serious consequences.  Depending on the duration of pacing inhibition, light-
headedness, syncope, or death could result (Last, 1998).  
 
ICDs may be more vulnerable to consequences of pacing inhibition from EMI, as the 
programmed settings of the ICD can influence the response of the device to EMI.  
ICDs are required to be programmed at a high sensitivity setting in order to sense 
cardiac arrhythmias and deliver the appropriate therapy, however, this increased 
sensitivity makes the ICDs more susceptible to EMI and can cause oversensing of 
the extracardiac signals (Pinski and Trohman, 2002).  Asynchronous pacing will not 
occur due to lack of reliable ICD noise reversion modes. Therefore, EMI induced 
prolonged inhibition and spurious tachyarrhythmia detection become likely.  
 
Triggering of rapid or premature pacing  
Oversensing of EMI by the atrial channel of a pacemaker programmed to a tracking 
mode can trigger ventricular pacing at or near the upper tracking rate limit (Last, 
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1998).  Rapid pacing due to atrial oversensing is observed when the CIED is placed 
in an electromagnetic field.  As the electromagnetic field becomes stronger, the 
period of atrial oversensing is followed by a period of ventricular oversensing in the 
CIED.  Patients who experience this are typically symptomatic and complain of rapid 
palpitations. If sustained, inappropriate CIED acceleration induced by atrial 
oversensing may cause palpitations, hypotension, or angina. Very rapid pacing could 
induce ventricular fibrillation (Pinski and Trohman, 2002).   
 
Noise reversion mode  
CIEDs incorporate protective algorithms against prolonged inhibition from spurious 
signals.  A common response is transient reversion to asynchronous pacing  
(Strathmore, 1995).  Within the CIED, a safety feature identifies and classifies EMI 
that is outside of the cardiac rate range (5 Hertz).  On identifying and classifying EMI, 
the CIED delivers pacing stimuli to the heart and CIED noise reversion mode is 
activated.  CIED noise reversion minimises the types of EMI that can cause the CIED 
to be inhibited. The CIED will continuously pace the heart at the programmed low 
rate of the CIED in the presence of EMI.  
 
Hudson et al (2010) used the study by Souliman et al in 1994 to report that EMI had 
no impact on pacemaker malfunction.  A further study by Hurkmans et al (2012) 
stated that EMI effects are mainly temporary or reversible and they concluded that 
EMI did not seem to be of clinical relevance.  In 2015, Zaremba et al stated that the 
effects of EMI are usually transient and EMI typically does not pose any threat to the 
function of CIEDs, as in his study no events of symptomatic inhibition or rapid pacing 
was observed during radiotherapy treatment.  
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3.11    Rate response activated CIEDs  
As a result of the development and improvement in CIED technology, rate response 
activated CIEDs are increasingly being implanted in patients for the management of 
their cardiac conditions.  However, there is no research into the effect of ionising 
radiation and / or EMI on these devices. 
 
Rate-adaptive pacing is designed to increase the heart rate according to metabolic 
needs during physical, mental or emotional activity.  Rate responsive CIEDs control 
heart rate by sensing physiological or non-physiological signals other than the 
patient’s atrial rate.  Rate response activated CIEDs have specialised sensors built 
into the pulse generator that can sense increasing activity and / or increased rate of 
breathing. The sensors will automatically increase or decrease the heart rate 
according to the body's needs.  
 
Activity-driven (accelerometer) rate response activated CIEDs 
Accelerometer rate-adaptive CIEDs are non-physiological and non-specific because 
they do not respond to an increased metabolic demand unrelated to exercise.   The 
devices sense body motion by means of an integrated circuit accelerometer located 
on the circuit board.  The accelerometer responds to activity in the frequency range 
of typical physiological activity (1–10 Hz). An algorithm translates the measured 
acceleration in this range into a rate increase above the lower rate limit set. 
 
Minute ventilation rate response activated CIEDs 
Minute ventilation CIEDs are highly physiological as they react to the patient’s 
metabolic demand and therefore are also highly specific.   These devices use 
impedance minute ventilation sensors to change the pacing rate in response to 
variations in the patient’s minute ventilation.   Minute ventilation is the product of 
respiratory rate and tidal volume.  Up to the anaerobic threshold, minute ventilation is 
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approximately linearly related to heart rate.  At exercise levels beyond the anaerobic 
threshold, the relationship is still approximately linear but at a reduced slope.  
 
Figure 3.3: Graph to show rate response activated CIED (minute ventilation) – 
Response of device 
 
(Bostonscientific.com, 2017). 
 
The minute ventilation sensor for rate adaptation is derived by means of 
transthoracic impedance measurement. Approximately every 50ms (20 Hz), the 
device will drive a current excitation waveform between the selected (atrial or 
ventricular) lead ring electrode and the pacemaker case (Boston Scientific, 2012).  
 
EMI can trigger rapid pacing (up to the sensor-triggered upper rate limit) by activating 
the sensor in minute ventilation pacemakers.  Minute ventilation CIEDs may also 
erroneously interpret the signals generated by a range of hospital equipment, such 
as respiratory monitors, diagnostic echo imaging and surface ECG monitors 
(Bostonscientific.com, 2017).  Pacing returns to normal once the minute ventilation 
sensor in the CIED is deactivated. CIED manufacturer, Boston Scientific 
(Bostonscientific.com, 2017).  issued the following caution: 
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 “electrical signals introduced into the body by some hospital monitoring 
and / or diagnostic equipment may result in accelerated pacing, possibly 
up to the maximum sensor-driven rate, when minute ventilation is 
programmed ON.  Examples of this equipment include, but are not limited 
to, respiratory monitors, diagnostic echo imaging, surface ECG monitors, 
and hemodynamic monitors.  Therefore, deactivation of the minute 
ventilation sensor is required when interaction with this equipment is 
suspected”.  
 
3.12    Effect of ionising radiation and EMI on CIED leads 
As discussed in Chapter Two, CIED leads are insulated flexible wires that conduct 
electrical signals from the generator to the heart muscle and relay information 
concerning the heart’s intrinsic electrical activity back to the CIED pulse generator.  
Although ionising radiation may affect the function of the CIED, CIED leads are 
considered to be resistant to these effects.  None of the CIED manufacturers have 
issued any ionising radiation tolerance doses for CIED leads.  CIEDs are afforded 
some protection against exposure to ionising radiation and EMI, however, the CIED 
leads still remain vulnerable to noise pickup and the effects of EMI. 
 
CIED lead malfunction and failure 
CIED lead malfunction is defined as not performing according to specifications or 
intentions and it is the most common cause of CIED therapy failure.   Even when all 
the electrical parameters are within normal limits, structural compromises in a lead 
may still pose dangers to the patient through cardiac perforation, thrombogenesis, 
bacterial infection, interference with adjacent leads, and difficulty in extraction (Maisel 
et al, 2009 and Hauser et al, 2013).  Pacemaker or ICD lead failure in patients, can 
result in morbidity in the form of symptomatic bradycardia, inappropriate ICD shock 
therapy, arrhythmias, as well as mortality due to failure to pace or deliver therapy.   
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Lead failure can have more serious and immediate consequences than failure of the 
CIED pulse generator.  The consequences of CIED lead failure include high pacing 
or shock impedance, over-sensing, under-sensing, failure to capture and a failure to 
defibrillate.  The most common clinical presentation of lead failure is over-sensing; 
resulting in delivery of multiple inappropriate shocks and is the most serious cause of 
lead failure.  CIED malfunction can be managed by the surgical replacement of the 
device, but the management issues are more complex in the case of lead failure.   
 
3.13    Previous studies  
Various studies have been undertaken to consider the implications of level and rate 
of radiation doses delivered during radiotherapy treatment, as well as the risk of EMI 
upon the CIED.  There is limited research undertaken on the impact reported on 
CIED leads.  Previous studies have either used laboratory-based (in vitro) methods 
where exposure occurs only to the pacemaker itself on the bench, or ‘live’ (in vivo) 
studies, which investigated the effects caused by radiation and EMI, directly or 
indirectly, to the implanted device in the patient during their radiotherapy treatment.  
 
3.13.1  In vitro studies: Effect of ionising radiation and EMI on pacemakers (see 
Appendix A – Table 1) 
The majority of cancer patients receive their radiotherapy treatment via external 
megavoltage photon beams with a daily radiotherapy treatment dose of 1.5 – 2Gy to 
the tumour per fraction up to a total dose of between 50 – 60Gy given in 20 to 30 
fractions over five to six weeks.   For the treatment of breast cancer, patients receive 
a radiotherapy treatment dose of 40Gy in 15 daily fractions over 3 weeks and for the 
treatment of lung cancer, patients receive a radiotherapy treatment dose of 55Gy in 
20 daily fractions over 4 weeks (Royal College of Radiologists, 2006). 
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The earliest pacemaker in vitro study was carried out by Souliman and Christie in 
1994, in which eighteen multi-programmable pacemakers were irradiated to a total 
dose of 70Gy (2.8Gy per fraction) using 8MeV photons.  Results showed that no 
pacemakers failed at a dose less than 16.8Gy.   Eleven of the eighteen pacemakers 
failed between doses of 16.8Gy and 70Gy, with no device recovery observed.  Five 
of the eighteen pacemakers experienced device malfunctions, such as loss of atrial 
pacing combined with a decrease in pulse rate and increased pulse interval and 
corresponding pulse rate reduction. Two pacemakers showed no failure before 
reaching 70Gy.  Souliman and Christie (1994), concluded that pacemakers could 
temporarily or permanently fail at radiation dose levels commonly used in 
radiotherapy treatment and in this study they deemed that EMI had no effect on the 
devices.   They reinforced the need that all patients with a pacemaker should be 
monitored closely during their radiotherapy treatment.  
 
In 2002, Mouton et al. conducted an in vitro study, which provided data on radiation 
tolerance doses and the effect of dose rates on pacemaker function.  In this study 
they used explanted pacemakers.  Explanted pacemakers are devices which have 
been surgically removed from the body as a result of infection around the 
implantation site of the device, battery depletion requiring a battery change within the 
device generator, the device reaching the end of its ‘working life’ and needing to be 
replaced by a more modern device or the death of the patient.  Ninety-six explanted 
pacemakers were irradiated to a total dose of 200Gy (ranging from scatter radiation 
to four times the normal dose rate for direct irradiation), using a range of dose rates.  
Results showed that a number of pacemakers could withstand a radiation tolerance 
dose of up to 140Gy but some pacemakers failed at very low radiation dose levels. 
For example, one pacemaker exhibited clinically significant disturbances at a 
cumulative dose of only 0.15Gy. Two pacemakers exhibited defects at a dose of 1Gy 
and nine pacemakers failed at a cumulative dose of 2Gy. A further thirteen 
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pacemakers failed at a cumulative dose of 5Gy.  This study found pacemakers to be 
more sensitive to ionising radiation than previous studies that had defined the 
maximum tolerance dose to be as high as 5–10Gy. Mouton et al (2002), concluded 
that the maximum radiation tolerance dose of 2–5Gy quoted by the pacemaker 
manufacturers is not reliable in all situations.  They concluded that there is no safe 
ionising radiation dose level due to pacemaker failures appearing at doses equivalent 
to scatter radiation.  They proposed that pacemaker manufacturers should redesign 
devices with radiation-hardened circuitry, or at the very least specify safe ionising 
radiation doses for each individual pacemaker.   
 
CIED manufacturers have since updated their recommendations and guidelines.  
However, the recommendations are not consistent for all manufacturers.  Boston 
Scientific (Boston Scientific, 2012) state that no level of cumulative ionising radiation 
dose is ‘safe’ to both pacemakers and ICDs.  Medtronic (Medtronic, 2013) state that 
for pacemakers, tests have revealed minor radiation damage at doses as low as 
5Gy.  Therefore, they recommend monitoring after each radiotherapy treatment when 
this limit is reached.   They also list specific, ionising radiation tolerance doses for its 
eleven various models of ICD, in two of these models the radiation tolerance dose is 
5Gy and in the remaining nine ICD models the radiation tolerance dose is 1Gy.  St. 
Jude Medical (St. Jude Medical, 2013) states that its pacemakers have been tested 
to 30Gy cumulative ionising radiation dose without adverse effect. They reinforce 
Last’s (1998) comments  regarding the patient management during radiotherapy 
treatment.  Biotronik’s (Biontronik, 2011) product information sheet states that 
pacemakers have functional disturbances at 20Gy cumulative ionising radiation 
doses and less severe damage at 5Gy.  
 
Hurkmans et al, in 2005 irradiated nineteen pacemakers to a total dose of up to 120–
130Gy (end point failure) with 6MeV photons.  Results showed that malfunctions 
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varied from 10Gy to 120Gy, while five pacemakers irradiated to 130Gy exhibited no 
malfunctions.  Hurkmans et al (2005), classified these failures into five groups; 
changes in pacing pulse, pacing frequency, sensing threshold changes, telemetry 
and miscellaneous (battery problems and lead impedance changes). Five 
pacemakers exhibited no errors and some experienced a combination of device 
malfunctions.  In seven pacemakers, a complete loss of signal was observed.  Three 
pacemakers showed an amplitude deviation >25%. Eight pacemakers experienced 
pacing frequency inhibition during irradiation, but stopped when the radiation beam 
was switched off.  Three pacemakers experienced temporary or permanent loss of 
telemetry. The researchers proposed that the AAPM guidelines (Marbach et al, 1994) 
were still valid; but more studies were needed to quantify pacemaker malfunctions 
and issue further guidelines when treating patients with pacemakers.  This is 
therefore, one of the factors leading to this current study. 
 
Zaremba et al (2014), conducted an in vitro study to compare the effect of high-
energy and low-energy photon beams on modern CIEDs.  They irradiated ten 
pacemakers with a dose of 2Gy per fraction to a cumulative dose of 150Gy using 
6MeV and 18MeV photon beams.  Results showed that in the 6MeV group, one 
episode of pacemaker malfunction was detected after 150Gy. In the 18MeV group, a 
total of fourteen episodes of malfunction were detected starting at 30Gy in all five 
pacemakers.  They concluded that photon beam energy plays a considerable role in 
inducing pacemaker malfunctions. Low-energy radiotherapy may be safer in CIED 
patients despite relatively high ionising radiation dose to the devices.   
 
3.13.2  In vitro studies: Effect of ionising radiation and EMI on ICDs (see 
Appendix A – Table 2) 
The majority of in vitro studies observing the effects of radiotherapy focus on the 
effect of ionising radiation and EMI on pacemakers.  Understanding of the relevant 
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data on the effects of ionising radiation and EMI on ICDs is limited.  However, 
Hurkmans et al (2012) in vitro study on patients with ICDs and radiotherapy, 
irradiated eleven new ICDs exposed to a total dose of up to 120–130Gy (end point 
failure) with 6MeV photons induced malfunctions which varied from 0.5Gy to 120Gy.   
The study by Hurkmans et al (2012) found that malfunctions and / or failures were 
observed in all ICDs.  The first malfunctions were observed at 0.5Gy, with shock 
energy deviations >25%. Four ICDs reached their point of failure at 2.5Gy. A fifth ICD 
reached the end point failure dose of 120Gy.  No other ICD failed at doses less than 
10Gy.  Sensing interference was observed in all of the ICDs, in four ICDs, VT or VF 
detection occurred.  This would trigger the ICD to deliver an inappropriate shock.  No 
significant changes in pulse amplitude, pulse frequency and telemetry problems, 
were recorded. The researchers concluded that EMI did not have any effect on the 
ICDs but recommended management and monitoring protocols for patients with ICDs 
receiving radiotherapy treatment. 
 
Uiterwaal et al (2006) reported a study on ICD irradiation in 2006.  Eleven new ICDs 
were irradiated to 20Gy in a fractioned regime, in order to assess EMI interference.    
Interference was observed in all ICDs that were placed inside the irradiation field, this 
interference caused pacing inhibition or rapid ventricular pacing. Four out of the 
eleven ICDs incorrectly detected VT or VF, which would have caused tachycardia-
terminating therapy and lead to an inappropriate shock therapy.  No interference was 
observed in all the ICDs placed outside the irradiation field.  The researchers made 
recommendations for the management of ICD patients, including the need to 
reprogram the ICD to ‘monitor only’ to avoid inappropriate delivery of a shock.  They 
also emphasised the need for access to emergency resuscitation equipment, 
including an external defibrillator when treating these patients.    
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In 2008, Kapa et al, irradiated twelve ICDs and eight CRT-ICDs to 4Gy of scattered 
ionising radiation from a 6MeV photon beam.  The ICDs were interrogated prior to 
radiation exposure, after each fraction, on completion of the radiation course and 
one-week post completion. Interrogation reports showed there was no evidence of 
device reset or malfunction during or after radiation. Kapa et al (2008), concluded 
that there was no clear contraindication to radiotherapy in patients with ICDs or CRT-
ICDs.   However, they stated that ICDs should not be exposed to direct ionising 
radiation and there is a need for patients to be monitored during their radiotherapy 
treatment.  
 
In contrast, the Mollerus et al, study in 2014, showed that modern ICDs can 
withstand a greater cumulative ionising radiation dose than the 4Gy dose 
investigated by Kapa et al (2008).  Mollerus at al (2014) irradiated four modern ICDs 
and four older generation ICDs to escalating doses of ionising radiation from a 6MeV 
photon beam.  Results showed that the four modern ICDs remained functional at a 
cumulative ionising radiation dose of 131.11Gy but three of the ICDs exhibited minor 
memory faults.  All four of the older generation ICDs failed to deliver shock therapy 
after 41.11Gy and exhibited changes in lead impedance.  The researchers therefore, 
concluded that modern ICD design might be more robust than earlier generation 
ICDs. 
 
The 2014 in vitro study, conducted by Zaremba et al (2014), compared the effect of 
high-energy and low-energy photon beams on modern CIEDs.  They irradiated two 
ICDs with a dose of 2Gy per fraction to a cumulative ionising radiation dose of 150Gy 
using 6MeV and 18MeV photon beams.  Results showed that no episodes of device 
malfunction occurred in either groups and concluded that photon beam energy plays 
a considerable role in inducing device malfunctions.  Low-energy radiotherapy may 
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therefore be safer in CIED patients despite relatively high radiation dose to the 
device. 
 
3.13.3  In vivo studies: Effect of ionising radiation and EMI on pacemakers (see 
Appendix A – Table 3) 
In the period 2000 to 2012, five studies produced case reports for patients with a 
pacemaker receiving radiotherapy and documented the effect of ionising radiation 
and EMI on the devices.  Tsekos et al. in 2000 irradiated a pacemaker that was 
located in the lower lateral quadrant of the treatment field to treat a neuroendocrine 
carcinoma to 50.4Gy in 28 fractions.  During treatment, there was a decrease in 
magnet rate of the pacemaker, which returned to normal four months post 
radiotherapy treatment.  Results showed that no malfunction was evident.  In 2001, 
Nibhanupudy et al. reported on a patient with left breast carcinoma, where the 
pacemaker was re-sited, away from the radiotherapy treatment field, to the contra 
lateral pectoral pocket, and the pacemaker received a total ionising radiation dose of 
1.8Gy during treatment. No malfunction was recorded in this case.   Mitra et al. 
(2006) reported a similar case where pacemaker relocation was contra indicated due 
to patient instability. The pacemaker was situated just inside the radiotherapy 
treatment field and the device received a total dose of 1.66Gy.  No malfunction was 
recorded in this case. In 2013, Munshi et al reported that when treating a left breast 
carcinoma, the pacemaker was originally directly in the radiotherapy treatment field.  
This required medical physics to optimise the radiotherapy treatment plan to 
minimise the ionising radiation dose to the pacemaker of 4.3Gy.  This device 
exhibited no malfunction.  In 2012, Kesek et al, documented the treatment of a 
patient with left sided lung cancer.  The device could not be re-sited as this would 
require either use of a lead extender and tunnelling or implantation of a third 
electrode through the right subclavian vein already occupied by a venous port. 
Radiotherapy proceeded and the pacemaker received a total dose of 48Gy and no 
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malfunction was observed.   
 
During the period 2002 – 2012, five studies investigated the effects of ionising 
radiation on pacemakers.  These studies irradiated the pacemakers to a range of 
ionising radiation doses and all reported that the pacemakers exhibited no 
malfunctions.  In 2002, Santhanam et al presented the results of their study of six 
patients with pacemakers receiving radiotherapy. In five patients, no malfunctions 
were recorded in radiotherapy doses ranging from 0.5Gy to 1.3Gy.  One patient, 
whose pacemaker was situated within the radiotherapy treatment field, received a 
total dose 26.7Gy and no malfunction was recorded.  In 2014, Ampil et al produced a 
study on the use of radiotherapy for the palliation for lung cancer patients with 
compromised hearts.  They reported that the devices received a negligible dose of 
ionising radiation and no malfunctions were detected.  Croshaw et al, in 2011 
reported that in three patients having radiotherapy for the treatment of breast cancer, 
the pacemakers received doses ranging from 0.23Gy to 0.73Gy with a 6MeV photon 
beam.  No malfunctions in these devices were observed.  In Wadasadawala et al, 
2011 study of eight patients receiving radiotherapy, with a total dose ranging from 
0.14Gy to 60Gy to the pacemaker, the devices exhibited no malfunctions. They 
concluded that radiotherapy could be safely delivered in patients with pacemakers. 
However, the dose to the pacemaker needs to be kept as low and possible and close 
liaison with the cardiologist before, during and after the course of radiotherapy 
treatment is essential to ensure patient safety.  Makkar et al, in 2012 found no device 
malfunctions after irradiating fifty pacemakers.  They concluded that pacemaker 
malfunction due to indirect ionising radiation is uncommon.   
 
From 2011 to 2015, three studies investigated the effects of ionising radiation on 
pacemakers.  In these studies, pacemakers were irradiated with a range of ionising 
radiation doses and all reported device malfunctions.  Soejima et al (2011), reported 
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on sixty patients with pacemakers receiving radiotherapy to a variety of different 
treatment sites.  One patient, who was receiving radiotherapy for prostate cancer 
exhibited a device malfunction as the device reset during their radiotherapy 
treatment.  This device required reprogramming.  The researchers concluded that 
pacemaker malfunctions can occur when the pacemaker is away from the 
radiotherapy treatment site and receiving a negligible dose of ionising radiation.  EMI 
could be the causal factor for the device malfunction.  In 2014, Gossman et al 
irradiated sixty-seven pacemakers where malfunctions were observed in four 
devices.  One pacemaker failed at 0.3Gy, one pacemaker exhibited an increased 
sensor rate during ionising radiation delivery, one patient had an irregular heartbeat 
leading to device reprogramming, and one patient complained of ‘twinging’ in the 
chest wall that resulted in a respiratory arrest.   However, the researchers do not 
detail the nature of the clinical consequences.  The most recent study by Zaremba et 
al in 2015, irradiated three hundred and nighty-four pacemakers.  Ten pacemakers 
exhibited device malfunctions.  Nine of which were reset or deprogrammed during 
their radiotherapy treatment and one device showed an increase in atrial pacing 
threshold from 1.25V to 2.75V.  These pacemakers required reprogramming by the 
Cardiology department.  Zaremba et al (2015), concluded that the damaging effects 
of radiotherapy on pacemakers seem to be transient and indicates that beam energy 
has a pivotal role in inducing impairments.  
 
3.13.4  In vivo studies: Effect of ionising radiation and EMI on ICDs (see 
Appendix A – Table 4) 
From 2004 to 2015, out of the nine in vivo studies investigating the effect of ionising 
radiation and EMI on ICDs, only three reported that no malfunctions were observed 
in ICDs during radiotherapy treatment (Sepe et al, 2007; Croshaw et al, 2011 and 
Soejima et al, 2011).  In 2007, Sepe et al, published a case report, where an ICD 
received a total dose of 2.5Gy when treating a patient with head and neck cancer.  
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The ICD was deactivated during each radiotherapy treatment and the device was 
checked by their Cardiology department and no malfunction was recorded at any 
stage during their radiotherapy treatment.  Croshaw et al, in 2011 reported that in two 
patients having radiotherapy for the treatment of breast cancer, the ICDs received a 
total dose of 1.01Gy and 1.68Gy with a 6MeV photon beam.  No malfunctions in 
these devices were observed.  Soejima et al (2011) reported on two patients with 
ICDs receiving radiotherapy.  The ICDs were away from the treatment sites, so 
received a negligible dose of ionising radiation and no device malfunctions were 
detected. 
 
In comparison, Thomas et al (2004) and Nemec (2007) published case reports where 
malfunctions were observed in ICDs during radiotherapy treatment.  Thomas et al. 
(2004) reported a patient receiving radiotherapy to the right lung.  As the ICD was 
away from the treatment site, it received a negligible dose of ionising radiation.  
During the post radiotherapy cardiology follow-up, it was discovered that an electrical 
reset of the ICD had occurred during the patient’s radiotherapy treatment. The 
patient who was not ICD dependent, had not shown any physical symptoms, and the 
reset of the ICD had gone undetected.  Nemec (2007) published a case report for a 
patient being treated for lung cancer and documented the potentially lethal effect on 
the patient due to ICD failure. An ionising radiation dose to the ICD could not be 
obtained, as the incident occurred during the third fraction (this dose would have 
accumulated to <5Gy).  During the radiotherapy planning process because the ICD 
was not in the treatment field it was not re-sited.  However, the patient collapsed 
during their third fraction of radiotherapy treatment requiring cardiopulmonary 
resuscitation.  Therefore, the ICD was removed and the patient continued 
radiotherapy treatment.  Following a cardiology investigation there was found to be 
no fault with the ICD.  This malfunction could be as a result of random access 
memory (RAM) damage. 
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Between 2009 and 2015, four studies investigated the effects of ionising radiation on 
ICDs.  In these studies, ICDs were irradiated with a range of ionising radiation doses 
and all reported device malfunctions.  Gelblum and Amols (2009) irradiated thirty-
three ICDs with a radiation dose ranging from 0.1Gy to 2.99Gy.  Two patients who 
were receiving radiotherapy to the pelvic region using a 15MeV photon beam (rectal 
cancer and prostate cancer) experienced a reset of the ICDs back to its factory 
settings and required cardiology intervention to re-programme the devices.  In both 
these patients the ICDs were away from the radiotherapy treatment site.  The 
researchers suspect that both device resets were caused by neutron radiation.  In 
2012, Makkar et al. irradiated nineteen ICDs using a 16MeV photon beam.  Two 
patients’ ICDs displayed a partial reset with the loss of historic diagnostic data after 
exposure to 0.04Gy and 1.23Gy.  In a study by Elders et al (2013), fifteen ICD 
patients received radiotherapy treatment with 6 to 8MeV photon beams.  All ICDs 
received a total ionising radiation dose of <1Gy. During irradiation, the researches 
noted disturbances in the memory data, inappropriate VF detection due to external 
noise and a device data error.  Upon interrogation, the ICDs of two patients showed 
invalid data retrieval, one patient’s ICD reset during radiotherapy treatment and one 
patient’s ICD reset and nine months later a trend data error was reported.   They 
concluded that there is a possible correlation between the beam energy and the 
malfunctions displayed by the ICDs. This correlation may be due to an interaction 
between neutrons produced in the head of the linear accelerator at beam energies 
≥10MeV.  The most recent study by Zaremba et al in 2015, irradiated seventy-three 
ICDs and four devices exhibited malfunctions.  Three ICDs were reset or 
deprogrammed during their radiotherapy treatment and one device showed an 
increase in pacing threshold.  These devices required reprogramming by their 
Cardiology department.  
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3.13.5  In vivo studies: Effect of ionising radiation and EMI on CIED leads 
There is limited literature and no research into the effects of ionising radiation and 
EMI on CIED leads.  From 2004 to 2012, four case reports were published, with one 
recording malfunction to the CIED and CIED leads (John and Kaye, 2004).  In 2004, 
John and Kaye reported an ICD malfunction after radiotherapy treatment for left 
sided breast cancer.  While the ICD had been shielded, the leads received a full dose 
of ionising radiation with partial exposure of the ICD.  At the post radiotherapy 
cardiology follow-up appointment it was deemed that a new ICD was required due to 
battery depletion. During the procedure it was discovered that the shock impedance 
had increased, suggestive of shock coil failure, possibly due to structural damage to 
the leads.  The leads were tested four times and similar values were obtained, 
consequently a new lead was implanted. The researchers concluded that it was likely 
that damage to the shock coil during high dose irradiation resulted in high shock 
impedance and caused a malfunction in the ICD and the leads.  In 2008, Munshi et al 
published a case report for a breast cancer patient where their CIED leads were in 
the radiotherapy treatment field.  The patient was monitored throughout their 
radiotherapy treatment and the cardiologist documented that there was no 
malfunction to their CIED.  The researchers concluded that the dose to the CIED and 
leads should be kept as low as possible.  In 2011, Dasgupta et al published a case 
report for the successful radiation treatment of anaplastic thyroid carcinoma 
metastatic to the right cardiac atrium and ventricle in a pacemaker dependent 
patient.  The cumulative ionising radiation dose to the CIED was 0.37Gy and the 
cumulative radiation dose to the CIED leads was 5Gy.  The patient was monitored 
throughout the radiotherapy treatment and a single episode of ventricular under-
sensing with pacing stimuli during T-waves was successfully addressed by the 
reprogramming of the CIED.  In 2012, Kirova et al published a case report for a 
patient receiving palliative radiotherapy to the thoracic spine.  The cumulative 
ionising radiation dose to the CIED was 0.1Gy and the cumulative ionising radiation 
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dose to the CIED leads was 5Gy.  No change in CIED function was observed during 
and after the radiotherapy treatment.  The researchers concluded that all patients 
with CIEDs, especially ICDs should be monitored during their radiotherapy treatment.   
 
3.14   Safety measures  
The major manufacturers of CIED devices (Biotronik, 2011; Boston Scientific, 2012; 
Medtronic, 2013 and St. Jude Medical, 2013) do not provide specific guidelines on 
the safe management of patients with a CIED who are receiving radiotherapy 
treatment but some issue recommendations in relation to ionising radiation tolerance 
doses to the CIEDs.   However, these recommendations differ considerably.  
Medtronic state that their pacemakers should be able to tolerate cumulative ionising 
radiation doses of 1-5Gy depending on the model (Medtronic, 2013).  Boston 
Scientific and St. Jude Medical cannot rule out that their devices might fail even at 
low ionising radiation doses, stating that no dose limit be regarded as safe Boston 
Scientific, 2012 and St. Jude Medical, 2013). Boston Scientific further state that there 
is no safe ionising radiation dose to their devices due to the random nature of scatter 
ionising radiation and the effect this may have on RAM which is a common element 
in all devices (Lau et al, 2008).   
 
The CIED manufacturers state that previous research has shown EMI to have an 
insignificant effect on CIEDs, as EMI is only present briefly when the radiation beam 
is turned on or off.  With advances in radiotherapy treatment technology and delivery, 
for example IMRT and IGRT, there is an increased presence of EMI, therefore there 
may be a more significant effect on CIEDs than previous conventional radiotherapy 
treatments.  Additionally, Biotronik and Medtronic highlight the importance of beam 
energy, due to the damaging effects of secondary neutrons with a recommendation 
to limit photon energy to 10MeV (Medtronic, 2013 and Biontronik, 2011).  While CIED 
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manufacturers give different recommendations, all state that the CIED should not be 
located in the radiotherapy treatment field (Biotronik, 2011; Boston Scientific, 2012; 
Medtronic, 2013 and St. Jude Medical, 2013). 
 
The American Association of Physicists in Medicine (AAPM) (Marbach et al,1994) 
published a report on the safe use of radiotherapy in patients with permanent 
pacemakers. The AAPM report is the basis of most of the CIED departmental 
radiotherapy policies used in the UK before 2015.  Frizzell (2009) published a more 
contemporary review and a distinction was made between pacemakers and ICDs. 
Both the AAPM and Frizzell reports are widely referenced in the literature and appear 
to have the most robust evidence base to support them. Despite this, the AAPM 
report is now twenty-four years old and does not reflect advances in CIED or 
radiotherapy technology.  
 
Summary of the AAPM (Marbach et al, 1994) and Frizzell (2009) 
recommendations:  
AAPM Recommendations (pacemakers):  
1. Pacemakers should not be placed in the direct (unshielded) radiotherapy 
beam 
2. The absorbed dose to be received by the pacemaker should be estimated 
before treatment and limited to 2Gy 
3. If the total estimated dose to the pacemaker might exceed 2Gy, pacemaker 
function should be checked before radiotherapy and possibly at the start of 
each following treatment week by a cardiologist 
4. Patients should be closely observed during the first radiotherapy treatment on 
a linear accelerator 
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Frizzell Recommendations (ICDs):  
1. The absorbed dose to be received by the ICD should limited to 0.5Gy 
2. A magnet should be placed over an ICD when a patient is exposed to 
radiation 
3. Notify all patients about the possibility of ICD malfunction, failure or both 
 
Monitoring recommendations:  
1. Patients should be monitored with a continuous electrocardiogram (ECG) 
strip during the first radiotherapy treatment.  This strip should then be 
reviewed for any evidence of pacing disruption when radiotherapy is being 
administered  
2. ICD patients should undergo daily monitoring and staff should document any 
changes in the patient’s physical status and any changes in the ECG trace 
3. Monitoring should be carried out by fully trained and competent health 
professionals. If therapeutic radiographers are monitoring patients, they 
should receive specific training on the management and monitoring of these 
patients 
4. If at any point malfunction is suspected or detected, the clinical oncologist 
and cardiologist should be immediately informed 
 
Consent recommendations:  
1. The patient is aware of potential adverse effects of radiotherapy on CIEDs 
2. The patient is aware the ICD will be deactivated during radiotherapy 
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3.15    Chapter conclusion 
In discussing the role that radiotherapy plays in the management of patients with 
CIEDs, this chapter provides the theoretical background, clinical observations and 
study results of the effects of ionising radiation and EMI on CIEDs and CIED leads. 
! !
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Chapter Four 
Research Methods 
 
4.1    Introduction 
The overall aims of the research were to determine the effect of ionising radiation 
and EMI on CIEDs and CIED leads and to provide UK guidelines for the safe 
management of cancer patients with CIEDs receiving radiotherapy treatment.  The 
review of current literature and scientific studies were discussed in previous 
chapters. This information led to the formulation of the research questions and 
objectives and the development of the research design and the studies undertaken 
within the context of this PhD project.  
 
The specific research questions and objectives as discussed in chapter one are: 
• To establish current UK practice regarding the management of patients 
with CIEDs receiving radiotherapy treatment 
• To determine the effects of ionising radiation and EMI on patients with 
CIEDs receiving radiotherapy treatment at a RCW 
• To evaluate the relationship between cumulative ionising radiation dose 
and EMI and damage sustained to CIEDs 
• To evaluate the relationship between cumulative ionising radiation dose 
on the physical condition of the CIED leads 
• To determine whether there is a safe minimum radiation tolerance dose to 
CIEDs and CIED leads 
• To determine the effect of ionising radiation and EMI on rate response 
activated CIEDs 
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These research questions and objectives are discussed in six studies, under three 
headings: 
 
1. Test compliance, knowledge, understanding and perception 
• Study 1: 
To establish current UK practice regarding the management of patients 
with CIEDs undergoing radiotherapy treatment and to compare this 
practice with current ‘gold standard’ evidence-based guidelines. 
• Study 2: 
To conduct clinical audits to determine the effects of ionising radiation and 
EMI on patients with CIEDs receiving radiotherapy treatment at a RCW 
 
2. Scientific research 
• Study 3: 
To investigate and evaluate the relationship between cumulative ionising 
radiation dose and the damage sustained to CIEDs (pacemakers and 
ICDs). 
• Study 4: 
To investigate and evaluate the relationship between cumulative ionising 
radiation dose and / or EMI and the damage sustained to CIED leads. 
• Study 5: 
To investigate and evaluate the relationship between EMI and the damage 
sustained to CIEDs (pacemakers, ICDs and rate response activated 
CIEDs). 
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3. Research outcomes 
• Study 6: 
To provide evidence based guidelines for the safe management of cancer 
patients with CIEDs receiving radiotherapy treatment. 
 
The purpose of this chapter is to outline and explain the reasoning and approach by 
which the research was undertaken.  This chapter addresses the research questions 
and the development of the research methodology and method for each study, which 
is explained in detail. 
 
Firstly, this chapter will explain the choice of research approach and research 
method to establish current UK practice regarding the management of patients with 
CIEDs undergoing radiotherapy treatment.  Secondly, this chapter will detail the 
choice of research approach and present the research design, as well as the 
advantages and disadvantages of the research tools chosen.  This will be followed 
by a discussion of their ability to produce valid results, therefore meeting the aims 
and objectives set by this work.  This chapter will then discuss the preliminary study, 
data collection and data analysis procedures that were decided to be most suitable 
for addressing the formulated research questions.  It concludes with addressing how 
the preliminary study informed the PhD research project and a discussion on the 
ethical considerations posed by the research methodology. 
 
Next, this chapter will discuss the choice of research approach when conducting a 
systematic review to determine current ‘gold standard’ practice for the safe 
management of patients with a CIED receiving radiotherapy treatment.  In 
conjunction with the results and findings of this PhD project, this will provide up to 
date, evidence based recommendations for the management of cancer patients who 
have a CIED and are receiving radiotherapy.  Finally, this chapter outlines the 
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implementation of the PhD research project, detailing the research method and data 
collection procedures for all six studies. 
 
4.2    Test compliance, knowledge, understanding and perception 
4.2.1   Study 1  
To establish current UK practice regarding the management of patients with CIEDs 
undergoing radiotherapy treatment and to compare this practice with current ‘gold 
standard’ evidence-based guidelines. 
 
As part of the PhD research project, it was considered fundamental to establish 
current UK practice regarding the management of patients with CIEDs receiving 
radiotherapy treatment and compare this practice to current ‘gold standard’ evidence-
based guidelines. 
 
Method  
Literature review 
A literature search was conducted to contextualize the study aims and map them to 
existing research and provide an overview of the two study areas: 
• The roles and responsibilities of healthcare professionals involved in the 
patient pathway 
• The treatment and management guidelines for patients with CIEDs receiving 
radiotherapy treatment 
 
The literature review was divided into two stages.  The first was a broad exploratory 
‘Ovid Medline’ search, designed to identify appropriate medical subject headings 
(MeSH).  The keywords used at this stage were radiotherapy, pacemaker, 
 105 
defibrillator, ICD and cardiac device.  Hand searching of journals, relevant books, 
and review articles was also carried out.  
 
The second stage of the process was the application of the generated MeSH terms 
and keywords in a comprehensive search of the following databases: MEDLINE, 
EMBASE, and Cancerlit.  Subject headings were modified as required by individual 
databases.  
 
The comprehensive search was limited to publications commencing 1994, the year in 
which the first documented guidelines (AAPM, 1994) were published.  All subsequent 
published literature on the use of radiotherapy in patients with CIEDs was reviewed 
using the Critical Appraisal Skills Programme (CASP - Critical Appraisal Skills 
Programme, 2018) in order to define best practice (see appendix B.1) 
 
Critical appraisal is the process of carefully and systematically examining research to 
judge its trustworthiness, and its value and relevance in a particular context (Burls, 
2016).  Critical appraisal is a formal, unbiased, systematic approach to assess the 
quality and relevance of evidence presented in a paper and its applicability to 
determine current ‘gold-standard’ practice for the management of patients with 
CIEDs receiving radiotherapy treatment.  It included evaluation of the 
appropriateness of the study design for the research question and an assessment of 
information relevant to the research area. 
 
The CASP framework and protocol was used to reduce any potential bias, in 
analysing the literature to eliminate any preconceived ideas about the subject area, 
identify literature sources and the selection of articles to include and the evaluation of 
the evidence (see appendix B.2) 
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Policy review 
UK radiotherapy departments were identified using the Society and College of 
Radiographers’ database (see appendix C).  In March 2013, all radiotherapy 
department managers were emailed asking them to participate in a national audit.  
Radiotherapy departments were asked to either provide their current CIED policy or 
to indicate if there was no policy (seen appendix D). 
 
A proforma was created to analyse CIED policies comprising two sections; the first 
section defined the roles and responsibilities of healthcare professionals involved in 
the patient pathway and the second section assessed the treatment and 
management guidelines (see appendix E).  All data collected was anonymised. A 
spreadsheet  (Microsoft Excel) was created for the entry and analysis of audit data. 
Guidelines were compared with current best practice. Results are presented as 
simple frequencies and percentages. 
 
4.2.2   Study 2  
To conduct clinical audits to determine the effects of ionising radiation and EMI on 
patients with CIEDs receiving radiotherapy treatment at a RCW 
 
The first audit included all patients with a CIED receiving radiotherapy treatment.  
During this audit it was observed that patients with a rate response activated CIED 
displayed a distinct type of clinical adverse side effect during radiotherapy treatment.  
Consequently, a second audit was undertaken which focused on patients with a rate 
response activated CIED receiving radiotherapy treatment at RCW. 
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• Audit 1: Clinical audit – all patients with a CIED receiving radiotherapy 
treatment 
• Audit 2: Clinical audit – patients with a rate response activated CIEDs 
receiving radiotherapy treatment 
 
Audit 1: Clinical audit – all patients with a CIED receiving radiotherapy 
treatment 
Therapy radiographers (qualified members of the CIED monitoring team) from RCW 
observed that an increasing number of patients with CIEDs displayed adverse 
cardiac side effects during and after their radiotherapy treatment.  This required 
further investigation and as part of this work, these effects were studied in order to 
determine their extent and also investigate why more patients with CIEDs were 
thought to be exhibiting clinical adverse reactions during and after their radiotherapy 
treatment. 
 
The aims of the clinical audit were to: 
• Define radiotherapy induced device malfunction 
• Assess device malfunction in patients with a CIED that have been exposed to 
ionising radiation and EMI as part of their radiotherapy treatment at a RCW 
• Provide evidence and data showing that ionising radiation and / or EMI affect 
patient’s CIEDs when receiving radiotherapy treatment. 
 
Study Design 
As part of this work, it was necessary to determine device malfunction in patients 
with a CIED undergoing radiotherapy treatment at a RCW.  Therefore, a 
retrospective clinical audit was conducted, using patient information data collected 
after the patient had received radiotherapy treatment. 
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A clinical audit is a proven method of quality improvement, that seeks to improve 
patient care and outcomes through a systematic review of care against explicit 
standards and the implementation of change (NICE, 2002).  Prior to commencement, 
audit permission was obtained from the Cardiology Department and the RCW 
involved.  All patients were treated in accordance with departmental policies and 
protocols. All data was collected retrospectively from patient records, patient CIED 
identification cards and radiotherapy treatment documents. 
 
Audit 2: Clinical audit – patients with a rate response activated CIEDs receiving 
radiotherapy treatment 
Earlier chapters have documented the developments and improvement in pacing 
CIED technology.  One such advancement is rate response activated CIEDs, which 
are increasingly being implanted in patients for the management of their cardiac 
conditions.  However, there is no research into the effect of ionising radiation and 
EMI on these devices, hence why a clinical audit was carried out to assess device 
malfunction in patients with a rate response activated CIED that received 
radiotherapy treatment at a RCW. 
 
As discussed in chapter three, rate response activated CIEDs can be affected by 
EMI from the radiotherapy treatment machine, but the reaction is highly specific to 
the make, model, design and CIED manufacturer. The manufacturers acknowledge 
that patients with a rate response activated CIED, might experience transient heart 
rate increases during the delivery of the radiotherapy treatment.  They advise that the 
rate response setting on the device is switched to ‘OFF’ or ‘PASSIVE’ to mitigate any 
potential interference from EMI.  However, there is no research into the effect of 
ionising radiation and EMI on rate response activated CIEDs during radiotherapy 
treatment. 
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Thus as part of this work, a clinical audit was undertaken to: 
• Define CIED mediated tachycardia 
• Assess device malfunction in patients with a rate response activated CIEDs 
that have been exposed to ionising radiation and EMI as part of their 
radiotherapy treatment at a RCW 
• Provide evidence and data showing that ionising radiation and / or EMI affect 
rate response activated CIEDs when receiving radiotherapy treatment. 
 
Materials and Methods 
In order to determine device malfunction in patients with a rate response activated 
CIED, a retrospective clinical audit was conducted.  For this clinical audit, a ‘CIED 
mediated tachycardia’ was defined as any conditions in which a CIED paces the 
ventricle at rates that are inappropriately fast.  CIED manufacturer, Boston Scientific 
describe CIED mediated tachycardia as ‘the repeated cycle of sensing and tracking 
and can continue until conduction is lost in the CIED. CIED mediated tachycardia can 
result in ventricular pacing rates as high as the maximum tracking rate’. 
 
In this audit, this is observed by the patient’s clinical presentation and heart rate 
during their radiotherapy treatment.  All patients were monitored with a continuous 
ECG strip and observed during treatment with audiovisual monitoring and monitoring 
staff documented any changes in the patient’s physical status and changes in the 
ECG trace.  If at any point malfunction is suspected or detected, the clinical 
oncologist and cardiologist were immediately informed. 
 
All patients from a cardiology department at a RCW, that had a rate response 
activated CIED implanted and presented for radiotherapy treatment at a RCW were 
included in this audit.  These patients received radiotherapy treatment and were 
treated in accordance with the department’s CIED policy.  All data was collected 
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retrospectively from patient records, patient CIED identification cards and 
radiotherapy treatment documents. 
 
4.3    Scientific research (Studies 3 – 5) 
Research approach 
These studies make use of a quantitative research strategy and adopted an 
experimental approach to data collection, using information obtained as a result of 
the preliminary study (discussed below).  Due to the nature and involvement of 
ionising radiation in the research, at this stage it would be inappropriate to expose 
patients to the ionising radiation doses required to investigate the destructive effects 
upon the CIEDs and leads by ionising radiation and EMI.  The effects of this testing 
has the potential to have catastrophic effects to the patient, such as inducing 
secondary malignancies and / or cause cardiac malfunctions and failure.  The 
research was therefore conducted under laboratory conditions, exposing CIEDs and 
CIED leads (separately) to ionising radiation, EMI and physical testing.  This was 
undertaken using a range of ionising radiation doses based upon published previous 
studies and the preliminary study. 
 
Research design and method 
The research design is the researcher’s overall plan for obtaining answers and 
evidence to the research questions guiding the study.  It is the set of methods and 
procedures used in collecting and analysing data of the variables specified in the 
research questions. Polit et al (2001) describe the research design as a blueprint, or 
outline, for conducting the study in such a way that maximum control will be 
exercised over factors that could interfere with the validity of the research results.  
Research design refers to the plan or strategy of shaping the research, that can 
include the entire process of research from conceptualising a problem to writing 
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research questions, data collection, analysis, interpretation and report writing 
(Creswell, 2008).  This research used a quantitative experimental design to identify, 
analyse and describe factors contributing to the effect of ionising radiation and EMI 
on CIEDs and leads. 
 
Quantitative research  
Quantitative research is an objective, systematic process for obtaining quantifiable 
information, presented in numerical form and analysed through the use of statistics.  
It is used to gain information, describe and test variables and to examine the cause-
and-effects of relationships and attempts to control the environment in which the data 
is collected (Given, 2008).  The overarching aim of this research was to classify 
features and construct statistical models in an attempt to explain what is observed 
when CIEDs and leads are exposed to ionising radiation and EMI.  This study aimed 
to quantify the factors identified as contributing to the adverse effects of the 
functioning of CIEDs when exposed to ionising radiation and EMI and to gather 
evidence that allowed conclusions to be reached. 
 
Characteristics of quantitative research  
When conducting quantitative research, the researcher should have clearly defined 
research questions to which objective answers are sought, obtaining numerical data 
in a controlled investigative setting.   There are three primary types of quantitative 
research designs; experimental / quasi-experimental, descriptive and correlational.  
The research design and method should be transcribed in a systematic and logical 
order, which may be replicated or repeated by other researchers given its high 
reliability.  Reliability and validity of the testing equipment and instruments are 
essential.  Statistical analysis is conducted to organise data, determine significant 
relationships and identify differences and/or similarities within and between data sets. 
Personal bias can be avoided by following the quantitative research methodology 
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and using accepted computational techniques to analyse data and assess the 
relationship between variables. 
 
Experimental design  
An experiment tries to measure the effects of X on Y by controlling X and measuring 
Y, while at the same time keeping everything else constant Creswell, 2008).  
Experimental research has a range of definitions but in the strictest sense, 
experimental research is called a ‘true experiment’.  True experimental design is 
considered the most accurate and reliable form of experimental research as it uses 
statistical analysis to try to prove or disprove a hypothesis (Creswell, 2008). 
 
Experimental research uses manipulation and controlled testing to understand causal 
processes.  The experimental methodology is a systematic approach in which the 
researcher establishes a control group and manipulates one or more variables and 
measures any change in other variables.  This allows the researcher to establish 
cause-and-effect relationships between a group of variables and assess the 
correlation between them.  Experimental designs are developed to answer 
hypotheses, formulated by researchers to address specific testable questions.  The 
researchers set up an experimental study and collect and analyse data, which will 
support or disprove the hypothesis.  Hypotheses can be based on theory, on 
previous research findings, a pilot study or a theory that the researcher may wish to 
examine further.  
 
Adopting an experimental approach to the research, enabled manipulation and 
control of the testing variables to investigate the effects of increasing the ionising 
radiation dose exposed to CIEDs and leads (separately) and also to investigate the 
effects of exposure to EMI on CIEDs.  The results from these experiments enable an 
understanding of causal processes and possible cause-and-effect relationships as 
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well as assessing the correlation between them.  The research design and method 
for each study is discussed in further detail under the sub-heading implementation of 
the study.   
 
Data validity 
The aim of quantitative experimental research is to gather data and evidence that 
allows a reasonable conclusion to be drawn as to whether or not a particular variable 
causes a particular effect or result.  Moskal and Leydens (2002) defined validity as 
“the degree to which the evidence supports that the interpretations of the data are 
correct and the manner in which interpretations used are appropriate”.  Quantitative 
experimental research should be conducted using a representative sample under 
carefully controlled conditions so that the conclusion can reasonably be generalised 
to a larger cohort or population.  In this study, a representative sample of CIEDs 
could not be used, due to the cost and availability of the devices within the time 
constraints of the research project.  The CIEDs that were used in the research were 
all from manufacturers X, Y and Z and the same make and model which conformed 
to set manufacturer standards.  This is a limitation of the study, however it does not 
appear to be detrimental to the research, as the same devices were used and the 
subsequent results could be compared and analysed.  
 
According to Creswell (2008) there are several threats of validity that raise issues 
about the accuracy of the data or results or application of statistical tests to conclude 
the effects of an outcome. They are internal validity threats, external validity threats 
and statistical conclusion threats.  For example, experimental samples may be too 
small or may be made up of participants that do not accurately represent the larger 
population.   All of these threats can cast doubt upon a research study’s conclusions. 
An experimental approach to data collection is said to be an effective means of 
strengthening:  
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• Internal validity – This relates to how far a study has established whether a 
variable under investigation has had an effect and whether there is sufficient 
evidence to support the claim. 
• External validity – This relates to whether findings from a specific sample in 
a study can be generalised to a larger, specific population. 
 
The basic requirement to interpret an experiment is to clearly define internal validity. 
Internal validity threats are experimental procedures, treatments or experiences of 
the participants that threaten the researcher's ability to draw correct inferences from 
the data in an experiment. External validity threats arise when the researcher 
concludes incorrect inferences from the sample data and commutates to other 
persons.  A statistical conclusion validity threat arises when experimenters draw 
inaccurate inferences from the data because of the violation of the assumptions of 
the statistical test being used for the collected data.  
 
The internal validity threats that could arise from data collection and the tools used 
for collecting the data, were clearly defined.  These were: 
• Changes in the instrument may produce changes in outcomes 
• Measurement errors that result from changes in the calibration of an 
instrument or changes in the instrument itself 
 
In order to avoid these threats, the experiment, testing equipment tools and 
instruments were set up by the researcher and the same testing instruments were 
used throughout the PhD research project.  All data was stored in approved 
proformas in Microsoft Excel, and saved on a USB for later analysis.  To mitigate the 
threat of external validity, all data was sorted accurately and assigned to their 
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particular study and results quantified to that study. This data was interrogated using 
statistical analysis and conclusions were subsequently drawn. 
!
4.3.1    Preliminary Study 
Introduction 
A small-scale preliminary pilot and feasibility study was conducted to gather 
information prior to the PhD research project.  It was undertaken at RCW, 
radiotherapy department from May 2013 to August 2013.   The purpose of this study 
was to ensure that the ideas and methods behind the research ideas were sound, 
identify design issues, permit preliminary testing of the hypothesis and to identify and 
address any issues in the study protocol. 
 
The feasibility aspect of the preliminary study answered whether or not the study 
could be done and was used to estimate important parameters that were needed to 
design the main study.  The pilot study was a miniature version of the main study to 
test logistics and determine whether the components of the main study could all work 
together.  As a result, the focus and nature of the PhD study was determined and the 
research questions and objectives were refined.  Using results and information from 
the preliminary study, the design and testing protocol were evaluated and amended 
prior to the commencement of the full-scale PhD research project. 
 
Preliminary study research questions (predicted measures): 
The study examined 4 different predicted measures: 
1. The effect of ionising radiation on CIED function 
2. The effect of ionising radiation on CIED lead function 
3. At what ionising radiation dose CIEDs exhibited clinical malfunctions 
4. At what ionising radiation dose CIEDs failed 
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Hypothesis  
As the level of ionising radiation dose increases, the greater the likelihood of CIED or 
CIED lead malfunction or failure increases.  
 
Method 
Research design 
The preliminary study used a quantitative research strategy and adopted an 
experimental approach to data collection.   
 
Part 1 - CIED testing - Equipment:   
CIEDs 
A total of six pacemakers were included in the study; two pacemakers from each of 
the three CIED manufacturers (Biotronik, Boston Scientific and St. Jude Medical) 
were tested in this study.  All the devices were new (no used devices were tested, as 
they might have a history of use which could influence results).  Inter-device reliability 
was tested utilising three of the same make/model devices for each of the following 
manufacturers - Biotronik, Boston Scientific and St. Jude Medical. 
 
CIED programmed: 
• Minimum frequency – 60bpm and maximum frequency – 120bpm 
• Pulse duration – 0.5ms 
• Pulse amplitude – 2.5V 
• Sense threshold – 0.18mV 
• Dummy load resistor of 500Ω 
 
In order to mimic clinical practice, the CIEDs were placed in a clear plastic 
polymethylmethacrylate (plexiglass) block and tissue equivalent bolus material 
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placed on top of it, such that the middle of the device was located at the maximum 
dose depth for 6MeV photon beam (1.5cm).  The CIED being irradiated and 
interrogated was positioned precisely along the projected central axis (isocentre) of 
the primary radiation beam.   
 
Radiotherapy treatment room – LINAC 
A standard radiotherapy unit (Varian 650c linear accelerator with 120MLC, portal 
imaging, beam energy 6MeV set as a dose rate of 600MU/minute) was used to 
deliver the ionising radiation. The x-ray field collimators were open to encompass the 
CIED within the primary photon beam. 
 
Environmental conditions: 
• LINAC room temperature and room pressure recorded as part of the daily QA 
procedure prior to data collection to ensure LINAC output was within 
expected tolerance  
• Linear accelerator beam energy – 6MeV* 
 
* The energy of ionising radiation is measured in electronvolts (eV). One electronvolt 
is an extremely small amount of energy. Commonly used multiple units are 
kiloelectron (keV) and megaelectronvolt (MeV).   
 
CIED programmer and telemetry wand 
A programmer is a device that communicates with the CIED with radio frequencies in 
the Medical Implant Communication System (MICS) band.  This is a low-power, 
short-range (2 m), high-data-rate, 401–406 MHz (the core band is 402–405 MHz) 
communication network that has been accepted worldwide for transmitting data to 
support the diagnostic or therapeutic functions associated with medical implant 
devices. The programmer functions by running a user-friendly operating system to 
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check the integrity of the CIED system and control the functioning of the device.  
CIED programmers have evolved into dedicated computers, which have made 
possible extensive programming of CIEDs and advanced interrogation of device 
diagnostics.  CIEDs have a micro-antenna which is able to communicate with an 
external transmitter via its attached telemetry wand. The programmer is able to read 
information stored in the logs of the CIED, interrogate its current status and to modify 
its settings.  In this study, the programmer replicated the electrical behaviour of a 
paced heart and established the function of the CIED, tested electrocardiogram 
(ECG) parameters, differentiated between natural sinus beats and paced beats and 
defined the refractory period. 
 
Figure 4.1: Photograph showing the CIED programmer and attached telemetry 
wand 
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CIED ionising radiation testing protocol: 
1. Pre-ionising radiation exposure: 
• CIED programmer telemetry wand placed around the CIED under 
investigation (outside of the RT treatment room) 
• On the programmer, ‘Quick Start’ was selected, in order to run the CIED 
interrogation and diagnostic evaluation 
• The programmer carried out the following basic tests: 
- CIED pulse rate 
- CIED pulse width  
- CIED inhibition sensitivity 
- CIED mode setting - to determine if the devices were in ‘interference 
mode’ or ‘safe mode 
• One completion of the device interrogation, a full service report was provided 
(which could either be downloaded onto USB or printed) 
 
2. CIED ionising radiation exposure: 
• In the radiotherapy treatment room, the CIED was placed in the phantom and 
tissue equivalent bolus placed on top and positioned on the treatment couch, 
so that the CIED was within the primary radiotherapy photon beam 
• LINAC accelerator switched ON 
• In order to determine at which point the CIED exhibited malfunctions, the 
devices were irradiated to a total dose of 50Gy in twenty-five fractions 
(increasing dose by 2Gy per fraction) 
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3. Post-ionising radiation exposure: 
• After every five fractions (increasing dose delivered by 10Gy every five 
fractions) the CIEDs were subjected to functionality base-line tests to 
determine if the device was still operating correctly 
• If these tests proved that no adverse damage had been caused to the device, 
they were further irradiated for another 10Gy (in five fractions) 
• This process continued until the device had received a cumulative ionising 
radiation dose of definite point-of-failure (120Gy) 
 
Part 2 - CIED lead Testing – Equipment: 
CIED leads 
• A total of twelve CIED leads were included in the study; four leads from each 
of the three CIED manufacturers (Biotronik, Boston Scientific and St. Jude 
Medical). 
• All twelve leads were irradiated but only six leads (two from each 
manufacturer) were subjected to stress testing to determine whether this 
process replicated the stress placed on the lead when implanted in a patient 
 
Radiotherapy treatment machine and environmental conditions as per 
preliminary study. 
!
CIED lead ionising radiation testing protocol: 
1. CIED lead ionising radiation exposure: 
• In the radiotherapy treatment room, the whole CIED lead was placed in the 
phantom and tissue equivalent bolus placed on top and positioned on the 
treatment couch, so that the CIED lead is within the primary radiotherapy 
photon beam.   
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• LINAC accelerator switched ON 
• In order to determine if ionising radiation affected the physical condition of 
CIED leads, they were irradiated to a total dose of 60Gy in six fractions 
(increasing dose by 10Gy per fraction).   
 
2. Post-ionising radiation exposure: 
To monitor the physical effects and to determine the effect of ionising radiation on the 
physical condition of the leads, specific testing equipment was designed.  With every 
heartbeat, the displacement of the heart occurs in three directions; radial, long axis 
and rotational.  The majority of displacement is radial; classically seen as systolic 
function on 2-D imaging.  Within the equipment set-up, this will be replicated by linear 
vibration and rotational stressing, with a heart rate of 70bpm and a displacement in 
all directions of 1cm.  Clinical observations showed that leads tend to stick to blood 
vessels and other structures at discrete places (at the junction of the superior vena 
cava and right atrium and in the right atrium and around the tricuspid valve), this was 
replicated by a hinge-like movement. 
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Figure 4.2: Photographs showing the lead testing equipment 
 
 
In order to determine if ionising radiation affected the physical condition of the CIED 
leads, all leads (non-stressed leads and stressed leads) were subjected to electric 
and magnetic testing.  A novel microwave experiment (see below) was used to 
provide measurement of the electrical conductivity of the CIED lead sheath polymer 
at microwave frequencies. The resonant cavity was connected to the vector network 
analyser (VNA) to provide data on any polymer changes in the sheath layer of the 
CIED leads. The electrical energy from the VNA is stored in the cavity, which 
resonates at a very precise frequency (analogous to striking a bell, the energy from 
the strike makes the bell ring at a particular note). This is the so-called un-loaded 
cavity resonance and serves as a reference. The sheath layer of the CIED lead was 
then inserted into the cavity and the electrical field at the top of the hairpin structure 
interacted with the CIED lead sheath material. This allowed for a direct measurement 
of the electrical properties of the CIED lead sheath material and any residual 
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conductivity in that material (in the form of free electrons liberated as a result of 
broken polymer bonds).  This conductivity ‘loads’ the cavity and thus changes the 
characteristic resonance. (Analogous to holding the bell while ringing it, it makes a 
thud as opposed to a ping). Since the cavity resonance is extremely sensitive to 
small changes, any de-polymerisation from the radiation field should affect the cavity 
resonance. There are three principle changes that occur to a cavity resonance when 
it is loaded.  
1. Shift in resonant frequency.  
2. Change in the bandwidth of the resonance 
3. Insertion loss; where the power entering the cavity is consumed.  
 
Preliminary study – Data analysis 
The preliminary study used quantitative methods to collate data and investigate the 
relationship between variables that can cause damage to CIEDs and CIED leads.  
Information from the CIED programmer provided raw data on the effect of ionising 
radiation on the CIED and data from electric and magnetic testing on the CIED leads 
provided information to investigate the physical condition of CIED leads when 
exposed to ionising radiation.  The preliminary study led to the development of the 
research questions and research hypotheses, the results of which will underpin the 
testing protocol and data collection procedure for the PhD research project (studies 
3-5). 
 
Preliminary study informed PhD research project 
The preliminary study revealed shortcomings in the design of the proposed testing 
protocol and data analysis procedure.  Firstly, when conducting the CIED testing, the 
results from the programmer only alerted and flagged up the basic CIED parameters 
affected by ionising radiation.  Therefore, the level of detail needed to determine if 
the CIED had been adversely effected by ionising radiation and at which dose this 
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effect occurred could not be obtained.  In consultation with the CIED manufacturers, 
additional testing protocols, which utilised more advanced programming and 
functionality tests that the programmer was equipped to perform were adopted.  In 
the PhD project, detailed tests will be conducted ‘live’ by interrogating the CIEDs 
using the programmer to pinpoint the exact ionising radiation dose at which the CIED 
start to exhibit clinical malfunctions.  The programming tests will show if the ionising 
radiation has affected the hardware or software components of the CIED and the 
functionality tests will show any alternations in the programmed working function of 
the CIED.   Conducting these advanced tests will allow a more detailed breakdown 
and analysis. 
 
Secondly, the CIEDs were placed in a clear plastic polymethylmethacrylate 
(plexiglass) block and tissue equivalent bolus material was placed directly on top of 
it.  As this was a proof of principle study, this worked as it proved that the bolus 
placed on top could mimic human tissue and to the depth to which the CIED would 
be implanted in a patient.  In the resultant PhD study, a phantom will be designed 
using the polymethylmethacrylate block and encapsulate the CIED and lead within in.  
This will be achieved by channeling out a ‘groove’ in which the CIED lead can sit and 
a ‘hole’ that the CIED can be placed in.  These will then be flush with the block and 
the bolus can sit directly on top with no air gaps, which could affect the distance the 
ionising radiation has to travel before reaching the CIED and lead.  In doing this, 
there will be a truer representation of the clinical placement of the CIEDs and the 
leads when in-situ in patients. 
 
The preliminary study, proved valuable in highlighting additional tests and changes 
that can be included in the PhD research project.  In the preliminary study, the 
investigation was limited to 6MeV beam energy on a Varian linear accelerator.  A 
study by Hurkmans et al in 2005 only irradiated their devices using a 6MeV photon 
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beam, as they believed that different beam energies or type (photons or electrons) 
would have the same effect on the pacemakers.  They referenced a previous study 
by Rodriguez et al, in which devices were irradiated at different beam energies and 
they concluded that no difference to device function was determined in using the 
different beam energies.  In clinical practice, results from study two, showed that 
patients receiving radiotherapy treatment at a RCW exhibited a range of cardiac and 
CIED changes during their radiotherapy treatment.  These occurred when being 
treated using both 6MeV and 10MeV photon beams.  Therefore, in the PhD research 
project the testing protocol will remain the same but this protocol will use both beam 
energies (6MeV and 10MeV) to irradiate the CIEDs and the CIED leads.    
 
Conducting the preliminary study identified design issues with the testing protocol 
regarding the measurement of ionising radiation dose received by the CIED.  To 
address this for the later PhD studies, in-vivo dosimetry was used to verify the 
planned dose was administered to the CIED.  A surface thermoluminescent 
dosimeter (TLD) was placed on the device and this recorded the entrance ionising 
radiation beam dose.  TLDs use small ‘chips’ of lithium fluoride (LiF), a material that 
gives off light when heated after it has been exposed to ionising radiation. The 
amount of light given off was measured using a photomultiplier tube while the chip 
was heated in an oven inside a light-tight enclosure. The amount of light given off 
was used to estimate the ionising radiation dose received.  Medical physicists then 
compared this dose to the planned ionising radiation dose and verified that the 
correct dose was received to the CIED. 
The preliminary study also identified an area of concern, as the CIEDs received a 
2Gy per fraction dose of ionising radiation and there is the potential that the exact 
point at which the CIED first started to exhibit clinical malfunctions are not detected.  
Therefore, study 3 of this work will test CIEDs starting at 0.5Gy and further test 
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increments of 0.5.Gy per fraction, to a total cumulative ionising radiation dose 
whereby the device fails and onto end-point failure (test to destruction 60-120Gy).  
Using this low incremental value will allow accurate identification at which point any 
ionising radiation dose clinical defect occurs.  As per the preliminary study, CIED and 
lead exposure to ionising radiation will occur on a daily basis to enable device and 
lead recovery between fractions.  The preliminary study used six CIEDs from three of 
the CIED manufacturers.  In order for a robust statistical and analytical evaluation, 
the preliminary study highlighted the need to test more CIEDs and CIED leads in the 
PhD research project. 
 
Results from the preliminary study showed that subjecting the CIED leads to 
‘stressing’ did not have an impact on the physical condition of the leads.  Therefore, 
in study four of the PhD research project, the testing protocol will not include this part 
of the research method and protocol.  When stressing the CIED lead (in the 
preliminary study), the whole lead was required to provide a clinical representation of 
the route/path the CIED lead would take when in-situ in a patient.  However, as the 
PhD research project will be investigating the effects of physical construction, 
physical condition and levels of degradation as a result of ionising radiation exposure 
and EMI, the whole lead is not required to be tested.  Liaising with CIED 
manufacturers and the cardiology department it was decided that CIED lead testing 
could proceed using 5cm sections of the CIED lead.  The irradiating protocol remains 
the same.  This would allow for an increased number of sections of the lead to be 
tested and improve reliability and accuracy of the results. 
 
Significantly, the preliminary study only investigated the effects of ionising radiation 
on CIEDs and the leads.  Results from the literature review, showed that EMI could 
potentially cause the CIED to exhibit clinical malfunctions and failure (Zaremba, 
2015).  Therefore, study five of the PhD research project, will undertake to determine 
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the effect of EMI on CIEDs.  This will allow for a comprehensive analysis of the exact 
effects of both ionising radiation and EMI on CIEDs. 
 
Summary 
In this section, the methods and analysis of the preliminary study data has been 
discussed.  The focus of the preliminary study has been maintained to determine the 
relationship between ionising radiation and EMI and the damage it causes to CIEDs 
and their leads.  The experimental approach chosen for the preliminary study used a 
quantitative methodology of data collection to quantify the levels of damage to the 
CIEDs and leads caused by ionising radiation and / ore EMI.  In conclusion, this 
preliminary study provided the framework to develop and extend the PhD research 
project but as a proof of principle exercise it was highly beneficial. 
 
4.3.2    Ethical requirements 
At the start of the PhD research project, the research did not include patients or 
patient participation; therefore formal NHS ethical approval was not required.  
However, during the data collection phase of the study, patient information, such as  
patients’ medical history, CIED information and their radiotherapy treatment 
information was required to be included in case studies.  Therefore an application 
was made and NHS ethical approval was granted.  During the application process, 
strict parameters were identified; there would be no contact and communication with 
patients (and their families); there would be no change in any aspect of their 
radiotherapy or cardiology treatment and all information would be annoymised and 
kept confidential, in compliance with the Data Protection Act 1998.  All information 
and data collected in the course of this research project will only be used for the 
purpose of the study and will remain confidential. 
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4.3.3    Risk review 
With respect to the use of premises and equipment, the PhD research project has 
been subjected to risk review and peer review and been awarded R&D approval from 
RCW R&D Committee. Permission has also been given for access to radiotherapy 
machines and equipment from RCW. The study will be conducted primarily after 
clinical usage of radiotherapy treatment units, for example after-hours, weekends 
and/or planned breaks.  Researchers conducted a thorough risk analysis of the 
effects of ionising radiation in conjunction with the Radiation Protection Advisor at 
RCW.  All health care professionals participating in the research will be aware of the 
issues related to the exposure of ionising radiation, and will fully comply with the 
‘Ionising Radiation (Medical Exposure) Regulations 2000’. 
 
4.4    Research outcomes 
Study 6 
To provide evidence based guidelines for the safe management of cancer patients 
with CIEDs receiving radiotherapy treatment 
 
Research approach  
Study six adopted a systematic review as the research methodology.  It reviewed the 
evidence and literature to determine current ‘gold standard’ practice and provide 
evidence-based recommendations and guidelines for the management of cancer 
patients who have a CIED and are receiving radiotherapy treatment.    
 
Systematic reviews are ranked highly in research and are considered the most valid 
form of medical evidence, as they provide a complete summary of the current 
literature relevant to a research question (Gopalakrishnan and Ganeshkumar, 2013). 
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Research design and method 
A systematic review is designed to provide a complete, exhaustive summary of 
current literature relevant to specific research questions.  The Cochrane 
Collaboration defined a systematic review as “a review of a clearly formulated 
question that uses systematic and explicit methods to identify, select and critically 
appraise relevant research, and to collect and analyse data from the studies that are 
included in the review” (Higgins and Green, 2011).  According to Gough, Oliver, and 
Thomas (2013), a systematic review is a research method that is undertaken to 
review research literature, using systematic and rigorous methods. Systematic 
reviews are often referred to as ‘original empirical research’ because they review 
primary data, which can be either quantitative or qualitative.  Systematic reviews can 
be considered as the ‘gold standard’ for reviewing the current literature on a specific 
topic as it synthesises the findings of previous research investigating the same or 
similar questions (Boland et al, 2008) 
The systematic review process employs literature review methods to select only 
those studies that meet specific criteria, which reasonably confirm the rigour of the 
evidence produced, by a previously published study. Essential to a systematic 
review, is to establish a rigorous set of criteria, to appraise the reliability and validity 
of published research and develop an organised method of locating, analysing and 
evaluating such literature.   
 
This study reviewed the research systematically in three stages.  Firstly, it identified 
all relevant published and unpublished evidence and research and subsequently 
selected the studies for inclusion in the review.  Secondly, it critically appraised the 
research methods and assessed the quality of each study and finally it synthesised 
and presented the findings in an unbiased way.  The research design and method for 
each study is discussed in further detail under the sub-heading implementation of the 
study.  
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Data analysis 
Data from this study was presented narratively.  Narrative methods of synthesis can 
be used to synthesise both quantitative and qualitative studies and can be used 
when the experimental and quasi-experimental studies included in a systematic 
review are not sufficiently similar for a meta-analysis to be appropriate (Mays et al, 
2005). 
 
Narrative synthesis is used in different ways. In this study, it was used as an 
overarching term to describe the method for synthesising data narratively, focusing 
on the application of clinical guidelines for patients with CIEDs receiving radiotherapy 
treatment.  A narrative synthesis was used to systematically define and organise the 
data, highlight important characteristics of the studies and describe and comment on 
the methodological quality (risk of bias) of each study. 
Data synthesis in this study involved the collation, combination and summary of the 
findings of individual studies included in the systematic review, through a narrative 
approach.   The strength of evidence was assessed and the management guidelines 
and recommendations for patients with CIEDs receiving radiotherapy treatment 
across the studies were analysed and possible reasons for inconsistencies were 
investigated. This enabled reliable conclusions to be drawn from the included 
studies.  In the data analysis phase, the strength of the evidence was assessed and 
used to draw conclusions and inform the development of guidelines and 
recommendations.  
 
Data validity 
Research can vary considerably in methodological approach and rigour.  Flaws in the 
design or conduct of a study/report can result in bias and important themes and 
results can lack clarity.  The strengths and weaknesses of the included studies were 
documented, which provided an indication of whether the results have been 
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influenced by the study design, analysis process and/or the researchers.  Having 
assessed the quality of the study, results can inform the aims and protocols of the 
research.  Quality assessment justified if the studies were robust and reliable enough 
to provide clinical guidelines for the management of patients with CIEDs receiving 
radiotherapy treatment. 
 
Bias refers to systematic deviations from the true underlying effect brought about by 
poor study design or conduct in the collection, analysis, interpretation, publication or 
review of data. In order to mitigate the bias effect in this systematic review, the 
impact of search limitations and publication bias were minimised by not restricting the 
search to only electronic databases, which consist mainly of published journal 
articles.  Wider searching identified articles circulated as reports, conference papers 
and discussion papers.  Searching databases that included unpublished studies 
reduced the impact of publication bias.  
 
Selection process bias was minimised by including or excluding certain studies due 
to pre-formed opinions.  The process for study selection was documented in an 
explicit and objective way ensuring that this process is reproducible.  In order to 
assess the quality of documents, a proforma and checklist was created, which 
ensured all the studies were assessed are critically appraised in a standardised 
systematic way. 
 
4.5    Implementation of method  
4.5.1    Study 3 
To investigate and evaluate the relationship between cumulative ionising radiation 
dose and the damage sustained to CIEDs (pacemakers and ICDs). 
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Research questions: 
• What is the relationship between cumulative ionising radiation dose and 
damage sustained to CIEDs (pacemakers and ICDs)? 
• Is there is a safe minimum ionising radiation tolerance dose to CIEDs 
(pacemakers and ICDs)? 
• How will any damage to the CIED impact the patient clinically? 
 
Hypothesis: 
• As the level of ionising radiation dose increases, the greater the likelihood of 
CIED malfunction or failure also increases. 
 
Research design and method 
Research design 
The study was conducted under laboratory conditions and used a quantitative 
research strategy and adopted an experimental approach to data collection.  
 
CIEDs: 
• Total of thirty-three CIEDs was investigated in the study 
• Twenty-one explanted fully functioning pacemakers (seven pacemakers from 
manufacturer X, seven pacemakers from manufacturer Y and seven 
pacemakers from manufacturer Z) were tested.  3 pacemakers (one from 
each manufacturer) were used as a control, therefore, not exposed to any 
ionising radiation. 
• Twelve explanted fully functioning ICDs (five ICDs from manufacturer X, five 
ICDs from manufacturer Y and two ICDs from manufacturer Z) were tested.  3 
ICDs (one from each manufacturer) were used as a control. 
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• Reasons for explanation – patient died, not related to CIED and at time of 
death CIEDs were working correctly 
• All explanted CIEDs were decontaminated and suitable for safe handling 
• All explanted CIEDs had not been previously exposed to ionising radiation 
• Using the CIED programmer, it is vital to obtain a baseline report for the 
CIEDs prior to any exposure to ionising radiation as part of this study, as they 
are explanted devices and will each have different set parameters.  Using this 
baseline report will allow for accurate comparison of subsequent changes 
 
CIEDS programmed: 
The CIEDs were programmed with standard settings (DDD). 
• Dual (atrial and ventricular) pacing 
• Dual (atrial and ventricular) sensing 
• Dual response (inhibited and triggered) to sensing 
 
DDD is the standard programming of dual chamber CIEDs, in this mode both atrium 
and ventricle are sensed and paced.  For example, if both the sinoatrial node (SA) 
and atrioventricular (AV) node are functioning correctly, the CIED will only sense this 
activity and not be required to act.  If the atrium does not produce a pulse/beat, the 
CIED will pace the atrium at a preprogramed rate.  If this beat is not propagated 
through into the ventricles, the CIED will pace the ventricle.  This mode ensures 
atrioventricular (AV) synchronisation at rest and during exercise.  In DDD mode, the 
pacemaker follows the fastest rate, whether spontaneous atrial or sensor-driven. The 
maximum tracking rate and the maximum sensor-driven rate are independently 
programmable.  The DDD mode is the standard setting, for all pacemaker patients.  
On an ECG, the tracings may show spontaneous and paced atrial events as well as 
spontaneous and paced ventricular events. Schematically, both chambers might be 
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paced, or any combination of paced and sensed events from the atrium and 
ventricle. 
 
CIED programmed settings: 
• Minimum frequency – 60bpm and maximum frequency – 120bpm 
• Pulse duration – 0.5ms 
• Pulse amplitude – 2.5V 
• Sense threshold – 0.18mV 
• Dummy load resistor of 500Ω 
 
Additional programmed settings for ICDs only: 
• Antitachycardia pacing and shock therapies inactivated (to avoid discharge 
during handling and testing) 
• Ventricular tachycardia (VT) and ventricular fibrillation (VF) monitor zones 
were programmed active 
- VT zone from 167 bpm 
- VF zone from 214 bpm 
 
Environmental conditions: 
• In order to mimic clinical practice, CIEDs were placed in a phantom and 
tissue equivalent bolus material was placed on top of it, such that the middle 
of the device was located at the maximum dose depth to provide full 
backscatter conditions.  In this study, the maximum depth dose for the 6MeV 
photon beam was 1.5cm and 2.5cm for 10MeV photon beam.   The phantom 
had been developed as a result of the preliminary study and undergone and 
passed stringent quality assurance tests.   The design was necessary, as no 
 135 
phantom of this nature existed and it is highly adaptable and can be modified 
to test CIEDs and/or leads.  
• A standard radiotherapy unit (Varian 650c linear accelerator with 120MLC, 
portal imaging, beam energy 6MeV and 10MeV set as a dose rate of 
600MU/minute) was used to deliver ionising radiation. The distance from the 
head of the linear accelerator to the surface of the phantom including the 
tissue equivalent bolus was 100cm and the ionising radiation field size was 
set at 10x10cm2 
• LINAC room temperature and room pressure recorded as part of the daily QA 
procedure prior to data collection to ensure LINAC output was within 
expected tolerance  
• Linear accelerator beam energy – 6MeV / 10MeV 
 
CIED ionising radiation exposure: 
• As in the preliminary study, the CIED programmer telemetry wand was placed 
around the CIED under investigation (outside of the RT treatment room) 
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Figure 4.3: Photograph showing the testing set-up for CIED interrogation by 
the CIED programmer 
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Figure 4.4: Photograph showing the telemetry wand placed around the CIED in 
the phantom to allow for CIED interrogation  
 
 
• CIED programmer interrogated the CIED and provided a full service report 
• In the radiotherapy treatment room, the CIED was placed in the phantom and 
tissue equivalent bolus placed on top and positioned on the treatment couch, 
so that the CIED is within the primary radiotherapy photon beam.   
• The preliminary study identified an area of concern, as the CIEDs received a 
2Gy per fraction dose of ionising radiation.  Therefore, there was the potential 
that the exact point at which the CIED first started to exhibit clinical 
malfunctions were not detected.  Previous studies had indicated that a dose 
as low as 0.5Gy, may cause clinically significant defects.  Mouton et al (2002) 
observed small changes in pacing rate at even lower cumulative doses 
(<0.05Gy).  However, in the preliminary study, no evidence of CIED 
malfunction occurred at this level.  Therefore, the PhD research project tested 
CIEDs starting at 0.5Gy and further test increments of 0.5.Gy per fraction to 
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60Gy (end point failure).  Using this low incremental value allowed accurate 
identification at which point any device malfunctions occurred. 
• The CIEDs were also interrogated after every exposure to ionising radiation, 
using the CIED manufacturer-specific standard programmer and telemetry 
equipment.  
• The presence or absence of the following events were recorded:  
- Noise during the radiation exposure 
- Spontaneous change in programmed device parameters without reset to 
backup mode 
- Reset to backup mode or other error recoverable using the programmer 
- Error not recoverable using the programmer 
- Clinically significant reduction in battery capacity 
- Inappropriate antitachycardia pacing or delivery of shock therapy in the 
ICDs (even though this feature of the ICDs were deactivated during 
irradiation) 
- Loss of telemetry 
• CIEDs were irradiated to a total cumulative ionising radiation dose whereby 
the device exhibited failure and after reaching a cumulative ionising radiation 
dose of 60Gy, the dose per fraction was increased and delivered in 10Gy 
increments to CIED end-point failure (test to destruction 120Gy).   
• The testing protocol was repeated for both 6MeV and 10MeV photon beams. 
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Table 4.1 :  Testing protocol for CIED exposure to ionising radiation 
CIED  
type 
CIED 
Manufact. 
Control 6MeV 10MeV 
PM X PM  
X1 
PM  
X2 
PM  
X3 
PM  
X4 
PM  
X5 
PM  
X6 
PM  
X7 
PM Y PM 
Y1 
PM  
Y2 
PM  
Y3 
PM  
Y4 
PM  
Y5 
PM  
Y6 
PM  
Y7 
PM Z PM 
Z1 
PM  
Z2 
PM  
Z3 
PM  
Z4 
PM  
Z5 
PM  
Z6 
PM  
Z7 
ICD X ICD 
X1 
ICD 
X2 
ICD 
X3 
ICD 
X4 
ICD 
X5 
ICD Y ICD 
Y1 
ICD 
Y2 
ICD 
Y3 
ICD 
Y4 
ICD 
Y5 
ICD Z ICD 
Z1 
ICD 
Z2 
PM = Pacemaker    /   ICD = Implantable cardioverter defibrillator  
 
CIED interrogation: 
• On the programmer, ‘Quick start’ selected, this will automatically identify and 
interrogate the CIED and provide diagnostic evaluation.  
 
Figure 4.5: Screenshot of the CIED programmer switch on ‘welcome’ screen 
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• Programmer carried out the following advanced tests, which analysed and  
presented data in the initial interrogation screen (figure 4.6): 
- CIED pulse rate 
- CIED pulse width  
- CIED inhibition sensitivity 
- CIED mode setting - to determine if the devices were in ‘interference 
mode’ or ‘safe mode 
 
Figure 4.6: Screenshot of the CIED programmer - initial interrogation screen 
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• The CIED programmer will then conduct the following tests and provide 
individual reports for analysis:  
- Determine battery status  
 
Figure 4.7: Screenshot of the CIED programmer – battery status report (circled) 
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- Check lead / impedance integrity 
 
Figure 4.8: Screenshot of the CIED programmer – lead integrity / impedance 
reports (circled) 
 
 
Figure 4.9: Screenshots of the CIED programmer – lead integrity / impedance 
report 
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- Check sensing threshold 
Figure 4.10: Screenshots of the CIED programmer – sensing threshold reports  
 
 
Figure 4.11: Screenshots of the CIED programmer – sensing threshold reports 
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- Check pacing threshold 
Figure 4.12: Screenshot of CIED programmer – pacing threshold reports 
 
 
Figure 4.13: Screenshot of CIED programmer – pacing threshold reports 
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- Analyse diagnostics 
Figure 4.14: Screenshot of CIED programmer – diagnostic report 1 
 
 
 
Figure 4.15: Screenshot of CIED programmer – diagnostic report 2 
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- Assess current parameters 
Figure 4.16: Screenshot of CIED programmer – current parameters (circled) 
 
 
Figure 4.17: Screenshot of CIED programmer – current parameters – therapy 
guide 
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• Once interrogation was completed, a full service report was provided (which 
can either be downloaded onto USB or printed).  
 
Figure 4.18: Screenshot of CIED programmer – Full service report - selection 
 
 
4.5.2   Implementation of the method  
Study 4 
To investigate and evaluate the relationship between cumulative ionising radiation 
dose and the damage sustained to CIED leads 
 
Introduction 
Although ionising radiation may affect the function of the CIED, CIED leads are 
considered to be resistant to these effects (Lau, 2008).  However, anecdotal 
evidence from clinical practice suggests that ionising radiation might not just have an 
impact on the CIED but may also affect the physical condition, construction and the 
movement and vibration of the CIED leads that monitor and activate the device.  
Also, no CIED manufacturers have issued any ionising radiation tolerance doses for 
CIED leads. 
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Lead malfunction is the most common cause of CIED therapy failure (Lau, 2008).  
Lead malfunction has been defined as not performing according to specifications or 
intentions (Lau, 2008).  Even when all the electrical parameters are within normal 
limits, structural compromises in a CIED lead may still pose dangers to the patient 
through cardiac perforation, thrombogenesis, bacterial infection, interference with 
adjacent leads and difficulty in extraction (Lau, 2008). 
 
Aim: 
• To determine the effect of ionising radiation and or EMI on CIED leads 
 
Research questions: 
• What is the relationship between cumulative ionising radiation dose and 
damage sustained to CIED leads? 
• Does exposure to ionising radiation affect the dielectric properties of CIED 
leads? 
• Is there is a safe minimum ionising radiation tolerance dose to CIED leads? 
• How will any damage to the CIED lead impact the patient clinically? 
 
Hypothesis: 
• As the level of ionising radiation dose increases, the greater the likelihood of 
CIED lead damage and therefore lead malfunction or failure.  
 
Research design and method 
Research design 
The study was conducted under laboratory conditions and used a quantitative 
research strategy and adopted an experimental approach to data collection.  
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CIED lead testing 
This study looked to determine effects of physical construction (as this differs 
between leads), physical condition and levels of degradation as a result of exposure 
to ionising radiation. 
 
This study consisted of two parts: 
1. CIED lead testing – exposure to ionising radiation 
2. CIED laboratory lead testing – the measurement of the effect of ionising 
radiation on the dielectric properties of the poly(ether)urethane sheath that 
insulates the CIED leads. 
 
CIED lead conditions 
• Thirty-six CIED leads (four different lead types) from manufacturer X were 
investigated in this study. 
 
Lead Testing  
• A standard radiotherapy unit (Varian 650c linear accelerator with 120MLC, 
portal imaging, beam energy 6MeV and 10MeV set at a dose rate of 
600MU/minute) was used to deliver the ionising radiation.  
• The distance from the head of the linear accelerator to the surface of the 
phantom including the tissue equivalent bolus was 100cm and the ionising 
radiation field size was set at 10x10cm2. 
• In order to mimic clinical practice, the CIED lead sat in a ‘groove’ in a clear 
polymethylmethacrylate block phantom and tissue equivalent bolus material 
was placed on top of it, such that the lead was located at the maximum dose 
depth to provide full backscatter conditions (1.5cm for 6MeV photon beam 
and 2.5cm for 10MeV photon beam).   
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• The CIED lead being irradiated and interrogated was positioned precisely 
along the projected central axis (isocentre) of the primary radiation beam.   
 
Environmental conditions: 
• LINAC room temperature and room pressure recorded as part of the daily QA 
procedure prior to data collection to ensure LINAC output was within 
expected tolerance  
• Linear accelerator beam energy – 6MeV and 10MeV* 
 
Testing protocol: 
Research has shown that CIED leads are considered to be resistant to effects of 
ionising radiation and EMI (Hurkmans, 2005 and Zaremba 2015).  Results from the 
preliminary study suggested that CIED leads can be effected starting at a cumulative 
ionising radiation dose of 30Gy.   Therefore, phase 1 of the study tested CIED leads 
starting at 20Gy and further test increments of 10Gy per fraction to 120Gy.  The 
leads were subjected to magnetic and electrical testing, which measured the 
dielectric properties of the polymer / sheath of the CIED lead.  If the CIED leads 
showed any changes in physical construction, physical condition or showed evidence 
of degradation, phase two testing was undertaken.   As the CIED leads have been 
previously irradiated in 10Gy increments, identification of the ionising radiation dose 
range that caused this change was recorded.  Therefore, phase two testing used the 
same testing set-up and protocol but the leads were irradiated in 2Gy increments.  
The leads were then subjected to the same magnetic and electrical testing.  Using 
this lower incremental fractionation allowed for accurate identification at which point 
any changes in the CIED lead occurred.  The CIED leads were irradiated to a total 
cumulative ionising radiation dose at which point the CIED lead failed (120Gy).  The 
testing protocol was repeated for both the 6MeV and 10MeV photon beams. 
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Table 4.2 :  Testing protocol for CIED lead exposure to ionising radiation 
LEAD CIED 
Manufact. 
Control 6MeV 10MeV 
Lead 
Type 1 
X L1 
X1 
L1 
X2 
L1 
X3 
L1 
X4 
L1 
X5 
L1 
X6 
L1 
X7 
L1 
X8 
L1 
X9 
Lead 
Type 2 
X L2 
X1 
L2 
X2 
L2 
X3 
L2 
X4 
L2 
X5 
L2 
X6 
L2 
X7 
L2 
X8 
L2 
X9 
Lead 
Type 3 
X L3 
X1 
L3 
X2 
L3 
X3 
L3 
X4 
L3 
X5 
L3 
X6 
L3 
X7 
L3 
X8 
L3 
X9 
Lead 
Type 4 
X L4 
X1 
L4 
X2 
L4 
X3 
L4 
X4 
L4 
X5 
L4 
X6 
L4 
X7 
L4 
X8 
L4 
X9 
 
Figure 4.19: Photograph showing the CIED lead sheath interrogation 
equipment set-up 
 
 
This research investigated the dielectric properties of the poly(ether)urethane sheath 
that insulates the CIED leads.  The aim of the study was to determine the dielectric 
strength and identify if the physical condition of the polyurethane sheath has been 
altered and damaged due to the exposure to ionising radiation.  
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As part of this study, a novel microwave experiment was established to test this 
hypothesis.  Measurements of the electrical conductivity of the polymer at microwave 
frequencies were taken. A microwave resonant cavity (hairpin resonator) was 
connected to a vector network analyser and the sections of CIED lead sheath were 
inserted into the cavity in order to ‘perturb’ or change the cavity characteristics. This 
technique is well established but has never before been used to characterise any 
polymer changes in CIED leads.  
 
Figure 4.20: Schematic representation showing the CIED sheath lead testing 
set-up
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4.5.3   Implementation of the method 
Study 5 
To investigate and evaluate the relationship between EMI and the damage sustained 
to CIEDs (pacemakers, ICDs and rate response activated CIEDs)  
 
Aim: 
• To determine the effect of EMI on CIEDs (pacemakers and ICDs) 
 
Research questions: 
• What is the relationship between EMI and damage sustained to CIEDs? 
• How will any damage to the CIED impact the patient clinically? 
 
Hypothesis: 
• As exposure to EMI increases, the greater the likelihood of CIED damage and 
therefore CIED malfunction or failure.  
 
Research design and method 
Research design 
The study was conducted under laboratory conditions and used a quantitative 
research strategy and adopted an experimental approach to data collection.  
 
This study consisted of 3 parts: 
1. Electro-magnetic field measurements – the measurement of 
electromagnetic fields in the radiotherapy treatment room (linear accelerator) 
2. Laboratory tests – the measurement of the effect of non-ionising radiation 
electromagnetic fields on CIEDs in a laboratory setting  
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3. CIED testing with ionising radiation – the measurement of the effect of 
ionisng radiation electromagnetic fields on CIEDs in the radiotherapy 
treatment room (linear accelerator) 
 
1.  Electro-magnetic field measurements 
The electromagnetic spectrum is organised by frequency; lower frequency radiation 
is on the left, and higher frequency radiation is on the right.  The properties of 
electromagnetism change at different frequencies, and electric and magnetic fields 
behave differently along the spectrum.  The interaction between electro-magnetic 
radiation and matter changes as the frequency changes.  In order to determine the 
effect of EMI on CIEDs, firstly the levels of EMI emitted from the linear accelerator 
during ionising radiation exposure were measured and recorded.  
 
A standard Varian 650c linear accelerator was used, with 120MLC, portal imaging, 
beam energy 6MeV and 10MeV set at a dose rate of 600MU/minute was used. In a 
linear accelerator electrons are accelerated by the action of radio-frequency 
electromagnetic waves. Relatively low energy electrons are injected into an 
accelerating structure and gain energy as they travel down the structure. In most 
electron linear accelerators, very high frequency waves (usually of wavelength of 
around 10cm equal to approximately 3 GHz) are used and these are made to 
propagate down the accelerating structure in the same direction as the electrons.   
The RF power at 3 GHz, used for electron acceleration, is well contained within the 
transmission and accelerating waveguides in the linear accelerators (Burke et al, 
2099).  In practice the RF power levels needed to perform electron acceleration are 
such that this action cannot be sustained continuously and almost all linacs operate 
in a pulsed repetitive mode, thereby emitting RF noise while producing pulsed 
radiation (Carlone et al 2008, 2007) due to the switching of large voltages. For 
example, discharging of the pulse-forming network in the modulator causes large 
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currents and voltages to be switched in several linac components (e.g., magnetron, 
thyratron, etc), which can lead to unwanted RF emissions.  Burke et al (2009), In a 
study by Burke et al (2009), they investigated the RF emissions produced by three 
different clinical linear accelerators at both 6MeV and 15MeV operations.  They 
concluded that the RF spectra produced, showed little dependence on beam energy.  
Results from study two of this research project shows that patients had exhibited 
cardiac reactions when receiving radiotherapy treatment at both 6MeV and 10MeV 
even when their CIED received a negligible dose of ionising radiation.  Therefore, as 
part of this study RF noise was investigated at both beam energies, to determine if 
that linear accelerator caused different CIED reactions depending on the beam 
energy.   The results from this provided radiofrequency (RF) measurements, which 
are measurements of ambient (surrounding) electromagnetic fields produced by the 
linear accelerator, which can penetrate through many materials and reflect off others. 
 
The electromagnetic field measurements were performed and recorded using 
sensors, probes (antenna) and a FieldFox vector network analyser (VNA).  The 
measurement system consisted of a field antenna and a frequency selective receiver 
or spectrum analyser, which monitored the frequency range of interest.  The field 
antenna was placed in the radiotherapy treatment room, next to the treatment couch, 
near the couch midpoint.  When the linear accelerator was switched ON, the VNA 
scanned the resulting RF emissions.  The EMI signals were amplified and recorded 
using a signal analyser and the EMI frequency spectra was produced. 
 
A VNA is a test system, precision measuring tool that tests the electrical performance 
of high frequency components, in the radio frequency (RF), microwave, and 
millimetre-wave frequency bands. The VNA is a stimulus response test system, 
composed of an RF source and multiple measurement receivers.  This research 
determined the EMI frequency spectra within the RF range and was used to measure 
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the scattering parameters (S-parameters) of RF components.  S-parameters 
describe the electrical behaviour of linear electrical networks when undergoing 
various steady state stimuli by electrical signals.  Although applicable at 
any frequency, S-parameters are mostly used for networks operating at radio 
frequency (RF) and microwave frequencies where signal power and energy 
considerations are more easily quantified than currents and voltages.  This research 
investigated within this range.  
 
One of the most fundamental concepts of high-frequency network analysis involves 
incident, reflected and transmitted waves traveling along transmission lines.  RF 
waves travelling along a transmission line can be thought of in a similar way to the 
way light waves travel through a medium.  Consider what happens when incident 
light strikes a lens of different materials.   If the lens is clear, most of the light passes 
through and only a small amount of light is reflected off the surface of the lens.  On 
the other hand, if the lens has a mirrored surface, then most of the light will be 
reflected and little or none would be transmitted through the lens. This principle also 
applies to RF signals; except the electromagnetic energy is in the RF range and 
electrical devices replace the lenses and mirrors. Network analysis is concerned with 
the accurate measurement of the ratios of the reflected signal and the transmitted 
signal to the incident signal.  
 
2.  Laboratory tests 
The influence of EMI on CIEDs was tested in the laboratory under experimental 
conditions.  A coil was connected to an alternating current (AC) supply, which 
produced electro-magnetic fields in the frequency range of 10-10000Hz.  The CIED 
was placed in the phantom and then inside the coil.  The CIEDs were connected to a 
simulator and a CIED programmer to replicate the electrical behaviour of a paced 
heart. The output pulse was monitored using an oscilloscope and an ECG machine.  
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The CIED’s operating parameters and signal were generated by the arbitrary wave 
generator and connected to the digital oscilloscope and synchronised the patients 
intrinsic heart beat with the function of the CIED.  The operation of the CIED was 
monitored throughout exposure to the electromagnetic fields.  The CIEDs were 
subjected to programming and functionality tests after each electromagnetic field 
exposure. 
 
Figure 4.21: Schematic representation of the design principle and set-up for 
EMI testing 
 
 
3.  CIED testing with ionising radiation 
CIED conditions 
• Total of sixteen CIEDs from manufacturer X were investigated in this study: 
- Five new pacemakers 
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- Six new pacemakers with rate response activated (three with rate 
response sensor accelerometer detection and three with rate response 
sensor minute ventilation detection) 
- Five new ICDs from manufacturer X were tested 
- The control group consisted one pacemaker, one pacemaker with rate 
response sensor accelerometer detection, one pacemaker with rate 
response sensor minute ventilation detection and one ICD.  These 
devices were not exposed to EMI 
-  
Table 4.3 :  Testing protocol for CIED exposure to EMI 
CIED  
type 
CIED 
Manufact. 
Control 6MeV 10MeV 
PM X PM  
X8 
PM  
X9 
PM  
X10 
PM  
X11 
PM  
X12 
PM 
*1 
X PM  
X1RA 
PM  
X2RA 
PM  
X3RA 
PM 
*2 
X PM  
X1RMV 
PM  
X2RMV 
PM  
X3RMV 
ICD X ICD 
X6 
ICD 
X7 
ICD 
X8 
ICD 
X9 
ICD 
X10 
*1 -  Rate response activated CIED.  Sensor – Accelerometer (A) detection 
*2 -  Rate response activated CIED.  Sensor – Minute (MV) detection 
 
Environmental conditions 
• LINAC room temperature and room pressure recorded as part of the daily QA 
procedure prior to data collection to ensure LINAC output was within 
expected tolerance  
• Linear accelerator beam energy – 6MeV and 10MeV* 
 
A standard radiotherapy Varian linear accelerator unit was used in this study.  When 
the linear accelerator was switched on it produced both ionising radiation and 
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electro-magnetic fields.   In order to classify the damage sustained to the CIEDs as a 
result of exposure to these electro-magnetic fields only, the CIEDs (in the phantom) 
were not placed within or in close proximity to the radiotherapy treatment beam.  
Therefore, the calculated cumulative ionising radiation dose to the CIED was 
negligible and all effects exhibited by the CIED would be due to interference (EMI) 
with the electromagnetic fields generated by the linear accelerator.   
 
CIED testing / irradiation 
The CIEDs were connected to a simulator and a CIED programmer to replicate the 
electrical behaviour of a paced heart.  The output pulse was monitored using an 
oscilloscope and an ECG machine and a stepped attenuator was used to give preset 
amplitude inhibition pulses.  The CIED’s operating parameters and signal was 
generated by the arbitrary wave generator and connected to the digital oscilloscope 
and synchronised the patients intrinsic heart beat with the function of the CIED. 
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Figure 4.22: Schematic representation of the design principle and set-up for 
EMI testing – between the radiotherapy treatment room and control room 
 
 
Figure 4.23: Photograph showing EMI testing equipment in the radiotherapy 
treatment room 
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In order to determine at which point the CIED exhibited malfunctions, the devices 
were exposed to levels of EMI as per daily radiotherapy treatment, six separate 
radiation beams per fraction: 
• Pre-EMI beam On exposure (1 minute) 
• Beam ON - switch ON point (Instant) 
• During beam ON - when the LINAC is emitting ionising radiation (90 seconds) 
• Beam OFF - switch OFF point (Instant) 
• Post-EMI beam OFF exposure (1 minute) 
 
Total CIED exposure to EMI occurred on a daily basis for ten fractions with a two-day 
break after five fractions to enable device recovery between fractions.   The CIEDs 
were subjected to programming and functionality tests after each ionising radiation 
exposure. This testing protocol was repeated for both the 6MeV and 10MeV photon 
beams. 
 
CIED interrogation  
Before and after each EMI exposure, measurements were taken of the CIEDs pulse 
rate, pulse width and inhibition sensitivity.  During exposure, the simulator provided 
programming and functionality data, which was then analysed to determine if the 
program memory has been corrupted.  The devices inhibition will also checked to 
determine whether the devices were in ‘interference mode’ or ‘safe’ mode.    
 
The CIED were subjected to the following programming and functionality tests after 
each ionising radiation exposure:  
• Noise during the EMI exposure 
• Spontaneous change in programmed device parameters without reset to 
backup mode 
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• Reset to backup mode or other error recoverable using the programmer 
• Error not recoverable using the programmer 
• Clinically significant reduction in battery capacity 
• Inappropriate antitachycardia pacing or delivery of shock therapy in the ICDs 
(even though this feature of the ICDs were deactivated during irradiation) 
• Loss of telemetry 
• Pacing inhibition 
• Inappropriate tracking 
• CIEDs failure 
• Runaway pacing with induction of potentially life-threatening ventricular 
arrhythmias 
 
4.6    Research outcomes 
Study 6  
To provide evidence based guidelines for the safe management of cancer patients 
with CIEDs receiving radiotherapy treatment 
 
Introduction 
In 2013, as part of the PhD research project, the researcher conducted and 
published a national review of cardiac device policies in use in radiotherapy 
departments across the UK and reported that most policies do not reflect current best 
evidence (Lester el al, 2014).
  
In 2014, The Royal College of Radiologists, the 
Society and College of Radiographers and the Institute of Physics and Engineering in 
Medicine formed a multidisciplinary working party comprising clinical oncology, 
cardiology, therapeutic radiography and medical physics expertise to develop 
guidelines for the management of cancer patients receiving radiotherapy with a 
CIED.  Based on the researcher’s previous research in this field, specific PhD 
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research and aims and publications, they were appointed to co-chair this working 
party.  This paper was published for clinical use in UK radiotherapy departments 
(Sor.org, 2015). (See appendix F). 
 
The PhD research project has investigated the effects of ionising radiation and EMI 
on CIEDs and leads.  Results from this research will provide recommendations that 
will allow for the publication of up to date, evidence based guidelines for the safe 
management of patients with a CIED receiving radiotherapy treatment.  
 
Aim: 
• Review the evidence and literature to determine current ‘gold standard’ 
practice  
• Provide recommendations for the management of cancer patients who have a 
CIED and are receiving radiotherapy. 
 
Research design and method 
Research design 
The study adopted a systematic review as the research methodology.  It reviewed 
the evidence and literature to determine current ‘gold standard’ practice and in 
conjunction with the findings of the PhD research project, provided recommendations 
for the management of cancer patients who have a CIED and are receiving 
radiotherapy. 
 
This systematic review was conducted prospectively, using a pre-defined proforma 
and checklist that guided the data collection and synthesis process, it defined and 
logically structured all steps in the systematic review 
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Step 1 – Review question   
The review questions were set to establish an objective methodology and search 
criteria, which guided the systematic review 
 
Step 2 – Literature search 
The literature review was divided into two stages.  The first was a broad exploratory 
Ovid Medline search, designed to identify appropriate medical subject headings 
(MeSH).  The keywords used at this stage were radiotherapy, pacemaker, 
defibrillator, ICD and cardiac device.  Hand searching of journals, relevant books, 
and review articles was also carried out. The second stage of the process was the 
application of the generated MeSH terms and keywords in a comprehensive search 
of the following databases: MEDLINE, EMBASE, and Cancerlit.  Subject headings 
were modified as required by individual databases. All published literature on the use 
of radiotherapy in patients with CIEDs was reviewed to define best practice and 
inform guideline development.  
 
Step 3 – Critical appraisal  
An in-depth appraisal of the selected studies was conducted by judging it against 
criteria identified at the first stage.  All subsequent published literature on the use of 
radiotherapy in patients with CIEDs was reviewed using the Critical Appraisal Skills 
Programme (CASP - Critical Appraisal Skills Programme, 2018) in order to define 
best practice. 
 
Step 4 – Data extraction  
Data extraction is ‘the process by which researchers obtain the necessary 
information about study findings from the included studies’.  In this step, all relevant 
findings meeting the selection criteria to form the body of evidence regarding the 
research questions were extracted. 
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Step 5 – Data synthesis 
The reviewed studies were summarised to form the outcome of the systematic 
review.  The strength of the study findings was assessed, using agreed upon, 
specified assessment criteria and summarised the results in a systematic, evidence-
based literature review document. 
 
4.7    Chapter conclusion 
This chapter outlines and explains the reasoning and approach by which the 
research was undertaken; it addresses the research questions stated and the 
development of the research methodology and method for each study.  In discussing 
the preliminary study, the methods of data collection and data analysis procedures 
were detailed.  It concludes with explaining how the results from the preliminary 
study informed the PhD research project.  Finally, this chapter outlines the 
implementation of the PhD research project and details the research method and 
data collection procedures for all six studies.  The results from these studies will be 
discussed in subsequent chapters. 
!
! !
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Chapter Five 
Test compliance, knowledge, understanding and perception 
 
 
5.1    Introduction 
As part of the PhD research project, it was considered fundamental to establish 
current UK practice regarding the management of patients with CIEDs undergoing 
radiotherapy treatment and compare this practice to current ‘gold standard’ evidence-
based guidelines.  This chapter details the findings of the national audit and 
reinforces the outcomes that show patients with CIEDs are being put at significant 
risk of harm when exposed to ionising radiation and EMI when receiving radiotherapy 
treatment.   
 
A series of audits of clinical practice at a Welsh radiotherapy centre were carried out 
to determine the effects of ionising radiation and EMI on all patients with CIEDs 
receiving radiotherapy treatment.  This chapter outlines radiotherapy induced device 
malfunction and discusses the results from this audit. 
 
Earlier chapters have documented the developments and improvement in pacing 
CIED technology, one such advancement being rate response activated CIEDs, 
which are increasingly being implanted in patients for the management of their 
cardiac conditions.  However, there is no research into the effect of ionising radiation 
and EMI on these particular devices, hence a second clinical audit was carried out to 
assess device malfunctions in these patients.  This chapter details the observed 
clinical reactions in patients and discusses the need for research into the effect of 
ionising radiation and EMI on these contemporary CIEDs as part of the PhD research 
project. 
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5.2    Study 1 
To establish current UK practice regarding the management of patients with CIEDs 
undergoing radiotherapy treatment and to compare this practice with current ‘gold 
standard’ evidence-based guidelines. 
 
Results 
In total, sixty-seven radiotherapy centres were identified in the UK and contacted. 
Overall, 47/67 (70%) centres responded to the request to provide their policy for 
inclusion in the audit. Forty-five centres provided their policy and two centres were 
currently re-writing their CIED policy and thus excluded from the results. Twenty 
centres did not respond to the request. The analysis was carried out on the forty-five 
polices submitted that are currently in use. 
 
Table 5.1:  Results - Roles and responsibilities of healthcare professionals 
 
Roles and responsibilities 
Number of 
radiotherapy 
department 
policies  
n= 45 
% 
Consultant oncologist:   
Identify patient’s CIED status and highlight on radiotherapy referral form 39 87 
Contact patient’s cardiology department before starting radiotherapy treatment 41 91 
Request cardiology assessment 34 76 
Provide medical physics with information to calculate cumulative radiotherapy dose 
to CIED 
36 80 
Dose to the implantable internal pacemaker does not exceed 2 Gy 31 69 
Dose to the ICD does not exceed 2 Gy 5 11 
Consent – patient aware of potential adverse effects of radiotherapy on cardiac 
device 
12 27 
Consent – switch off ICD during radiotherapy 5 11 
Planning radiographers:   
Annotated patient’s CIED status 34 76 
CIED included in scan if in/close to the radiotherapy treatment field 35 78 
Medical physics informed of patient’s CIED status 35 78 
Contact consultant if CIED is within radiotherapy treatment field or estimated dose 
too high 
29 64 
Treatment radiographers:   
Appropriate monitoring procedure for patients with pacemakers 14 31 
Appropriate monitoring procedure for patients with ICDs 12 27 
Medical physics:   
Dose estimation calculated for CIEDs and leads  36 80 
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Overall, 39/45 (87%) policies require the clinical oncologist to state whether a CIED 
is present on the radiotherapy referral form; 41/45 (91%) policies require the clinical 
oncologist to contact the patient’s cardiology department before starting 
radiotherapy; 34/45 (76%) policies require a cardiology assessment prior to 
commencement of radiotherapy treatment; 36/45 (80%) policies require the clinical 
oncologist to provide relevant information to medical physics to allow the calculation 
of the estimated cumulative dose to the CIED before starting radiotherapy; 12/45 
(27%) policies require patients fitted with CIEDs to be informed of the risks to 
themselves and their device before starting radiotherapy; 5/45 (11%) policies state 
that patients fitted with ICDs should be informed about the possibility of ICD 
malfunction or failure during radiotherapy treatment and must give consent to 
deactivate the ICD during radiotherapy treatment.  !
 
 
Of note is that in only 29/45 (64%) policies is it mandatory for the planning 
radiographer to contact the treating consultant if the CIED is within a radiotherapy 
treatment field or if the estimated dose is too high. Less than a third of policies 
include appropriate monitoring procedures for treatment radiographers in patients 
with pacemakers or ICDs. There is no requirement for medical physics to calculate 
the estimated dose to CIEDs and leads in 9/45 (20%) policies.  
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Table 5.2:  Results - Adherence to American Association of Physics in 
Medicine (AAPM) (Marbach et al, 1994) and Frizzell (2009) Guidelines 
 
 
Adherence to American Association of Physics in  
Medicine (AAPM) and Frizzell Guidelines 
Number of 
radiotherapy 
department 
policies 
(n=45)  
% 
Pacemakers - AAPM guidelines:   
2 Gy radiotherapy tolerance dose to device stated 31 69 
Requirement to contact cardiology if radiotherapy dose to pacemaker exceeds 2 Gy 21 (of 31) * 68 
No radiotherapy tolerance dose stated 14 31 
Do not contact cardiology 14 (of 14) * 100 
Cardiology follow-up made after radiotherapy completed 30 67 
ICDs - Frizzell Report:   
0.5 Gy radiotherapy tolerance dose to device stated 5 11 
Requirement to contact cardiology if radiotherapy dose to ICD exceeds 0.5 Gy 5 (of 5) * 100 
1 Gy radiotherapy tolerance dose to device stated (exceeding 0.5 Gy tolerance dose) 9 20 
Do not contact cardiology if radiotherapy dose to ICD exceeds 1 Gy 9 (of 9) * 100 
2 Gy radiotherapy tolerance dose to device stated (exceeding 0.5 Gy tolerance dose) 14 31 
Do not contact cardiology if radiotherapy dose to ICD exceeds 2 Gy 13 (of 14) * 93 
No radiotherapy tolerance dose stated 17 38 
Do not contact cardiology if no radiotherapy tolerance dose is stated 17 (of 17) * 100 
Cardiology follow-up made after radiotherapy completed 30 67 
* represents different ‘n’ 
 
31/ 45 (69%) policies define the radiotherapy tolerance dose to the pacemaker 
recommended in the AAPM guidelines. Of these, 21/31 (68%) policies require the 
cardiology department to be contacted to discuss safe management of the patient. In 
total, 14/45 (31%) policies do not define a tolerance dose limit to the pacemaker and 
none of these radiotherapy centres contact the patient’s cardiology department. Only 
5/45 (11%) policies define the radiotherapy tolerance dose limit to the ICD as 0.5Gy 
and all five of these radiotherapy centres contact the cardiology department to 
discuss the management of the patient; 23/ 45 (51%) policies define a dose limit of 
>0.5Gy to the ICD and 17/45 (38%) policies do not define a dose limit. 39/40 (98%) 
policies that use an incorrect tolerance dose limit or do not define a dose limit do not 
mandate contacting the patient’s cardiology department for advice. 30/45 (67%) 
policies require a follow-up appointment to be made with the patient’s cardiology 
department after the completion of radiotherapy.  
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Table 5.3:  Results – Monitoring requirements for patients with CIEDs receiving 
radiotherapy 
 
 
Clinical practice - monitoring of patients with cardiac devices 
Number of 
radiotherapy 
department 
policies 
(n=45) 
% 
Pacemakers - AAPM guidelines:   
Appropriate monitoring procedure 14 31 
Appropriate staff used to monitor patients 14 31 
Close observation of patient using cardiac monitor on first fraction of radiotherapy 14 31 
Subsequent monitoring requirements assessed and annotated 14 31 
ICDs - Frizzell report:   
Appropriate monitoring procedure 12 27 
Appropriate staff used to monitor patients 12 27 
12 lead continuous strip ECG before first fraction of radiotherapy 12 27 
Deactivate ICD with magnet during radiotherapy 12 27 
Continuous strip ECG monitoring for all subsequent treatments 12 27 
Document any change in patient’s status 12 27 
 
Overall, 31/45 (69%) policies do not define monitoring procedures for patients with 
pacemakers in line with the AAPM guidelines (Marbach et al, 1994) and none 
mandate the use of appropriately trained staff to monitor patients. Similarly, 33/45 
(73%) policies do not define monitoring procedures for patients with ICDs in line with 
the Frizzell report (2009) and none mandate the use of appropriately trained staff to 
monitor patients.  
!
Discussion 
The number of patients with CIEDs undergoing radiotherapy treatment is increasing 
(National Radiotherapy Advisory Group, 2007).  The audit of UK radiotherapy 
departments’ CIED policies highlighted substantial differences in the management of 
patients who have a CIED and are receiving radiotherapy treatment (Lester et al, 
2014).  Whilst most medical treatments pose little danger to the functioning of CIEDs, 
some such as radiotherapy have the potential to cause undesirable interactions.   A 
further complication is the variability in behaviour of any given CIED when it is in, or 
in close proximity to, the radiotherapy treatment field (Solan et al, 2004).  In addition 
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to issues of radiation and electromagnetic interference effects, published literature is 
inconsistent in its findings and recommendations on the management of radiotherapy 
tolerance doses to cancer patients with a CIED.  An American report suggests that 
12% of oncology centres have neither a formal risk management strategy nor a CIED 
policy, and that only 15% actually have a written policy  (Solan et al, 2004).  As it is 
not clear whether the situation is similar here in the UK, the lack of written national 
policy and deviation from evidence-based guidelines such as the AAPM was of major 
concern.   Therefore, one of the aims of the audit was to determine current UK 
radiotherapy departmental practice and if necessary, reinforce the need for a national 
policy documenting the safe and efficient management of patients with CIEDs who 
undergo radiotherapy.  This audit used the 1994 AAPM guidelines  (Marbach et al, 
1994) and recommendations of Frizzell (2009) as the benchmark to analyse UK 
radiotherapy centres’ current CIED policies, as these guidelines had the most robust 
evidence-base to support them. 
 
The aim of the audit was to determine how many UK radiotherapy centres have a 
CIED policy in routine use. All radiotherapy department managers were asked to 
provide their current CIED policy for analysis.  The audit yielded a response rate of 
70%; 45 respondents provided their policy while two centres stated that they were in 
the process of re-writing their policy.  A third follow-up email was sent from the 
Society and College of Radiographers asking radiotherapy centres to forward their 
policy or to inform them if they did not have one.  At that point, it wasn’t known 
whether the remaining 20 radiotherapy centres who had not responded had a policy.  
The lack of an over-arching national policy on this therapy area is not specific to the 
UK. As Solan et 2004 shows the United States to have similar deficiencies.  
 
 
 172 
The audit results highlight major differences between policies in the roles and 
responsibilities of healthcare professionals involved in the patient pathway and the 
management of patients with a CIED receiving radiotherapy.  From the results of the 
audit, in 87% of radiotherapy centres, the treating Clinical Oncologist determines 
CIED status and highlights it on the radiotherapy referral form. This means that in 
13% of the policies included in this review, it is left to radiographers to identify 
whether a CIED is present. Anecdotal evidence from this audit shows that in some 
cases, a CIED is not discovered until a patient attends for radiotherapy.  One 
radiotherapy department highlighted an incident whereby a patient informed the 
treatment radiographer on the first day of radiotherapy that they had a pacemaker.  
Records show that the patient had not previously been asked if they had a CIED.  
Therefore, radiotherapy treatment could not commence that day.  There was further 
delay, while the patient’s cardiology department was contacted and all information 
regarding the patient and their CIED was obtained.  This information revealed that 
patient had an ICD, which required the device to be switched off during radiotherapy 
treatment and close monitoring. This potentially dangerous scenario is less likely if 
the treating Clinical Oncologist determines early on in the treatment pathway that a 
CIED is present and informs the planning and treatment teams.  
 
Worryingly, in only 29/45 (64%) policies is it mandatory for the treating consultant to 
be contacted if the CIED is within a radiotherapy treatment field or if the estimated 
dose is too high. In most cases, this communication would probably happen even in 
the absence of policy. However, given the potential harm to the patient, this should 
be explicit. There is clearly a need for policies in use to include monitoring 
procedures for treatment radiographers in patients with pacemakers or ICDs. These 
procedures are currently included in less than one-third of policies and it is vital that 
patients having treatment are monitored to minimise the chance of harm. There is no 
requirement for medical physics staff to calculate the estimated dose to CIEDs and 
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leads in 9/45 (20%) policies. Without this estimation being made before radiotherapy 
starts, patients may be exposed to doses of radiation that exceed the limits 
recommended by AAPM and Frizzell  (Marbach et al, 1994 and Frizzell, 2009). 
 
The AAPM report recommended that the cumulative radiotherapy dose to the 
pacemaker be limited to less than 2Gy (Marbach et al, 1994).  In the audit, only 69% 
of radiotherapy centres limit the cumulative dose to the pacemaker to 2Gy and of 
these, only 68% communicate with the cardiology department if the dose exceeds 
2Gy. It is concerning that 32% of policies defined no tolerance dose to the 
pacemaker.  There is evidence that even low cumulative doses of radiotherapy may 
damage CIEDs and it is likely that patients are being put at risk of harm with the 
current CIED policies in use (Last, 1998).  If the calculated dose to the pacemaker is 
greater than 10Gy, the Clinical Oncologist must immediately contact the referring 
cardiology department with a view to re-siting the pacemaker.  This consultation 
should be completed as soon as possible, as further surgery for re-siting will cause a 
delay in the delivery of the patient’s radiotherapy treatment.  If the cumulative dose to 
the pacemaker is between 2-10Gy, the Clinical Oncologist would need to liaise with 
medical physics to discuss how to optimise the patient’s radiotherapy plan and limit 
the dose to the pacemaker.  At one radiotherapy department, during the radiotherapy 
planning process, it was noted that 3 patients would be receiving a total dose of 
greater than 2Gy to the pacemaker.  The referring cardiology department was 
immediately contacted and the patients were reviewed and underwent a device 
check.  The cardiology department then informed the Clinical Oncologist that the 
patient’s radiotherapy treatment could commence, but close monitoring was deemed 
necessary. During radiotherapy treatment, Patient One displayed ‘device 
malfunctions’, due to a change in sensitivity and experienced symptoms typical of 
bradycardia (dizziness), which prompted a device, check midway through their 
treatment.  Patient Two displayed ‘device malfunctions’, due to a change in capture 
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threshold during radiotherapy treatment. Both patients’ cardiac devices required re-
programming post-radiotherapy treatment.  Patient Three received a mid-therapy 
check due to an increased total dose of 2.8Gy received by the device but no re-
programming was necessary.  In following the AAPM guidelines (Marbach et al, 
1994), this radiotherapy department recognised the increased dose to the 
pacemaker and correctly followed their departmental guidelines.  Had the policy not 
been adhered to, damage to the pacemaker could have occurred and had a 
detrimental effect on the patient.   
 
Frizzell (2009) recommends a lower radiotherapy tolerance dose of 0.5Gy for ICDs 
and that they should be deactivated prior to radiotherapy by placing a magnet over 
the device to prevent inappropriate therapy or shock delivery as a result of accidental 
sensing of EMI interference (Frizzell, 2009).  The audit shows that only 11% of 
radiotherapy centres limit the ICD dose to 0.5Gy. That means that in the majority of 
centres with a CIED policy, ICDs are potentially exposed to doses of radiotherapy 
that may affect function and cause serious harm to the patient.  In addition, it is of 
major concern that only 14% of CIED policies differentiate between pacemakers and 
ICDs and subsequently apply the appropriate radiotherapy tolerance dose limits to 
both types of device.  In these policies, ICDs are subject to the same radiotherapy 
tolerance dose limits and the same monitoring procedures as pacemakers. As a 
result, ICDs are almost certainly being subjected to radiotherapy doses beyond 
tolerance and ICD malfunction has potentially life-threatening consequences.   
 
Patients consenting for any type of treatment need to be informed of potentially 
serious side effects related to that treatment. They should be made aware of 
potential damage that radiation can cause in both the short and long term and as a 
result they will be subject to close monitoring and further follow-up procedures.  On 
receiving this information, patients are able to make an informed decision and give 
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consent as to whether they want to proceed.  Nearly 75% of policies do not mandate 
discussion of potential damage to the CIED during and after radiotherapy in the 
treatment consent process.  Given the lack of contemporary research in this area, it 
is not possible to quantify this risk of damage or harm at present, but consideration 
should be given to discussing potential complications in all patients with a CIED. It is 
likely that ICDs are susceptible to radiotherapy damage at lower doses than 
pacemakers, and ICD patients should be informed about the possibility of 
malfunction, failure or both of their ICD during radiotherapy treatment as the 
consequences may be life-threatening.  ICD patients also need to be told in advance 
of radiotherapy that their device will be deactivated using a magnet during treatment.  
 
The AAPM report and Frizzell recommend that all patients with CIEDs be monitored 
with a continuous ECG strip during their first radiotherapy treatment and reviewed for 
any evidence of pacing disruption (Marbach et al, 1994 and Frizzell, 2009).  
Particular attention should be given to any pacing discrepancies when the radiation 
beam is turned on and off.  If the patient is classified as ‘low risk’ (dose to the cardiac 
device is <2Gy and the patient is non-pacemaker dependent) and there were no 
changes on the ECG monitoring, the patient would not require further monitoring 
during the remainder of their radiotherapy treatment.  If the patient is classified as 
‘intermediate or high risk’ (dose to the cardiac device is >2Gy and the patient is 
pacemaker dependent or has an ICD) they will require ECG monitoring throughout 
the course of their radiotherapy.  One radiotherapy department in the audit stated 
that if there were limited monitoring resources for the patient on their first 
radiotherapy treatment, treatment could proceed but monitoring would be carried out 
on the patient’s second treatment.  Departmental policies should clearly state that 
monitoring of this classification of patient must be carried out for every treatment.  
ICD patients would also require daily monitoring due to their device being switched 
off during radiotherapy treatment.  Monitoring staff should document any changes in 
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the patient’s physical status and any changes in the ECG trace should be 
documented after every radiotherapy treatment.  If at any point, any malfunction is 
suspected or detected the Clinical Oncologist and Cardiologist should be 
immediately informed.  This monitoring should be carried out by fully trained and 
competent health professionals.  If therapeutic radiographers are monitoring patients, 
they should receive specific training on the management and monitoring of such 
patients.  All staff should be conversant with their departmental policies and protocols 
and be able to safely manage CIED related issues if and when they occur. The audit 
shows that only 32% of policies require the use of an appropriately trained health 
professional to carry out the monitoring. Therefore, a substantial number of patients 
with CIEDs are undergoing radiotherapy with no monitoring and in those that are 
monitored; the majority of staff involved may not have appropriate training to interpret 
ECG or clinical changes.   
 
Last (1998) highlighted the importance of both short and long term follow-up 
monitoring for patients who have a CIED and have received radiotherapy treatment.  
Patients should have their CIED checked within two weeks of completion of their 
radiotherapy treatment.  The results of the audit show that 67% of the policies require 
a follow-up appointment to be made with patient’s cardiology department following 
completion of radiotherapy.  A study in one Welsh radiotherapy centre and cardiology 
department evaluated the follow-up assessment of 26 patients with varying CIEDs 
who had received radiotherapy between July 2005 and March 2011 (68 months).   
The results showed that at the patient’s first cardiology follow-up appointment, two 
patients’ CIEDs experienced malfunctions.   Patient One’s CIED experienced a 
change in capture threshold and Patient Two’s CIED showed changes in sensitivity 
threshold.  These changes were deemed ‘significant’ as they required device re-
programming and were classified as ‘radiotherapy induced malfunctions’.   There are 
a limited number of previous clinical studies with which comparisons can be made. 
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The largest of these prospectively analysed 37 pacemaker patients and 8 ICD 
patients who underwent radiotherapy, and found varying malfunctions that occurred 
after a median follow-up of 26 months (Ferrara et al, 2010).  Two smaller studies with 
a combined total of 15 pacemakers also reported no detrimental effects from 
radiotherapy (Wadasadawala et al, 2011 and Kapa et al, 2008).  Research suggests 
that devices exhibiting signs of a malfunction should be followed-up with increased 
frequency. This will allow for determination of a temporary malfunction that may 
occur due to a build-up of charge within the semiconductor, or more permanent 
circuitry damage.  Should any additional changes be observed during the follow-up 
period then immediate device revision is likely to be necessary.   
 
Conclusion 
One of the aims of the PhD was to audit and establish current UK practice regarding 
the management of patients with implanted CIEDs undergoing radiotherapy and 
compare this practice to current ‘gold standard’ evidence-based guidelines. 30% of 
radiotherapy centres did not respond to the audit so it is not appropriate to draw 
definitive conclusions on UK practice, but important themes have emerged 
nevertheless.  The outcomes and implications of this audit were sent for external 
peer review and subsequently published in Clinical Oncology, the international 
journal of the Royal College of Radiologists (Lester et al, 2014).  It is clear that 
policies differ between radiotherapy centres and the implementation of these policies 
is variable. In addition, a significant proportion of policies do not adhere to current 
established tolerance doses for CIEDs.  It can be concluded that as a consequence, 
it is very likely that patients are being put at significant risk of harm.   
!
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5.3    Study 2  
To undertake an audit of clinical practice to determine any effects of ionising 
radiation and EMI on patients with CIEDs receiving radiotherapy treatment at a 
RCW. 
 
Audit 1 :Clinical audit – all patients with a CIED receiving radiotherapy 
treatment 
 
Results 
In this clinical audit, ‘radiotherapy induced device malfunction’ was defined as any 
change to the device that required reprogramming (Tondato et al, 2009).  Twenty-six 
patients with CIEDs presented for radiotherapy at a Welsh radiotherapy department.  
59% of patients were male, 41% were female, and the mean age at commencing 
their RT treatment was seventy-six years of age. 
 
Table 5.4:  Results – Patient demographics 
Demographics Total  
Number of patients 22 
Number of RT treatments 22 
Gender Male = 13 Female = 9 
Mean age at RT start (years) 76 
 
 
Effect of ionising radiation and EMI on CIED function 
In the audit, patients’ radiotherapy treatment areas were classified into three 
anatomical radiotherapy treatment sites; 50% of these patients were receiving 
radiotherapy treatment to the thorax (chest), 32% to the pelvis and 18% to the head 
and neck region.  CIEDs are implanted within the thoracic (chest) cavity, therefore 
the CIEDs of patients receiving radiotherapy to the thoracic region, will receive a 
higher dose of ionising radiation than other parts of the body.  
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Table 5.5:  Results – Radiotherapy treatment information!
Radiotherapy treatment site Total (22 patients) 
Head and neck 4 
Pelvis 7 
Thorax  11 
 
From the total irradiated CIEDs, seventeen were pacemakers (sixteen dual-chamber, 
one single-chamber), four were ICDs and one was a CRT-D, which is a cardiac 
resynchronisation therapy (CRT) with defibrillator capability.  Of the patients’ CIEDs 
in the audit, nine were manufactured of by Medtronic, five by St. Jude Medical, three 
by Biotronik, two by Boston Scientific and one from Biotec, Sorin and Vitatron  
 
From the twenty-two patients in this audit, three patients (14%) received a total 
cumulative dose of greater then the AAPM recommendations of 2Gy.   These 
patients were treated and monitored according to the department’s Cardiac 
Pacemaker and ICD Policy.  All three patients received a mid-radiotherapy CIED 
check at the cardiology department.  One of the three patients (Patient A) who was 
receiving radiotherapy to the left lung (thorax) had a radiotherapy induced device 
malfunction, which required a programming revision.  Of the other two patients, their 
mid-radiotherapy CIED check found that no revisions were deemed necessary.  
Patient B was receiving radiotherapy to the left maxillary antrum (head and neck 
region), therefore their CIED was receiving a negligible dose of ionising radiation.  
However, during radiotherapy treatment the patient exhibited symptoms of 
bradycardia.  Following departmental policy, the radiotherapy department arranged a 
mid-radiotherapy CIED cardiology check at the cardiology department and results 
showed that the CIED required a programming revision. 
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Table 5.6:  Results – CIED information 
CIED  Total (22 patients) 
Dual chamber 16 
Single chamber 1 
ICD 4 
CRT-D 1 
 
Table 5.7:  Results – CIED manufacturer 
CIED manufacturer Total (22 patients) 
Medtronic 9 
St. Jude Medical 5 
Biotronik 3 
Biotec 1 
Guidant/Boston Scientific 2 
Sorin 1 
Vitatron 1 
 
Table 5.8:  Results – Patient information - effect of ionising radiation on their 
CIED 
 Dose to 
Device (Gy) 
Area of RT Parameter changed? 
Patient A 2.8Gy Left lung Ventricular Sensitivity – Reduced R-wave 
amplitude (15mV to 2.5mV) 
Patient B 0Gy (>10cm 
away) 
Left 
maxillary 
antrum 
Ventricular capture threshold – Increased 
from 0.5V @ 0.4ms to 3.75V @ 0.4ms 
 
 
Discussion 
The aim of this retrospective clinical audit was to assess device malfunction in 
patients with a CIED that have been exposed ionising radiation and EMI and as part 
of their radiotherapy treatment.  Previous studies have concluded that radiotherapy 
can potentially cause damage and malfunction to CIEDs, by direct ionising radiation 
and/or EMI (Hurkmans et al, 2012 and Zaremba et al, 2015). 
 
From this audit, twenty-two patients with a CIED presented for radiotherapy 
treatment.  The CIEDs of two patients (A and B) required a revision to the 
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programming at their mid-radiotherapy CIED check.  These changes were classed as 
significant, as they required an immediate intervention in the form of device re-
programming.  
 
Patient A was having radiotherapy to the left lung for lung cancer; their CIED 
received a cumulative ionising radiation dose of 2.8Gy.  At their mid-radiotherapy 
CIED check a change in sensitivity threshold (reduction in sensitivity) was observed 
and required a programming revision.  As the CIED received a greater cumulative 
ionising dose than that of 2Gy recommended by AAPM, this malfunction could be a 
result of the higher dose of ionising radiation.  Patient B was having radiotherapy to 
the left maxillary antrum and their CIED was receiving a negligible dose of ionising 
radiation as the CIED was further than 10cm from the radiotherapy treatment site.  
However, during the radiotherapy treatment they exhibited symptoms of bradycardia 
and a mid-radiotherapy CIED check was carried out.  The CIED showed a change in 
capture threshold (increase in capture threshold) and required a programming 
revision.  As the CIED was not exposed to direct ionising radiation, this malfunction 
could be a result of scatter radiation or EMI.   
 
Patient A and B’s CIEDs were manufactured by Medtronic. Medtronic states that 
radiotherapy can cause interference, memory errors, or permanent damage. They 
suggest that scattered neutron radiation is the primary mechanism for memory 
errors, such as device reset, although they provide no evidence for this. Medtronic 
state a tolerance of 5Gy for their pacemakers, and between 1-5Gy for ICDs 
(Medtronic, 2013).  It is of note that both the CIEDs in this audit, requiring mid-
radiotherapy programme revisions received a cumulative ionising radiation dose less 
than the 5Gy stated by the manufacturer.   
In this audit, all patients were treated and monitored in accordance to departmental 
policy, based on the AAPM recommendations.  An American report suggests that 
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12% of oncology centres have neither a formal risk management strategy nor a CIED 
policy, and that only 15% actually have a written policy (Solan et al, 2004).   As it is 
not clear whether the situation is similar here in the UK, the lack of written national 
policy and deviation from evidence-based guidelines such as the AAPM is of major 
concern. This supported publication of the national audit, to determine current UK 
radiotherapy departmental practice regarding the management of patients with a 
CIED receiving radiotherapy treatment. 
 
Conclusion 
The aim of this retrospective clinical audit was to assess device malfunction in 
patients with CIEDs that have been exposed to ionising radiation and EMI as part of 
their radiotherapy treatment.  The number of cancer patients with CIEDs receiving 
radiotherapy treatment is increasing.  Radiotherapy can be delivered if direct 
irradiation of CIEDs is avoided, appropriate monitoring and the cumulative ionising 
radiation dose to the pacemaker is below 2Gy and the ICD is below 0.5Gy.  The 
results of this audit highlighted the need for further research.  A key aim of this PhD 
research project is to define the effect of radiotherapy on CIEDs, the effect on 
patients and to issue management guidelines.   
 
Audit 2: Clinical audit – patients with a rate response activated CIEDs receiving 
radiotherapy treatment 
 
Results 
One hundred and thirty-two patients with CIEDs presented for radiotherapy treatment 
at a Welsh radiotherapy department.  Fifty-three devices (40%) had the rate 
response setting switched to ON and sixteen devices (12%) had rate response 
setting switched to PASSIVE.  Therefore, sixty-nine devices (52%) were susceptible 
to EMI effects during irradiation.  Twenty-eight devices  (21%) had the rate response 
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setting switched to OFF and for thirty-five devices (27%), the rate response setting 
was unknown. 
 
Table 5.9:  Results – Patient data set 
CIED – Rate  
response setting 
Patient Numbers 
(N = 132) 
ON 53 
PASSIVE 16 
OFF 28 
Unknown 35 
  
 
Effect of EMI on rate response activated CIED function 
This audit included patients from the cardiology department at one hospital only, 
therefore data collection proceeded with twenty-two patients, of which fourteen 
patients (64%) exhibited a clinical reaction during their radiotherapy treatment.  From 
the twenty-two patients in the audit, no patients CIEDs’ received a total cumulative 
ionising radiation dose of greater than the AAPM recommendations of 2Gy (Marbach 
et al, 1994). 
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Table 5.10:  Results – Observed CIED mediated tachycardia (clinical reactions)   
Patient Radiotherapy  
treatment 
region 
Clinical observation 
1 Pelvis Patient’s heart rate accelerated to 145bpm on numerous 
occasions. Had CIED check half way through RT 
2 Thorax HR increased to 200+bpm halfway through RT for beam 
3 Thorax HR increased at end of RT beam exposure.   
Discussed with cardiac pacing clinic - not inclined to reset rate 
response if the patient can tolerate the increased HR.   
Fraction 2 - rate response switched off - no change in HR.   
Fraction 5  - HR increased on Beams1,3,4 - cardiology reinstated 
rate response.  
Fraction 6 - copper sheet applied over pacemaker - no effect.  RT 
beam stopped every 8mu to allow HR to decrease to 80bpm 
before beaming on.   
Fraction 7 - limit to 25mu before beaming off 
Remaining fractions (total 15 fractions) continuous problems with 
increased HR on all fractions 
Patient was in extreme discomfort during RT – “could feel it 
pounding” / hot / nausea 
4 Pelvis Pacing throughout.  HR rapidly increased from 62-73bpm.  
Delivered 170mu – HR rapid increase – beam on stopped until HR 
decreased to 62.  Delivered remained of RT before HR reached 
73bpm. 
5 Thorax Problems pacing throughout.   
Fraction 1 - HR increased to 110bpm.   
Fraction 2 - ventricular paced HR to 110bpm.  Stop/start treatment 
to allow HR to decrease - cardiology department informed.   
Assessed by SHO  -pain not related to heart 
6 Thorax HR affected - increased to 78bpm throughout RT beam on.  Heart 
rate affected during numerous fractions of RT 
7 Pelvis HR increased to 135 (upper limit) on delivery of RT, dose delivered 
stopping every 55-60 MU to allow HR to return to lower limit. HR 
observed 65-135. Pacing clinic informed. 
8 Pelvis HR increased on delivery of RT  
9 Pelvis HR increased rapidly on delivery of RT  
10 Pelvis HR increased and erratic on RT   
11 Thorax ECG trace - Double sensing throughout treatment.  Erratic and 
increased heart rate 
12 Head and 
neck 
Patients heart rate increased to 98bpm 
13 Pelvis Fraction 2 - HR increased during CBCT (102bpm) Mixture of 
pacing and non pacing rhythms .   
Fraction 3 -irregular pacing associated with ectopic episode , HR 
not stable..   
Fraction 5 - HR 140bpm.    
Fraction 11 = peaked 110bpm during CBCT.   
Fractions 16-20 - not pacing at all  
14 Pelvis Irregular pacing throughout RT 
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In the audit, the patients of who exhibited CIED mediated tachycardia reactions, were 
classified into three anatomical radiotherapy treatment sites; 57% of these patients 
were receiving radiotherapy treatment to the pelvis, 36% to thorax (chest), and 7% to 
the head and neck region.!
 
A clinical observation of CIED mediated tachycardia, where the patient’s baseline 
heart rate increased to over 100 beats per minute during the delivery of the 
radiotherapy treatment was detected in eighteen radiotherapy courses (fourteen 
patients).  These patients received their radiotherapy treatment using different 
radiotherapy treatment modalities, including linear accelerators (manufacturers 
Elekta and Varian) and Xstrahl (superficial radiotherapy treatment unit). 
 
In twelve of the fourteen patients that were observed with CIED mediated 
tachycardia; their CIEDs were from same manufacturer.  All CIEDs were implanted 
between 2004 and 2014 (average lifetime of device seven years). No CIED mediated 
tachycardia was observed in patients implanted with CIEDs from the remaining 
manufacturers. 
 
Of the fourteen patients were observed with CIED mediated tachycardia.  Ten 
patients had DDDR (both chambers capable of being paced and sensed) and four 
patients were VVIR (ventricular pacing and sensing).  There should be no difference 
in clinical response of DDR vs VVIR as the CIEDs should react the same.  The ratio 
is consistent with current implant rates at 70/30 in favour of DDDR.  VVIR is only for 
patients in atrial fibrillation and currently there is a reduction in their clinical use. 
 
No trend in treatment modality, cumulative ionising radiation dose to the CIED or 
leads, radiotherapy treatment site or CIED mode (DDDR/ VVIR) indicate which 
patients are at risk of CIED mediated tachycardia.  All clinical observations are based 
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on acute reactions observed by cardiac monitoring trained radiographers during the 
patients’ radiotherapy treatment.  No long-term effects have been reported or 
documented by the cardiology department on review of the patients and their CIEDs 
at the post radiotherapy device follow-up appointment. 
 
Discussion 
The findings of the national audit (Lester et al, 2014), in study 1 identified an 
inadequate understanding and compliance with existing guidelines.  Together with 
the advances in CIED technology, there are now a wide variety of complex multi-
programmable CIEDs and programmable pacing modes used in the treatment of 
cardiovascular disease.  This underlines the need for this research.  As documented 
in chapter three, rate response activated CIEDs can be affected by EMI from the 
radiotherapy treatment machine, but the reaction is highly specific to the make, 
model, design and CIED manufacturer.  For example, a CIED that uses a minute-
ventilation sensor for rate response can be caused to operate at the upper limit and 
trigger rapid pacing by activating the sensor due to EMI interference.  Rate response 
activated CIEDs may also erroneously interpret the signals generated by the 
radiotherapy treatment machine (linac) and this can lead to the CIED increasing the 
patient’s heart rate.   
 
The aim of this clinical audit was to assess CIED mediated tachycardia in patients 
with a rate response activated CIED that have been exposed to ionising radiation 
and EMI as part of their radiotherapy treatment at a Welsh radiotherapy department. 
A CIED mediated tachycardia, could be due to: 
1. A rate response setting that is too sensitive 
2. Tracking of atrial noise (an effect of EMI) 
3. Inappropriate CIED manipulation with rate response switched on 
4. Tracking of an atrial tachyarrhythmia related to upper rate setting 
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A pre-requisite of the PhD research project was an understanding of the functions of 
CIEDs, how device malfunction is presented on an ECG trace and the clinical 
symptoms exhibited as a result of CIED damage.  During the PhD research, it was 
identified that an increasing number of patients are presenting for radiotherapy 
treatment with rate response activated CIEDs and a proportion of these patients 
displayed CIED mediated tachycardia.  Further investigation was needed to establish 
if guidelines existed for the safe management of these patients.  On conducting a 
literature review, there was no research in this area.  Therefore, working with the 
cardiologist to review the evidence from this audit, device specific (rate-response 
activated) testing was devised as part of the PhD study methodology. 
 
The interrogated data for those patients who exhibited heart rate changes and CIED 
mediated tachycardia during their radiotherapy treatment was reviewed.  Due to the 
sampling frequency for data collection of the programmed CIED, it is not possible to 
view the rate trends at the exact point of observed reaction during their radiotherapy. 
There are no prolonged high-rate episodes documented. Some of the patients were 
in atrial fibrillation with no pacing observed. Consequently there is quite a beat-to-
beat variation in the R-R (rest rate) cycle length. This will give rise to a variance on 
the heart rate monitor despite the patient being at rest.  No programming changes or 
electrical reset have been brought about from the radiotherapy treatment. Rate 
increases due to sensor activation are recognised by the CIED manufacturers and 
they recommend deactivation of the sensor during therapy if changes are observed. 
As the different CIED manufacturers use different activity sensors, the response can 
vary between the manufacturers. 
 
One of the CIED manufacturers (St. Jude Medical, 2013) recognise in their own 
literature that 'linear accelerators produce strong electromagnetic fields as well as 
ionising radiation, which can also affect device operation.'  
 188 
They list potential effects of exposure to radiation as follows: 
• Permanent damage 
• Temporary loss of sensing 
• Temporary loss of device inhibition 
• Temporary loss of capture 
• Temporary increased sensor rate 
• Temporary rate changes 
• Device reset or reversion to back up VVI pacing 
  
Consequently, St. Jude Medical (2013) state that 'for rate-adaptive devices, if the 
sensor is ON, exposure to radiation may cause the device to pace at rates up to the 
programmed maximum sensor rate.  Therefore, to prevent such transient rate 
increases the sensor can be programmed to PASSIVE or OFF before administering 
the radiotherapy treatment. 
 
Conclusion 
Radiotherapy departments’ CIED policies and guidelines need to include the 
management of patients with rate response activated CIEDs.   Cardiology knowledge 
and understanding of radiotherapy induced CIEDs reactions, and subsequent 
management is dependent on feedback from radiotherapy departments and 
healthcare professionals employed to monitor patients during radiotherapy.  
However, not all radiotherapy departments liaise with the cardiology department prior 
to radiotherapy, and/or monitor patients with CIEDs receiving radiotherapy.  
Therefore there is a risk of patients with rate response activated CIEDs experiencing 
unmanaged tachycardia during their radiotherapy treatment.  
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This research found that there is no overarching documented guidance governing the 
management of patients with rate response activated CIEDs receiving radiotherapy 
treatment.  St Jude Medical (2013) recommend that rate response activated CIEDs 
be switched off during radiotherapy treatment, however this is not always possible, 
especially in the case of emergency treatments. Therefore, awareness is required for 
radiotherapy and cardiology departments of the potential issues and their 
subsequent management.   
 
The results of the clinical audit show that a significant number of patients exhibited 
CIED mediated tachycardia while receiving radiotherapy treatment at a Welsh 
radiotherapy department.  This department’s CIED policy was following current ‘gold-
standard’ recommendations, thereby identifying adverse clinical reactions, monitoring 
these and liaising with the cardiology department.  Recently, there has been a 
marked increase in the number of patients with rate response activated CIEDs 
receiving radiotherapy treatment and the current guidelines do not include 
recommendations for the management of patients with rate response activated 
CIEDs.  Therefore, this research will investigate the effect of ionising radiation and 
EMI as part of the device specific testing of the PhD study methodology.  Results 
from this will lead to the development of national guidelines and radiotherapy 
tolerance doses to rate response activated CIEDs. 
 
5.4    Chapter conclusion 
The results from the national audit concluded that CIED policies vary between 
radiotherapy departments and the implementation of these policies is inconsistent. In 
addition, a significant proportion of policies do not adhere to current established 
tolerance doses for CIEDs.  It can be concluded that as a consequence, it is very 
likely that patients are being put at significant risk of harm.   
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These results and those from both clinical audits, reinforce the need for further 
research in this area and to publish up-to-date clinical guidelines for the management 
of patients with CIEDs receiving radiotherapy treatment.   
!
! !
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Chapter Six 
Scientific Research 
 
6.1    Introduction 
The previous chapter discussed the findings of the initial studies 1 and 2, which 
looked at the knowledge and perceptions of healthcare staff within UK radiotherapy 
centres toward the management of cancer patients having implanted cardiac devices 
and the implications of them receiving radiotherapy.  This was followed up by a 
series of audits within one RCW to investigate the possible effects of radiation and 
EMI to support anecdotal evidence that these occur.  The ongoing scientific empirical 
investigations resulted and this chapter will discuss the outcomes from these under 
the following study headings: 
• Study 3 - To investigate and evaluate the relationship between cumulative 
ionising radiation dose and the damage sustained to CIEDs (pacemakers and 
ICDs). 
• Study 4 - To investigate and evaluate the relationship between cumulative 
ionising radiation dose and the damage sustained to CIED leads. 
• Study 5 - To investigate and evaluate the relationship between EMI and the 
damage sustained to CIEDs (pacemakers, ICDs and rate response activated 
CIEDs).  
 
This chapter will present the findings, analyse the study’s results and discuss the 
mechanisms that cause CIED malfunctions and / or failure.  In reporting CIED 
malfunctions and failure the effect of radiotherapy treatment and the clinical impact to 
the patient will be discussed. Recommendations regarding radiotherapy tolerance 
doses to all CIEDs will be made. 
! !
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6.2    Study 3 
6.2.1    Introduction 
The aim of this study was to investigate and evaluate the relationship between 
cumulative ionising radiation dose and the damage sustained to CIEDs (pacemakers 
and ICDs).  This section will present the findings of study three, analyse the results 
and discuss the mechanisms that cause malfunctions and / or failure in CIEDs when 
exposed to ionising radiation.  In discussing specific CIED malfunctions and failure, 
the effect of radiotherapy and the clinical impact to the patient will be discussed.  
This study outcome concludes by recommending safe radiotherapy tolerance doses 
to all CIEDs. 
 
6.2.2   Data analysis – Effect on ionising radiation on CIEDs 
(pacemakers) 
Table 6.1: Results – First malfunction observed resulting in pacemaker failure - 
Classified by type of device malfunction 
Pacemaker Pacemaker failure RT Dose (Gy) 
1 - Pacing pulse  
6MeV 
PM X3 
 
No output and amplitude deviations (atrial channel).  
Point of failure = Device failure 
120Gy 
3 – Sensing  
10MeV 
PM Y7 
 
Unable to sense  
Point of failure = Device failure 
52Gy 
4 – Telemetry  
6MeV 
PM Z3 
 
No output / permanent loss of telemetry.   
Point of failure = Device failure 
23Gy 
10MeV 
PM X5 
 
No communication 
Point of failure = Device failure 
28Gy 
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22% of pacemakers (4 pacemakers; PM X3, PM Y7, PM Z3 and PM X5) irradiated at 
both 6MeV and 10MeV, exhibited POF in the range of 23Gy to 120Gy.   
At 6MeV, POF was first observed in PM Z3 at 23Gy due to no output resulting in 
permanent loss of telemetry and second POF was observed in PM X3 at 120Gy (test 
to destruction ionising radiation dose) due to no output and amplitude deviations in 
the atrial channel resulting in pacing pulse failure.  At 10MeV, POF was observed in 
PM X5 at 28Gy due to no communication resulting in permanent loss of telemetry 
and second POF was observed in PM Y7 at 52Gy due to the pacemaker being 
unable to sense resulting in sensing failure. 
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Table 6.2: Results – First malfunction observed in pacemakers during 
exposure to ionising radiation – Classified by type of device malfunction  
(Malfunctions are only indicated when seen at each respective energy) 
 
  
Pacemaker Pacemaker malfunction RT Dose (Gy) 
1 – Pacing pulse 
6MeV 
PM X4 
 
Output discrepancies 70Gy 
PM X3 
 
No output.  Point of failure = Device failure 120Gy 
2 – Pacing frequency 
6MeV 
PM Y3 
 
Inhibition during irradiation longer than 5s 44Gy 
10MeV 
PM X6 
 
Deviation in pacing frequency  2.5Gy 
3 – Sensing 
6MeV 
PM X2 
 
Under sensing 3Gy 
PM Y4 
 
Sensing discrepancies 10.5Gy 
10MeV 
PM Y5 
 
Programming error 4.5Gy 
PM Y6 
 
Programming error 7Gy 
PM Y7 
 
Unable to sense  
Point of failure = Device failure 
52Gy 
PM Z5 
 
Sensing error 41Gy 
4 – Telemetry 
6MeV 
PM Z2 
 
Communication error 20.5Gy 
PM Z3 
 
No output.  Point of failure = Device failure 23Gy 
10MeV 
PM X5 
 
No communication 
Point of failure = Device failure 
28Gy 
PM X7 
 
Communication error 
 
17Gy 
PM Z6 
 
Communication error 21Gy 
PM Z7 
 
Communication error 8.5Gy 
5 – Battery 
6MeV 
PM Z4 
 
Battery problems 12Gy 
6 – Lead impedance changes 
6MeV 
PM Y2 
 
Increased lead impedance 80Gy 
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• 1, Pacing pulse malfunctions 
At 6MeV, 22% of the pacemakers (2 pacemakers: PM X4 and PM X3) both from 
CIED manufacturer X exhibited CIED pacing pulse malfunctions as the first 
malfunction.  In PM X4 output discrepancies were observed at a cumulative ionising 
radiation dose of 70Gy.  In PMX3, no output was recorded, resulting in POF 
observed at point of destruction 120Gy. 
 
• 2, Pacing frequency malfunctions 
At 6MeV, 11% of pacemakers (1 pacemaker: PM Y3) from CIED manufacturer Y 
exhibited pacing frequency malfunctions as the first malfunction.   Inhibition during 
irradiation longer than 5s was observed at a cumulative ionising radiation dose of 
44Gy.  At 10MeV, 11% of pacemakers (1 pacemaker, PM X6) from CIED 
manufacturer X exhibited a deviation in pacing frequency as the first malfunction at 
2.5Gy.  
 
• 3, Sensing malfunctions 
At 6MeV, 22% of pacemakers (2 pacemakers: PM X2 and PM Y4) from CIED 
manufacturers X and Y exhibited sensing malfunctions as the first malfunction.   In 
PM X2, under sensing was observed at a cumulative ionising radiation dose of 3Gy 
and sensing discrepancies was observed at 10.5Gy in PM Y4.  At 10 MeV, 44% of 
pacemakers (4 pacemakers: PM Y5, PM Y6, PM Y7 and PM Z5) from CIED 
manufacturers Y and Z exhibited sensing malfunctions as the first malfunction.   
From manufacturer Y, PM Y5 and PM Y6 exhibited programming errors as the first 
malfunction at a total cumulative ionising radiation dose of 4.5Gy and 7Gy 
respectively and PM Y7 reached a POF at 52Gy, as the device was unable to sense.  
PM Z5 from manufacturer Z exhibited a sensing error as the first malfunction at a 
total cumulative ionising radiation dose of 41Gy.   
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• 4, Telemetry malfunctions 
At 6MeV, 22% of pacemakers (2 pacemakers: PM Z2 and PM Z3) both from CIED 
manufacturer Z exhibited telemetry malfunctions as the first malfunction.   In PM Z2, 
a communication error was observed at a cumulative ionising radiation dose of 
20.5Gy.  In PM Z3, no output was recorded resulting in POF at 23Gy.  At 10MeV, 
44% of pacemakers (4 pacemakers: PM X5, PM X7, PM Z6 and PM Z7) from CIED 
manufacturers X and Z exhibited telemetry malfunctions in the form of 
communication errors as the first malfunction.   The first communication error was 
displayed at 8.5Gy in PM Z7, in PM X7 at 17Gy followed by PM Z6 at 21Gy.  PM X5 
reached a POF at 28Gy, as the device was no longer able to communicate.     
 
• 5, Battery malfunctions 
At 6MeV, 11% of pacemakers (1 pacemaker: PM Z4) from CIED manufacturer Z 
exhibited battery malfunctions as the first malfunction.   Battery problems / warning 
alert was observed at a cumulative ionising radiation dose of 12Gy. 
 
• 6, Lead impedance changes 
At 6MeV, 11% of pacemakers (1 pacemaker: PM Y2) from CIED manufacturer Y 
exhibited lead impedance changes as the first malfunction.   Increased lead 
impedance was observed at a cumulative ionising radiation dose of 80Gy. 
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Table 6.3: Results – Pacemaker malfunctions observed during exposure to 
ionising radiation – Classified by type of device malfunction 
(Malfunctions are only indicated when seen at each respective energy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Pacemaker Pacemaker malfunction RT Dose (Gy) 
2 – Pacing frequency 
6MeV 
PM X4 Inhibition during irradiation longer than 5s 94Gy ! 
PM Y3 Inhibition during irradiation longer than 5s 44Gy ! 
PM Z2 Inhibition during irradiation longer than 5s  20.5Gy ! 
3 – Sensing 
6MeV 
PM X2 Under sensing 
 
3Gy ! 
5Gy ! 
PM X4 Communication error 90Gy ! 
PM Y4 Sensing discrepancies 10.5Gy ! 
10MeV 
PM X7 Under sensing 
Sensing inhibition during irradiation 
30Gy ! 
56Gy ! 
PM Y5 Under sensing 
Sensing inhibition during irradiation 
5Gy ! 
50Gy ! 
PM Y6 Sensing inhibition during irradiation 18Gy! 
PM Z5 Sensing inhibition during irradiation 41Gy! 
PM Z6 Sensing inhibition during irradiation 21Gy! 
4 – Telemetry 
6MeV 
PM Z2 Communication error 90Gy ! 
10MeV 
PM Z6 Communication error 90Gy ! 
PM Z7 Communication error (battery problems) 29Gy ! 
6 – Lead impedance changes 
6MeV 
PM Y2 Continued increase in lead impedance 82Gy ! 
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• 2, Pacing frequency malfunctions 
At 6MeV, 38% (3 pacemakers:  PM X4, PM Y3 and PM Z2) exhibited inhibition 
during irradiation longer than 5s resulting in pacing frequency malfunctions.  
Inhibition during irradiation longer than 5s was observed at a cumulative ionising 
radiation dose starting at 20.5Gy in pacemakers from manufacturer Z, next at a 
cumulative ionising radiation dose starting at 44Gy in pacemakers from manufacturer 
Y and finally at a cumulative ionising radiation dose starting at 94Gy in pacemakers 
from manufacturer X. 
 
• 3, Sensing malfunctions 
At 6MeV, 38% (3 pacemakers: PM X2, PM X4 and PM Y4) exhibited sensing 
malfunctions. PM X2, exhibited under sensing at a cumulative ionising radiation dose 
starting at 3Gy and sensing inhibition during irradiation starting at a cumulative 
ionising radiation dose of 5Gy.  PM X4, exhibited communication errors at a 
cumulative ionising radiation dose starting at 90Gy and PM Y4 exhibited sensing 
discrepancies at a cumulative ionising radiation dose starting at 10.5Gy.  At 10MeV, 
63% (5 pacemakers: PM X7, PM Y5, PM Y6, PM Z5 and PM Z6) exhibited sensing 
malfunctions.  The first sensing malfunction during ionising radiation exposure was 
exhibited by PM Y5 starting a total cumulative ionising radiation dose of 5Gy.  This 
device then exhibited further sensing malfunctions, as it displayed sensing inhibition 
during irradiation at a total cumulative ionising radiation dose of 50Gy.  The same 
sequence of sensing malfunctions was also observed in PM Y7 from manufacturer Y, 
but at higher ionising radiation doses.  This device exhibited under sensing firstly at 
30Gy and then sensing inhibition during irradiation at 56Gy.  All 3 remaining 
pacemakers (PM Y6, PM Z5 and PM Z6) displayed sensing inhibition during 
irradiation.  Firstly PM Y6 starting at a total cumulative ionising radiation dose of 
18Gy, then PM Z6 and PM Y5 starting at a cumulative ionising radiation doses of 
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21Gy and 50Gy respectively.  Therefore 100% of the pacemakers exhibited sensing 
inhibition during irradiation exposure.   
 
• 4, Telemetry malfunctions 
At 6MeV, 13% of pacemakers (1 pacemaker: PM Z2) exhibited telemetry problems in 
the form of no communication.  This clinical malfunction was observed at a 
cumulative ionising radiation dose starting at 90Gy.   At 10MeV, 22% of pacemakers 
(2 pacemakers: PM Z6 and PM Z7) both from manufacturer Z exhibited telemetry 
problems in the form of communication errors.   This observed clinical malfunction 
(further defined as battery problems) was observed firstly in PM Z7 starting at a 
cumulative ionising radiation dose of 29Gy and then in PM Z6 starting at a 
cumulative ionising radiation dose of 90Gy.  Of note, PM Z6 first exhibited sensing 
malfunctions (sensing inhibition during irradiation) starting at a cumulative ionising 
radiation dose of 21Gy.  
 
• 5, Battery malfunctions 
No effects were seen due to battery failure. 
 
• 6, Lead impedance changes malfunctions 
At 6MeV, 13% of pacemakers (1 pacemaker: PM Y2) exhibited a continued increase 
in lead impedance.  This clinical malfunction was observed at a cumulative ionising 
radiation dose starting at 82Gy.    
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Table 6.4: Results – Point of device failure (POF) observed in pacemakers – 
Classified by type of device malfunction 
 
(Malfunctions are only indicated when seen at each respective energy) 
Pacemaker Pacemaker failure RT Dose (Gy) 
1 - Pacing pulse 
6MeV 
PM X2 No output and amplitude deviations  
(atrial channel) 
120Gy 
PM X3 No output and amplitude deviations  
(atrial channel) 
120Gy 
PM Y4 No output and amplitude deviations  
(atrial channel) 
120Gy 
10MeV 
PM X6 No output 90Gy 
3 - Sensing 
6MeV 
PM Y4 Unable to sense  120Gy 
10MeV 
PM Y5 Unable to sense  70Gy 
PM Y6 Unable to sense  90Gy 
PM Y7 Unable to sense  52Gy 
PM Z5 Unable to sense  120Gy 
4 – Telemetry 
6MeV 
PM X4 No communication 120Gy 
PM Y2 No output  120Gy 
PM Y3 No output  120Gy 
PM Z2 No communication 120Gy 
PM Z3 No communication 23Gy 
PM Z4 No communication 13.5Gy 
10MeV 
PM X5 No communication 28Gy 
PM X7 No communication 100Gy 
PM Z6 No communication 90Gy 
! !
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5 - Battery 
6MeV 
PM Y4 Elective replacement indicator  (ERI) 120Gy 
10MeV 
PM Y5 Elective replacement indication (ERI) 70Gy 
PM Z7 Elective replacement indication (ERI) 120Gy 
 
Point of failure - Total cumulative ionising radiation dose 
At 6MeV, the POF at 120Gy was observed in 78% of the pacemakers (7 
pacemakers: PM X4, PM Y2, PM Y3, PM Z2, PM X2, PM X3 and PM Y4).  57%  (4 
pacemakers: PM X4, PM Y2, PM Y3 and PM Z2) exhibited no communication 
resulting in telemetry POF.   29% (2 pacemakers: PM X2 and PM X3) exhibited no 
output and amplitude deviations in the atrial channel resulting in pacing pulse POF.  
14% (1 pacemaker: PM Y4) exhibited no output and amplitude deviations in the atrial 
channel and was unable to sense and the battery elective replacement indicator 
warning was observed resulting in both sensing and battery POF.   The telemetry 
POF resulting from no communication in the remaining 22% of the pacemakers (2 
pacemakers: PM Z3 and PM Z4) was observed at 23Gy and 13.5Gy respectively 
both from manufacturer Z.   At 10MeV, the POF at 120Gy was observed in 22% (2 
pacemakers: PM Z5 and PM Z7) of the pacemakers.  11% (1 pacemaker: PM Z5) 
was unable to sense resulting in sensing failure and 11% (1 pacemaker: PM Z7) 
displayed battery elective replacement indicator (ERI) resulting in battery failure.   
 
At 10MeV, 40% of pacemakers (4 pacemakers: PM Y5, PM Y6, PM Y7 and PM Z5) 
from CIED manufacturers’ Y and Z exhibited POF due to being unable to sense 
resulting in sensing failure.  75% of the pacemakers were from manufacturer Y. PM 
Y7 exhibited the first sensing POF at a cumulative ionising radiation dose of 52Gy, 
followed by PM Y5 at 70Gy and then PM Y6 at 90Gy.  PM Z5 from manufacturer Z 
reached a sensing POF at the test to destruction cumulative ionising radiation dose 
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of 120Gy.  30% of pacemakers (3 pacemakers: PM X5, PM X7 and PM Z6) from 
CIED manufacturers X and Z exhibited telemetry malfunctions.    PM X5 was the first 
device to display no communication resulting in telemetry POF at 28Gy.  The same 
observation was seen in PM Z6 and PM X7 but at the higher cumulative ionising 
radiation doses of 90Gy and 100Gy respectively.   20% of pacemakers (2 
pacemakers: PM Y5 and PM Z7) from CIED manufacturer Y and Z exhibited elective 
replacement indicator warning resulting in battery POF.  PM Y5 was the first device 
to exhibit this POF at total cumulative ionising radiation dose of 70Gy and then it was 
observed in PM Z7 at the test to destruction cumulative ionising radiation dose of 
120Gy.  10% of pacemakers (1 pacemaker: PM X6) from CIED manufacturer X 
exhibited no output resulting in POF at a cumulative ionising radiation dose of 90Gy. 
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Table 6.5: Results – POF in pacemakers – Test to destruction ionising radiation 
dose (120Gy) – Classified by CIED manufacturer 
(Malfunctions are only indicated when seen at each respective energy) 
 
Pacemaker Pacemaker failure RT Dose (Gy) 
Manufacturer X 
6MeV 
PM X2 Pacing pulse 
No output and amplitude deviations (atrial channel) 
120Gy 
PM X3 Pacing pulse 
No output and amplitude deviations (atrial channel) 
120Gy 
PM X4 Telemetry 
No communication 
120Gy 
Manufacturer Y 
6MeV 
PM Y2 Pacing pulse 
No output  
120Gy 
PM Y3 Pacing pulse 
No output  
120Gy 
PM Y4 Sensing 
Unable to sense  
Battery 
Elective replacement indicator 
120Gy 
Manufacturer Z 
6MeV 
PM Z2 Telemetry 
No communication 
120Gy 
10MeV 
PM Z5 Sensing 
Unable to sense  
120Gy 
PM Z7 Battery 
Elective replacement indication (ERI) 
120Gy 
 
At 6MeV, 22% of pacemakers (2 pacemakers: PM X2 and PM X3) both from CIED 
manufacturer X exhibited CIED pacing pulse malfunctions at a cumulative ionising 
radiation dose of resulting in POF observed at point of destruction 120Gy.  11% of 
pacemakers (1 pacemaker: PM Y4) from CIED manufacturer Y was unable to sense 
and the battery elective replacement indicator warning was observed resulting in 
both sensing and battery POF. 17% (1 pacemaker: PM X4) exhibited no 
communication, therefore 100% of the pacemakers from manufacturer X reached 
POF at 120Gy.  33% of pacemakers (2 pacemakers, PM Y2 and PM Y3) from 
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manufacturer Y exhibited no output, therefore 100% of these pacemakers also 
reached POF at 120Gy.   
 
At 10MeV, the POF at the test to destruction ionising radiation dose of 120Gy was 
observed in 22% of pacemakers (PM Z5 and PM Z7).  100% of the pacemakers POF 
was observed at 120Gy were from manufacturer Z.  50% were unable to sense, 
which resulted in sensing POF and 50% received an elective replacement indicator 
warning (ERI), which resulted in battery POF. 
 
Table 6.6: Results – POF in pacemakers – Below 120Gy – Classified by CIED 
manufacturer 
(Malfunctions are only indicated when seen at each respective energy) 
 
Pacemaker Pacemaker failure RT Dose (Gy) 
Manufacturer X 
10MeV 
PM X5 Telemetry 
No communication 
28Gy 
PM X6 Pacing pulse 
No output 
90Gy 
PM X7 Telemetry 
No communication 
100Gy 
Manufacturer Y 
10MeV 
PM Y5 Sensing 
Unable to sense  
Battery 
Elective replacement indicator (ERI) 
70Gy 
 
70Gy 
PM Y6 Sensing 
Unable to sense  
90Gy 
PM Y7 Sensing 
Unable to sense  
52Gy 
Manufacturer Z 
6MeV 
PM Z3 Telemetry 
No communication 
23Gy 
PM Z4 Telemetry 
No communication 
13.5Gy 
10MeV 
PM Z6 Telemetry 
No communication 
90Gy 
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At 6MeV, from manufacturer Z, 67%, 2 pacemakers (PM Z3 and PM Z4) exhibited no 
communication resulting in telemetry POF at ionising radiation dose of 23Gy and 
13.5Gy respectively. 
 
At 10MeV, in the remaining 78% (7 pacemakers) the POF ranged from 28Gy to 
100Gy.  All 3 of the pacemakers from CIED manufacturer X, failed at a cumulative 
ionising radiation dose below test to destruction (120Gy).  PM X5 was the first 
pacemaker to exhibit POF as communication was lost resulting in telemetry POF, 
which occurred at 28Gy.  PM X7 also displayed telemetry POF, as no communication 
was observed but this occurred at a high cumulative ionising radiation dose of 
100Gy.  PM X6 was the only pacemaker to display pacing pulse POF as a result of 
no output and this occurred at 90Gy. 
 
100% of the pacemakers from CIED manufacturer Y exhibited POF due being unable 
to sense resulting in sensing POF.  PM Y7 reached POF at 52Gy, PM Y5 at 70Gy 
and PM Y6 at 90Gy.  Of note at POF PM Y5, also exhibited battery failure of the 
same dose.  Therefore, at 70Gy this device displayed two distinct forms of failure.   
 
PM Z6 was the only pacemaker from CIED manufacturer Z to reach POF below 
120Gy; it displayed no communication resulting in telemetry POF at 100Gy. 
 
 
! !
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6.2.3   Data analysis – Effect on ionising radiation on CIEDs (ICDs) 
Table 6.7: Results – First malfunction observed resulting in ICD failure – 
Classified by type of device ICD malfunction 
(Malfunctions are only indicated when seen at each respective energy) 
ICD ICD malfunction RT Dose (Gy) 
1 – Pacing Pulse 
6MeV 
ICD Y3 Output error 0.5Gy 
 
3 – Sensing 
6MeV 
ICD X2 Sensing threshold too low 60Gy 
ICD X4 No sensing 
= Device failure 
120Gy 
ICD Y2 Inhibition during sensing 4Gy 
ICD Y3 Over sensing 0.5Gy 
 
ICD Z2 Sensing threshold too high 1.5Gy 
10MeV 
ICD Y4 Sensing threshold too low 5Gy 
4 – Telemetry 
6MeV 
ICD Y3 Communication discrepancies  0.5Gy 
 
10MeV 
ICD Y5 Communication discrepancies 12.5Gy 
5 – Battery 
10MeV 
ICD X4 Battery charge time increase  
= Device failure 
120Gy 
ICD Y5 Battery error 12.5Gy 
7 – Shock 
6MeV 
ICD X3 Shock energy too low 45Gy 
10MeV 
ICD X5 Shock energy too low 10Gy 
ICD Z3 Shock energy too low 8.5Gy 
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100% of all ICDs (10 ICDs) exhibited device malfunctions when exposed to 6MeV 
and 10MeV ionising radiation.   
 
At 6MeV, the first ICD malfunctions were observed in ICD Y3.  This device exhibited 
sensing, pacing pulse and telemetry malfunctions at a cumulative ionising radiation 
dose of 0.5Gy.  Of note, this is the radiation tolerance dose to ICDs for patients 
receiving radiotherapy treatment.   
 
60% of ICDs (3 ICDs; ICD Y2, ICD Y3 and ICD Z2) exhibited their first malfunction at 
a cumulative ionising radiation dose below 4Gy at 6MeV.  100% of these devices, 
showed sensing malfunctions as the first malfunction.  40% of ICDs (2 ICDs; ICD X2 
and ICD X3) both from manufacturer X, exhibited their first malfunction at a 
cumulative ionising radiation dose above 45Gy.  ICD X3 exhibited shock 
malfunctions as the first malfunction at 45Gy and ICD X2 exhibited sensing 
malfunctions as the first malfunction at 60Gy. 
 
At 10MeV, the first ICD malfunctions were observed in ICD Y4, this device exhibited 
a sensing threshold too low resulting in sensing malfunctions at a cumulative ionising 
radiation dose of 5Gy. 80% of ICDs (4 ICDs; ICD X5, ICD Y4, ICD Y5 and ICD Z3) 
exhibited their first malfunction at a cumulative ionising radiation dose below 12.5Gy. 
ICD X5 and ICD Z3 displayed shock energy too low resulting in shock malfunctions 
at 10Gy and 8.5Gy respectively.  ICD Y5 displayed a battery error resulting in battery 
malfunctions and communications discrepancies resulting in telemetry malfunctions 
at a cumulative ionising radiation dose of 12.5Gy.  ICD X4 displayed its first 
malfunction and POF failure as the battery charge time increased resulting in battery 
failure, at the test to destruction ionising radiation dose of 120Gy,  
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ICD malfunctions: 
• 1, Pacing pulse malfunctions 
At 6MeV, 20% of ICDs (1 ICD: ICD Y3) exhibited an output error resulting in pacing 
pulse malfunctions at 0.5Gy as one of the first malfunctions in this particular ICD.  
  
• 3, Sensing malfunctions 
At 6MeV, 80% of ICDs (4 ICDs: ICD X2, ICD Y2, ICD Y3 and ICD Z2) from all 3 
CIED manufacturers (X, Y and Z) exhibited sensing malfunctions as the first 
malfunction.  In 3 ICDs (ICD Y3, ICD Z2 and ICD Y2) these malfunctions occur at a 
low ionising radiation dose, below 4Gy (ICD Y3 at 0.5Gy, ICD Z2 at 1.5Gy and ICD 
Y2).  Therefore 100% of ICDs from CIED manufacturer Y exhibited sensing 
malfunctions as the first malfunction at low ionising radiation dose (below 4Gy).  Both 
these devices displayed inhibition during sensing and ICD Y3 (0.5Gy) also displayed 
over sensing.  ICD X2 displayed a sensing threshold too low resulting in sensing 
malfunctions as the malfunction but at a higher ionising radiation dose of 60Gy. 
 
At 10MeV, 17% of ICDs (1 ICD: ICD Y4) exhibited a sensing threshold too low, 
resulting in sensing malfunctions as the first malfunction at 5Gy. 
 
• 4, Telemetry malfunctions 
At 6MeV, 20% of ICDs (1 ICD: ICD Y3) exhibited communication discrepancies 
resulting in telemetry malfunctions at 0.5Gy as one of the first malfunctions in this 
particular ICD.  At 10MeV, 17% of ICDs (1 ICD: ICD Y5) exhibited communication 
discrepancies, resulting in telemetry malfunctions as the first malfunction at 12.5Gy. 
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• Battery malfunctions 
At 10MeV, 33% of ICDs (2 ICDs: ICD X4 and ICD Y5) from all CIED manufacturers 
(X and Y) exhibited battery malfunctions as the first malfunction.  ICD Y5 exhibited a 
battery error at 12.5Gy and ICD X4 reached POF due to battery failure at test to 
destruction ionising radiation dose of 120Gy. 
 
• 7, Shock malfunctions 
At 6MeV, 20% of ICDs (1 ICD: ICD X3) exhibited shock energy too low resulting in 
shock malfunctions at 45Gy.  This device tolerated the largest dose of ionising 
radiation before exhibiting the first device malfunction.  At 10MeV, 33% of ICDs (2 
ICDs; ICD X5 and ICD Z3) exhibited shock energy too low resulting in shock 
malfunctions at 8.5G and 10Gy respectively.  
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Table 6.8: Results – ICD malfunctions observed during exposure to ionising 
radiation – Classified by type of device malfunction 
(Malfunctions are only indicated when seen at each respective energy) 
 
ICD ICD malfunction RT Dose (Gy) 
3 – Sensing 
6MeV 
ICD X2 Ventricular tachycardia (VT) – Cause inappropriate 
delivery of shock therapy 
70Gy ! 
ICD X3 Inhibition during sensing  46Gy ! 
ICD Y2 Under sensing 5Gy ! 
ICD Z2 Ventricular tachycardia (VT) – Cause inappropriate 
delivery of shock therapy 
1.5Gy ! 
10MeV 
ICD Y4 Inhibition during sensing  5Gy ! 
 
ICD Y5 Inhibition during sensing  12.5Gy ! 
 
ICD Z3 Ventricular tachycardia (VT) – Cause inappropriate 
delivery of shock therapy 
9Gy ! 
4 – Telemetry 
10MeV 
ICD X5 Communication discrepancies 20Gy ! 
ICD Y4 Communication discrepancies 6Gy ! 
ICD Y5 Communication discrepancies 14Gy ! 
7 – Shock 
6MeV 
ICD Y2 Shock energy too low 5Gy ! 
8 – Battery 
6MeV 
ICD Y2 Battery warning 40Gy ! 
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• 3, Sensing malfunctions  
At 6MeV, 80% of ICDs (4 ICDs; ICD X2, ICD X3, ICD Y2 and ICD Z2) exhibited 
sensing malfunctions when exposed to ionising radiation.   ICD Y2 was the only 
device that exhibited under sensing resulting in sensing failure during irradiation and 
this occurred at 5Gy. 
 
100% of ICDs from CIED manufacturer X exhibited sensing malfunctions during 
irradiation at a higher ionising radiation dose.  ICD X3 exhibited inhibition during 
sensing starting at 46Gy and ICD X2 exhibited ventricular tachycardia (VT) causing 
inappropriate delivery of shock therapy starting at 70Gy resulting in sensing 
malfunctions.  In comparison ICD Z2 also exhibited ventricular tachycardia (VT) 
causing inappropriate delivery of shock therapy but at a much lower cumulative 
ionising radiation of 1.5Gy. 
 
At 10MeV, 50% of ICDs (3 ICDs; ICD Y4, ICD Y5 and ICD Z3) exhibited sensing 
malfunctions when exposed to ionising radiation.  100% of the ICDs from 
manufacturer Y exhibited inhibition during sensing malfunctions during irradiation.    
ICD Y4 was the first ICD to display this at a cumulative ionising radiation dose 
starting at 5Gy and ICD Y5 displayed this malfunction starting at 12.5Gy.  ICD Z3 
exhibited ventricular tachycardia (VT) which can cause inappropriate delivery of 
shock therapy if the ICD is activated starting at a cumulative ionising radiation dose 
of 9Gy. 
 
• 4, Telemetry malfunctions  
At 10MeV, 50% of ICDs (3 ICDs; ICD X5, ICD Y4 and ICD Y5) exhibited telemetry 
malfunctions when exposed to ionising radiation.    100% of the ICDs from 
manufacturer Y exhibited communication discrepancies resulting in telemetry 
malfunctions during irradiation.    ICD Y4 was the first ICD to display this at a 
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cumulative ionising radiation dose starting at 4Gy and ICD Y5 displayed this 
malfunction starting at 14Gy.  ICD X5 from manufacturer X exhibited communication 
discrepancies resulting in telemetry malfunctions starting at a cumulative ionising 
radiation dose of 9Gy. 
 
• 7, Shock malfunctions 
At 6MeV, ICD Y2 had exhibited sensing malfunctions during irradiation at 5Gy; also 
at this ionising radiation dose the device exhibited a shock energy too low resulting in 
shock malfunction. 
 
• 8, Battery malfunctions 
At 6MeV, ICD Y2 exhibited sensing and shock malfunctions during irradiation at 5Gy.  
At 40Gy this device displayed a battery warning resulting in a battery malfunction.   
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Table 6.9: Results – Point of device failure (POF) observed in ICDs – Classified 
by type of device (ICD) malfunction 
(Malfunctions are only indicated when seen at each respective energy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Point of failure - Total cumulative ionising radiation dose: 
At 6MeV, 100% (5 ICDs) reached POF before the test to destruction ionising 
radiation dose of 120Gy. 60% of the ICDs (3 ICDs: ICD X2, ICD X3 and ICD Y2) 
reached a POF in the range of 70-100Gy.  100% of the ICDs from CIED 
ICD ICD failure RT Dose (Gy) 
1 – Pacing pulse 
6MeV 
ICD X2 Device failure 
No output 
100Gy 
ICD X3 Device failure 
No output 
70Gy 
 
ICD Y3 Device failure 
No output 
1Gy 
ICD Z2 Device failure 
No output 
3.5Gy 
10MeV 
ICD Y4 Device failure 
No output 
15Gy 
ICD Y5 Device failure 
No output 
No signal 
120Gy 
ICD Z3 
 
Device failure 
No signal 
10Gy 
3 – Sensing 
10MeV 
ICD X4 Device failure 
No sensing 
120Gy 
7 – Shock 
6MeV 
ICD X3 Device failure 
No shock 
70Gy 
ICD Y2 Device failure 
No shock 
90Gy 
ICD Z2 Device failure 
No shock 
3.5Gy 
10MeV 
ICD X5 Device failure 
No shock 
80Gy 
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manufacturer X (ICD X2 and ICD X3) reached POF because of no output resulting in 
pacing pulse failure.  ICD X2 exhibited this at 100Gy and ICD X3 exhibited pacing 
pulse POF at 70Gy due to both no output and no shock.  ICD Y2 exhibited POF at 
90Gy due to no shock resulting in pacing pulse failure and no shock resulting 
sensing failure.  
 
40% of the ICDs (2 ICDs: ICD Y3 and ICD Z2) reached a POF in the range of 1-
3.5Gy.  ICD Y3 reached POF at 1Gy and exhibited no output resulting in pacing 
pulse failure.  ICD Z2 also displayed no output resulting in pacing pulse failure at 
POF 3.5Gy.  At this ionising radiation dose, ICD Z2 also displayed no shock resulting 
in shock failure. 
 
ICD Y3 was the first ICD to reach POF at a cumulative ionising radiation dose of 
1Gy.  Followed by ICD Z2, which reached POF at a cumulative ionising radiation 
dose of 3.5Gy.  Both ICDs from manufacturer X, reached POF at higher cumulative 
ionising radiation doses of 100Gy and 70Gy respectively. 
 
4 ICDs (ICD X2, ICD X3, ICD Y3 and ICD Z2) failed due to no output resulting in 
pacing pulse failure.  ICD Y3 was the first ICD to reach POF at a cumulative ionising 
radiation dose of 1Gy.  Followed by ICD Z2 which reached POF at a cumulative 
ionising radiation dose of 3.5Gy.  Both ICDs from manufacturer X, reached POF at 
higher cumulative ionising radiation doses of 100Gy and 70Gy respectively. 
 
3 ICDs (ICD X3: ICD Y3, and ICD Z2) failed due to no shock resulting in shock 
failure.  ICD Z2 exhibited both pacing pulse failure and shock failure at a cumulative 
ionising radiation dose of 3.5Gy.  ICD X3 and ICD Y2 reached POF at higher 
cumulative ionising radiation doses of 70Gy and 90Gy respectively.  ICD Y2 was the 
only ICD to exhibit a sensing defect resulting in sensing POF at 90Gy. 
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At 10MeV, 40% (2 ICDs: ICD X4 and ICD Y5) reached POF at test to destruction 
ionising radiation dose of 120Gy.   ICD X4 was unable to sense resulting in pacing 
pulse failure at 120Gy and ICD Y5 had no output and no signal resulting in sensing 
failure at 120Gy.  
 
60% (3 ICDs; ICD Y4, ICD X5 and ICD Z3) reached POF in the range of 10-80Gy.  
ICD Y4 and ICD Z3 were the first devices to exhibited failure, as no output and no 
signal resulted in pacing pulse failure at a cumulative ionising radiation dose of 15Gy 
and 10Gy respectively.  ICD exhibited no shock resulting in shock failure at a POF of 
80Gy. 
 
  
 216 
Table 6.10: Results – POF observed in ICDs – Classified by CIED manufacturer 
(Malfunctions are only indicated when seen at each respective energy) 
6MeV 
ICD ICD failure RT Dose (Gy) 
Manufacturer X 
6MeV 
ICD X2 Pacing pulse 
No output 
 
100Gy 
ICD X3 Pacing pulse 
No output 
Shock 
No shock 
 
70Gy 
 
70Gy 
10MeV 
ICD X4 Sensing 
No sensing 
120Gy 
ICD X5 Shock 
No shock 
80Gy 
Manufacturer Y 
6MeV 
ICD Y2 Sensing 
Sensing defect 
Shock 
No shock 
 
90Gy 
 
90Gy 
ICDY3 Pacing pulse 
No output 
 
1Gy 
10MeV 
ICD Y4 Pacing pulse 
No output 
15Gy 
ICD Y5 Pacing pulse 
No output 
No signal 
120Gy 
Manufacturer Z 
6MeV 
ICD Z2 Pacing pulse 
No output 
No shock 
 
3.5Gy 
10MeV 
ICD Z3 
 
Pacing pulse 
No signal 
Shock 
No shock 
10Gy 
 
10Gy 
 
100% of the ICDs from CIED manufacturer X (ICD X2 and ICD X3) reached POF 
because of no output resulting in pacing pulse failure at 6MeV.    ICD X2 exhibited 
this at 100Gy and ICD X3 exhibited pacing pulse POF at 70Gy due to both no output 
and no shock.  ICD Y2 exhibited POF at 90Gy due to no shock resulting in pacing 
pulse failure and no shock resulting sensing failure.  
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At 6MeV, ICDs from CIED manufacturer Y (ICD Y2 and ICD Y3) reached POF 
because due to sensing, shock and pacing pulse failure.  ICD Y2 exhibited both 
sensing and shock failure at 90Gy.  ICD Y3 exhibited POF at a much lower ionising 
radiation dose of 1Gy due to no output resulting in pacing pulse failure.100% of the 
ICDs from CIED manufacturer Z (ICD Z2) reached POF because of no output and no 
shock resulting in pacing pulse failure at 3.5Gy 
 
From manufacturer X, ICD X4 reached POF because of no sensing at test to 
destruction ionising radiation dose of 120Gy and ICD X5 reached POF because of no 
shock resulting in shock failure at 80Gy at 10MeV. 
 
At 6MeV, 100% of ICDs from CIED manufacturer Y (ICD Y4 and ICD Y5) reached 
POF because due to pacing pulse failure.  ICD Y4 exhibited no output at 15Gy, in 
comparison to ICD Y5 that exhibited POF at a much higher ionising radiation dose of 
120Gy due to no output and no signal resulting in pacing pulse failure.  ICD Z3 from 
manufacturer Z failed at a low cumulative ionising radiation dose of 10Gy due to no 
signal resulting in pacing pulse failure and no shock resulting in shock failure.   
!
6.2.4   Effect of ionising radiation on CIEDs   
The CIED malfunctions and failures from this study are discussed under the following 
headings: 
1. Pacing pulse malfunctions and failure 
2. Sensing malfunctions and failure 
3. Telemetry malfunctions and failure 
4. Battery malfunctions and failure 
5. Shock malfunctions and failure 
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Pacing pulse malfunctions and failure: 
Over the past three decades, one of the technological advances in CIEDs is 
software-based developments to minimise pacing energy and threshold (pace the 
cardiac chamber of interest with the lowest feasible energy) but with good safety 
margins.  The pacing threshold is the lowest electrical pulse, delivered outside the 
natural refractory periods, that consistently elicits the propagation of a depolarising 
wave-front.  The pulse energy of the CIED has to be programmed and set to high to 
stimulate the heart. Usually, the pulse energy is programmed at an approximately 
50% higher value than the lower threshold value to stimulate the heart of an 
individual patient. The patient will therefore probably not notice an energy drop of 
25%, however, it might indicate that the pacemaker has been damaged during 
exposure to ionising radiation.  A failure of output is suspected if the heart rate is 
below the programmed lower rate of the CIED.  This malfunction would be observed 
on an ECG trace, as no pacing spike would be present despite an indication to pace.  
This may be due to battery failure, lead fracture, break in lead insulation, oversensing 
(inhibiting pacer output), poor lead connection and 'cross-talk' (ie a phenomenon 
seen when atrial output is sensed by a ventricular lead in a dual-chamber pacer) 
(Atlee and Bernstein, 2001).   
 
In this study, three pacemakers and seven ICDs exhibited pacing pulse device 
failure.   Two of the three pacemakers exhibited no output and amplitude deviations 
in the atrial channel resulting in pacing pulse failure both at 120Gy.  One pacemaker 
exhibited no output and amplitude deviations in the atrial channel resulting in pacing 
pulse failure at 90Gy. Out of the seven ICDs that exhibited pacing pulse failure, five 
ICDs displayed no output at 1Gy to 100Gy, one ICD displayed no signal at 10Gy and 
one ICD displayed both no output and no signal at 120Gy all resulting in device 
failure.  Pacing threshold changes may vary over time because of a spontaneous 
threshold rise after CIED implantation, micro dislodgment of a CIED lead, myocardial 
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ischemia and exposure to radiation or magnetic waves (Curtis et al, 1991). These 
variations in pacing threshold may narrow the safety margin of pacing stimulation, 
therefore raising potential safety issues regarding the functioning of the CIED and the 
clinical effect on the patient.  The CIEDs in this study exhibited pacing pulse failure, 
as they would not stimulate a patient’s heart to elicit propagation of a depolarising 
wavefront and therefore not pace the cardiac chamber appropriately.  As a result 
patients’ lives would be put at risk. 
 
A study by Souliman and Christie in 1994 irradiated three pacemakers with daily 
fractions of 2.8Gy.  They reported that all three pacemakers lost atrial chamber 
output at 16.8Gy to 28Gy and this was followed by a loss of ventricular chamber 
pacing at 36.4Gy to 64.4Gy.  All devices exhibited some form of permanent pacing 
pulse malfunctions, for example as the pulse interval of the ventricular channel 
increased, at the same time atrial channel failure was observed.  Transient or 
permanent loss of the ability to inhibit output and reduction in pulse rate occurred in 
all the pacemakers before complete loss of output resulting in device failure.  The 
authors reported that pacemakers frequently exhibit the loss of atrial pacing and a 
reduction in the pulse rate when their batteries are depleted.  Study three of this 
research, also observed this effect as one pacemaker exhibited pacing pulse failure 
at 90Gy and was unable to sense and the battery elective replacement indicator 
warning was alerted resulting in sensing and battery failure at the same ionising 
radiation dose.    
 
The results from Study 3 show that pacing pulse failure in pacemakers occurred at 
higher ionising radiation doses (90Gy and test to destruction ionising radiation dose 
of 120Gy) than in the Souliman and Christie (1994) study.  However, ICDs were not 
included in their research.  As more patients are presenting for radiotherapy 
treatment with ICDs, which are more susceptible to the effect of ionising radiation 
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(Frizzell, 2009) they were included in study three of this research.  Results showed 
that they exhibited pacing pulse failure in the range of 1Gy to 100Gy, with three ICDs 
displaying pacing pulse device failure at 10Gy and below.  Therefore, the results 
show that they are more sensitive to ionising radiation than pacemakers, exhibiting 
device failure at 1Gy.  However, due to the range of ionising radiation doses that 
caused ICDs pacing pulse failure it was not possible to identify the exact point at 
pacing pulse failure occurred. 
 
A study by Hurkmans et al in 2005 irradiated nineteen new pacemakers and eleven 
new ICDs.  Results showed that at 120Gy, three pacemakers exhibited amplitude 
deviations, two pacemakers displayed amplitude changes at both the atrial and 
ventricular channel and one pacemaker displayed amplitude deviation at the atrial 
channel only.  A complete loss of signal was observed in seven pacemakers 
resulting in device failure at 80Gy to 130Gy.  One ICD exhibited an amplitude 
increase during exposure to ionising radiation at 80Gy and this device subsequently 
displayed device failure.  Seven ICDs exhibited complete loss of signal resulting in 
no output at 0.5Gy to 120Gy.  
 
Results from Study 3 of this research support the findings of Hurkmans et al (2005) 
in respect to the higher ionising radiation doses that the pacemakers were found to 
withstand and pacing pulse failure in ICDs was exhibited at both low and high 
ionising radiation doses.  In study three, pacing pulse failure occurred in pacemakers 
at 90Gy to 120Gy and in ICDs at 1Gy to 100Gy.  Hurkmans et al found pacing pulse 
failure in pacemakers at 80Gy to 130Gy and in ICDs at 0.5Gy to 120Gy.  Importantly, 
the cumulative ionising radiation tolerance dose to ICDs recommended by Frizzell 
(2009) is 0.5Gy.  Therefore, both studies reinforce that ICDs are more susceptible to 
ionising radiation than pacemakers and that ICDs should be deactivated during 
radiotherapy treatment to prevent inappropriate anti-tachycardia shock therapy. 
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Sensing malfunctions and failure: 
Sensing, or sensitivity defines the ability of a CIED to correctly detect and sense an 
intrinsic electrical signal and spontaneous cardiac events.  The devices are equipped 
with entrance filters to allow the specific sensing of P waves in the atrium and R 
waves in the ventricle, based on the analysis of characteristics of these incoming 
electrical signals.  The programmed sensitivity settings indicate the minimum intra-
cardiac signal that will be sensed (seen) by the CIED to initiate the CIED response 
(inhibited or triggered).  The correct programming of the sensing level should allow 
the detection of all spontaneous cardiac events occurring in the chamber containing 
the lead and should reject events of other origins, such as crosstalk from another 
chamber, myopotentials, or radiation and electromagnetic interference.   
 
In this study, five pacemakers and one ICD were unable to sense resulting in sensing 
device failure.  Of these five pacemakers; sensing device failure was observed at 
52Gy, 70Gy, 90Gy and two pacemakers at 120Gy and sensing device failure was 
observed in one ICD at 120Gy.  However, during exposure to ionising radiation, 
CIEDs in this study exhibited sensing malfunctions, such as sensing discrepancies, 
undersensing, oversensing and sensing threshold changes even when the cause for 
device failure was not a result of sensing failure.  For example one pacemaker 
exhibited undersensing during irradiation but device failure occurred as a result of 
pacing pulse failure.  In a study by Rodriguez et al(1991) he found that the first 
failures in pacemakers were sensitivity related.  The study by Hurkmans et al, in 
2005 reported that two ICDs were unable to sense any signal after an ionising 
radiation dose of 120Gy resulting in sensing device failure.  Also, sensing 
interference detection was observed for all ICDs during exposure to ionising 
radiation, which was often caused by inhibition of the atrial channel, ventricular 
channel, or both.   Therefore, all studies show that sensing device failure occurs in 
both pacemakers and ICDs.  In addition, results from this PhD study and the study by 
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Hurkmans et al, show that sensing malfunctions occur during exposure to ionising 
radiation, irrespective of the specific cause of the device failure. 
 
This study identified three pacemakers and one ICD exhibiting undersensing 
malfunctions during exposure to ionising radiation.  Undersensing occurs when the 
CIED fails to detect spontaneous myocardial depolarisation, which results in 
asynchronous pacing.  Atrial or ventricular pacing spikes arise regardless of P waves 
or QRS complex.  The CIEDs incorrectly miss intrinsic depolarisation and pace 
despite intrinsic activity.  On an ECG trace, the appearance of too many pacing 
spikes would be observed.  The main causes of undersensing are CIED 
programming problems (incorrect sensing threshold) and this may be due to poor 
lead positioning, lead dislodgment, lead or CIED failure, low battery states, or 
myocardial infarction (Haghjoo, 2011).   A patient experiencing undersensing would 
clinically present with heart palpitation and on the ECG trace skipped beats would be 
observed.  These both indicate that the CIED is not working appropriately.  To treat 
undersensing in patients, the CIED programmed settings would need to be adjusted 
to increase the CIEDs sensitivity, so that they could detect intrinsic electrical signals.  
 
Also, in this study one ICD exhibited oversensing malfunctions during exposure to 
ionising radiation.  Oversensing occurs when the CIED senses electrical signals that 
it should not normally encounter, which results in inappropriate inhibition of the 
pacing stimulus. In addition to the native cardiac depolarisation signals (P or R 
waves), any electrical signal with sufficient amplitude and frequent occurrence can 
be sensed and can inhibit the CIED when pacing is required. The CIED incorrectly 
senses electrical activity and is inhibited from correctly pacing.  Oversensing can be 
caused by the device programmed incorrectly, battery failure, lead failure or 
physiological signals like T waves or by myopotential and non-physiological signals 
like electromagnetic interference (Haghjoo, 2011).  In CIEDs exhibiting oversensing, 
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the device has become too sensitive.  Therefore, the device senses the wrong 
signals and causes it to reset and increase the amount of time before the next 
discharge.  A patient experiencing oversensing would clinically present with fatigue, 
bradycardia, hypotension and / or syncope and on the ECG trace the paced beats 
occur later than they should.  These both indicate that the CIED is not working 
appropriately.  To treat oversensing in patients, the CIED programmed settings 
would need to be adjusted to decrease the CIEDs sensitivity, so that the CIED could 
only detect intrinsic electrical signals that they are required to.  The CIED settings 
should also be programmed to increase the minimum heart rate that the CIED 
senses.     
 
Sensing threshold is the voltage of the minimum signal that consistently activates the 
pulse generator function.  Sensing thresholds in most pacemakers are programmed 
to a constant value.  Ventricular sensing channels in pacemakers typically operate at 
sensing thresholds of 2.5 to 3.5mV, which is about ten times less sensitive than 
those in ICDs (Kaszala and Ellenbogen, 2010).  In this study, three ICDs exhibited 
sensing threshold malfunctions during exposure to ionising radiation at 1.5Gy, 9Gy 
and 70Gy.  Therefore, the first sensing threshold malfunction occurred at a low 
ionising radiation dose of 1.5Gy but another ICD exhibited the same malfunction but 
at a higher ionising radiation dose of 70Gy.  Also, in three ICDs ventricular 
tachycardia detection occurred.  If these ICDs were implanted in patients and anti-
tachycardia therapy was switched on, it would cause inappropriate shock therapy.  In 
the study by Hurkmans et al, it was reported that in several ICDs the lower 
ventricular sensing threshold was 50–65% lower than programmed, with this usually 
occurring at the point of device failure.  Results also showed that in four ICDs 
ventricular tachycardia or ventricular fibrillation occurred which would result in the 
inappropriate delivery of a shock.  Both these studies show that ionising radiation 
changes the CIED sensing thresholds, which would cause CIEDs to either 
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undersense or oversense.  For patients with ICDs, changes in sensing thresholds 
can lead to the incorrect detection of ventricular tachycardia or ventricular fibrillation, 
resulting in the delivery of inappropriate shock therapy. 
 
Telemetry malfunctions and failure: 
CIEDs are now multi-chamber systems with extensive programmability.  In order to 
monitor and evaluate these CIEDs, manufacturers have incorporated diagnostic tools 
in the devices; these tools are essential to determine what the CIED is doing and 
why it is doing it.  Complementing the interrogation of programmed data is the 
provision of measured data, including data obtained from the CIED detailing 
information on lead function, battery function, demand and asynchronous pacing 
rates.  Telemetry is the ability to non-invasively change the functional and diagnostic 
parameters of the pacing system by coded commands transmitted to the CIED from 
the programmer.  The CIEDs uses bidirectional telemetry, as the communication is 
two way, which means the CIED and the programmer can communicate with each 
other.  Information and data can be transferred from the CIED to the programmer for 
evaluation and any programming changes relayed back to the CIED.  
 
In this PhD study, nine pacemakers exhibited telemetry failure, as seven devices 
were unable to communicate and two devices had no output resulting in telemetry 
device failure.  Six pacemakers exhibited telemetry failure at of 90Gy to 120Gy and 
three pacemakers failed at 13.5Gy to 28Gy.  Hurkmans et al (2005) study reported 
that one pacemaker reached its point of failure due to loss of output, at a cumulative 
ionising radiation dose of 100Gy.  At that time, no telemetry problems were observed 
but one-week later telemetry was lost.  One other pacemaker showed problematic 
telemetry at 10Gy and lost total telemetry capability at 20Gy.  The third pacemaker 
lost telemetry at 130Gy. Both the studies show that telemetry device failure can 
occur over a range of ionising radiation doses.  If the devices are unable to 
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communicate the patients are being put at risk because there is no feedback 
mechanism to determine the status of the CIED and to show if it is programmed and 
working correctly.   
 
Battery malfunctions and failure 
The power source for CIEDs is a solid chemical battery; the most commonly used 
battery chemistry is lithium-iodine (LiI) (Kalahasty and Ellenbogen, 2010).  CIEDs 
use half of their battery power for cardiac stimulation and the other half for monitoring 
and data logging.  CIED batteries should last between five and fifteen years (average 
six to seven years), depending on how active the CIED is.  The primary functions of a 
CIED battery is to store enough energy to stimulate the heart by generating 5V of 
power and to provide power to the sensors and timing devices. The battery must 
retain its power over many years, with a minimum time frame of four years and have 
a predictable life cycle providing an alert as to when the battery needs replacement.  
The battery must be able to function when hermetically sealed.  
 
In this study, three pacemakers exhibited battery failure, as all the devices displayed 
the elective replacement indicator (ERI).  Two pacemakers exhibited battery failure at 
120Gy and one pacemaker exhibited battery failure at 70Gy.  Prior to irradiation, all 
CIEDs were interrogated; results showed that all three of the pacemaker’s batteries 
were full or nearly full.  Therefore, exposure to ionising radiation, caused depletion of 
the batteries to an extent whereby the elective replacement indicator alert was 
observed.  Battery drainage, could result in the CIED not working appropriately.  In a 
study by Hurkmans et al, five pacemakers showed an elective replacement indicator 
and the authors recommended that the pacemaker should be replaced within a few 
weeks, to avoid the loss of therapy due to an empty battery.   These studies show 
that ionising radiation does have an effect on battery life and this occurs at higher 
ionising radiation doses. 
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Shock malfunctions and failure: 
ICDs provide continuous monitoring and treatment for cardiac arrhythmias. The ICD 
is a complex device and it is able to detect and distinguish between atrial and 
ventricular rhythms. The ICD can detect if the heart is beating in a regular rhythm 
(sinus rhythm), if the heart rhythm is irregular (atrial fibrillation) or if the heart rhythm 
is too fast (ventricular tachycardia or ventricular fibrillation).  The ICD also has a 
pacemaker function, to regulate the rhythm should the heart beat too slowly.   
 
If the ICD detects an abnormally fast heart rhythm it will monitor for a few seconds to 
see if it stops.  If it does stop, the ICD will record that an episode of non-sustained 
arrhythmia has occurred.  If the arrhythmia does continue, the ICD will initially try to 
treat by pacing out the arrhythmia by delivering a number of pre-set paced beats 
(anti-tachycardia pacing).  During this therapy, some patients may experience a 
fluttering sensation in their chest.  If anti-tachycardia pacing does not stop the 
arrhythmia, the ICD will deliver shock therapy and the patient will feel a firm thump in 
their chest.  
 
In this study four ICDs exhibited shock failure, as all the devices were unable to 
shock.  One ICD exhibited no shock at the low ionising radiation dose of 3.5Gy and 
three ICDs exhibited no shock at the higher ionising radiation doses of 70Gy, 80Gy 
and 90Gy.  In a study by Hurkmans et al  (2012) six ICDs were unable to deliver a 
shock.  Four devices were unable to deliver a shock at very low ionising radiation 
doses; one ICD exhibited no shock at 0.5Gy, two ICDs at 1.5Gy and one ICD at 
2.5Gy.   The authors commented that after they failed to deliver a shock, the 
amplitude dropped and the ICDs showed a complete loss of function.  Two ICDs 
exhibited no shock at the higher ionising radiation doses of 80Gy and 120Gy.  The 
main life-saving therapy delivered by ICDs is shock therapy.  Results from these 
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studies show that at even low ionising radiation doses, ICDs exhibited failure, as they 
are unable to shock and this could have serious implications for the patient. 
  
6.2.5    Study 3 Conclusion 
In this study, pacemakers exhibited a range of temporary and permanent 
malfunctions starting at cumulative ionising radiation dose of 3Gy.  The AAPM report 
recommended that the maximum dose to a pacemaker should be limited to less than 
2Gy (Marbach et al, 1994).   A study by Mouton et al supported the AAPM 
recommendations (Mouton et al, 2002) as results showed that one pacemaker 
exhibited clinically significant disturbances at a cumulative ionising radiation dose of 
only 0.15Gy, two pacemakers exhibited defects at 1Gy and nine pacemakers failed 
at 2Gy (Mouton et al, 2002).  Hurkmans et al (2005). reported that the most common 
damage observed was loss of device output at higher ionising radiation doses 
(Hurkmans et al, 2005).  In contrast, in the Mouton study (2002) only one pacemaker 
malfunctioned below 50Gy, suggesting modern pacemakers may be relatively 
radioresisitant.   Results from Study 3 of the research project agree with Mouton et 
al’s  (2002) findings as three pacemakers failed at or below 52Gy and one 
pacemaker failed at 120Gy. Therefore, results from this and previous studies 
conclude that the AAPM recommendations are still valid.  
 
In 2009 Frizzell published a more contemporary review of CIEDs and radiotherapy, 
concluding that the AAPM recommendations were no longer comprehensive as ICDs 
were not discussed (Frizzell, 2009).  ICDs are more sophisticated and have the 
ability to automatically defibrillate the heart by monitoring the patient’s heart rate and 
deliver the appropriate electrical therapy. Frizzell (2009) recommended a lower 
radiotherapy tolerance dose of 0.5Gy for ICDs. This tolerance dose is partly based 
on work by Hurkmans et al (2012), where it was found that the ionising radiation 
dose at the first ICD malfunction was as low as 0.5Gy.  Results from Study 3 of this 
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research project also observed the first ICD malfunction at a cumulative ionising 
radiation dose of 0.5Gy.  Therefore, results from this and previous studies conclude 
that the Frizzell (2009) recommendations are still valid.  Using results from this study, 
chapter seven will make recommendations regarding all aspects of the patient 
management for patients with CIEDs receiving radiotherapy treatment is discussed 
leading to the publication of UK guidelines.  
!
6.3    Study 4: 
6.3.1    Introduction 
CIED leads are insulated flexible wires that conduct electrical signals from the 
generator to the heart muscle and relay information concerning the heart’s intrinsic 
electrical activity back to the CIED pulse generator.  The results from Study 3 
showed that ionising radiation might affect the function of the CIED but that CIED 
leads are considered to be resistant to these effects.  No CIED manufactures have 
issued any ionising radiation tolerance doses to CIED leads.   
 
The aim of this study was to investigate and evaluate the relationship between 
cumulative ionising radiation dose and / or EMI and the damage sustained to CIED 
leads.  This section will present the findings of Study 4, analyse the study’s results 
and discuss malfunctions and or failure in CIED leads when exposed to ionising 
radiation.  In discussing observed CIED malfunctions and failure, the effect of 
radiotherapy on the CIED leads and the clinical impact to the patient will be 
discussed.  It concludes by stating the precautions that need to be considered when 
CIED leads are in the radiotherapy treatment field.   
 
 
 
 229 
6.3.2    CIED leads  
In this study, the effect of ionising radiation and EMI on the CIED lead sheath was 
investigated following anecdotal evidence and clinical audits of practice.  The sheath 
is made from poly(ether)urethane, which is a synthetic, segmented polymer with very 
high tensile strength and resistance to mechanical abrasion. Due to its physical 
properties, it can be used as a thin layer of insulation to cover the CIED lead 
conductors.  Polyurethane has excellent lubricity (the measure of the reduction in 
friction and or wear by a lubricant) and handling characteristics, with a low frictional 
coefficient, which can facilitate implantation of two or three lead systems by 
decreasing the physical interactions between the leads.   Pacing lead insulation is a 
critical and vulnerable component but it can also be the cause of lead failure.  For 
example, polyurethane leads are stiff and not fully biostable and may be subject to in 
vivo polymer degradation that can cause insulation and late lead failure.  All 
insulating materials fail at some level of applied voltage.  This study investigated the 
dielectric strength of the CIED lead sheaths; that is the voltage a material can 
withstand before breakdown occurs. 
 
In the study, four different leads from CIED manufacturer X were used.  Lead type 
one were bipolar pacemaker leads and composed of two individually coated 
conductor wires co-radially wound together to form a single conductor coil.  The lead 
included a silicone rubber or polyurethane outer insulation layer.   Pacing and 
sensing occurs between the distal pole and the ring electrode and fixing to the 
myocardium is achieved by silicone rubber tines.  Lead type two was also bipolar 
pacemaker leads and consisted of a multi-strand conductor coil-within-a-coil design 
that provides a conductive pathway and acts as a drive mechanism for extending and 
retracting the fixation helix.  The conductors are each sheathed in a thin-walled tube 
of silicone rubber insulation.  This lead has a proprietary coating that makes the 
silicone lead surface feel more lubricious. The coating reduces both the static and 
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dynamic coefficients of friction, making the lead feel like polyurethane.  Lead type 
three was bipolar pacemaker leads and consisted of a coaxial design that includes 
single-filar inner and outer coils designed for MRI conditional use.  The conductors 
are separated by both a silicone rubber and polytetrafluroethylene (PTFE) lining.  
Both the inner and outer coil are covered in ethylene tetrafluroethylene (ETFE) for 
extra insulation protection.  The whole lead body is encompassed in a polyurethane 
outer insulation.  The extendable and retractable helix fixation design anchors the 
distal tip electrode to the endocardial surface with support of trabecular structures. 
Lead type four, was bipolar ICD leads and consist of two coaxial coils, each of which 
is made up of several parallel wires.  The coils make up the conduction paths to the 
tip and ring electrodes.  They are insulated from each other and from the 
environment using silicone rubber.  Pacing and sensing occurs between the distal 
pole and the ring electrode.   
 
6.3.3    Results - Effect of ionising radiation on CIED leads 
The results from Study 3 showed that ionising radiation affected the function of 
CIEDs.  However, CIED leads are considered to be resistant to these effects.  In this 
study the effect of ionising radiation and EMI on the insulation sheath of the CIED 
lead was investigated.   
 
Laboratory testing - Insulation sheath of CIED leads  
Individual sections of the CIED leads sheath were irradiated using a Varian linear 
accelerator at doses of 0.5Gy, 1Gy, 2Gy, 5Gy, 10Gy, 60Gy and 120Gy. The basic 
premise of this experiment was to determine if de-polymerisation occurred in the 
sheath material layer of the CIED lead as a result of exposure to ionising radiation 
and / or EMI. Essentially, high-energy photons produced by the linear accelerator 
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interacted with the polymer material of the CIED lead.  This can cause long chain 
polymer bonds to break resulting in possible embrittlement of the polymer.  
 
Initial results showed that this technique has the potential to provide the necessary 
insight into polymer degradation of CIED leads following exposure to ionising 
radiation and EMI.  The graph below shows the change in the so-called figure of 
merit (FoM) as a function of ionising radiation dose received.  The figure of merit is 
defined as a numerical expression taken as representing the performance or 
efficiency of a given device, material, or procedure. 
 
The FoM combines all three parameters above in the form: 
FoM = Insertion Loss x Change in bandwidth / Change in resonant frequency 
 
This non-optimised experimental configuration highlighted that for ionising radiation 
doses at 40-120Gy, there is an observable change in FoM as the dose increased 
(see figure 6.1). Suggesting that, with further experimentation, a reliable means of 
quantifying CIED lead sheath damage could be feasible. 
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Figure 6.1: Graph of results to show FoM - ionising radiation dose delivered to 
insulation sheath of CIED leads) 
 
 
6.3.4    Clinical effect of ionising radiation and EMI on CIED leads 
There is little research into the effects of ionising radiation and EMI on CIED leads.  
However, two reports have been published documenting the effect of ionising 
radiation on CIED leads.  A case study published by John and Kaye in 2004 reported 
an ICD malfunction after a patient’s radiotherapy treatment for left breast cancer.  
While the ICD had been shielded, the CIED leads received a full dose with partial 
exposure of the ICD.  During the post radiotherapy cardiology follow-up appointment, 
the patient’s CIED battery was found to have depleted.  CIED interrogation showed 
the shock impedance of the ICD had increased, which resulted in shock coil failure, 
possibly due to structural damage to the CIED leads when exposed to ionising 
radiation.  Therefore, the patient required surgical intervention and implantation of a 
new CIED and CIED leads.  In 2011, Dasgupta et al published a case report, 
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detailing the radiotherapy treatment to the right cardiac atrium and ventricle of a 
patient with a pacemaker.  The cumulative ionising radiation dose to the CIED leads 
was 5Gy.  They were monitored throughout their radiotherapy treatment and a single 
episode of ventricular under sensing with pacing stimuli during T-waves was 
successfully addressed by the reprogramming of the CIED.  Therefore, the authors 
suggested that ionising radiation had an effect on CIED leads.   
 
Clinical observations were made of a patient with a pacemaker receiving 
radiotherapy treatment in a RCW.  This patient exhibited a marked clinical cardiac 
reaction during their radiotherapy treatment.  The patient was receiving thoracic 
radiotherapy of 20Gy in five fractions.  The pacemaker was 6cm away from the 
radiotherapy treatment site, therefore receiving a negligible dose of ionising radiation.  
However, the CIED leads were directly in the radiotherapy treatment field.  Medical 
physics calculated that the cumulative ionising radiation dose to the CIED leads was 
14Gy.  Shortly after radiotherapy treatment commenced the patient exhibited a rapid 
heart rate, experienced chest pain, felt light headed, dizzy and nauseous and 
appeared flushed and was sweating.  Liaising with the consultant oncologist and 
consultant cardiologist, the patient was reviewed and the CIED was checked.  It was 
found that the CIED showed no malfunctions or failure and they concluded that the 
reaction was due to the direct irradiation of the CIED leads.  All three cases indicate 
that ionising radiation and or EMI have an effect on CIED leads as manifested in 
these patients’ clinical reaction or CIED function.   
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Figure 6.2: CT images of a patient radiotherapy treatment planning scan 
 
 
However, two reports from Munshi et al (2008) and Kirova et al (2012) documented 
that they had found no effects on CIED function or adverse effect to the patient when 
the CIED leads were exposed to ionising radiation and EMI.  In 2008, Munshi et al 
published a case report for a breast cancer patient where the CIED leads were in the 
radiotherapy treatment field.  They documented that there was no malfunction to the 
patient’s CIED but concluded that the dose to the CIED and CIED leads should be 
kept as low as possible.  In 2012, Kirova et al published a case report for a patient 
receiving radiotherapy to the thoracic spine.  The cumulative ionising radiation dose 
to the CIED leads was 5Gy.  They observed no change in CIED function during and 
after radiotherapy treatment and concluded that all patients with CIEDs should be 
monitored during their radiotherapy treatment.  Both cases state that ionising 
radiation has no effect on CIED leads or a clinical effect on patients but they also 
recommend that all patients with CIEDs are monitored during their radiotherapy 
treatment.   
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6.3.5    Study 4 Conclusion 
There is limited published evidence to inform ionising radiation dose constraints to 
CIED leads and also no consensus in the results reported from case studies 
regarding clinical reactions of patients with CIED when the CIED leads were exposed 
to ionising radiation. Therefore, when treating patients with CIEDs with radiotherapy, 
every effort should be made to keep the CIED leads out of the radiotherapy 
treatment field. If this is not possible, then the ionising radiation dose to the CIED 
leads should be kept as low as possible. 
 
6.4    Study 5 
6.4.1    Introduction 
The aim of this study was to investigate and evaluate the relationship between EMI 
and the damage sustained to CIEDs.  This section will present the findings of Study 
5, analyse the results and discuss the mechanisms that cause malfunctions and or 
failure in CIEDs when exposed to EMI.  In discussing specific CIED malfunctions and 
failure, the effect of EMI and the clinical impact to the patient will be discussed.  The 
section concludes by recommending the monitoring requirements for all patients with 
CIEDs presenting for radiotherapy treatment. 
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6.4.2    Effect of EMI on CIEDs 
Table 6.11: Results – Effect of EMI on pacemakers 
DEVICE 
Pacemakers 
6MeV At what point CIED  
malfunction observed Fraction CIED malfunctions observed 
 
 
 
 
 
 
PM X9 
 
1 – 3 
3 – Sensing 
Over sensing of EMI by the atrial channel – trigger 
ventricular pacing near upper tracking rate limit  
During EMI exposure 
 
4 
1 – Pacing pulse 
Noise reversion mode triggered 
During EMI exposure 
5 – 6 
 
No CIED malfunction observed or recorded 
7 – 9 1 – Pacing pulse 
Noise reversion mode triggered 
During EMI exposure 
10 1 – Pacing pulse 
Noise reversion mode triggered  
Reset to backup mode 
During EMI exposure 
 
PM X10 
1 – 7 No CIED malfunction observed or recorded 
8 – 10 2 – Pacing frequency 
Inappropriate pacing inhibition – Every beam 
Beam ON 
During EMI exposure 
10MeV 
 
PM X11 
1 – 10 2 – Pacing frequency 
Inappropriate pacing inhibition – Every beam 
Pacing error – ‘dropped beats’ 
Beam ON 
During EMI exposure 
 
 
PM X12 
1 – 9 1 – Pacing pulse 
Noise reversion mode triggered 
During EMI exposure 
10 1 – Pacing pulse 
Noise reversion mode triggered  
Unable to detect cardiac activity = pacing error 
During EMI exposure 
 
All CIEDs used in this study were from CIED manufacturer X.  At 6MeV and 10MeV, 
100% of pacemakers exhibited malfunctions related to EMI exposure.  PM X9 
exhibited sensing malfunctions during EMI exposure on the first to fourth fraction.  
The device was over sensing EMI by the atrial channel, which would trigger 
ventricular pacing near the upper tracking rate limit.   Also, on the fourth fraction, 
during EMI exposure the device triggered noise reversion mode resulting in a pacing 
pulse malfunction.  During the fifth and sixth fraction, no CIED malfunction was 
observed or recorded.  On the seventh, eight and ninth fractions once again during 
EMI exposure the device triggered noise reversion mode resulting in a pacing pulse 
malfunction.  On the final fraction, at the point of beam ON the device triggered noise 
reversion mode again then during exposure to EMI, the pacemaker reset to backup 
mode. 
 237 
No CIED malfunctions were observed or recorded for PM X10 for the first seven 
fractions.  In fraction eight to ten, at the point of beam ON and during EMI exposure 
during every beam the pacemaker exhibited inappropriate pacing inhibition resulting 
in pacing frequency malfunctions.  
 
In PM X11, for all ten fractions at the point of beam ON and during EMI exposure 
during every beam the pacemaker exhibited inappropriate pacing inhibition and the 
‘dropped beat’ pacing error resulting in pacing frequency malfunctions.  
 
In PM X12, during EMI exposure on the first to ninth fractions the device triggered 
noise reversion mode resulting in a pacing pulse malfunction.  In the final fraction 
noise reversion mode was triggered but the device was also unable to detect cardiac 
activity resulting in a pacing error. 
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Table 6.12: Results – Effect of EMI on ICDs 
DEVICE 
Pacemakers 
6MeV At what point CIED  
malfunction observed Fraction CIED malfunctions observed 
 
ICD 
X7 
1 – 9 2 – Pacing frequency 
Pacing error – ‘Dropped beats’ 
Beam ON 
10 5 – Battery 
Decrease in battery capacity 
Post beam OFF 
 
 
ICD 
X8 
1 – 6 1 – Pacing pulse 
Noise reversion mode triggered 
During EMI exposure 
7 3 – Sensing 
Ventricular fibrillation (VF) – Cause inappropriate delivery of 
shock therapy 
During EMI exposure 
8 – 10 1 – Pacing pulse 
Noise reversion mode triggered 
During EMI exposure 
10MeV 
 
ICD 
X9 
1 – 5 No CIED malfunction observed or recorded- 
6 – 10 7 – Shock 
Deactivation of shock therapy by reversion to OFF mode 
During EMI exposure 
 
 
ICD 
X10 
1 – 3 No CIED malfunction observed or recorded- 
4 – 6 2 – Pacing frequency 
Pacing error – Transient inhibition 
Beam ON 
7 – 10 2 – Pacing frequency 
Pacing error – ‘Dropped beats’ 
Pacing error – Transient inhibition 
Beam ON 
 
At 6MeV and 10MeV, 100% of ICDs exhibited malfunctions related to EMI exposure.  
At 6MeV, during fractions one to eight, ICD X7 exhibited pacing frequency 
malfunctions at the point of beam ON.  The device exhibited the ‘dropped beat’ 
pacing errors.  For fractions nine and ten, post beam OFF the device showed a 
decrease in battery capacity resulting in battery malfunctions.   
 
ICD X8 for the first eight fractions noise reversion mode was triggered during EMI 
exposure resulting in pacing pulse malfunctions.  On the seventh fraction, during EMI 
exposure the device was over sensing EMI by the atrial channel, which would trigger 
ventricular pacing near the upper tracking rate limit.   For fraction eight to ten during 
EMI exposure the ICD again triggered noise reversion mode resulting in pacing pulse 
malfunctions.   
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At 10MeV, ICD X9 exhibited no CIED malfunctions for the first five fractions.  During 
EMI exposure on fraction six to ten, the device showed that the ICD shock therapy 
had been deactivated by reversion to OFF mode.  ICD X10 exhibited no CIED 
malfunctions for the first three fractions.  On the first to sixth fraction at the point of 
beam ON, the device exhibited transient inhibition resulting in a pacing error causing 
pacing frequency malfunctions.  On the remaining three fractions at the point of 
beam ON, the device exhibited both transient inhibition and dropped beats resulting 
in pacing errors causing pacing frequency malfunctions.   
 
Table 6.13: Results – Effect of EMI on rate response activated CIEDs 
Rate response  
activated CIEDS 
6MeV At what point CIED 
malfunction observed Fraction CIED malfunctions observed 
PM 
X3RA*1 
1 – 10 No CIED malfunction observed or recorded 
PM 
X3RMV*2 
1 – 10 2 – Pacing frequency 
Accelerated pacing – to maximum sensor driven rate 
During EMI exposure 
10MeV 
PM  
X2RA*1 
1 – 10 No CIED malfunction observed or recorded 
PM  
X2RMV*2 
1 – 10 2 – Pacing frequency 
Accelerated pacing – to maximum sensor driven rate 
During EMI exposure 
 
At 6MeV and 10MeV, both rate response activated devices that utilise accelerometer 
sensors (PM X3 RA*1 and PM X2 RA*1) exhibited no CIED malfunctions when 
exposed to EMI.  In comparison both rate response activated devices that utilise 
minute ventilation sensors (PM X3 RMV*2 and PM X2 RMV*2) exhibited pacing 
frequency malfunctions during EMI exposure.  The devices exhibited accelerated 
pacing up to maximum sensor driven rate. 
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6.4.3    Electro-magnetic interference (EMI)  
In the electro-magnetic field measurement section of this study, the aim was to 
determine the levels of EMI emitted from the linear accelerator during ionising 
radiation exposure.   The background electro-magnetic fields were captured using a 
EMC antenna connected to the field fox in ‘spectrum analyser’ mode.  This provided 
a trace of power versus frequency.  As radiotherapy treatment rooms are extremely 
well shielded from external sources of electro-magnetic radiation, the system was 
sensitive enough to detect external sources, for example radio broadcasts (BBC in 
97-99MHz) and radiofrequency (RF) signals related to the hospital pager network.  
However, despite this level of sensitivity, no discernable power was observed that 
could be correlated with the linear accelerator system.  This experiment was 
repeated and on all occasions, the antenna and field fox did not identify levels of EMI 
emitted from the linear accelerator system.  This could simply be due to the transient 
nature of EMI or the resultant power is too great to be detected by the antenna.  
Furthermore, the sweep parameters and bandwidth used with the field fox could be 
too fast or too narrow respectively.  Further investigation is required to determine the 
factors effecting detection of EMI in the radiotherapy treatment room. 
 
6.4.4    Device responses to EMI  
The most frequent responses to EMI are inappropriate inhibition or triggering of 
pacemaker stimuli, reversion to asynchronous pacing, and spurious ICD 
tachyarrhythmia detection. Reprogramming of operating parameters and permanent 
damage to the device circuitry or the electrode to tissue interface are much less 
frequent (Pinski and Trohman, 2002).   
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Pacing Inhibition 
 In this study, two pacemakers and two ICDs exhibited device malfunctions that 
caused pacing inhibition.  One pacemaker exhibited inappropriate pacing inhibition 
on every radiotherapy treatment delivery beam for the last two fractions of exposure 
to EMI and the other pacemaker exhibited inappropriate pacing inhibition on all ten 
fractions of EMI exposure.  This occurred on every beam and also, throughout EMI 
exposure pacing errors occurred in the form of dropped beats. In both pacemakers, 
pacing inhibition was observed when the radiotherapy treatment machine / radiation 
beam was switched ON and also during EMI exposure.   
 
For nine fractions of EMI exposure, one ICD exhibited pacing inhibition and dropped 
beats were observed when the radiotherapy treatment machine / radiation beam was 
switched ON.  Subsequently, on the final fraction post EMI exposure the device 
displayed a decrease in battery capacity.  The other ICD exhibited no device 
malfunction for the first three fractions of EMI exposure but then on fractions four to 
six, pacing errors were observed and on the remaining three fractions dropped beats 
and transient inhibition was observed when the radiotherapy treatment machine / 
radiation beam was switched ON.   
 
Triggering of rapid or premature pacing  
One pacemaker and one ICD exhibited sensing malfunctions causing the devices to 
pace rapidly.  For the first four fractions that the pacemaker was exposed to EMI, 
during exposure oversensing of EMI by the atrial channel occurred which 
subsequently triggered ventricular pacing near the upper tracking rate limit.  In the 
ICD on the seventh fraction of EMI exposure, during exposure the device sensed 
rapid pacing resulting in ventricular fibrillation.  If the device were implanted in a 
patient, this would cause the ICD to inappropriately deliver shock therapy.  
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Noise reversion mode  
Two pacemakers and two ICDs exhibited pacing pulse malfunctions resulting in the 
devices triggering noise reversion mode.  One pacemaker had displayed 
oversensing for the first three fractions of EMI exposure and noise reversion mode 
was triggered on the fourth fraction during EMI exposure.  Then on the final (tenth) 
fraction during EMI exposure the device reset to back-up mode.  The other 
pacemaker triggered noise reversion mode on the first fraction of EMI exposure and 
during EMI exposure on the final fraction the pacemaker was unable to detect 
cardiac activity resulting in device failure.  One ICD triggered noise reversion mode 
during EMI exposure for the first six fractions of EMI exposure, on the seventh 
fraction ventricular fibrillation was sensed and during EMI exposure on the remaining 
fraction noise reversion mode was triggered again. The other ICD exhibited noise 
reversion mode during EMI exposure on the sixth to tenth fraction of exposure and 
this caused the deactivation of ICD shock therapy by the reversion switching shock 
to OFF mode.  
 
Hudson et al (2010) used the study by Souliman et al in 1994 to report that EMI had 
no impact on pacemaker malfunction.  A further study by Hurkmans et al (2012) 
stated that EMI effects are mainly temporary or reversible and they concluded that 
EMI did not seem to be of clinical relevance.  In 2015, Zaremba et al, stated that the 
effects of EMI are usually transient and EMI typically does not pose any threat to the 
function of CIEDs, as in his study no events of symptomatic inhibition or rapid pacing 
was observed during radiotherapy treatment.  However, in this PhD study pacing 
inhibition, triggering of rapid pacing and activation of noise reversion mode was 
observed in a number of pacemakers and ICDs.   
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6.4.5    Rate response activated CIEDs 
In this study both rate response activated devices that utilised minute ventilation 
sensors exhibited pacing frequency malfunctions during EMI exposure.  The devices 
exhibited accelerated pacing up to the maximum sensor driven rate.  The results 
from CIED exposure to EMI showed that both CIEDs reacted as outlined in the 
Boston Scientific caution. 
 
The results from audit two (in study two), showed that CIED mediated tachycardia, 
was observed in all patients with rate response activated minute ventilation CIEDs 
undergoing radiotherapy treatment at a Welsh radiotherapy department.  CIED 
mediated tachycardia occurred when the patient’s baseline heart rate increased to 
over 100 beats per minute during the delivery of the radiotherapy treatment.  Once 
again, the results from this audit support the caution from Boston Scientific.  
However, they recommend that the CIED MeV sensor should be deactivated when 
exposed to equipment that can cause an effect.  This audit showed the clinical 
reactions that all patients exhibited.  In one case the patient exhibited a marked 
cardiac physiological reaction during radiotherapy treatment as they felt “like they 
were having a heart attack on the bed”.  In liaising with the patient’s cardiology 
department, the CIED MeV sensor was deactivated.  However the patient could not 
tolerate the cardiac clinical consequences of this and the MeV sensor had to be 
reactivated.  Radiotherapy treatment continued but treatment delivery time was 
increased.  The radiation beam was switched ON and the patients heart rate 
increased to the upper tracking limit, at that point the radiation beam was switched 
OFF.  This allowed that patient’s heart rate to return to normal.  This process was 
repeated until the prescribed ionising radiation treatment dose was administered.   
 
 244 
6.4.6    Study 5 Conclusion 
CIEDs (pacemakers, ICDs and rate response activated devices) exhibited a range of 
effects when exposed to EMI produced by the linear accelerator.  When investigating 
these effects, the devices were not in, or in close proximity to, the radiotherapy 
treatment beam, therefore they received a negligible dose of ionising radiation.  
These reactions were a direct consequence of exposure to EMI only.   
 
Results from Study 1, showed that a number of radiotherapy departments do not 
monitor CIED patients if the patient’s CIED is not receiving an ionising dose of 
radiation.  However, results from this study show that EMI is produced during 
irradiation and is present in the radiotherapy treatment room.  Thus EMI can have an 
effect on CIEDs.  Therefore, it is recommended that all patients with a CIED and 
receiving radiotherapy treatment should be monitored during their treatment.!
!
! !
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Chapter Seven 
Research outcomes 
 
7.1    Introduction 
Chapter five presented the data obtained from the UK Survey of radiotherapy 
practice in patients with CIEDs receiving radiotherapy treatment and the result of 
audits of clinical practice.  Chapter six presented the scientific studies investigating 
the effect of ionising radiation and EMI on the CIEDs and CIED leads.  Detailed 
consideration was also given to looking at possible justification and explanation for 
the findings obtained and relating these to previous studies.  Results from study one 
showed that most UK radiotherapy departments’ CIED policies do not reflect current 
best evidence.  There is also a substantial difference in CIED policies regarding the 
management and monitoring of patients with a CIED receiving radiotherapy 
treatment.  In addition, the majority of policies do not adhere to current established 
ionising radiation tolerance doses for CIEDs and it concluded that as a consequence, 
it is very likely that patients are being put at significant risk of harm (Lester et al, 
2014). 
 
The results from studies three, four and five show that CIEDs and CIED leads are 
sensitive to the effects of ionising radiation and / or EMI.  Therefore, these results 
have provided a basis for the recommendations for the safe management of patients 
with a CIED receiving radiotherapy treatment.   This chapter outlines how these 
recommendations were taken forward as supporting evidence (study six) to a 
national panel set up between the three professional bodies responsible for 
radiotherapy practice within the UK (Society and College of Radiographers, Royal 
College of Radiologists and Institute of Physics and Engineering in Medicine).  This 
panel, of which the researcher was co-chair, subsequently published up to date, 
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evidence based clinical guidelines for the use of radiotherapy in patients with 
inserted cardiac devices (Sor.org, 2015) (see appendix H and I). 
 
7.2    Summary of recommendations 
• CIEDs should not be placed directly in the radiotherapy treatment beam   
• The photon beam energy should be <10MeV   
• The cumulative ionising radiation dose received by a pacemaker should not 
exceed 2Gy 
• The cumulative ionising radiation dose received by an ICD should not exceed 
0.5Gy   
• The cumulative ionising radiation dose received by CIED leads should be 
kept as low as possible 
• Patients with rate-response adaptive CIEDs should be reviewed in 
conjunction with the Cardiology Department and consideration given to 
temporary deactivation of the sensor whilst receiving radiotherapy treatment 
• The dose contribution from on-treatment verification imaging should be taken 
into account when calculating cumulative radiotherapy dose to the CIED 
• The patient’s cardiologist should be informed in advance of any planned 
radiotherapy treatment for advice on monitoring during radiotherapy and 
subsequent follow-up   
• Patients with CIEDs should be fully informed of the potential short and long-
term risks of radiotherapy treatment. This should be included in patient 
information available from the cardiology department in addition to the 
radiotherapy patient information   
• All patients with a CIED should be monitored during their radiotherapy 
treatment 
 
 247 
• Appropriately trained staff should be involved in CIED monitoring during 
radiotherapy treatment  
 
7.3    Before radiotherapy   
All patients should be screened for the presence of a CIED as part of their 
radiotherapy planning process. When identified, CIED information should be 
annotated as stated on the patients’ CIED identification card.  Staff should be aware 
that some cardiologists place the CIED on the patients’ right side if they are left-
handed.  Anecdotal evidence from earlier in the PhD showed that in some cases, a 
CIED is not discovered until a patient attends for radiotherapy treatment (Lester et al, 
2014).  This results in treatment being delayed or proceeding without appropriate 
safety measures in place.  Planned radiotherapy treatment details should be 
recorded as per standard practice.  The cardiology department should be informed 
as soon as possible to facilitate patient review before radiotherapy treatment to 
establish CIED functionality and to detect any possible change in pacing-dependency 
of the patient.  If an examination of technical CIED function has not been conducted 
within the previous three months, it is recommended that it should be carried out 
prior to the patient commencing radiotherapy treatment.  The cardiologist should also 
recommend appropriate CIED monitoring during and after radiotherapy treatment.  
 
7.4    Radiotherapy planning   
If the CIED is near or in the radiotherapy treatment field or volume, it should be 
included in the planning CT scan.  This allows accurate estimation of the cumulative 
ionising radiation dose received by the CIED.  The CIED should not be in the 
planning target volume (PTV) in order to minimise radiation dose to the device.  
Radiotherapy beam energy no greater than 10MeV should be used to avoid neutron 
contamination (Hurkmans et al, 2012; Gauter-Fleckenstein et al, 2015 and Gelblum 
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et al, 2009).  The medical physics/radiotherapy planning team should be informed of 
the presence of a CIED and every effort should be made in the planning process to 
limit the cumulative ionising radiation dose to the CIED.  
 
7.5    Ionising radiation tolerance doses to CIEDs and CIED leads 
It is not possible to predict the exact behaviour of any given CIED when it is in, or in 
close proximity to, the radiotherapy treatment field (Gauter-Fleckenstein et al, 2015).  
Results from this research show that the risk of CIED malfunction increases as 
cumulative ionising radiation dose to the CIED increases and that EMI can cause 
device malfunctions, even when the CIED is receiving a negligible dose of radiation.  
In addition, the risk to the patient is greater if the patient is pacing-dependent, 
including patients whose pacemaker is pacing all the time (and who are at risk of 
asystole if the pacemaker malfunctions).  Patients with a resynchronising pacemaker 
may be at risk of increased heart failure symptoms in an event of device malfunction.  
 
Pacemakers: 
In this research, pacemakers exhibited a range of temporary and permanent 
malfunctions starting at a cumulative ionising radiation dose of 3Gy.  The AAPM 
report recommended that the maximum dose to a pacemaker should be limited to 
less than 2Gy (Marbach et al, 1994).   Mouton et al supported the AAPM 
recommendations (Mouton et al, 2002) where their results showed that pacemakers 
exhibited defects at 1Gy and subsequently failed at 2Gy (Mouton et al, 2002).  
Therefore, results from this work and previous studies conclude that the AAPM 
recommendations are still valid.   
 
ICDs: 
Frizzell (2009) recommended a lower radiotherapy tolerance dose of 0.5Gy for ICDs.  
This tolerance dose is partly based on work by Hurkmans et al (2012), where it was 
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found that the ionising radiation dose at the first ICD malfunction was as low as 
0.5Gy.  Results from Study 3 of this research project also observed the first ICD 
malfunction at a cumulative ionising radiation dose of 0.5Gy.  Therefore, results from 
this research and previous studies conclude that the Frizzell (2009) 
recommendations are still valid.   
 
CIED leads: 
It is recommended that every effort should be made to keep the CIED leads out of 
the radiotherapy treatment field.  If this is not possible, then the ionising radiation 
dose to the CIED leads should be kept as low as possible.  There is no definitive 
ionising radiation tolerance dose to the CIED leads with current knowledge and!
future!work!should!be!carried!out!to!determine!if!there!is!any!guidance!limit. 
 
7.6    Electromagnetic interference 
Results from this research show that the EMI emitted from the LINAC when switched 
ON, can affect CIEDs.  There is no clear, identifiable point at which EMI was 
observed to affect CIEDs.  This research has also shown that rate response 
activated CIEDs are more susceptible to EMI and could lead to the patient exhibiting 
symptoms of CIED induced tachycardia during the radiotherapy treatment.  
Therefore, it is recommended that the cardiology department should review patients 
with rate response activated CIEDs before a planned course of radiotherapy 
treatment begins and consideration is given to deactivating the rate response sensor. 
  
7.7    Risk group  
In 2015, Gauter-Fleckenstein et al. proposed a risk categorisation that incorporates 
the CIED risk group based on their pacing dependency and estimated cumulative 
ionising radiation dose to the CIED (Gauter-Fleckenstein et al, 2015).  
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Table 7.1 Gauter-Fleckenstein et al (2015) risk catergorisation group 
  
 Risk categorisation determined by dependence  
and cumulative radiotherapy dose to pacemaker 
<2Gy 2 – 10Gy >10Gy 
Pacing independent Low risk Medium risk High risk 
Pacing dependent Medium risk High risk High risk 
 
Table 7.2 Gauter-Fleckenstein et al (2015) risk catergorisation group definition 
Risk Group  
Low risk  
patients 
Pacemaker independent, and the device is anticipated to receive a 
cumulative radiotherapy dose of less than 2Gy 
 
Medium risk 
patients 
Pacemaker dependent, and the device is anticipated to receive a 
 cumulative radiotherapy dose of less than 2Gy   
Pacemaker independent and the device is anticipated to receive a 
cumulative radiotherapy dose of between 2Gy and 10Gy 
 
 
High risk 
patients 
Pacemaker dependent, and the device is anticipated to receive a 
cumulative radiotherapy dose of between 2Gy and 10Gy   
All patients (pacemaker dependent and independent) and the 
device is  anticipated to receive a cumulative radiotherapy dose of 
more than 10Gy 
Patients with an ICD in situ should be regarded as high risk. The 
estimated cumulative radiotherapy dose to the ICD should not 
exceed 0.5Gy 
 
EMI can affect CIEDs, at any point during the patient’s radiotherapy treatment 
regardless of whether the device is in or in close proximity to the radiotherapy 
treatment field.  Therefore, there is no distinct risk classification and all patients 
should be regarded as high risk and monitored accordingly (see below). 
 
7.8    Consent  
Patients consenting for any type of treatment need to be informed of potentially 
serious side effects related to that treatment. During the consent process the clinical 
oncologist (or consenting healthcare practitioner) should discuss the potential 
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damage to the CIED and the potential complications during and after radiotherapy 
treatment.  Patients should be told they will be subject to close monitoring during 
radiotherapy treatment and further follow-up on completion of their treatment.  
 
7.9    During radiotherapy  
• All patients with CIEDs should be monitored with a continuous ECG strip 
during their radiotherapy treatments.  This strip should then be reviewed for 
any evidence of pacing disruption when radiotherapy treatment is being 
administered.  Particular attention should be given to any pacing 
discrepancies when the ionising radiation beam is switched ON and OFF 
 
• All patients should be observed during radiotherapy treatment by audio-visual 
monitoring.  Monitoring staff should document any changes in the patient’s 
physical status, and any changes in the ECG trace should be documented 
and reviewed after every radiotherapy treatment 
 
• The minimum level of training received by monitoring staff should include 
Immediate Life Support (ILS) and appropriate resuscitation equipment should 
be available at all times. If therapeutic radiographers are monitoring patients, 
they should receive specific training on the management and monitoring of 
these patients.  If at any point CIED malfunction is suspected or detected, the 
clinical oncologist and cardiologist should be immediately informed 
 
• Patients who have an ICD will require their device to be deactivated each day 
of their radiotherapy treatment, by placing a magnet over the device to 
prevent inappropriate therapy or shock delivery as a result of accidental 
sensing of ionising radiation interference.  When deactivating ICDs, there 
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should be the ability to externally pace the patient if appropriate.  Defibrillation 
devices available should be able to deliver external pacing and staff with 
Advanced Life Support (ALS) training or an ability to deliver external pacing 
should be available.  
 
Table 7.3 Roles and responsibilities of staff involved in the management of CIED 
patients receiving radiotherapy 
Clinical oncologist 
Identify patient’s CIED status and highlight on radiotherapy referral form  
Contact patient’s cardiology department before commencing their radiotherapy treatment  
Request cardiology assessment / CIED device check  
Provide medical physics with information to calculate cumulative radiotherapy dose to CIED  
Check the dose to the pacemaker does not exceed 2Gy  
Check the dose to the ICD does not exceed 0.5Gy   
Consent – patient aware of potential adverse effects of radiotherapy on CIED  
Consent – patient aware that ICD will be switched off during radiotherapy  
Planning radiographers 
Annotate patient’s CIED status  
CIED included in CT planning scan if in/close to the radiotherapy treatment field  
Medical physics informed of patient’s CIED status  
No direct placement of CIED in radiotherapy beam 
Limitation of radiotherapy beam energy to 10Mv 
Contact consultant clinical oncologist if the CIED is within the radiotherapy treatment field or 
the estimated cumulative dose is too high 
Appropriately trained radiographers 
Assess patient prior to commencing their radiotherapy treatment  
Highlight patient’s monitoring requirements  
Monitor the patient during their radiotherapy treatment  
If the patient has an ICD, deactivate the device during each fraction of radiotherapy treatment  
Arrange follow-up appointment with the patient’s cardiology department  
Treatment radiographers 
Do not commence patient’s radiotherapy treatment without ensuring correct procedure has 
been followed  
Do not commence patient’s radiotherapy treatment without the presence of the appropriately 
trained staff to monitor the patient  
Read and be conversant in CIED department policy  
Medical physics 
Calculate estimated cumulative radiotherapy dose to the CIED and leads prior to the patient 
commencing radiotherapy treatment. Previous radiotherapy courses received must be taken 
into consideration 
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Table 7.4  Summary of management of CIED patients receiving radiotherapy 
 
Before radiotherapy 
Consultant clinical oncologist highlights CIED status 
CIED information annotated as stated on the patient device identification card: 
• Type of device: eg bradycardia pacemaker, resynchronising pacemaker, ICD, or 
combined  pacemaker/ICD, resynchronising pacemaker/ICD   
• Manufacturer   
• Make   
• Model   
• Date of implantation   
• Implantation site   
• Patient dependence on CIED   
Radiotherapy treatment details recorded: 
• Radiotherapy treatment site   
• Radiotherapy prescription   
• Radiotherapy treatment technique  
Clinical oncologist should liaise with patient’s cardiology department regarding:  
• Monitoring requirements   
• Requirement for device reprogramming or deactivation   
• Follow-up and review appointments   
CIED to be included in CT planning scan if close to anticipated radiotherapy treatment field 
Medical physics calculate estimated cumulative radiotherapy dose to the CIED 
Patients allocated a risk categorisation  
Patients with CIEDs should be fully informed on the potential short and long term risks of 
radiotherapy and consent appropriately 
During radiotherapy 
High risk patients 
(all CIEDs) 
Potential CIED relocation 
Audio-visual and ECG monitoring by appropriately trained staff for 
every fraction of radiotherapy treatment  
Weekly CIED check by patient’s cardiology department  
ICD patients Day one of radiotherapy – 12 lead ECG should be performed by an 
appropriately trained staff member as a baseline 
Appropriately trained staff member must deactivate the ICD during 
radiotherapy treatment by placing the specialist magnet over the ICD 
Audio-visual and ECG monitoring by appropriately trained staff for 
every fraction of radiotherapy treatment  
Weekly ICD check by patient’s cardiology department  
After radiotherapy 
CIED device check up, two weeks after radiotherapy treatment by cardiology department  
Cardiology follow-up one, three and six months after radiotherapy treatment or as advised by 
cardiology department  
 
 
7.10    On-treatment verification imaging  
For all CIEDs, the potential ionising radiation dose received from on-treatment 
verification imaging should also be taken into account.  This is especially important 
with ICDs, which have a much lower recommended maximum cumulative 
radiotherapy dose of 0.5Gy.   
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There are no published guidelines that make recommendations on the potential 
contribution of imaging techniques to the cumulative ionising radiation dose to the 
CIED.  Murphy et al (2004) stated that the dose from a kilovoltage cone beam CT 
scan is likely to be in the region of 10-80mGy.  In 2008, Kan et al (2008) reported 
mean skin doses of 6.4cGy per kilovoltage cone beam CT chest scan. 
 
Even using 
the lower limit of 10mGy from Murphy et al, it is possible that daily cone beam CT in 
a twenty fraction radical lung treatment may contribute as much as 0.2Gy.  Using the 
Kan et al skin dose estimates, it is possible the CIED may receive significantly more 
than 0.2Gy.  An estimation of the dose contribution from the image verification 
method used should be made, and this should be taken into consideration when 
allocating CIED patients to a risk catergorisation group.  
 
7.11    After radiotherapy  
The importance of both short and long term follow-up monitoring for patients who 
have a CIED and have received radiotherapy was highlighted in a paper by Last 
(Last, 1998).  Patients should have their CIED checked within two weeks of 
completion of their radiotherapy treatment and then one, three and six months after 
radiotherapy treatment.  Devices exhibiting signs of malfunction should be followed-
up with increased frequency.  This will allow discrimination to be made between a 
temporary CIED device malfunction that may occur owing to a build-up of charge 
within the semiconductor, and more permanent circuitry damage (results from study 
three).  Should any additional changes be observed during the follow-up period then 
immediate device revision is likely to be necessary.  
 
7.12    Chapter conclusion 
The overall aim of study six of this research was to provide evidence to support the 
publication of guidelines for the management of patients with CIEDs receiving 
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radiotherapy treatment.  This chapter outlined the process by which the national 
guidelines were produced and discussed how the results of this research together 
with previous studies and literature led to the development of the first UK guidelines 
in the field. 
 
! !
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Chapter Eight 
Final remarks 
 
 
8.1    Introduction 
The purpose of this final chapter is to summarise the key findings of the research, 
relate these findings to the implications for theory and practice and finally offer 
recommendations for future work. 
 
With an ageing population, and an increase in the incidence of both cardiovascular 
morbidity and cancer, the number of patients with CIEDs presenting for radiotherapy 
treatment will likely increase (Kalache and Keller, 2002; Brooks et al, 2005 and Boon 
et al, 2006).  Although most medical treatments pose little danger to the functioning 
of CIEDs, radiotherapy has the potential to alter CIED function.  CIEDs may be 
affected in two ways: direct damage via ionising radiation and electromagnetic 
interference (EMI), both of which may cause temporary or permanent CIED 
malfunction (Last, 1998), with consequences for the patient that range from mild 
inconvenience e.g. needing to be disconnected from their cardiac monitor during 
radiotherapy, through to possible severe effects causing catastrophic failure of the 
device, which could lead to implications for their heart condition. 
 
The focus of this research project was to investigate the effects of radiotherapy 
treatment on cancer patients with CIEDs.  This research identified how CIEDs are 
adversely affected by ionising radiation and / or EMI and how these effects can be 
minimised.  It also looked to provide safe radiotherapy tolerance doses to CIEDs and 
provide data to support the issuing of national guidelines for the safe management of 
patients with CIEDs undergoing radiotherapy treatment.  This study is important 
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because previous data in this field originated from small-scale patient studies or in-
vitro experiments.  Carrying out both clinical audits and laboratory based testing, this 
research provides new data regarding the effect of ionising radiation and / or EMI on 
CIEDs and also importantly upon the CIED leads, an area not previously studied. 
 
8.2   Implications for theory and practice 
i.  One of the initial aims of the PhD research project was to audit and establish 
current UK practice regarding the management of patients with CIEDs 
undergoing radiotherapy and to compare this practice to current ‘gold standard’ 
evidence-based guidelines.  Results from this study showed that 30% of 
radiotherapy centres did not respond to the audit so it is not appropriate to 
draw definitive conclusions on widescale UK practice, but important themes 
emerged nevertheless.  It is clear that policies differ between radiotherapy 
centres and the implementation of these policies is variable.  In addition, a 
substantial proportion of policies do not adhere to established ionising radiation 
tolerance doses for CIEDs.  Therefore, it can be concluded that as a 
consequence, it is very likely that patients are being put at significant risk of 
harm. 
 
ii.  In order to determine the effects of ionising radiation and EMI on patients 
with CIEDs receiving radiotherapy treatment at a RCW, two clinical audits were 
conducted.  The aim of the first audit was to assess device malfunction in 
patients with a CIED that have been exposed to ionising radiation and EMI as 
part of their radiotherapy treatment.  From this audit, twenty-two patients with a 
CIED presented for radiotherapy treatment and two of the twenty-two patients 
required a revision to the programming of their CIED.  The results from the 
second clinical audit showed that an increasing number of patients with rate 
response activated CIEDs had presented for radiotherapy treatment and a 
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large number of these patients exhibited a physiological response due to CIED 
mediated tachycardia during their treatment.  The results of these audits 
identified that patients with CIEDs exhibited clinical reactions when receiving 
radiotherapy treatment.  These clinical reactions could be a consequence of 
CIED malfunction or failure due to exposure to ionising radiation and EMI.  
Therefore, these audits reinforced the need for further research in this area.!
 
iii.  The empirical scientific arm of this research project focused on the effect of 
ionising radiation and EMI on CIEDs and CIED leads.  Results showed that 
CIEDs exhibited a range of temporary and permanent malfunctions.  
Pacemakers exhibited a range of malfunctions starting at a cumulative ionising 
radiation dose of 3Gy.  The 1994 AAPM report (which was utilised as the basis 
for previous guidelines) recommended that the maximum dose to a pacemaker 
should be limited to less than 2Gy (Marbach et al, 1994).  Results from this 
study agreed with the radiotherapy dose to pacemakers of 2Gy and concluded 
that the AAPM recommendations are still valid. Results also showed that ICDs 
exhibited device malfunctions starting at a cumulative ionising radiation dose of 
0.5Gy.  In 2009, Frizzell (2009) published a review of CIEDs and radiotherapy 
and concluded that the AAPM recommendations were no longer 
comprehensive as ICDs were not discussed and recommended a lower 
radiotherapy tolerance dose of 0.5Gy to ICDs.  Results from this PhD study 
also observed that the first ICD malfunction occurred at a cumulative ionising 
radiation dose of 0.5Gy, thereby concluding that the Frizzell recommendations 
are also still valid.   
 
iv.  There is limited published evidence to inform ionising radiation dose level 
constraints to CIED leads and also no consensus in the results reported from 
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other case studies regarding the clinical reactions of patients with CIED when 
the CIED leads were themselves exposed to ionising radiation.  Results from 
this research indicated that when treating patients who have a CIED with 
radiotherapy, every effort should be made to keep the CIED leads out of the 
radiotherapy treatment field.  If this is not possible, then the ionising radiation 
dose to the CIED leads should be kept as low as possible. 
 
v.  All CIEDs (pacemakers, ICDs and rate response activated devices) 
exhibited an effect when exposed to EMI produced by the linear accelerator.  
When investigating these effects, the devices were not in, or in close proximity 
to, the radiotherapy treatment beam, thereby receiving a negligible dose of 
ionising radiation.  These CIED malfunctions or failures were thus deemed to 
be a direct consequence of exposure to EMI only.  It is therefore recommended 
that all patients with a CIED who are receiving radiotherapy treatment should 
be monitored during their treatment as a result of the presence of EMI in the 
radiotherapy treatment room having an effect on the CIED. 
 
vi.  The over-arching aim of this research project was to publish up-to-date 
evidence based guidelines for the management of cancer patients with CIEDs 
receiving radiotherapy treatment.  Results from study one showed that CIED 
policies differ between radiotherapy centres in the UK and a significant number 
of policies do not adhere to current established tolerance doses for CIEDs.  In 
the departments where there is a CIED policy, the majority do not reflect best 
evidence (Lester et al, 2014).  There is limited published research on the effect 
of radiotherapy on CIEDs, but the results from studies three to five of this 
research show that radiotherapy, even at low doses, can cause device 
malfunctions and / or failure with potentially life-threatening consequences.
 
Based on these results and given the risk to patients, study six stated that all 
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radiotherapy centres should have policies in place to support the safe delivery 
of radiotherapy treatment to patients with CIEDs.  Publication of these 
guidelines will have a direct impact on UK radiotherapy departments treatment 
policies and protocols and subsequently patient management and care 
(Sor.org, 2015). 
 
8.3    Final words 
8.3.1    Limitations of the study 
If this research were to be repeated, different makes and models of CIEDs and CIED 
leads from all CIED manufacturers should be used.  This would allow for a 
comprehensive understanding of how ionising radiation and / or EMI affect all CIEDs 
and CIED leads implanted in patients. 
 
This research showed that EMI had an effect on the function of CIEDs, in particular 
rate response-activated devices.  However, the level of EMI emitted from the linear 
accelerator during irradiation was unable to be identified using the Keysight Field Fox 
spectrum analyser.  This could be due to the transient nature of EMI or the resultant 
power frequency being outside the range of the antenna used.  Furthermore, the 
sweep parameters and bandwidth used with the Field Fox could be too fast or too 
narrow respectively.   Therefore, further research is needed to establish equipment 
design and test protocol. 
 
When investigating the effect of ionising radiation and / or EMI on CIED leads, a 
novel microwave experiment was used to provide measurements of the electrical 
conductivity of the CIED lead sheath polymer at microwave frequencies.  Initial 
results showed that this technique has the potential to provide the necessary insight 
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into polymer degradation of CIED leads following exposure to ionising radiation and 
EMI. 
 
8.3.2.  Recommendations for future work 
From this research the following recommendations for future work have emerged: 
 
• This research was conducted on one manufacturer’s radiotherapy treatment 
linac (Varian).  As per research testing protocol, the ionising radiation dose 
delivered to the CIED will remain the same regardless of the linac 
manufacturer.  Therefore, this future study should determine if different 
manufacturers linear accelerators emit different levels of EMI and the 
resultant effects on CIEDs. 
 
• This research adopted an experimental approach to data collection (static 
bench tests).  Future work should use the same testing methodology but the 
testing protocol should be amended to include different radiotherapy 
treatment techniques in current clinical use. 
 
• As the level of EMI emitted from the linear accelerator could not be 
established, further investigation is required to determine if there are other 
means of identifying and quantifying the levels of EMI within the radiotherapy 
treatment room. 
 
• When investigating the effect of ionising radiation and / or EMI on CIED 
leads, the design set up and proof of principle testing functioned appropriately 
and provided data.  Results showed that the equipment and testing protocol 
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could be used as a reliable means of quantifying CIED lead sheath damage.  
However, further experimentation is needed to develop this testing protocol. 
 
• All CIED manufacturers should be involved in research to allow for the 
quantification of the exact ionising radiation tolerance doses and / or EMI 
levels to CIEDs and CIED leads.  This would enable cross-industry baseline 
limits to be established. 
 
• This research was conducted using photon beam energy.  Proton treatment is 
increasingly being used as a treatment modality in clinical practice.  
Therefore, in future research, the testing methodology and protocol will be 
replicated using proton beam energies.   
 
 
 
!
! !
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Appendix A 
 
 
Year Author n Beam type Beam  
energy  
(MV) 
Maximum 
CIED 
dose (Gy) 
Main results 
1994 Souliman 18 Photons 8 70 •  Complete failure at 16.8-70Gy in 11 PMs 
•  No effect from EMI alone 
1999 Mouton 42 Photons (n=19) 
Co-60 (n=23) 
LINAC = 4 
Co-60 source  
= 1.17-1.33 
140 •  No malfunction at therapeutic doses (n=15) 
•  Frequency modifications (n=9) starting at 
2Gy 
•  Deprogramming and modification in battery 
characteristics (n=11) starting at 4Gy 
•  Destruction of PM (n=7) at 44-77Gy 
2002 Mouton 96 Photons 18 200 •  Amplitude change >10% in 38 PMs at 
2-130Gy 
•  Silence >10s in 35 PMs at 0.15-74Gy 
•  Permanent silence in 12 PMs at 0.5-170Gy 
2005 Hurkmans 19 Photons 6 120;  
130 (n=2) 
•  5 PMs = no malfunction 
•  7 PMs = no output at 80-130Gy 
•  5 PMs = ERI at 120-130Gy 
•  2 PMs = no communication at 20-130Gy 
•  8 PMs = inhibition during direction 
irradiations 
2014 Zaremba 10 Photons 6 / 18 150 6MV group: 
•  1 episode of malfunction at 150Gy 
18MV group: 
•  14 episodes of malfunctions starting at 
30Gy 
Appendix A – Table 1 
 
Studies examining the effects of radiotherapy on pacemakers in vitro (since 1994)  
Year Author n Beam type Beam  
energy  
(MV) 
Maximum 
CIED 
dose (Gy) 
Main results 
2002 Hoecht 5 NA NA Scatter = 
>50 
•  No effects from EMI 
•  Scatter radiation = 1 fallback 
•  Direct exposure = malfunctions at >50Gy, 
unspecified 
2005 Hurkmans 11 Photons 6 120 •  Sensing failure in all ICDs – which would 
have resulted in shock delivery in 4ICDs 
•  Failure of all devices at 0.5-120Gy 
•  Complete loss of function at 0.5-1.5Gy in 4 
ICDs 
2008 Kapa 20 Photons 6 4 •  No malfunctions 
2013 Hashii 10 Photons 10 / 18 Scatter •  More soft errors during irradiation with 
18MV photons compared with 10MV 
photons 
•  No hard errors or permanent malfunctions 
2014 Mollerus 8 Photons 6 131.11 •  4 contemporary devices remained functional 
after 131.11Gy despite minor memory faults 
in 3 of them  
•  4 older devices failed to deliver shock 
therapy after 41.11Gy and had changes in 
lead impedance 
2014 Zaremba 2 Photons 6 / 18 150 6MV group: 
•  No malfunctions 
18MV group: 
•  No malfunctions, except the loss of patient 
data after 44Gy 
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Studies examining the effects of radiotherapy on ICDs in vitro (since 1994)  
Year Author n Tumour Beam type Beam  
energy  
(MV) 
Tumour 
dose  
(Gy) 
 
CIED  
dose  
(Gy) 
Outcome Clinical 
consequence 
2000 Tsekos 1 RT lower 
arm & 
axilla  
NA NA 50.4 50.4 Decrease in magnet  
rate; returning to  
normal 4 
months later 
Replacement 
of the device 
2001 Nibhanupudy 1 LT breast 
& SCF 
Photons 6 50.4 1.82 No malfunctions - 
2006 Ampil 3 Lung Photons NA 20-60 NA No malfunctions - 
2006 Mitra 1 RT lung & 
mediastinum 
Photons NA 40 1.66 No malfunctions - 
2008 Kapa 8 Head and  
neck;  
thorax 
Photons 6 
 
30-69.96 NA No malfunctions - 
2009 Zweng 1 Oesophagus Photons NA 
 
30 0.11 Runaway PM;  
Change from  
DDD to AAI with  
a fixed rate of  
185bpm;Corruption  
Of the software 
Circulatory 
collapse; 
replacement  
of the  
device 
2010 Ferrara 37 Various Photons; 
electrons 
6 / 18 8-79.2 >2 (n=5) 
<2 (n=32) 
 
No malfunctions 
 
- 
2011 Croshaw 3 Breast Photons 6 38.5 0.23-0.73 No malfunctions 
 
- 
2011 Dasgupta 1 Heart Photons 6 37.5 0.37 Transient 
ventricular 
undersensing 
Devices  
successfully 
reprogrammed  
2011 Soejima 60 Various NA NA 20-74 20.69 in 1 
patient  
otherwise  
not exceed  
4.78 
1 CRT-P was found  
Initialised at 46Gy 
and 56Gy (treated 
with 74Gy) 15MV  
photons 
Device 
successfully 
reprogrammed  
 
2011 
 
Wadasadawala 8 Head and  
neck;   
breast; 
lung 
Co-60  
(n=3) 
Photons 
(n=5) 
Photons 
6MV (n=3) 
15MV (n=2) 
45-70 0.14-60 No malfunctions - 
2012 Kesek 2 Lung Photons 6 80 48 No malfunctions - 
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Studies examining the effects of radiotherapy on pacemakers in vivo (since 1994) - 1  
Year Author n Tumour Beam type Beam  
energy  
(MV) 
Tumour 
dose  
(Gy) 
 
CIED  
dose  
(Gy) 
Outcome Clinical 
consequence 
2012 Kirova 1 Thoracic 
spine  
Photons 20 30 0.3 (leads 
irradiated 
directly) 
No malfunctions - 
2012 Makkaer 50 Various Photons; 
electrons 
Photons: 6 
(n=26); 16 
(n=24).  
Both with or 
without 
electrons 
NA 0.844 +/- 
0.997 
No malfunctions - 
2014 Ampil 2 Head &  
neck  
Photons 6 NA NA No malfunctions - 
2014 Gossman 67 Various Photons Various NA <2 in 85% 
>2 in 15% 
Not  
Exceed 
6.5Gy 
 
Failure at 0.3Gy (n=1) 
Increase in sensor 
rare during RT (n=1) 
Irregular heartbeat 
leading to 
reprogramming (n=1) 
Twinging in the chest 
wall resulting in 
respiratory arrest 
(n=1) 
Not specific in 
more detail  
2015 Zaremba 487 Various  MV 
photons, 
kV 
photons,  
electrons 
9 Various NA Reset or 
deprogramming (n=9); 
increase in atrial 
pacing threshold from 
1.25 to 2.75V (n=1) 
out of 394 PMs 
Devices 
successfully 
reprogrammed. 
No device 
replacements.  
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 Studies examining the effects of radiotherapy on pacemakers in vivo (since 1994) - 2 
Year Author n Tumour Beam type Beam  
energy  
(MV) 
Tumour 
dose  
(Gy) 
 
CIED  
dose  
(Gy) 
Outcome Clinical 
consequence 
2002# Hoecht# 4# NA# NA# NA# NA# NA# 2#ICDs#of#the#same#model#in#
the#same#pa9ent#fell#into#the#
fall#back#mode#at#<0.5Gy#to#
the#ICD#(RT#to#pelvis)#
The#device#was#
replaced#due#to#the#
ﬁrst#episode##
2004# John# 1# LT#breast# NA#
#
NA# 50# Leads:#50#
Par9al#
exposure#to#
generator##
Shock#coil#failure#due#to#
structural#damage#during#RT#
was#suspected#(shock#
impedance#>125ohms)#
A#new#system#was#
implanted#
2004# Thomas# 1# RT#lung# Photons# 18# 56# NA#(outside#
the#ﬁeld)#
Electrical#reset## Unspeciﬁed#
(asymptoma9c)#
2007# Nemec# 1# LT#lung# NA#
#
NA#
#
59.4# NA#(outside#
the#ﬁeld)#
Rapid#pacing#triggering#
polymorphic#VT#during#the#
3rd#frac9on#of#1.8Gy#
Collapse#requiring#
resuscita9on.##Device#
removal#a\erwards##
2007# Sepe# 1# Larynx# Photons# 6# 60# 2.5# No#malfunc9ons# ]#
2008# Kapa# 5# Various# Photons# 6# 18]56# NA#(outside#
the#ﬁeld)#
#
No#malfunc9ons#
#
]#
2008# Lau# 1# Prostate# Photons# 23# 74# 0.004# Resets#during#2nd#and#9th#
frac9ons#of#2Gy#
RT#completed#
without#other#events.##
Normal#ICD#
parameters#
a\erwards.#
2009# Gelblum# 33# Various# Photons;#
Electrons#
(n=1)##
Photons#&#
electrons#
(n=1)##
6#(photons);#
6#MeV#
(electrons);#
6MV#&#
9MeV#
6]86.4# 0.01]2.99# Reset#in#2#pa9ents#treated#
with#15MV#photons,#outside#
RT#ﬁeld#
Devices#successfully#
reprogrammed##
2010# Ferrara# 8# Various# Photons#&#
electrons#
(95.6%);#
C0]60#(4.4%)#
6;#18#(59%)# 8]79.2# >1#(n=2)#
<1#(n=6)#
No#malfunc9ons# ]#
2011# Croshaw# 2# Breast# Photons#
#
6# 38.5# 1.01,#1.68# No#malfunc9ons# ]#
#
2011# Soejima# 2# Various# NA#
#
NA#
#
20]74# NA# No#malfunc9ons#
#
]#
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Studies examining the effects of radiotherapy on ICDs in vivo (since 1994) - 1 
Year Author n Tumour Beam type Beam  
energy  
(MV) 
Tumour 
dose  
(Gy) 
 
CIED  
dose  
(Gy) 
Outcome Clinical 
consequence 
2012# Makkar# 19# Various# Photons;#
Photons#&#
electrons##
6:#16.##Both#
with#or#
without#
electrons#
(6]16MeV)#
NA# 0.921#+/]#
0.726#
Par9al#resets#in#2#devices#
a\er#1.23Gy#and#0.04Gy#
16MV#photons#to#the#ICD,#
respec9vely#
RT#completed#
successfully#in#both#
pa9ents#
2013# Dell’Oca# 1# Medias9num# Photons# 6# 64# <5# No#malfunc9ons# ]#
2013# Elders# 15# Various# Photons;#
Photons#&#
electrons##
(n=1)#
6]18# 16]70# <1# 6#malfunc9ons#in#5#RT#
courses#at#10#and#18MV;#
invalid#data#(n=2),#reset#
(n=1),#inappropriate#
tachycardia#sensing#(n=1),#
reset#and#trend#data#error#9#
months#a\er#the#reset#(n=1).#
Distance#from#device#to#RT#
ﬁeld#5cm#and#8cm#
respec9vely#
RT#completed#
successfully#in#all#
pa9ents#
2013 Zaremba 5 Thorax Photons 6 ; 18 37 37 Converting to backup 
mode (n=1) 
None (animal study; 
all devices 
explanted after the 
irradiation) 
2014 Ahmed 1 Lung Photons 
 
15 69.6 52.4 No malfunctions - 
2014 Gossman 40 Various Photons 
 
Various NA <2 in 85% 
>2 in 15% 
Not  
exceeding 
6.5 
Failure at 0.3Gy (n=1); 
increase in sensor rate 
during RT (n=1); irregular 
heartbeat leading to 
reprogramming (n=1); 
twinging in the chest wall 
resulting in respiratory 
arrest (n=1) 
Not specified in 
more detail 
2015 Zaremba 73 Various MV 
photons, 
kV 
photons, 
electrons 
9 Various NA Reset (n=3), reset and 
increase in pacing 
threshold (n=1) 
Devices 
successfully 
reprogrammed 
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Studies examining the effects of radiotherapy on ICDs in vivo (since 1994) - 2 
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Critical	Appraisal	Skills	Programme	(CASP)	part	of	Better	Value	Healthcare	Ltd	www.casp-uk.net	
CASP	Checklist:	10	questions	to	help	you	make	sense	of	a	Systematic	Review	
How	to	use	this	appraisal	tool:	Three	broad	issues	need	to	be	considered	when	appraising	a	
systematic	review	study:	
	Are	the	results	of	the	study	valid?	(Section	A)	
	What	are	the	results?	 (Section	B)	
	Will	the	results	help	locally?	 (Section	C)	
The	10	questions	on	the	following	pages	are	designed	to	help	you	think	about	these	issues	
systematically.	The	first	two	questions	are	screening	questions	and	can	be	answered	quickly.	
If	the	answer	to	both	is	“yes”,	it	is	worth	proceeding	with	the	remaining	questions.	There	is	
some	degree	of	overlap	between	the	questions,	you	are	asked	to	record	a	“yes”,	“no”	or	
“can’t	tell”	to	most	of	the	questions.	A	number	of	italicised	prompts	are	given	after	each	
question.	These	are	designed	to	remind	you	why	the	question	is	important.	Record	your	
reasons	for	your	answers	in	the	spaces	provided.	
About:	These	checklists	were	designed	to	be	used	as	educational	pedagogic	tools,	as	part	of	a	
workshop	setting,	therefore	we	do	not	suggest	a	scoring	system.	The	core	CASP	checklists	
(randomised	controlled	trial	&	systematic	review)	were	based	on	JAMA	'Users’	guides	to	the	
medical	literature	1994	(adapted	from	Guyatt	GH,	Sackett	DL,	and	Cook	DJ),	and	piloted	with	
health	care	practitioners.	
For	each	new	checklist,	a	group	of	experts	were	assembled	to	develop	and	pilot	the	checklist	
and	the	workshop	format	with	which	it	would	be	used.	Over	the	years	overall	adjustments	
have	been	made	to	the	format,	but	a	recent	survey	of	checklist	users	reiterated	that	the	basic	
format	continues	to	be	useful	and	appropriate.	
Referencing:	we	recommend	using	the	Harvard	style	citation,	i.e.:	Critical	Appraisal	Skills	
Programme	(2018).	CASP	(insert	name	of	checklist	i.e.	Systematic	Review)	Checklist.	[online]	
Available	at:		URL.	Accessed:	Date	Accessed.	
©CASP	this	work	is	licensed	under	the	Creative	Commons	Attribution	–	Non-Commercial-
Share	A	like.	To	view	a	copy	of	this	license,	visit	http://creativecommons.org/licenses/by-nc-
sa/3.0/	www.casp-uk.net		
2	
Section	A:	Are	the	results	of	the	review	valid?	
1. Did	the	review	address	a
clearly	focused	question?
Yes	 HINT:	An	issue	can	be	‘focused’	In	terms	of	
• the	population	studied
• the	intervention	given
• the	outcome	considered
Can’t	Tell	
No	
Comments:	
2. Did	the	authors	look	for	the
right	type	of	papers?
Yes	 HINT:	‘The	best	sort	of	studies’	would	
• address	the	review’s	question
• have	an	appropriate	study	design
(usually	RCTs	for	papers	evaluating
interventions)	
Can’t	Tell	
No	
Comments:	
Is	it	worth	continuing?	
3. Do	you	think	all	the
important,	relevant	studies
were	included?
Yes	 HINT:	Look	for	
•	which	bibliographic	databases	were
used	
•	follow	up	from	reference	lists
•	personal	contact	with	experts
•	unpublished	as	well	as	published	studies
•	non-English	language	studies
Can’t	Tell	
No	
Comments:	
3	
4. Did	the	review’s	authors	do
enough	to	assess	quality	of
the	included	studies?
Yes	 HINT:	The	authors	need	to	consider	the	
rigour	of	the	studies	they	have	identified.	
Lack	of	rigour	may	affect	the	studies’	
results	(“All	that	glisters	is	not	gold”	
Merchant	of	Venice	–	Act	II	Scene	7)	
Can’t	Tell	
No	
Comments:	
5. If	the	results	of	the	review
have	been	combined,	was	it
reasonable	to	do	so?
Yes	 HINT:	Consider	whether	
•	results	were	similar	from	study	to	study
•	results	of	all	the	included	studies	are
clearly	displayed	
•	results	of	different	studies	are	similar
•	reasons	for	any	variations	in	results	are
discussed	
Can’t	Tell	
No	
Comments:	
Section	B:	What	are	the	results?	
6. What	are	the	overall	results	of	the	review? HINT:	Consider	
•	If	you	are	clear	about	the	review’s
‘bottom	line’	results	
•	what	these	are	(numerically	if
appropriate)	
•	how	were	the	results	expressed	(NNT,
odds	ratio	etc.)	
Comments:	
		
	 	
	
4	
7.	How	precise	are	the	results?	
	
	
HINT:	Look	at	the	confidence	intervals,	if	
given	
Comments:	
	
Section	C:	Will	the	results	help	locally?	
	
8.	Can	the	results	be	applied	to	
the	local	population?	
Yes	 	
	
HINT:	Consider	whether	
• the	patients	covered	by	the	review	
could	be	sufficiently	different	to	your	
population	to	cause	concern	
• your	local	setting	is	likely	to	differ	much	
from	that	of	the	review	
Can’t	Tell	 	
	
No	 	
	
	
Comments:	
	
9.	Were	all	important	outcomes	
considered?	
Yes	 	
	
HINT:	Consider	whether	
• there	is	other	information	you	would	
like	to	have	seen	Can’t	Tell	 	
	
No	 	
	
	
Comments:	
	
	
	
	
10.	Are	the	benefits	worth	the	
harms	and	costs?	
Yes	 	
	
HINT:	Consider	
• even	if	this	is	not	addressed	by	the	
review,	what	do	you	think?	Can’t	Tell	 	
	
No	 	
	
	
Comments:	
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Appendix C – List of Radiotherapy Departments / Oncology Centres in the UK 
 
 
   
Suffolk Oncology Centre  
 
Norfolk & Norwich University Hospital  
 
Mount Vernon Cancer Centre  
 
Peterborough District Hospital  
 
Addenbrooke's Hospital  
 
Southend University Hospital 
  
Colchester Hospital  
 
Cancer Partners UK, Elstree, Hertfordshire  
 
Barts and the London NHS Trust  
 
The London Clinic  
 
Queen’s Hospital  - Romford  
 
UCLH  
 
Royal Free Hospital  
   
Imperial College  
 
The Harley Street Clinic  
 
Hammersmith Hospitals 
 
BUPA Cromwell Hospital  
 
Guy’s and St Thomas’s   
 
Royal Marsden  
 
Wimbledon  
 
North Middlesex  
 
Kent Oncology Centre  
 
Oxford  
 
Kent & Canterbury Hospital  
 
Berkshire Cancer Centre 
 
Guildford -Surrey  
 
Portsmouth Haematology & Oncology Centre  
 
 
 
Royal Sussex - Brighton  
 
Southampton  
 
Northamptonshire Centre for Oncology  
 
Cancer Partners UK  - Portsmouth 
 
Cancer Partners Southampton  
 
Gloucestershire Oncology Centre  - Cheltenham  
 
Dorset Cancer Centre – Poole 
 
South Devon Healthcare NHS  
 
Bristol Haematology & Oncology Centre  
 
Royal Cornwall Hospital  
 
Derriford Oncology Centre – Plymouth 
 
Exeter Oncology Centre  
 
Royal United Hospital - Bath 
 
Beacon Centre - Taunton  
 
Middlesbrough 
 
Northern Centre for Cancer -  Newcastle  
 
Queen’s Centre for Oncology & Haematology – Hull 
 
North Humberside  
 
Lincolnshire 
 
Weston Park Hospital - Sheffield  
 
St James’s - Leeds  
 
Rosemere Cancer Centre - Lancashire  
 
Clatterbridge Cancer Centre NHS  
  
Christie Hospital NHS Trust  
 
Cumbria   
 
Staffordshire  
 
Arden Cancer Centre - Coventry  
 
  
Wolverhampton  
 
 Leicester  
 
Queen Elizabeth Hospital  - Birmingham  
 
Derby  
  
Nottingham  
 
Spire Hospital Little Aston - West Midlands  
 
Shrewsbury  
 
Velindre NHS Trust  
 
Singleton Hospital - Swansea  
 
North Wales Cancer Treatment Centre  
 
Beaston  
 
Dundee - Tayside 
 
Aberdeen  
 
Edinburgh  
 
Inverness  
 
Belfast  
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Appendix D – First e-mail request for radiotherapy departments – CIED policies 
 
 
Dear Radiotherapy Service Manager, 
 
I am contacting you to request your assistance in a National Audit I am conducting with the 
support of the Society and College of Radiographers, into radiotherapy departments’ current 
cardiac device policies.  In order to carry out this audit, I would be grateful if I could obtain a 
copy of your department’s policies.    
 
This audit will incorporated into the research project that I am undertaking as part of a PhD study 
at Velindre Cancer Centre into the effect of radiotherapy on cardiac devices.  One of the main 
objectives is to develop evidence-based clinical guidelines and clinical protocols for the safe 
administration of radiotherapy to patients who have a cardiac device in situ.  Depending on the 
outcomes, the research may lead to the development and publication of national guidelines as to 
the safe administration of radiotherapy to these patients. 
 
My research to date has shown that the number of patients with cardiac devices presenting for 
radiotherapy treatment is increasing.  Over the past three decades technological developments 
have resulted in manufacturers using modern pacemaker components which may be more 
sensitive to ionising radiation.  Pacemaker manufacturers publish their own guidelines regarding 
radiotherapy tolerances doses based anecdotal experience and research carried out in 1994 by the 
American Association of Physicists in Medicine.  Therefore, pacemaker policies in radiotherapy 
departments are based on evidence that is eighteen years old carried out on superseded 
technology.  This highlights the clinical need for research to determine the behaviour of modern 
pacemakers when in or close to the radiotherapy treatment field and to the publication of a 
clinical policy to reflect this.   
 
Your participation in the audit will greatly assist the research and I look forward to disseminating 
the results and recommendations to you in the future.  All information received will be treated 
anonymously and no individual hospital will be identified.  Please would you send all policies to 
me at laurenevans44@hotmail.co.uk . 
 
Many thanks for your co-operation regarding my research.   
Lauren Evans 
Appendix D – Second e-mail request for radiotherapy departments – CIED policies 
 
Dear Radiotherapy Service Manager, 
I am contacting you in reference to an email sent by the Society and College of Radiographers 
dated May 2012.  This email requested your assistance in the National Audit that is being 
conducted into radiotherapy departments’ current cardiac device policies.  
To date I have not received a copy of policies from all departments.  In order to obtain a detailed 
understanding of current working practices, I do require as many department’s policies as 
possible. 
If you have already responded to this request, I would like to thank you for your assistance.  
However, if you have not already done so, I would be extremely grateful if a copy of your policy 
could be sent to me at laurenevans44@hotmail.co.uk. 
Many thanks for your co-operation regarding my research.  
Lauren Evans 
Appendix D – Third e-mail request for radiotherapy departments – CIED policies 
 
 
Dear Radiotherapy Service Manager, 
I am contacting you in reference to two emails sent by the Society and College of Radiographers 
dated May 2012 and July 2012.  These emails requested your assistance in the National Audit of 
current cardiac device policies in radiotherapy departments.  
I presented preliminary findings of this audit at the Society Conference dated 2nd February based 
on a response rate of 51%.  It is necessary that more information is required on existing policies 
to successfully complete this audit.  
To date I have not received a reply from your department.  I would be extremely grateful if you 
would forward a copy of your policy or any existing documentation currently in use.  If you do 
not currently have a policy, would you also inform me.   
All information can be sent to me at laurenevans44@hotmail.co.uk. 
Many thanks for your co-operation. 
Lauren Evans 
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Pacemaker(pa*ent(pathway(
ICD(pa*ent(pathway(
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
General - Cardiac Devices - Pacemaker and ICD 
Patient referral - Completion of IRMER form – 
highlight pacemaker / ICD status 
Patient RT planning – consented to RT and 
possible effect on pacemaker / ICD function 
Medical physics informed of RT - cumulative 
dose calculated – annotated on eIRMER 
Patient advised to return to cardiology dept – 2 
weeks post RT - follow up 
Pacemaker - Pacemaker is involved in radiotherapy treatment field or cumulative dose > 2Gy 
Clinical decision - liaise with medical physics – 
planning optimisation 
RT not proceed without consulting cardiology 
dept of referring hospital 
Monitor all fractions of RT 
Pacemaker - Pacemaker is not involved in radiotherapy treatment field or cumulative dose < 2Gy 
Unipolar or pacemaker dependant patient – 
monitor all fractions of RT 
Non-pacemaker dependant patient –  
monitor first fraction of RT 
ICD 
Patient monitored throughout course of 
radiotherapy treatment 
Patients assessed by cardiology dept – mid RT 
treatment 
ICD - Cumulative dose > 0.5Gy 
Clinical decision - liaise with medical physics – 
planning optimisation 
RT not proceed without consulting cardiology 
dept of referring hospital 
Monitor all fractions of RT 
Pacemaker(/(ICD(pa*ent(pathway(
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Consultant Oncologist / Specialist Registrar  
eIRMER (RT planning tab) – pacemaker status 
ticked 
Non-registered patients – F.TP1 – pacemaker 
information recorded 
Pacemaker / ICD not in RT treatment volume 
If device is in RT treatment volume – 
cardiologist informed 
Maximum cumulative dose (medical physics)  
pacemaker not exceed 2Gy / ICD 0.5Gy 
Consent – patient aware of adverse effect of RT 
on device  
Planning Radiographers 
Annotated – pacemaker prior to scanning 
Pacemaker group aware of all subsequent 
appointments 
Pacemaker recorded on patients radiotherapy 
treatment sheet  
Medical physics informed – F.TP6 
Consultant informed if device within 
radiotherapy treatment area 
Treatment Radiographers 
Do not commence RT without the presence of a 
trained radiographer / SHO 
Medical Physics 
Dose estimation information – pacemaker and 
leads 
Information available 48 hours prior to patient 
undergoing radiotherapy (unless emergency) 
Any changes to dose estimation – forwarded to 
pacemaker group 
Roles(and(responsibili*es(–(Pacemakers((1)(((
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Appropriately trained radiographers – pacemaker monitoring  
Pacemakers 
Prior to radiotherapy treatment  
Contact referring cardiology dept 
 
Complete F.TD18 form 
 
Arrange cardiology follow up appointment  
Assess patient prior to commencing course of 
RT 
Highlight patients monitoring need of their RT 
treatment sheet 
Canisc – pacemaker highlighted under other tab 
selecting general description 
Pacemaker not sited within the treatment field – 
cumulative dose estimation less than 2Gy 
Dose estimation greater than 2Gy – appropriate 
shielding – clinical decision 
Dose estimation greater than 2Gy – medical 
physics informed 
Dose estimation greater than 2Gy – cardiologist 
informed 
On the first day of radiotherapy treatment 
SHO present – if pacemaker is in RT treatment 
field or concerns regarding patients condition 
2 appropriately trained radiographers present to 
assess the patient 
20 sec cardiac tracing – assessed and attached 
to form F.TD18 
Pacemaker patient checklist placed in front of 
the radiotherapy treatment sheet 
Assess if further monitoring is required – 
annotate / sign form F.TD18 
Roles(and(responsibili*es(–(Pacemakers((2)(((
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
During subsequent radiotherapy treatments 
Patient monitored by appropriately trained 
radiographer 
Completed RT – completed pacemaker details 
form F.TD18 filed with treatment sheet 
Annotate patient given advice letter F.TD30 and 
cardiology follow up appointment 
Roles(and(responsibili*es(–(Pacemakers((3)(((
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Appropriately trained radiographers – pacemaker monitoring  
ICD 
Prior to radiotherapy treatment  
Contact referring cardiology dept 
 
Complete F.TD18 form 
 
Arrange cardiology follow up appointment  
Assess patient prior to commencing course of 
RT 
Highlight patients monitoring need of their RT 
treatment sheet 
Canisc – pacemaker highlighted under other tab 
selecting general description 
ICD is not sited within the RT treatment field – 
cumulative dose  - less than 0.5Gy 
ICD is in the field or dose estimation greater 
than 0.5Gy - shielding 
ICD is in the field or dose estimation greater 
than 0.5Gy – medical physics informed 
ICD is in the field or dose estimation greater 
than 0.5Gy – cardiologist informed 
On the first day of radiotherapy treatment 
Ensure that patient has consented to switch off 
ICD during RT  
12 lead ECG prior to first treatment – attached 
to form F.TD18 
2 authorised radiographers / SHO present - 
monitor patient – staff for subsequent appts 
20 sec cardiac tracing – assessed and attached 
to form F.TD18 
Switch off ICD during RT 
Roles(and(responsibili*es(–(ICDS((1)(((
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
F.TD18 signed by SHO and trained 
radiographers 
During subsequent radiotherapy treatments 
Patient monitored by appropriately trained 
radiographer 
Completed RT – completed pacemaker details 
form F.TD18 filed with treatment sheet 
Annotate patient given advice letter F.TD30 and 
cardiology follow up appointment 
Roles(and(responsibili*es(–(ICDs((2)((
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Radiographer – record as much information as 
possible (device)  
No device information available – treat device 
as an ICD 
Radiographer complete for F.TD18 
Dose to pacemaker less than 0.5Gy / # 
Dose 5Gy or less -  device needs to be more 
than 1.5cm from any field edge 
Dose 5Gy – 10Gy - device needs to be more 
than 3.5cm from any field edge 
Pacemaker - SHO present and responsible – 
patient monitoring during RT treatment 
ICD – doughnut magnet placed over ICD during 
exposure 
ICD - SHO present and responsible – patient 
monitoring during RT treatment 
Referred back to radiotherapy planning dept 
 
Referred back to medical physics – dose 
estimation 
Referred back to pacemaker group 
Out(of(hours(and(emergency(pa*ent(pathway(
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Abstract
Aims: The number of patients with cardiac implantable electronic devices (permanent pacemakers and implantable cardioverter deﬁbrillators) undergoing
radiotherapy treatment is increasing. The aims of this audit were to establish current UK practice regarding the management of patients with implanted cardiac
devices undergoing radiotherapy and to compare this practice with current ‘gold standard’ evidence-based guidelines.
Materials and methods: All UK radiotherapy departments were contacted and asked to provide their current cardiac implantable electronic device policy or to
indicate if there was no current policy. A proforma was created to analyse these polices and to compare with current best practice.
Results: In total, 47/67 (70%) radiotherapy departments responded and 45 departmental policies were submitted; 31/45 (69%) policies deﬁned the radiotherapy
tolerance dose to permanent pacemakers and 14/45 (31%) deﬁned the monitoring procedure for patients in line with current best practice. Only 5/45 (11%)
policies deﬁned the radiotherapy tolerance dose to implantable cardioverter deﬁbrillators and 12/45 (27%) deﬁned the monitoring procedure in line with
current best practice.
Conclusion: Most UK cardiac device policies do not reﬂect current best evidence. Policies are based on research carried out in 1994 by the American Association
of Physicists in Medicine. This evidence does not account for advances in cardiac implantable electronic device technology. Further research is urgently needed
to establish the effect of radiotherapy on these devices.
! 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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Introduction
The life expectancy of the English and Welsh population
has increased bymore than 65% in the past century [1]. This
has resulted in a higher prevalence of cardiovascular
morbidity, leading to an increase in the number of patients
with cardiac implantable electronic devices (CIEDs) [2,3]. In
addition, the age-standardised incidence of cancer has
increased by more than 25% in the past 30 years [1]. It has
been estimated that 50e60% of all patients with cancer will
require radiotherapy during the course of their illness [4].
Therefore, with an ageing population and an increase in the
incidence of both cardiovascular morbidity and cancer, the
number of patients with CIEDs presenting for radiotherapy
treatment will probably increase [2,5,6].
There are two categories of CIED ﬁtted into patients;
permanent pacemakers and implantable cardioverter de-
ﬁbrillators (ICDs). Permanent pacemakers are referred to as
‘pacemakers’ in this paper. Pacemakers are permanent de-
vices and vary in sophistication. ICDs are more sophisti-
cated devices and have the ability to automatically
deﬁbrillate the heart by monitoring the patient’s heart rate
and delivering the appropriate electrical therapy.
Although most medical treatments pose little danger to
the functioning of CIEDs, radiotherapy has the potential to
cause device malfunction. Cardiac devices may be affected
in two ways; electromagnetic interference (EMI) and direct
damage to the circuitry via ionising radiation, both of which
may cause temporary and permanent device malfunction
[3]. Changes within the device parameters as result of EMI
are seen even when the CIED is placed outside the radio-
therapy treatment ﬁeld [7].
Over the past three decades, the design and technology
of CIEDs has evolved and the use of complementary metal
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oxide semiconductor circuits has expanded [8]. These are
more sensitive to ionising radiation than bipolar semi-
conductor devices used previously, possibly resulting in
increased damage and catastrophic failure of the cardiac
conduction system in the device [9,10].
It is not possible to predict the exact behaviour of a CIED
when it is in or close to the radiotherapy treatment ﬁeld
[11]. In addition, published results are not consistent in
their ﬁndings or recommendations. Radiotherapy has been
shown to cause malfunction of CIEDs, ranging from inap-
propriate triggering, device reprogramming or device fail-
ure [12e14]. Other investigators have reported a minimal
effect of radiotherapy on CIEDs [15].
There is concern that the photon energy of the treatment
beam may also be important. Gelblum and Amols [16] dis-
cussed the possible effects of neutron contamination from
high-energy photon beams. They recommended the use of
low-energy beams (<10 MV), but there is little evidence to
support this recommendation.
The American Association of Physicists in Medicine
(AAPM) [17] published a report in 1994 on the safe use of
radiotherapy in patients with permanent pacemakers. The
AAPM report is the basis of most of the current CIED
departmental radiotherapy policies in the UK (authors’
observation). Frizzell [18] published a more contemporary
review and a distinction was made between pacemakers
and ICDs. Both the AAPM and the Frizzell reports are widely
referenced in the literature and in our opinion have the
most robust evidence base to support them. Despite this,
the AAPM report is now nearly two decades old and does
not reﬂect advances in CIED or radiotherapy technology.
However, in the absence of more contemporary evidence-
based guidelines on treating CIED patients with radio-
therapy, it is reasonable to compare current UK policies
with the AAPM recommendations, using the Frizzell update
to deﬁne current best practice for ICD management.
Below is a summary of the AAPM and Frizzell
recommendations:
AAPM Recommendations (pacemakers):
1. Pacemakers should not be placed in the direct
(unshielded) therapy beam.
2. The absorbed dose to be received by the pacemaker
shouldbeestimatedbefore treatment and limited to2Gy.
3. If the total estimated dose to the pacemaker might
exceed 2 Gy, pacemaker function should be checked
before radiotherapy and possibly at the start of each
following treatment week by a cardiologist.
4. Patients should be closely observed during the ﬁrst
radiotherapy treatment on a linear accelerator.
Frizzell Recommendations (ICDs):
1. The absorbed dose to be received by the ICD should
limited to 0.5 Gy.
2. Amagnet should be placed over an ICDwhen a patient is
exposed to radiation.
3. Notify all patients about the possibility of ICD mal-
function, failure or both.
Monitoring recommendations:
1. Patients should be monitored with a continuous elec-
trocardiogram (ECG) strip during the ﬁrst radiotherapy
treatment. This strip should then be reviewed for any
evidence of pacing disruption when radiotherapy is
being administered.
2. ICD patients should undergo daily monitoring and staff
should document any changes in the patient’s physical
status and any changes in the ECG trace.
3. Monitoring should be carried out by fully trained and
competent health professionals. If therapeutic radiog-
raphers are monitoring patients, they should receive
speciﬁc training on the management and monitoring of
these patients.
4. If at any point malfunction is suspected or detected, the
clinical oncologist and cardiologist should be immedi-
ately informed.
Consent recommendations:
1. The patient is aware of potential adverse effects of
radiotherapy on CIEDs.
2. The patient is aware the ICD will be deactivated during
radiotherapy.
Currently, there are no UK or national guidelines on the
use of radiotherapy in patients with CIEDs and most
radiotherapy departments have no formal riskmanagement
strategy or policy in place [11]. The aims of this audit were
to establish current UK practice regarding the management
of patients with CIEDs undergoing radiotherapy and to
compare this practice with the current ‘gold standard’
AAPM and Frizzell recommendations.
Materials and Methods
UK radiotherapy centres were identiﬁed using the Soci-
ety and College of Radiographers’ database. Between May
2012 and March 2013, all radiotherapy department man-
agers were e-mailed asking them to participate in a national
audit. Centres were asked to either provide their current
CIED policy or to indicate if there was no policy.
A proforma was created to analyse CIED policies
comprising two sections: ﬁrst, the roles and responsibilities
of healthcare professionals; second, treatment and man-
agement guidelines. All data collected were anonymised. A
database (Microsoft Excel) was created for the entry and
analysis of audit data and departmental guidelines were
compared. The results are presented as simple frequencies
and percentages.
Results
In total, 67 radiotherapy centres were identiﬁed in the UK
and contacted. Overall, 47/67 (70%) departments responded
to the request to provide their policy for inclusion in the
audit. Forty-ﬁve departments provided their policy and two
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departments are currently re-writing their CIED policy and
were excluded from the results. Twenty departments did
not respond to the request. The analysis was carried out on
the 45 polices submitted that are currently in use.
Table 1 summarises the roles and responsibilities of
healthcare professionals. Overall, 39/45 (87%) policies
require the clinical oncologist to state whether a CIED is
present on the radiotherapy referral form; 41/45 (91%)
policies require the clinical oncologist to contact the pa-
tient’s cardiology department before starting radiotherapy;
34/45 (76%) policies require a cardiology assessment; 36/45
(80%) policies require the clinical oncologist to provide
relevant information to medical physics to allow the
calculation of the estimated cumulative dose to the CIED
before starting radiotherapy; 12/45 (27%) policies require
patients ﬁtted with CIEDs to be informed of the risks to
themselves and their device before starting radiotherapy; 5/
45 (11%) policies state that patients ﬁtted with ICDs should
be informed about the possibility of ICD malfunction or
failure during radiotherapy and must give consent to
deactivate the ICD during radiotherapy.
Of note is that in only 29/45 (64%) policies is it mandatory
for the planning radiographer to contact the treating
consultant if theCIED iswithina radiotherapy treatmentﬁeld
or the estimated dose is too high. Less than a third of policies
include appropriate monitoring procedures for treatment
radiographers in patients with pacemakers or ICDs. There is
no requirement for medical physics to calculate the esti-
mated dose to CIEDs and leads in 9/45 (20%) policies.
Table 2 summarises adherence to current guidelines: 31/
45 (69%) policies deﬁne the radiotherapy tolerance dose to
the pacemaker recommended in the AAPM guidelines. Of
these, 21/31 (68%) policies require the cardiology depart-
ment to be contacted to discuss safe management of the
patient. In total, 14/45 (31%) policies do not deﬁne a toler-
ance dose limit to the pacemaker and none of these radio-
therapy departments contact the patient’s cardiology
department. Only 5/45 (11%) policies deﬁne the radio-
therapy tolerance dose limit to the ICD as 0.5 Gy and all ﬁve
of these radiotherapy departments contact the cardiology
department to discuss the management of the patient; 23/
45 (51%) policies deﬁne a dose limit of >0.5 Gy to the ICD
and 17/45 (38%) policies do not deﬁne a dose limit. 39/40
(98%) policies that use an incorrect tolerance dose limit or
do not deﬁne a dose limit do not mandate contacting the
patient’s cardiology department for advice. 30/45 (67%)
policies require a follow-up appointment to be made with
the patient’s cardiology department after the completion of
radiotherapy.
Table 3 summarises the monitoring requirements for
patients with CIEDs receiving radiotherapy. Overall, 31/45
(69%) policies do not deﬁne monitoring procedures for pa-
tients with pacemakers in line with the AAPM guidelines
and none mandate the use of appropriately trained staff to
monitor patients. Similarly, 33/45 (73%) policies do not
deﬁne monitoring procedures for patients with ICDs in line
with the Frizzell report and none mandate the use of
appropriately trained staff to monitor patients.
Table 1
Roles and responsibilities
Roles and responsibilities Results (n ¼ 45 unless stated
otherwise)
Number of radiotherapy
department policies
%
Consultant oncologist
Identify patient’s CIED status and highlight on radiotherapy referral form 39 87
Contact patient’s cardiology department before starting radiotherapy treatment 41 91
Request cardiology assessment 34 76
Provide medical physics with information to calculate cumulative radiotherapy dose to CIED 36 80
Dose to the implantable internal pacemaker does not exceed 2 Gy 31 69
Dose to the ICD does not exceed 2 Gy 5 11
Consent e patient aware of potential adverse effects of radiotherapy on cardiac device 12 27
Consent e switch off ICD during radiotherapy 5 11
Planning radiographers
Annotated patient’s CIED status 34 76
CIED included in scan if in/close to the radiotherapy treatment ﬁeld 35 78
Medical physics informed of patient’s CIED status 35 78
Contact consultant if CIED is within radiotherapy treatment ﬁeld or estimated dose too high 29 64
Treatment radiographers
Appropriate monitoring procedure for patients with pacemakers 14 31
Appropriate monitoring procedure for patients with ICDs 12 27
Medical physics
Dose estimation calculated for CIEDs and leads 36 80
CIED, cardiac implantable electronic device; ICD, implantable cardioverter deﬁbrillator.
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Discussion
The number of patients with CIEDs undergoing radio-
therapy treatment is increasing [2,5,6]. There is limited
published research on the effect of radiotherapy on CIEDs,
but there is evidence to show radiotherapy at low doses can
cause malfunction or failure with potentially life-
threatening consequences [10]. Given this risk, all radio-
therapy centres should have policies in place to support the
safe radiotherapy treatment of patients with CIEDs.
This audit used the AAPM guidelines and Frizzell report
as the benchmark to compare UK radiotherapy de-
partments’ current CIED policies, as in the opinion of the
authors, these guidelines had the most robust evidence
base to support them [17,18].
The ﬁrst question we wanted to answer was how many
UK radiotherapy centres have a CIED policy in routine use.
All radiotherapy department managers were asked to pro-
vide their current policy for analysis. The request yielded a
response rate of 70%; 45 respondents provided their policy
and two centres stated that they are currently re-writing
their policy. A third follow-up e-mail has been sent from
the Society of Radiographers on behalf of the researchers
asking radiotherapy departments to forward their policy or
to inform the researchers if they do not have one. This will
allow a more detailed national picture to be established in
the future, but a response rate of 70% was felt high enough
to proceed with this review. At this point, it is not known
whether the remaining 20 radiotherapy departments who
have not responded have a policy, but it is possible that up
Table 2
Adherence to American Association of Physicists in Medicine (AAPM) and Frizzell guidelines
Guidelines Results (n ¼ 45 unless stated
otherwise)
Number of radiotherapy
department policies
%
Pacemakers e AAPM guidelines
2 Gy radiotherapy tolerance dose to device stated 31 69
Requirement to contact cardiology if radiotherapy dose to pacemaker exceeds 2 Gy 21 (of 31) 68
No radiotherapy tolerance dose stated 14 31
Do not contact cardiology 14 (of 14) 100
Cardiology follow-up made after radiotherapy completed 30 67
ICDs e Frizzell Report
0.5 Gy radiotherapy tolerance dose to device stated 5 11
Requirement to contact cardiology if radiotherapy dose to ICD exceeds 0.5 Gy 5 (of 5) 100
1 Gy radiotherapy tolerance dose to device stated (exceeding 0.5 Gy tolerance dose) 9 20
Do not contact cardiology if radiotherapy dose to ICD exceeds 1 Gy 9 (of 9) 100
2 Gy radiotherapy tolerance dose to device stated (exceeding 0.5 Gy tolerance dose) 14 31
Do not contact cardiology if radiotherapy dose to ICD exceeds 2 Gy 13 (of 14) 93
No radiotherapy tolerance dose stated 17 38
Do not contact cardiology if no radiotherapy tolerance dose is stated 17 (of 17) 100
Cardiology follow-up made after radiotherapy completed 30 67
ICD, implantable cardioverter deﬁbrillator.
Table 3
Monitoring
Clinical practice e monitoring of patients with cardiac devices Results (n ¼ 45 unless stated
otherwise)
Number of radiotherapy
department policies
%
Pacemakers e AAPM guidelines
Appropriate monitoring procedure 14 31
Appropriate staff used to monitor patients 14 31
Close observation of patient using cardiac monitor on ﬁrst fraction of radiotherapy 14 31
Subsequent monitoring requirements assessed and annotated 14 31
ICDs e Frizzell report
Appropriate monitoring procedure 12 27
Appropriate staff used to monitor patients 12 27
12 lead continuous strip ECG before ﬁrst fraction of radiotherapy 12 27
Deactivate ICD with magnet during radiotherapy 12 27
Continuous strip ECG monitoring for all subsequent treatments 12 27
Document any change in patient’s status 12 27
AAPM, American Association of Physicists in Medicine; ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator.
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to 30% of UK radiotherapy centres have no policy for man-
aging patients with CIEDs. Given the potential risk from
radiotherapy to patients with CIEDs, it is concerning that a
signiﬁcant proportion may not have a policy to guide
healthcare professionals. The lack of an over-arching na-
tional policy on this therapy area is not speciﬁc to the UK.
An American report suggests that 12% of US oncology de-
partments have neither a formal risk management strategy
nor a cardiac device policy and that only 15% have a written
policy [11].
The audit results highlight signiﬁcant differences be-
tween policies in the roles and responsibilities of healthcare
professionals involved in the patient pathway and the
management of patients with a CIED receiving radio-
therapy. From the results of the audit, in 87% of radio-
therapy departments the treating clinical oncologist
determines CIED status and highlights it on the radio-
therapy referral form. This means that in 13% of the policies
included in this review, it is left to radiographers to identify
whether a CIED is present. Anecdotal evidence from this
audit shows that in some cases, a CIED is not discovered
until a patient attends for radiotherapy. This results in
treatment being delayed or treatment proceeding without
safety measures in place. It is not known howmany patients
with CIEDs undergo radiotherapy without the knowledge of
the therapeutic radiographers, but this potentially
dangerous scenario is less likely if the treating oncologist
determines early on in the treatment pathway that a device
is present and informs the planning and treatment teams.
Worryingly, in only 29/45 (64%) policies is it mandatory for
the treating consultant to be contacted if the CIED is within
a radiotherapy treatment ﬁeld or the estimated dose is too
high. In most cases, this communication would probably
happen even in the absence of policy. However, given the
potential harm to the patient, this should be explicit. There
is clearly a need for policies in use to include monitoring
procedures for treatment radiographers in patients with
pacemakers or ICDs. These procedures are currently
included in less than one-third of policies and it is vital that
patients having treatment are monitored to minimise the
chance of harm. There is no requirement formedical physics
to calculate the estimated dose to CIEDs and leads in 9/45
(20%) policies. Without this estimation being made before
radiotherapy starts, patients may be exposed to doses of
radiation that exceed the limits recommended by AAPM
and Frizzell.
Patients consenting for any type of treatment need to be
informed of potentially serious side-effects related to that
treatment. Nearly three-quarters of policies do not mandate
discussion of potential damage to the CIED during and after
radiotherapy in the treatment consent process. Given the
lack of contemporary research in this area, it is not possible
to quantify this risk of damage or harm at present, but
consideration should be given to discussing potential
complications in all patients with a CIED. ICDs are probably
susceptible to radiotherapy damage at lower doses than
pacemakers and ICD patients should be informed about the
possibility of malfunction or failure during radiotherapy
treatment as the consequences may be devastating. ICD
patients also need to be told in advance of radiotherapy that
their device will be deactivated using a magnet during
treatment.
The AAPM report recommended that the cumulative
radiotherapy dose to the pacemaker be limited to less than
2 Gy [17]. In the audit, only 31/45 (69%) radiotherapy de-
partments limit the cumulative dose to the pacemaker to
2 Gy and of these, only 21/31 (68%) require communication
with the cardiology department if the dose exceeds 2 Gy. It
is concerning that nearly a third of policies deﬁne no
tolerance dose to the pacemaker. There is evidence that
even low cumulative doses of radiotherapy may damage
CIEDs and patients are probably being put at risk of harm
with the current policies in use.
The Frizzell report recommended a lower radiotherapy
tolerance dose of 0.5 Gy for ICDs and that they should be
deactivated before radiotherapy by placing a magnet over
the device to prevent inappropriate therapy or shock de-
livery as a result of accidental sensing of EMI interference
[18]. Worryingly, the audit shows that only 5/45 (11%)
radiotherapy departments limit the ICD dose to 0.5 Gy, 23/
45 (51%) radiotherapy departments specify a higher ICD
tolerance than recommended and 17/45 (38%) do not state a
radiotherapy tolerance dose. That means that in most cen-
tres with a cardiac device policy, ICDs are potentially
exposed to doses of radiotherapy that may affect function
and cause serious harm to the patient.
In addition, it is of signiﬁcant concern that only 6/45
(13%) CIED policies differentiate between pacemakers and
ICDs and subsequently apply radiotherapy tolerance dose
limits to both types of device. In these policies, ICDs are
subject to the same radiotherapy tolerance dose limits and
the samemonitoring procedures as pacemakers. As a result,
ICDs are almost certainly being subjected to radiotherapy
doses beyond tolerance and ICDmalfunction has potentially
life-threatening consequences.
The AAPM and Frizzell reports recommend that all pa-
tients with CIEDs be monitored with a continuous ECG strip
during their ﬁrst radiotherapy treatment for any evidence of
pacing disruption [17,18]. In addition, they should be
monitored by an appropriately trained health professional.
The audit shows that over two-thirds of policies do not
mandate the monitoring procedures deﬁned by AAPM and
Frizzell and less than one-third require the use of an
appropriately trained health professional to carry out the
monitoring. Therefore, a signiﬁcant number of patients with
CIEDs are undergoing radiotherapy with no monitoring and
in those that are monitored most of the staff involved may
not have appropriate training to interpret ECG or clinical
changes.
Conclusion
This audit of CIED policies is based on a 70% response rate
from radiotherapy centres in the UK. It cannot be deﬁnitive
in its conclusions, but important themes have emerged
nevertheless. It is clear that policies differ between radio-
therapy centres. In addition, a signiﬁcant proportion of
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policies do not adhere to current established tolerance
doses for CIEDs. As a consequence, it is very likely that pa-
tients are being put at signiﬁcant risk of harm. We are car-
rying out urgently needed research to further deﬁne the
effect of radiotherapy on modern cardiac devices. This
research will underpin the development of contemporary
evidence-based guidelines on the use of radiotherapy in
patients with these devices.
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Appendix G 
 
 
Summary – Effect of ionising radiation on pacemakers at 6MV and 10MV 
DEVICE 
 
First malfunction RT 
Dose 
(Gy) 
Other malfunctions  RT 
Dose 
(Gy) 
Point of Failure 
(POF) 
RT 
Dose 
(Gy) 
6MV 
PM X2 3 – Sensing 
 
3Gy 3 – Sensing 
 
3Gy ! 
5G ! 
1 – Pacing 
pulse 
120Gy 
120Gy 
PM X3 1 – Pacing pulse 
 
120Gy   1 – Pacing 
pulse 
120Gy 
PM X4 1 – Pacing pulse  70Gy 2 – Pacing 
frequency 
3 – Sensing 
70Gy ! 
90Gy ! 
4 – Telemetry  120Gy 
PM Y2 6 – Lead 
impedance 
changes 
80Gy 6 – Lead impedance 
changes 
80Gy ! 4 – Telemetry  90Gy 
PM Y3 2 – Pacing 
frequency 
44Gy 2 – Pacing 
frequency 
 
44Gy ! 4 – Telemetry  92Gy 
PM Y4 3 – Sensing 10.5Gy 3 – Sensing 10.5Gy ! 3 – Sensing  
5 – Battery 
120Gy 
PM Z2 4 – Telemetry  20.5Gy 2 – Pacing 
frequency  
4 – Telemetry 
 
20.5Gy ! 
90Gy ! 
4 – Telemetry  120Gy 
PM Z3 4 – Telemetry  23Gy   4 – Telemetry  23Gy 
PM Z4 5 – Battery 12Gy 5 – Battery 12Gy ! 4 – Telemetry 13.5Gy 
!
10MV 
PM X5 4 – Telemetry 28Gy   4 – Telemetry 28Gy 
PM X6 2 – Pacing 
frequency 
2.5Gy 1 – Pacing pulse  20Gy ! 
 
1 – Pacing pulse 90Gy 
PM X7 4 – Telemetry 17Gy 3 – Sensing 30Gy ! 
56Gy ! 
4 – Telemetry 100Gy 
PM Y5 3 – Sensing 4.5Gy 3 – Sensing 5Gy ! 
50Gy ! 
3 – Sensing 
Device failure 
Unable to sense  
5 – Battery 
Device failure 
Elective 
replacement 
indication (ERI) 
 
70Gy 
 
 
70Gy 
PM Y6 3 – Sensing 7Gy 3 – Sensing  18Gy ! 3 – Sensing 90Gy 
PM Y7 3 – Sensing 52Gy   3 – Sensing 52Gy 
PM Z5 3 – Sensing 41Gy  41Gy ! 
 
3 – Sensing 120Gy 
PM Z6 4 – Telemetry 21Gy 3 – Sensing 
4 – Telemetry 
21Gy ! 
90Gy ! 
4 – Telemetry 90Gy 
PM Z7 4 – Telemetry 8.5Gy 4 – Telemetry 29Gy ! 
 
5 – Battery 120Gy 
!
! !
Summary - Effect of ionising radiation on ICDs at 6MV and 10MV 
 
!
  
DEVICE 
 
First malfunction RT 
Dose 
(Gy) 
Other malfunctions  RT 
Dose 
(Gy) 
Point of Failure 
(POF) 
RT 
Dose 
(Gy) 
6MV 
ICD X2 3 – Sensing 
 
60Gy 3 – Sensing 
 
70Gy ! 
 
1 – Pacing pulse 
 
100Gy 
ICD X3 7 – Shock 45Gy 3 – Sensing 46Gy ! 1 – Pacing pulse 
7 – Shock 
 
70Gy 
70Gy 
ICD Y2 3 – Sensing 4Gy 
 
3 – Sensing 
7 – Shock 
5 – Battery 
5G ! 
5G ! 
40Gy ! 
3 – Sensing 
7 – Shock 
90Gy 
90Gy 
ICD Y3 3 – Sensing 
1 – Pacing pulse  
4 – Telemetry  
0.5Gy 
0.5Gy 
0.5Gy 
  1 – Pacing pulse 1Gy 
ICD Z2 3 – Sensing 1.5Gy 3 – Sensing 1.5Gy ! 1 – Pacing pulse 
7 – Shock 
3.5Gy 
3.5Gy 
10MV 
ICD X4 5 – Battery  120Gy   3 – Sensing 120Gy 
ICD X5 7 – Shock 10Gy 4 – Telemetry 20Gy ! 7 – Shock 80Gy 
ICD Y4 3 – Sensing  5Gy 3 – Sensing  
4 – Telemetry 
5Gy ! 
6Gy ! 
1 – Pacing pulse 
 
15Gy 
ICD Y5 4 – Telemetry 
5 – Battery 
12.5Gy 
12.5Gy 
3 – Sensing  
4 – Telemetry 
12.5Gy 
! 
14Gy ! 
1 – Pacing pulse 
 
120Gy 
ICD Z3 7 – Shock 8.5Gy 3 – Sensing 9Gy ! 7 – Shock 
1 – Pacing pulse 
10Gy 
10Gy 
Summary – Effect of EMI on CIEDs – Pacemakers 
DEVICE 
Pacemakers 
CIED malfunctions observed At what point CIED  
malfunction observed 
6MV 
 
 
 
PM X9 
#1 - #3 3 – Sensing  During EMI exposure 
#4 3 – Sensing During EMI exposure 
1 – Pacing pulse During EMI exposure 
#5 - #6 No CIED malfunction observed or recorded 
#7 - #9 1 – Pacing pulse During EMI exposure 
#10 1 – Pacing pulse During EMI exposure 
PM X10 #1 - #7 No CIED malfunction observed or recorded 
#8 - #10 2 – Pacing frequency Beam ON / During EMI exposure 
10MV 
PM X11 #1 - #10 2 – Pacing frequency Beam ON / During EMI exposure 
PM X12 #1 - #9 1 – Pacing pulse During EMI exposure 
#10 1 – Pacing pulse During EMI exposure 
!
Summary – Effect of EMI on CIEDs – ICDs 
DEVICE 
Pacemakers 
CIED malfunctions observed At what point CIED  
malfunction observed 
6MV 
ICD 
X7 
#1 - #8 2 – Pacing frequency Beam ON 
#9 - #10 5 – Battery Post beam OFF 
 
ICD 
X8 
#1 - #6 1 – Pacing pulse During EMI exposure 
#7 3 – Sensing During EMI exposure 
#8 - #10 1 – Pacing pulse During EMI exposure 
10MV 
ICD 
X9 
#1 - #5 No CIED malfunction observed or recorded- 
#6 - #10 7 – Shock During EMI exposure 
 
ICD 
X10 
#1 - #3 No CIED malfunction observed or recorded- 
#4 - #6 2 – Pacing frequency Beam ON 
#7 - #10 2 – Pacing frequency Beam ON 
!
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Overview 
 
A national review of cardiac device policies in use in radiotherapy 
departments across the UK in 2013 reported that most policies do not reflect 
current best evidence.1 The Radiotherapy Boarda formed a multidisciplinary 
working party comprising clinical oncology, cardiology, therapeutic 
radiography and medical physics expertise to develop evidence-based 
guidelines for the management of cancer patients receiving radiotherapy with 
a cardiac implanted electronic device.  
  
                                                        a The Radiotherapy Board was established in 2013 by The Royal College of Radiologists 
(RCR), the Society and College of Radiographers (SCoR), and the Institute of Physics and 
Engineering in Medicine (IPEM) to provide guidance, oversight and support for the continuing 
development of high-quality radiotherapy services for cancer patients in the UK. 
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1. Introduction 
The number of cancer patients with cardiac implantable electronic devices 
(CIEDs) receiving radiotherapy is increasing.2-4 There are two main categories 
of CIED: permanent pacemakers and implantable cardioverter defibrillators 
(ICDs). Electronic monitoring devices (eg implantable loop recorders) have no 
direct connection to the heart and are not covered in this guideline. Most 
permanent pacemakers (referred to as ‘pacemakers’ in this document) are 
implanted in patients who either have inappropriate bradycardia, or who are at 
risk of bradycardia. Bradycardia pacemakers generally only pace the heart 
when the patient’s heart rate is excessively slow (usually <50 beats/minute), 
otherwise the pacemakers simply monitor and therefore an electrocardiogram 
(ECG) may appear “normal” and not show any pacemaker activity. Cardiac 
resynchronisation pacemakers coordinate the sequence of cardiac contraction 
and are used in patients with heart failure. As such, these pacemakers tend to 
pace the heart continuously and an ECG usually shows paced beats. ICDs 
are more sophisticated devices; in addition to normal pacing capabilities (for 
bradycardia and/or for resynchronisation), ICDs have the ability to monitor the 
patient’s cardiac rate and rhythm, and deliver shock therapy when certain 
criteria are met. The simplest shock criteria involve heart rate; thus when 
sensed heart rate exceeds a pre-programmed value (usually >220 
beats/minute), shock therapy is delivered. Inappropriate shock therapy may 
arise when the ICD senses the cardiac rhythm incorrectly. 
 
Although most medical treatments pose little danger to the functioning of 
CIEDs, radiotherapy has the potential to alter device function. CIEDs may be 
affected in two ways - electromagnetic interference (EMI) and direct damage 
via ionising radiation - both of which may cause temporary or permanent 
device malfunction.5 Over the past three decades, the design and technology 
of CIEDs has evolved. The use of complementary metal oxide semiconductor 
(CMOS) circuits within CIEDs has increased.6 These are more sensitive to 
ionising radiation than the bipolar semiconductor devices previously used, 
with the potential of increased damage and catastrophic device failure.7,8 
CIEDs are also now more complex in design, they are smaller, have thinner 
housing, less shielding and have limited battery capacity. These CIEDs use 
random access memory (RAM) to hold patient-related data. Ionising radiation 
can damage the RAM and can lead to complete loss of CIED function.9 
It is not possible to predict the exact behaviour of a CIED when it is within or 
close to a radiotherapy treatment field.10 In addition, published results are not 
consistent in their findings or recommendations. Radiotherapy has been 
shown to cause malfunction of CIEDs, ranging from inappropriate triggering 
and device reprogramming to device failure.10-13 However, other investigators 
have reported minimal effect of radiotherapy on CIEDs.14-17 
The American Association of Physicists in Medicine (AAPM) published a 
report in 1994 on the safe use of radiotherapy in patients with permanent 
pacemakers.18 The AAPM report is the basis of most of the current CIED 
departmental radiotherapy policies in the UK.1  Frizzell published a more 
contemporary review in which a distinction was made between pacemakers 
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and ICDs.19 Both the AAPM and the Frizzell reports are widely referenced in 
the literature and, in our opinion, have the most robust evidence base to 
support them. The AAPM report is now nearly two decades old and does not 
take into account subsequent advances in CIED or radiotherapy technology 
and treatment delivery.1 A Dutch update of the 1994 AAPM guidelines was 
published by Hurkmans et al, in 20126 and in 2015 Gauter-Fleckenstein et al 
published the DEGRO/DGK guidelines.9 Both papers have been referenced in 
these guidelines where appropriate.6 In the absence of more contemporary 
research on safely treating CIED patients with radiotherapy, it is reasonable to 
use the AAPM recommendations, the Frizzell review, the Dutch update and 
DEGRO/DGK guidelines as the basis of a UK guideline document. 
Currently, there are no UK guidelines on the use of radiotherapy in patients 
with CIEDs. A national review of current cardiac device policies from 
radiotherapy centres across the UK reported that 30% of UK radiotherapy 
centres have no policy for managing patients with CIEDs.1 Results showed 
that policies differ between radiotherapy centres and a significant number of 
policies do not adhere to current established tolerance doses for CIEDs. In 
the departments where there is a CIED policy, the majority do not reflect best 
evidence.1 There is limited published research on the effect of radiotherapy on 
CIEDs, but there is evidence to show that radiotherapy even at low doses can 
cause malfunction or failure with potentially life-threatening consequences.11 
Given this risk, all radiotherapy centres should have policies in place to 
support the safe delivery of radiotherapy in patients with CIEDs.1  
In 2014, a multidisciplinary working party was established with the aim of 
providing national guidance for clinicians, therapy radiographers and medical 
physicists on the management of cancer patients with a CIED who are 
receiving radiotherapy.   
This document reviews the evidence and literature to determine current ‘gold 
standard’ practice and provides recommendations for the management of 
cancer patients who have a CIED and are receiving radiotherapy.  
 
 
2. Summary of recommendations 
 
• CIEDs should not be placed directly in the radiotherapy treatment 
beam 
• The cumulative radiotherapy dose received by a pacemaker should not 
exceed 2Gy 
• Patients with rate-adaptive pacemakers should be reviewed by 
cardiology and consideration given to temporary deactivation of the 
sensor whilst receiving radiotherapy  
• The cumulative radiotherapy dose received by an ICD should not 
exceed 0.5Gy 
• The photon beam energy should be <10MV 
• The dose contribution from on-treatment verification imaging should be 
taken into account when calculating cumulative radiotherapy dose 
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• The patient’s cardiologist should be informed in advance of any 
planned radiotherapy for advice on monitoring during radiotherapy and 
subsequent follow-up 
• Patients with CIEDs should be fully informed of the potential short- and 
long-term risks of radiotherapy. This should be included in patient 
information available from the cardiology department in addition to 
radiotherapy patient information 
• Patients should be allocated an appropriate risk categorisation group 
as defined in Table 1 
• Monitoring requirements based on the patient’s risk categorisation 
group should be implemented  
• Appropriately trained staff should be involved in CIED monitoring 
during radiotherapy 
 
 
3. Patient management 
 
The management of CIED patients undergoing radiotherapy is summarised in 
Table 2. The roles and responsibilities of staff involved in the management of 
these patients is summarised in Table 3. 
 
3.1 Before radiotherapy 
All patients should be screened for the presence of a CIED as part of the 
radiotherapy planning process. Once these patients have been identified, 
CIED information should be annotated as stated on the patients’ CIED 
identification card. Staff should be aware that some cardiologists place the 
CIED on the patients’ right side if they are left-handed. Anecdotal evidence 
from a national review showed that in some cases, a CIED is not discovered 
until a patient attends for radiotherapy.1 This results in treatment being 
delayed or proceeding without safety measures in place. Planned 
radiotherapy treatment details should be recorded as per standard practice. 
The cardiology team should be informed as soon as possible to facilitate 
patient review before radiotherapy with the aim of establishing CIED 
functionality. The purpose is to detect any possible change in pacing-
dependency of the patient. If an examination of technical CIED function has 
not been conducted within the previous three months, it is recommended that 
it should be carried out prior to the patient commencing radiotherapy. The 
cardiologist should also recommend appropriate CIED monitoring during and 
after radiotherapy. Patients with rate-adaptive CIEDs must be reviewed by 
cardiology before a planned course of radiotherapy begins and consideration 
given to deactivating the sensor. 
 
3.1.1 Radiotherapy planning 
If the CIED is near or in the anticipated treatment field or volume, it should be 
included in the planning computed tomography (CT) scan. This will allow 
accurate estimation of the cumulative radiotherapy dose received by the 
CIED. The CIED should not be in the planning target volume (PTV) in order to 
minimise the dose to the device. Radiotherapy beam energy no greater than 
10MV should be used to avoid neutron contamination.6,9,20 The medical 
physics team should be informed of the presence of a CIED and every effort 
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should be made in the  planning process to limit the cumulative dose to the 
device.   
 
3.1.2 Risk group 
It is not possible to predict the exact behaviour of any given CIED when it is 
in, or in close proximity to, the radiotherapy treatment field.9 Research 
indicates that the risk of CIED malfunction increases as the cumulative 
radiation dose to the CIED increases. In addition, the risk to the patient is 
greater if the patient is pacing-dependent. These include patients whose 
pacemaker is pacing all the time (and who are at risk of asystole if the 
pacemaker malfunctions) and patients with a resynchronising pacemaker 
where the patient may be at risk of increased heart failure symptoms in the 
event of device malfunction.  
 
Patients with a pacemaker should be allocated a risk group based on their 
pacing dependency and estimated cumulative radiotherapy dose received. In 
2015, Gauter-Fleckenstein et al proposed a risk categorisation that 
incorporates these two parameters (Table 1).9 
 
Low risk patients: 
• Pacemaker independent, and the device is anticipated to receive a 
cumulative radiotherapy dose of less than 2Gy  
 
Medium risk patients: 
• Pacemaker dependent and the device is anticipated to receive a 
cumulative radiotherapy dose of less than 2Gy  
• Pacemaker independent and the device is anticipated to receive a 
cumulative radiotherapy dose of between 2Gy and 10Gy 
 
High risk patients: 
• Pacemaker dependent and the device is anticipated to receive a 
cumulative radiotherapy dose of between 2Gy and 10Gy  
• All patients (pacemaker dependent and independent) and the device is 
anticipated to receive a cumulative radiotherapy dose of more than 
10Gy 
 
Patients with an ICD in situ should be regarded as high risk. The estimated 
cumulative radiotherapy dose to the ICD should not exceed 0.5Gy.  
 
For all CIEDs, the potential dose received from on-treatment verification 
imaging should also be taken into account. This is especially important with 
ICDs, which have a much lower recommended maximum cumulative 
radiotherapy dose of 0.5Gy.  
 
In patients identified as being medium or high risk, the clinical oncologist 
should liaise with medical physics to discuss how to optimise the patient’s 
radiotherapy plan and limit the cumulative dose to the CIED. If after 
optimisation of the radiotherapy plan the estimated cumulative dose exceeds 
those outlined above then a review of management options should take place. 
If radiotherapy is felt to be the most appropriate management option, it is 
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recommended that the clinical oncologist should liaise with the cardiology 
department.   
 
3.1.3 Consent 
Patients consenting for any type of treatment need to be informed of 
potentially serious side effects related to that treatment. During the consent 
process the clinical oncologist should discuss the potential damage to the 
CIED during and after radiotherapy. Patients should be told they will be 
subject to close monitoring during treatment and further follow-up after 
radiotherapy has finished. Given the lack of contemporary research in this 
area, it is not possible to quantify this risk of damage or harm at present, but 
discussion of potential complications should take place for all patients with a 
CIED. Patients with rate-adaptive CIEDs may have their sensor deactivated 
for the duration of radiotherapy treatment. It is important that the implications 
and risks of this are fully discussed with the patient by the cardiology team 
before any planned radiotherapy. ICDs are considered susceptible to 
radiotherapy damage at lower doses than pacemakers. For this reason, all 
ICD patients should be informed about the possibility of malfunction or failure 
resulting from radiotherapy treatment as the complications may be life 
threatening. ICD patients should be informed in advance of radiotherapy that 
their device will be deactivated using a magnet during treatment.9,19,20 
3.2 During radiotherapy  
All patients with CIEDs should be monitored with a continuous ECG strip 
during their first radiotherapy treatment.9,18-20 This strip should then be 
reviewed for any evidence of pacing disruption when radiotherapy is being 
administered. Particular attention should be given to any pacing discrepancies 
when the radiation beam is turned on and off. If the patient is classified as low 
risk (cumulative dose to the cardiac device is <2Gy and the patient is non-
pacemaker dependent) and there are no changes on the ECG monitoring, 
further monitoring is not required during the remainder of the radiotherapy 
treatments. If the patient is classified as medium or high risk (cumulative dose 
to the cardiac device is >2Gy or the patient is pacemaker dependent or has 
an ICD) they will require ECG monitoring throughout the course of their 
radiotherapy.6 Patients who have an ICD require daily monitoring owing to 
their device being deactivated during radiotherapy treatment. The patient 
should be observed during treatment with audiovisual monitoring. Monitoring 
staff should document any changes in the patient’s physical status, and any 
changes in the ECG trace should be documented and reviewed after every 
radiotherapy treatment. The minimum level of training received by monitoring 
staff should include Immediate Life Support (ILS) and appropriate 
resuscitation equipment should be available at all times. If therapeutic 
radiographers are monitoring patients, they should receive specific training on 
the management and monitoring of these patients. If at any point malfunction 
is suspected or detected, the clinical oncologist and cardiologist should be 
immediately informed. 
ICDs have a much lower cumulative radiotherapy dose limit of 0.5Gy.9,19,20 
ICDs should be deactivated prior to the patient’s daily radiotherapy treatment 
by placing a magnet over the device to prevent inappropriate therapy or shock 
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delivery as a result of accidental sensing of radiation interference. When 
deactivating ICDs, there should be the ability to externally pace the patient if 
appropriate. Defibrillation devices available should be able to deliver external 
pacing and staff with Advanced Life Support (ALS) training or an ability to 
deliver external pacing should be available. 
3.3 After radiotherapy 
The importance of both short- and long-term follow-up monitoring for patients 
who have a CIED and have received radiotherapy was highlighted in a paper 
by Last.5 Patients should have their cardiac device checked within two weeks 
of completion of their radiotherapy and then one, three and six months after 
treatment. Devices exhibiting signs of dysfunction should be followed up with 
increased frequency. This will allow discrimination to be made between a 
temporary dysfunction that may occur owing to a build-up of charge within the 
semiconductor and more permanent circuitry damage.21 Should any additional 
changes be observed during the follow-up period then immediate device 
revision is likely to be necessary.  
 
Table 1:  
Risk categorisation determined by dependence and cumulative radiotherapy 
dose to pacemaker 
 
 
 
 
< 2Gy 2 – 10Gy > 10Gy 
Pacing 
independent 
Low risk Medium 
risk 
High risk 
Pacing  
dependent 
Medium risk High risk High risk 
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Table 2: 
Summary of management of CIED patients receiving radiotherapy 
 
 
Before radiotherapy 
 
 
Consultant clinical oncologist highlights CIED status 
 
 
CIED information annotated as stated on the patient device identification 
card: 
• Type of device: eg bradycardia pacemaker, resynchronising 
pacemaker, ICD or combined pacemaker/ICD, resynchronising 
pacemaker/ICD 
• Manufacturer 
• Make 
• Model 
• Date of implantation 
• Implantation site 
• Patient dependence on CIED 
 
 
Radiotherapy treatment details recorded: 
• Radiotherapy treatment site 
• Radiotherapy prescription 
• Radiotherapy treatment technique 
 
 
Clinical oncologist should liaise with patient’s cardiology department 
regarding: 
• Monitoring requirements 
• Requirement for device reprogramming or deactivation 
• Follow-up and review appointments  
 
 
CIED to be included in CT planning scan if close to anticipated 
radiotherapy treatment field 
 
 
Medical physics calculates estimated cumulative radiotherapy dose to the 
CIED 
 
 
Patients allocated a risk categorisation 
 
 
Patients with CIEDs should be fully informed on the potential short- and 
long-term risks of radiotherapy and consent appropriately  
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During radiotherapy 
 
 
Low risk 
patients 
Day one of radiotherapy – audio-visual and ECG 
monitoring by appropriately trained staff 
Appropriately trained staff determine patient’s monitoring 
requirements for subsequent radiotherapy treatments 
 
Medium risk 
patients 
Audio-visual and ECG monitoring by appropriately 
trained staff for every fraction of radiotherapy treatment  
Weekly CIED check by patient’s cardiology department 
 
High risk 
patients 
Potential CIED relocation  
Audio-visual and ECG monitoring by appropriately 
trained staff for every fraction of radiotherapy treatment  
Weekly CIED check by patient’s cardiology department 
 
 
ICD 
patients 
Day one of radiotherapy – 12 lead ECG should be 
performed by an appropriately trained staff member as a 
baseline 
Appropriately trained staff member must deactivate the 
ICD during radiotherapy treatment by placing the 
specialist magnet over the ICD 
Audio-visual and ECG monitoring by appropriately 
trained staff for every fraction of radiotherapy treatment  
Weekly ICD check by patient’s cardiology department  
 
After radiotherapy 
 
 
CIED device check-up, two weeks after radiotherapy treatment by 
cardiology department  
 
 
Cardiology follow-up one, three and six months after radiotherapy 
treatment or as advised by cardiology department 
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Table 3:  
Roles and responsibilities of staff involved in the management of CIED 
patients receiving radiotherapy 
 
 
Clinical oncologist 
 
 
Identify patient’s CIED status and highlight on radiotherapy referral form 
 
Contact patient’s cardiology department before commencing their 
radiotherapy treatment 
 
Request cardiology assessment / CIED device check 
 
Provide medical physics with information to calculate cumulative 
radiotherapy dose to CIED 
 
Check the dose to the pacemaker does not exceed 2Gy  
 
Check the dose to the ICD does not exceed 0.5Gy 
 
Consent – patient aware of potential adverse effects of radiotherapy on 
CIED 
 
Consent – patient aware that ICD will be switched off during radiotherapy 
 
Planning radiographers 
 
 
Annotate patient’s CIED status 
 
CIED included in CT planning scan if in/close to the radiotherapy 
treatment field 
 
Medical physics informed of patient’s CIED status 
 
No direct placement of CIED in radiotherapy beam 
 
Limitation of radiotherapy beam energy to 10Mv 
 
Contact consultant clinical oncologist if the CIED is within the radiotherapy 
treatment field or the estimated cumulative dose is too high 
 
Appropriately trained radiographers 
 
 
Assess patient prior to commencing their radiotherapy treatment 
 
Highlight patient’s monitoring requirements 
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Monitor the patient during their radiotherapy treatment 
 
If the patient has an ICD, deactivate the device during each fraction of 
radiotherapy treatment  
 
Arrange follow-up appointment with the patient’s cardiology department 
 
Treatment radiographers 
 
 
Do not commence patient’s radiotherapy treatment without ensuring 
correct procedure has been followed 
 
Do not commence patient’s radiotherapy treatment without the presence 
of the appropriately trained staff to monitor the patient 
 
Read and be conversant in CIED department policy 
 
Medical physics 
 
 
Calculate estimated cumulative radiotherapy dose to the CIED and leads 
prior to the patient commencing radiotherapy treatment. Previous 
radiotherapy courses received must be taken into consideration 
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4. Evidence review 
 
4.1 Methodology 
A multidisciplinary working party was established to provide guidance for the 
management of cancer patients with a CIED who are receiving radiotherapy.  
The Cochrane Library and Medline via OVID were searched for articles, 
guidelines and systematic reviews. The search was performed in January 
2014, combining search terms ‘radiotherapy’ or ‘radiation therapy’, 
‘pacemaker’, ‘ICD’. In addition ‘hand searching’ of relevant clinical journals, 
guidelines and meeting abstracts was carried out.   
4.2 CIED technology 
The number of patients with CIEDs undergoing radiotherapy treatment is 
increasing.2,3,4 Although most medical treatments pose little danger to the 
functioning of CIEDs, radiotherapy has the potential to cause device 
malfunction.5 The design and technology of CIEDs has evolved, allowing 
improved efficiency and functioning. Over the past three decades the use of 
complementary metal-oxide semiconductor circuits in cardiac devices has 
expanded.6 These are more sensitive to ionising radiation than the older 
bipolar semiconductor devices used previously, possibly resulting in damage 
to the hardware and software components.7 Damage could be transient, with 
dropped beats, transient inhibition, altered sensitivity, increased or decreased 
pulse width and frequency or triggering of pacemakers. Severe damage 
caused by radiation may lead to catastrophic failure of the cardiac conduction 
system in the device.8 
 
4.3 Pacemakers 
The AAPM report recommends that the maximum dose to a pacemaker 
should be limited to less than 2Gy.18 A study by Mouton et al supported the 
AAPM recommendations.8 In their in vitro study, ninety-six patients having 
thoracic radiotherapy whose pacemakers were adjacent to the radiotherapy 
treatment field exhibited a range of short- and long-term side effects. Results 
showed that one pacemaker exhibited clinically significant disturbances at a 
dose rate of 0.2Gy/min at a cumulative dose of only 0.15Gy, two pacemakers 
exhibited defects at a cumulative dose of 1Gy and nine pacemakers failed at 
a cumulative dose of 2Gy.8 Hurkmans et al directly irradiated nineteen new 
pacemakers; the commonest damage reported was loss of output.11 In 
contrast, in the Mouton study only one pacemaker malfunctioned below 50Gy, 
suggesting modern pacemakers may be relatively radioresisitant.8 The 
authors concluded that the AAPM recommendations were still valid. 
Importantly, in the Mouton study, pacemakers were not returned to the 
manufacturers for a more detailed analysis after irradiation, so potentially 
significant damage may have been missed. There is little in the academic 
literature on the effect of radiotherapy on rate-adaptive CIEDs. It is the 
authors’ observation (unpublished) that they may be influenced by 
radiotherapy, causing temporary increased sensor rate and tachycardia.  
Other potential effects of radiotherapy on CIEDs include temporary loss of 
sensing, temporary device inhibition, temporary loss of capture and device 
reset [St Jude Medical – Effect of Therapeutic Radiation on St Jude Medical 
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Implantable Cardiac Rhythm Devices, October 2013]. This observation is also 
recognised in the Frizzell review.19 
 
4.4 ICDs 
Frizzell published a more contemporary review of CIEDs and radiotherapy, 
concluding that the AAPM recommendations were no longer comprehensive 
as ICDs were not discussed.19 ICDs are more sophisticated and have the 
ability to automatically defibrillate the heart by monitoring the patient’s heart 
rate and deliver the appropriate electrical therapy. Frizzell recommended a 
lower radiotherapy tolerance dose of 0.5Gy for ICDs. This tolerance dose is 
partly based on work by Hurkmans et al who directly irradiated 11 ICDs. This 
study observed that the dose at first malfunction was as low as 0.5Gy.19 It is 
also recommended that ICDs should be deactivated prior to each fraction of 
radiotherapy by placing a magnet over the device to prevent inappropriate 
therapy or shock delivery as a result of accidental sensing of Electromagnetic 
Interference (EMI).  
 
4.5 Beam energy 
Gelblum et al reported on 33 patients with ICDs receiving radiotherapy. Two 
ICDs were reset to the factory settings during treatment for pelvic cancers 
with 15MV photon beams.20 Elders et al reported on 15 patients with ICDs 
who underwent radiotherapy treatment on linear accelerators with beam 
energies of between 6 and 18MV. In total, six ICD malfunctions were found, 
and all occurred with beam energies > 10MV.22 Both authors postulated that 
the cause of the ICD malfunctions was related to neutron production with 
higher energy beams. This has lead to other guidelines recommending that 
photon beam energy is kept to <10MV when treating patients with CIEDs.6  
 
4.6 CIED leads 
No published guidelines make reference to lead dose. The consensus view is 
that leads are relatively insensitive to radiation damage compared to CIEDs.6 
However, there is no evidence to inform dose constraints to CIED leads and 
so, in the authors’ view, every effort should be made to keep the leads out of 
the treatment field. If this is not possible, then the dose to the lead should be 
kept as low as possible. 
 
4.7 On-treatment verification imaging 
No published guidelines make recommendations on the potential contribution 
of imaging techniques to the CIED cumulative dose.  Murphy et al reported 
that the dose from a kilovoltage cone beam CT scan is likely to be in the 
region of 10-80mGy.23 Kan et al reported mean skin doses of 6.4cGy per 
kilovoltage cone beam CT chest scan.24 Even using the lower limit of 10mGy 
from Murphy et al, it is possible that daily cone beam CT in a 20-fraction 
radical lung treatment may contribute as much as 0.2Gy. Using the Kan et al 
skin dose estimates, it is possible the CIED may get significantly more than 
0.2Gy. An estimation of the dose contribution from the image verification 
method used should be made and this should be taken into consideration 
when allocating CIED patients to a risk group. 
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5. Audit procedure 
 
Radiotherapy centres should conduct a regular audit looking at guideline 
implementation. 
 
The following compliance standards should be included in the audit: 
• Radiotherapy tolerance doses used for the specific CIEDs 
• Classification of patient risk category 
• Adherence to patient management pathway and implementation  
• Adherence to monitoring procedures  
• All staff members aware of their roles, responsibilities and scope of 
practice  
 
 
6. Implementation 
 
Radiotherapy centres should circulate this document to all relevant staff. 
Consideration should be given on how best to implement the 
recommendations and audit adherence to these recommendations. 
Adaptation of the guideline may be appropriate to best reflect local practice 
and expertise. 
 
 
7. Staff and department requirements 
 
• All staff involved in the requesting, planning and delivery of 
radiotherapy should be aware of the guideline and their role in ensuring 
appropriate and safe management of patients with CIEDs 
• Communication links between the radiotherapy and cardiology 
departments are vital. Staff should be aware of who to contact and how 
to seek advice 
• Monitoring staff should receive specific training on the management of 
CIED patients 
• The radiotherapy department is responsible for training the staff 
• The radiotherapy department is responsible for the availability of 
appropriate equipment for monitoring of patients 
 
8. Conclusion 
 
This is a guideline on the safe management of patients with a CIED receiving 
radiotherapy. It is based on current best evidence, and should be used and 
adapted to best suit local practice in radiotherapy departments. 
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9.  Pacemaker manufacturer documents 
 
Biotronik: 
Biotronik, Product information 512, Radiation Exposure of Implanted 
Pacemakers. 1-2, Berlin, Germany, 5/18/2001; 2001. p. 1-2.w   
 
Boston Scientific: 
Boston Scientific (2012) Therapeutic radiation and implantable device 
systems. 
http://www.bostonscientific.com/content/dam/bostonscientific/quality/educati
on-resources/english-a4/EN_ACL_Therapeutic_Radiation_20120925.pdf 
 
Medtronic: 
Medtronic (2013) Therapeutic radiation.  
http://www.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@corp/documents
/documents/crdm_sl_radiation.pdf 
 
St. Jude Medical: 
St. Jude Medical (2014)  Effects of Therapeutic Radiation on St. Jude Medical 
Implantable Cardiac Rhythm Devices 
http://www.sjm.com/~/media/pro/resources/emi/med-dental/fl-therapeutic-
radiation-110513.ashx?la=en 
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EDITORIAL HEADLINE
Development of the Patient Safety Incident 
Management System (DPSIMS) Project
The NRLS is a database of patient safety incident reports submitted by NHS 
organisations across England and Wales, and directly by patients, specifically for 
the purposes of learning. Hospitals regularly upload incident reports from their 
local systems to the NRLS, where they are analysed by national patient safety 
experts to spot trends, specific incidents of concern or emerging risks to patient 
safety. Radiotherapy departments include the TSRT trigger code in reports so 
that these might be highlighted for national analysis by PHE and lessons shared 
with the professional community.
The DPSIMS Project (previously known as the NRLS Development Project) was 
started in 2014. It is a three-year project to specify and procure a replacement 
for the NRLS, to support the ability of the NHS to learn and improve on the basis 
of reported experience.
Engagement to date has included a survey, focus group and workshops for 
patient advocates and professional users of the NRLS, providing an opportunity 
to influence the future of patient safety reporting and learning. More recently, a 
series of clinical site visits to explore the potential impact of various options for 
the NRLS successor system on local level provision has been conducted with 
ten sites, the findings of which will be published in the coming weeks.
Further information can be found at  
http://www.england.nhs.uk/ourwork/patientsafety/dpsims-dev/.
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Dates for the Diary
The Radiotherapy Team is based at 
PHE CRCE Chilton
Welcome to the 16th issue of Safer Radiotherapy. The aim 
of the newsletter is to provide a 
regular update on the analysis by 
PHE of radiotherapy error (RTE) 
reports. These anonymised reports 
are submitted on a voluntary basis 
through the National Reporting and 
Learning System (NRLS) of NHS 
England or directly to PHE, to promote 
learning and minimise recurrence of 
these events. 
Safer RT is designed to disseminate 
learning from RTEs to professionals 
in the radiotherapy community to 
positively influence local practice and 
improve patient safety.
Now published three times a year, 
Safer RT will contain key messages 
and trends from the preceding four-
month period of RTE reports.
Any comments and suggestions for 
inclusion in the newsletter would be 
gratefully received. They should be 
sent to radiotherapy@phe.gov.uk.
Thanks to all contributors to this issue. 
The next issue of Safer RT will be 
published in September 2015 and will 
be available at https://www.gov.uk/
government/collections/medical-
radiation-uses-dose-measurements-
and-safety-advice. 
Helen Best 
Editor
Patient Safety in Radiotherapy 
Steering Group (PSRT)
As highlighted in issues 14 and 15 
of Safer RT, the PSRT continues to 
develop the learning from RTEs and 
their analysis.
The draft causative factor taxonomy 
is currently being piloted across 
ten clinical sites. The final taxonomy 
will be made available for use across 
the radiotherapy community to support 
trends analysis.
In parallel, work on refining the 
pathway coding is underway (see 
page 3). Comments from across 
the radiotherapy community have 
already been received. In addition, it 
is proposed that this work will include 
the introduction of safety barriers, 
also known as critical control points or 
detection methods. These include any 
process steps whose primary function 
is to prevent the occurrence of errors.
Once agreed by the PSRT, this will be 
shared with the pilot sites for comment.
Safer Radiotherapy
Radiotherapy Newsletter of Public Health England
May 2015 Issue 16
The data analysed is submitted by the RT community. If you have any suggestions 
on how the process coding can be refined, please email the Radiotherapy Team at 
radiotherapy@phe.gov.uk.
Data Analysis
Submissions from 56 NHS UK RT 
departments contributed to this issue’s 
full data analysis, for 1 December 2014 
to 31 March 2015, which is available 
at https://www.gov.uk/government/
collections/medical-radiation-uses-
dose-measurements-and-safety-
advice. This is a slight increase from 
52 at the last analysis, reflecting the 
strong reporting culture that continues 
in the UK RT community.
The analysis includes data on 
primary process coding and severity 
classification of the RTEs. A 
breakdown of primary process codes 
by classification levels is also included.
New NHS radiotherapy providers 
are welcome to contact 
radiotherapy@phe.gov.uk for 
advice on how to submit data.
Classification of RTEs
Of those RTEs reported for the period 
December 2014 to March 2015, 
1772 out of 1851 reports (95.7%) 
were classified as minor radiation 
incidents, near misses or other non-
conformances (see Figure 1). This 
is consistent with previous analyses. 
These are lower level incidents which 
would have no significant effect on 
the planning or delivery of individual 
patient treatments.
Reportable radiation incidents (level 1) 
made up 46 (2.5%) of all reports. 
Pretreatment ‘positioning of patient’ 
comprised 6 (13%) and treatment 
‘on-set imaging: approval process’ 
comprised 5 (10.9%) of all level 1 
RTEs reported for this time period. 
Non-reportable radiation incident 
reports (level 2) made up 33 of all 
reports (1.8%). ‘On-set imaging: 
approval process’ and ‘movements 
from reference marks’ each comprised 
4 (12.1%) of all level 2 RTEs. 
Of the 536 minor radiation incidents 
(level 3) reported, 119 (22.2%) of 
this subset were related to ‘on-set 
imaging: production process’, making 
it the most frequently occurring code 
in this classification. The second most 
frequently occurring type of incident, at 
64 (11.9%), was ‘use of on-set imaging’. 
On-treatment imaging is discussed 
further in issue 12 of Safer RT. 
The most commonly occurring RTE 
process code in the near miss (level 4) 
classification was treatment ‘on-set 
imaging: approval process’, with 46 
reports (8.1%). 
Within the non-conformance (level 5) 
classification, ‘bookings made 
according to protocol’ had 49 reports 
RTE Data Analysis: December 2014 to March 2015
Figure 1 Classification breakdown of RTE reports using the TSRT9 trigger code, 
December 2014 to March 2015 (1851 reports)
Figure 2 RTE main themes (817 out of 1851 reports), for December 2014 to March 
2015 (with process code indicated)
(7.3%), making this the most frequently 
occurring RTE in this classification. 
Primary Process Code
The main themes (points in the patient 
pathway where the majority of reported 
RTEs occurred) for this dataset are 
shown in Figure 2. Imaging process 
codes contributed to 459 of the reports 
in the main themes (56.1%), making 
up 24.7% of all reports in this reporting 
period. Of note, ‘on-set imaging: 
production process’ contributed to 
143 of the reports in the main themes 
(17.5%). This will be discussed further 
in the Error of the Month.
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On-set imaging
TSRT Process Code: 
On-set imaging: production 
process (13z)
This code accounted for 143 (7.7%) 
RTEs reported from December 2014 
to March 2015. It has been the most 
commonly occurring RTE since 
June 2014. The majority of these 
reports, 138 (96.5%), were lower level 
incidents having little or no effect on 
the planning or delivery of individual 
patient treatments. 
This RTE is associated with the 
incorrect production of on-set imaging. 
The main themes highlighted within 
these reports included exposed 
images being unusable due to over-
exposure, the incorrect field size 
exposed or unsuitable positioning of 
the image panel. This RTE is also 
associated with equipment malfunction; 
such errors should also be reported 
locally and to the MHRA and the 
relevant manufacturer.
How can we minimise the risk of 
this RTE occurring?
Points to consider
1 Produce and follow clearly defined 
and up-to-date protocols 
2 Clearly define individual 
responsibilities 
3 Ensure staff are adequately trained, 
competent and appropriately 
entitled in the use of the technology
4 Ensure adequate instructions are 
available on the clinical requirement 
of imaging
5 Capture image parameters on day 1 
and action if further optimisation is 
required
6 Ensure on-set imaging has been 
optimised
7 Put in place contingency plans in 
case of equipment failure
8 Investigate repeat incidents. 
Consider removal of equipment 
from practice
9 Monitor locally reported RTEs to 
identify further preventive action
10 Audit repeated failure to review and 
update procedures
Consistency Checking
Consistency checking on the application of the TSRT classification and pathway 
coding by local RT departments is undertaken by PHE staff on all RTE reports.
Classification
The classification or severity of the event was amended for 31 (1.6%) reports in this 
reporting period. The amendments were made from 25 (80.6%) reports classified 
as near misses and 6 (19.4%) reports classified as non-conformances. Of the near 
misses reclassified, the majority (24) were changed to minor radiation incidents. 
If an RTE includes an unintended exposure, including on-set imaging, this will be 
classified as a minor radiation incident or above.
Classification 
allocated by 
department Text description
Reclassification 
in consistency 
checking Comments
Near miss Images taken for planning 
procedure, no confirmed 
diagnosis, departmental 
protocol requires confirmed 
diagnosis. Patient ultimately 
not for radiotherapy treatment
Reportable 
radiation  
incident
Although no treatment 
given, planning images 
taken before confirmed 
diagnosis, resulting in 
unnecessary dose
Near miss Digital moves completed in 
incorrect direction, on-set 
images acquired showing 
incorrect move. Re-set and 
moved in correct direction and 
repeated on-set imaging
Minor radiation 
incident
Although treatment in 
correct area, additional 
on-set imaging taken
Primary pathway coding
The pathway coding was amended for 127 (6.8%) reports in this reporting period.
The amendments were made on reports associated with the entire patient pathway. 
Of these, 78 (61.4%) were coded locally from ‘other’ process codes. PHE staff 
attributed existing pathway codes to these reports. This suggests there is a need 
to reduce the ambiguity of some of the terms used in the pathway coding. Reports 
locally coded as ‘other’ which could not be amended to existing pathway codes 
made up 82 (4.4%) of the reports in this reporting period.
This highlights the need for refinement of the pathway coding to reflect current 
practice. This work is currently being undertaken.
Original pathway codes for amended reports, December 2014 to March 2015
For this reporting period the most frequently changed pathway coding was found in 
the treatment unit process, at 62 (50.4%) reports.
Pathway coding 
allocated by department Text description Newly assigned pathway code
Treatment unit, setting of 
couch position (13q)
Skin blemish used 
instead of tattoo
ID of reference marks (13k)
Pretreatment activities, 
positioning of patient (10b)
Consultant unavailable 
for set-up as requested
Availability of staff with competency 
appropriate for procedure (20a)
Referral for treatment
Booking process
Pretreatment: preparation of patient
Pretreatment activities
Pretreatment planning process 
Treatment data entry
Treatment unit process
Miscellaneous
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DATES FOR THE DIARY
8–9 June UKRO, Coventry
28 September BIR, IR(ME)R 
update
23 October BIR, RTE study day
September Safer Radiotherapy, 
Issue 17
A national review of cardiac device policies being used in radiotherapy 
departments across the UK was 
carried out in 2013. This reported that 
most policies do not reflect current 
best evidence1. To address this, the 
Royal College of Radiologists, the 
Society and College of Radiographers 
and the Institute of Physics and 
Engineering in Medicine formed a 
multidisciplinary working party. This 
group, comprising clinical oncology, 
cardiology, therapeutic radiography 
and medical physics experts, has 
developed evidence-based guidelines 
for the management of cancer patients 
receiving radiotherapy with a cardiac 
implanted electronic device (CIED).
The number of cancer patients with 
CIEDs receiving radiotherapy is 
increasing2. Most medical treatments 
pose little danger to the functioning 
of CIEDs. However, radiotherapy has 
the potential to alter device function3. 
There is limited published research on 
the effect of radiotherapy on CIEDs, 
but there is evidence to show that 
radiotherapy even at low doses can 
cause malfunction or failure4.
The American Association of 
Physicists in Medicine (AAPM) 
published a report in 1994 on the 
safe use of radiotherapy in patients 
with pacemakers5. A later review was 
produced by Frizzell et al in 2009 and, 
in 2012, Hurkmans et al updated the 
AAPM guidelines6,7. The AAPM report 
does not take into account advances 
in CIED technology and radiotherapy 
treatment technology and delivery. 
Despite this, it still forms the basis of 
most CIED departmental radiotherapy 
policies in the UK1.
The multidisciplinary working party 
has developed a UK guideline which 
reviews the evidence, defines current 
‘gold standard’ practice and provides 
recommendations for the safe delivery 
of radiotherapy in patients who have 
a CIED.
Summary of recommendations
• CIEDs should not be placed directly 
in the radiotherapy treatment beam
• the cumulative radiotherapy dose 
received by the pacemaker should 
not exceed 2 Gy
• patients with rate-adaptive 
pacemakers should be reviewed by 
cardiology and consideration given 
to temporary deactivation of the 
sensor while receiving radiotherapy 
• the cumulative radiotherapy dose 
received by an implantable cardiac 
defibrillator (ICD) should not exceed 
0.5 Gy
• the photon beam energy should be 
less than 10 MV
• the dose contribution from on-
treatment verification imaging 
should be taken into account when 
calculating cumulative radiotherapy 
dose
• patients should be allocated an 
appropriate risk stratification group
• the patient’s cardiologist should 
be informed in advance of any 
planned radiotherapy for advice on 
monitoring during radiotherapy and 
subsequent follow-up
• patients with CIEDs should be fully 
informed of the potential short- and 
long-term risks of radiotherapy: this 
should be included in the patient 
information available from the 
cardiology department in addition to 
radiotherapy patient information
Conclusion
The guideline has been developed 
to support the safe management 
of patients with a CIED receiving 
radiotherapy. It is based on current 
best evidence, and can be adapted 
to suit local practice in radiotherapy 
departments. We are conducting 
research to further define the effect of 
radiotherapy on modern CIEDs.
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